r_datetime,url,title,citation,snippet
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Ubiquitin-interacting motifs of ataxin-3 regulate its polyglutamine toxicity through Hsc70-4-dependent aggregation.,Elife. 2020 Sep 21;9:e60742. doi: 10.7554/eLife.60742.,"UIMs function by interacting with the heat shock protein, Hsc70-4, whose reduction diminishes ataxin-3 toxicity in a UIM-dependent manner. Hsc70-4 also enhances pathogenicity of other polyglutamine proteins. Our studies provide a unique insight into the impac …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,"Methyl donor supply to heat stress-challenged polymorphonuclear leukocytes from lactating Holstein cows enhances 1-carbon metabolism, immune response, and cytoprotective gene network abundance.",J Dairy Sci. 2020 Sep 17:S0022-0302(20)30722-0. doi: 10.3168/jds.2020-18638. Online ahead of print.,"Compared with PMN receiving 0 μg of Chol/mL, heat-stressed PMN supplemented with Chol at 400 or 800 μg/mL had greater fold-change in abundance of CBS, CSAD, GSS, GSR, and GPX1. ...Both Chol and Met supply enhanced the cytoprotective characteristics of PMN through upregulat …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,RP11-462C24.1 suppresses proliferation and invasion of colorectal carcinoma cells by regulating HSP70 through PI3K/AKT signaling pathway.,Hum Cell. 2020 Sep 18. doi: 10.1007/s13577-020-00426-7. Online ahead of print.,"From the results, we found that RP11-462C24.1 was significantly decreased in CRC tumor tissues and the CRC cell lines, which were most significant in SW480 and HT-29 cell lines; moreover, transient overexpression of RP11-462C24.1 suppressed the growth and migration while promoted …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Small heat shock protein Hsp67Bc plays a significant role in Drosophila melanogaster cold-stress tolerance.,J Exp Biol. 2020 Sep 17:jeb.219592. doi: 10.1242/jeb.219592. Online ahead of print.,"Hsp67Bc in Drosophila melanogaster is a member of the small heat shock protein family, the main function of which is to prevent the aggregation of misfolded or damaged proteins. ...In addition, the deletion in the Hsp67Bc gene caused more prominent up-regulat …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,"LsHSP70 is induced by high temperature to interact with calmodulin, leading to higher bolting resistance in lettuce.",Sci Rep. 2020 Sep 16;10(1):15155. doi: 10.1038/s41598-020-72443-3.,"High temperatures have significant impacts on heat-tolerant bolting in lettuce. In this study, it was found that high temperatures could facilitate the accumulation of GA in lettuce to induce bolting, with higher expression levels of two heat shock protein ge …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Znonps AND GENE EXPRESSION IN BROILERS Effects of Zinc Oxide Nanoparticles on Regulatory Appetite and Heat Stress Protein Genes in Broiler Chickens Subjected to Heat Stress.,J Anim Sci. 2020 Sep 16:skaa300. doi: 10.1093/jas/skaa300. Online ahead of print.,"Our findings revealed that dietary ZnONPs altered the gene expression of cholecystokinin (ileum), HSP 70 (jejunum and ileum) and HSP 90 (duodenum, jejunum, and ileum). ...More studies are required to elucidate its complex physiological and biochemical functio …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Immune Responses of Asian Seabass Lates calcarifer to Dietary Glycyrrhiza uralensis.,Animals (Basel). 2020 Sep 11;10(9):E1629. doi: 10.3390/ani10091629.,"To understand the impacts of dietary Glycyrrhiza uralensis on the immune responses of Lates calcarifer, the expression of immune-related genes including crp, c-3, c-4, mtor, mlst-8, eif4e, hsp-70, hsp-90, il-8il-8, il-10, tgfβ1, tnf, ifn-γ1, and mxf in L. cal …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms.,Cancers (Basel). 2020 Sep 11;12(9):E2592. doi: 10.3390/cancers12092592.,"Heat shock proteins (HSPs) are cytoprotective stress-response chaperones involved in protein homeostasis and in many critical pathways, including inflammation. ...These HSPs include HSP70, HSP90 (chaperoning JAK2) and both HSP110 and HSP27, which are k …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,"Effects of chronic nitrate exposure on the intestinal morphology, immune status, barrier function, and microbiota of juvenile turbot (Scophthalmus maximus).",Ecotoxicol Environ Saf. 2020 Sep 15;207:111287. doi: 10.1016/j.ecoenv.2020.111287. Online ahead of print.,"Additionally, the expression of HSP70 and HSP90 heat-shock proteins, toll-like receptor-3 (TLR-3), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) significantly increased (P < 0.05), whereas that of transforming growth factor-β (TGF-β), …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Heat shock protein 90α in thymic epithelial tumors and non-thymomatous myasthenia gravis.,Oncoimmunology. 2020 May 13;9(1):1756130. doi: 10.1080/2162402X.2020.1756130.,"Heat shock proteins (HSPs) harbor great potential as cancer biomarkers and HSP inhibitors approach clinical cancer therapy. METHODS: To explore HSP pathophysiology, we assessed sera (immunoassays) and tissues (immunohistochemistry) of TETs (and …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,SEM and qRT-PCR revealed quercetin inhibits morphogenesis of Aspergillus flavus conidia via modulating calcineurin-Crz1 signalling pathway.,Mycology. 2020 Jan 13;11(2):118-125. doi: 10.1080/21501203.2020.1711826.,Significant inhibition of conidial swelling of A. flavus in comparison to control was observed at 4 and 7 h Quantitative real-time PCR for genes from calcium signalling pathway and heat-shock proteins family showed up-regulation of heat shock ( …
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,"Manipulation of Quercetin and Melatonin in the Down-Regulation of HIF-1α, HSP-70 and VEGF Pathways in Rat's Kidneys Induced by Hypoxic Stress.",Dose Response. 2020 Aug 28;18(3):1559325820949797. doi: 10.1177/1559325820949797. eCollection 2020 Jul-Sep.,"Over protein-expression of vascular endothelial growth factor and heat shock, protein-70 and mRNA of HIF-1α were also observed. ...HIF-1α and HSP-70 are implicated in the induction of hypoxia and its treatment...."
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Overexpression of miR-144-3p alleviates polycystic ovaries syndrome through targeting expression of HSP-70.,Gene Ther. 2020 Sep 11. doi: 10.1038/s41434-020-00191-0. Online ahead of print.,"Moreover, HSP-70 was a direct target of miR-144-3p. Furthermore, increased expression of HSP-70 rescued the effects of miR-144-3p on ovarian granulosa cell growth and apoptosis. In addition, knockdown of HSP-70 alleviated endocrine disord …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Hepatotoxic effect of lead and hepatoprotective effect of Hydrilla verticillata on hepatic transcriptional and physiological response in edible fish Labeo rohita.,Drug Chem Toxicol. 2020 Sep 9:1-8. doi: 10.1080/01480545.2020.1815762. Online ahead of print.,"The metal binding stress proteins, heat shock proteins (Hsp60 & Hsp70) and metallothionein were also upregulated due to lead toxicity. ...Administration of supplementary feed to the lead intoxicated protective group significantly decreased t …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.,Front Immunol. 2020 Aug 13;11:1816. doi: 10.3389/fimmu.2020.01816. eCollection 2020.,"We evaluated IVIgG alone, and with a Heat shock protein (HSP)-90 or proteasome inhibitor, using multiple myeloma and mantle cell lymphoma (MCL) cells in vitro, and with the proteasome inhibitor bortezomib in vivo. ...Preparations of IVIgG were found to contai …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Biological Responses to Cadmium Stress in Liverwort Conocephalum conicum (Marchantiales).,Int J Mol Sci. 2020 Sep 4;21(18):E6485. doi: 10.3390/ijms21186485.,"Oxidative damage (production and localization of reactive oxygen species) and related response mechanisms (activity of antioxidant enzymes), and induction of Heat Shock Protein 70 expression, have been studied in the toxi-tolerant liverwort Conocephalum conic …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Addition of exogenous proteins detected in oviductal secretions to in vitro culture medium does not improve the efficiency of in vitro fertilization in pigs.,Theriogenology. 2020 Aug 27;157:490-497. doi: 10.1016/j.theriogenology.2020.08.017. Online ahead of print.,"This work was designed to study whether HSP70-1A, HSP90α, ezrin or PDI4, proteins previously identified in porcine oviductal secretions, have a role in zona pellucida (ZP) resistance to enzymatic digestion, in vitro fertilization (IVF) and sperm viability. ...Sperm …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,[Clinical value of biomarkers in diagnosis and treatment of idiopathic pulmonary fibrosis].,Nan Fang Yi Ke Da Xue Xue Bao. 2020 Jul 30;40(7):1062-1065. doi: 10.12122/j.issn.1673-4254.2020.07.23.,"These biomarkers play important roles in early diagnosis (such as SP-D, MMP-7, and osteopontin), prognostic evaluation (such as telomerase length, KL-6, mtDNA, HSP-70, LOXL2, CXCL13, miRNA, ICAM-1, and CCL18), and guiding treatment of IPF (such as TOLLIP rs3750920 g …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Participation of Hsp70 and Hsp90α Heat Shock Proteins in Stress Response in the Course of Type 1 Diabetes Mellitus.,Dokl Biol Sci. 2020 Jul;493(1):124-127. doi: 10.1134/S0012496620040079. Epub 2020 Sep 7.,"The role of two heat shock proteins, Hsp70 and Hsp90α, on stress response in mice with severe diabetes mellitus induced by a high dose of alloxan (500 mg/kg body weight), as well as in RIN-m5F β cells cultured in the presence of cytokines (IL-1 and TNF …"
2020-09-23T05:53:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=HSP-70&sort=date&size=20,Cellular and functional adaptation to thermal stress in ovarian granulosa cells in mammals.,J Therm Biol. 2020 Aug;92:102688. doi: 10.1016/j.jtherbio.2020.102688. Epub 2020 Aug 12.,"Additionally, thermal stress induces upregulation of thermal shock proteins, such as HSP70 and HSP90. This review provides an update on the influence of thermal stress on GCs of mammals. Discussions include impacts to steroidogenesis (estradiol and progestero …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,"Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.",Oncogene. 2020 Sep 14. doi: 10.1038/s41388-020-01454-1. Online ahead of print.,"Herein, we show that novel combinations of JAK2 inhibitors (ruxolitinib and pacritinib) with SMO inhibitors (vismodegib and sonidegib) synergistically inhibited in vitro growth of TNBC and HER2-positive trastuzumab-resistant BT474-TtzmR cells. ..."
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives.,Hemasphere. 2020 Jul 21;4(4):e424. doi: 10.1097/HS9.0000000000000424. eCollection 2020 Aug.,"Newer JAK inhibitors that are distinguished from ruxolitinib and fedratinib by their ability to improve anemia (eg, momelotinib) or safety and efficacy in severely thrombocytopenic patients (eg, pacritinib) are in phase 3 clinical trials. ..."
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,"The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.",Curr Hematol Malig Rep. 2020 Aug 11. doi: 10.1007/s11899-020-00596-z. Online ahead of print.,"Fedratinib, momelotinib, and pacritinib are three newer-generation JAK inhibitors being prospectively evaluated and we will discuss their roles in the treatment of myeloproliferative neoplasms. ...Pacritinib has been studied in myelofibrosis patients with significan …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019.,Crit Care Explor. 2020 Jun 15;2(6):e0138. doi: 10.1097/CCE.0000000000000138. eCollection 2020 Jun.,"Cytokine release syndrome mediated by interleukin-6 is a critical driver of coronavirus disease 2019 mortality. Herein, we review and discuss key immunologic effects of direct interleukin-6 blockade, downstream nonselective Janus kinase inhibition, and selective Jan …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.,Ther Adv Hematol. 2020 May 15;11:2040620720925201. doi: 10.1177/2040620720925201. eCollection 2020.,"This medication was found to be effective in reduction of symptom burden and spleen size; however, the median duration of response is about 3 years. ...Additional JAK-i have been developed over the last 8 years, including fedratinib, momelotinib, and pacritinib …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.,Br J Haematol. 2020 May 11. doi: 10.1111/bjh.16665. Online ahead of print.,Relapse rates are high even with the integration of first-generation FMS-like tyrosine kinase 3 (FLT3) inhibitors in pre- and post-transplant regimes and as maintenance in FLT3-mutated AML. ...
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Management of Myelofibrosis: from Diagnosis to New Target Therapies.,Curr Treat Options Oncol. 2020 Apr 30;21(6):46. doi: 10.1007/s11864-020-00734-y.,"Median survival ranges from approximately 3.5 to 5.5 years; while the most frequent cause of death is the evolution to acute myeloid leukemia, also other conditions such as progression without transformation, complications due to cytopenias including i …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo.,Neurooncol Adv. 2020 Jan-Dec;2(1):vdaa020. doi: 10.1093/noajnl/vdaa020. Epub 2020 Feb 18.,RESULTS: We show that afatinib and pacritinib decreased BTSC growth and sphere-forming capacity in vitro. Combinations of the 2 drugs were synergistic and abrogated the activation of STAT3 signaling observed upon EGFR inhibition in vitro and in vivo. ...Combined inh …
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Management of myelofibrosis after ruxolitinib failure.,Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20.,"Ruxolitinib reduces splenomegaly to some degree in almost all treated patients; however, many patients cannot tolerate ruxolitinib due to dose-dependent drug-related cytopenias, and even patients with a good initial response often develop resistance to ruxolitinib after 2- …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,"A novel human colon signet-ring cell carcinoma organoid line: establishment, characterization and application.",Carcinogenesis. 2020 Jul 14;41(7):993-1004. doi: 10.1093/carcin/bgz178.,"An in vitro drug screening found that AT9283 and Pacritinib could be effective JAK2 inhibitors, which was consistent with the in vivo xenograft response. ..."
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Novel treatment strategies for myeloproliferative neoplasms.,Rinsho Ketsueki. 2019;60(9):1176-1185. doi: 10.11406/rinketsu.60.1176.,"Several newer JAK inhibitors (fedratinib, pacritinib, momelotinib) have shown activity in phase 3 trials in patients with myelofibrosis but have, for various reasons, not yet received regulatory approval; all these agents, however, remain in active clinical developm …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,"Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.",PLoS One. 2019 Sep 27;14(9):e0222944. doi: 10.1371/journal.pone.0222944. eCollection 2019.,"To provide further translational insights into clinical outcomes, we compared phenotypic biomarker profiles of ruxolitinib, fedratinib, momelotinib, and pacritinib in the BioMAP® Diversity PLUS panel of 12 human primary cell systems designed to recapitulate key aspe …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Preclinical Evidence of STAT3 Inhibitor Pacritinib Overcoming Temozolomide Resistance via Downregulating miR-21-Enriched Exosomes from M2 Glioblastoma-Associated Macrophages.,J Clin Med. 2019 Jul 2;8(7):959. doi: 10.3390/jcm8070959.,We found that GBM-associated macrophages (GAMs) secreted exosomes which were enriched with oncomiR-21. Coculture of GAMs (and GAM-derived exosomes) and GBM cell lines increased GBM cells' resistance against temozolomide (TMZ) by upregulating the prosurvival gene programmed …
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,"Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.",Invest New Drugs. 2020 Apr;38(2):340-349. doi: 10.1007/s10637-019-00786-4. Epub 2019 May 17.,"We determined that pacritinib, a JAK2/FLT3 inhibitor, has in vitro activity against FLT3-ITD and tyrosine kinase domain (TKD) mutations. ...Pacritinib was administered at a dose of 100 mg or 200 mg twice daily following a 3 + 3 dose-escalation in combi …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,New Concepts of Treatment for Patients with Myelofibrosis.,Curr Treat Options Oncol. 2019 Jan 24;20(1):5. doi: 10.1007/s11864-019-0604-y.,"Seven years after the approval of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, it remains the only drug licensed for the treatment of myelofibrosis. ...Pacritinib, a non-myelosuppressive JAK2-selective inhibitor, is currently in a dose-ranging …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Pacritinib in Patients with Myelofibrosis-Reply.,JAMA Oncol. 2018 Dec 1;4(12):1787. doi: 10.1001/jamaoncol.2018.4842.,
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Pacritinib in Patients With Myelofibrosis.,JAMA Oncol. 2018 Dec 1;4(12):1786-1787. doi: 10.1001/jamaoncol.2018.4830.,
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.,Oncotarget. 2018 Sep 7;9(70):33416-33439. doi: 10.18632/oncotarget.26058. eCollection 2018 Sep 7.,"Interleukin-1 receptor-associated kinases (IRAK1, IRAK2, IRAK3 [IRAK-M], and IRAK4) are serine-threonine kinases involved in toll-like receptor and interleukin-1 signaling pathways, through which they regulate innate immunity and inflammation. ..."
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Pacritinib to treat myelofibrosis patients with thrombocytopenia.,Expert Rev Hematol. 2018 Sep;11(9):707-714. doi: 10.1080/17474086.2018.1500456. Epub 2018 Jul 19.,"Treatment with ruxolitinib, a selective JAK1/2 inhibitor, has significantly improved the lives of patients with myelofibrosis. ...Safety concerns pertaining to cardiovascular events and bleeding that arose in an early analysis of PERSIST-2 were likely related to the …"
2020-09-23T05:53:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB&sort=date&size=20,Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis.,J Exp Pharmacol. 2018 May 9;10:9-17. doi: 10.2147/JEP.S150729. eCollection 2018.,"Although JAK2 inhibitors, such as the JAK1/2 inhibitor ruxolitinib and the JAK2/FLT3/CSF1R/IRAK1 inhibitor pacritinib suppress abnormal clone expansion in myelofibrosis, ruxolitinib does not appear to prevent or reverse bone-marrow fibrosis in most patients. ...METH …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Targeting the histone demethylase PHF8-mediated PKCα-Src-PTEN axis in HER2-negative gastric cancer.,Proc Natl Acad Sci U S A. 2020 Sep 21:201919766. doi: 10.1073/pnas.1919766117. Online ahead of print.,"GC cells treated with midostaurin or bosutinib significantly suppressed migration in vitro and in zebrafish models. Immunohistochemical analyses of PHF8, PKCα, and PTEN showed a positive correlation between PHF8 and PKCα but negative correlations between PHF8 and PTEN and …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Midostaurin in acute myeloid leukemia: review of current evidence and practical considerations in routine clinical use.,Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07014-7. Online ahead of print.,"We enumerate the practical issues faced in the use of midostaurin like antifungal prophylaxis, dosage of concomitant chemotherapy agents as well as available data on sequencing of the FLT3 inhibitors. Lastly we provide our perspective of the future directions for FLT3 inhi …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,FLT3 inhibitors in the treatment of Acute Myeloid Leukemia: current status and future perspectives.,Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.06989-X. Online ahead of print.,"First-generation multi-kinase inhibitors (sorafenib, midostaurin, lestaurtinib) are characterized by a broad-spectrum of drug targets, whereas secondgeneration inhibitors (quizartinib, crenolanib, gilteritinib) show more potent and specific FLT3 inhibition, and are thereby …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.,Eur J Haematol. 2020 Sep 18. doi: 10.1111/ejh.13518. Online ahead of print.,"In multivariate analysis, midostaurin use and allo-SCT in CR1 were the most significant factors affecting overall survival (OS). ...In low-AR patients, the midostaurin effect was much less prominent. CONCLUSIONS: Our results demonstrate benefits of midostaurin …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,"Indole alkaloids, synthetic dimers and hybrids with potential in vivo anticancer activity.",Curr Top Med Chem. 2020 Sep 8. doi: 10.2174/1568026620666200908162311. Online ahead of print.,"Vinblastine, midostaurin, and anlotinib as the representative of indole alkaloids, synthetic dimers and hybrids respectively have already been clinically applied to treat many types of cancers, demonstrating indole alkaloids, synthetic dimers and hybrids are useful scaffol …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,FLT3 Inhibition in Acute Myeloid Leukemia.,Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S5-S6. doi: 10.1016/S2152-2650(20)30441-9.,The approved FLT3 tyrosine kinase inhibitors (TKIs) midostaurin and gilteritinib improve survival in AML with FLT3 mutations. ...
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis.,Cancers (Basel). 2020 Aug 19;12(9):E2341. doi: 10.3390/cancers12092341.,"Anti-myeloma activity of FLT3 inhibitors (midostaurin, gilteritinib) was tested in vitro on MM cell lines and primary MM cells by (3)H-tymidine incorporation assays or flow cytometry. ..."
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program.,Leuk Lymphoma. 2020 Aug 19:1-8. doi: 10.1080/10428194.2020.1805109. Online ahead of print.,RADIUS-X (NCT02624570) was an expanded access program providing access to midostaurin during regulatory review and extending the understanding of the safety and tolerability of midostaurin. ...Midostaurin demonstrated a manageable safety profile and was assoc …
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.,Oncotarget. 2020 Jul 21;11(29):2807-2818. doi: 10.18632/oncotarget.27656. eCollection 2020 Jul 21.,"Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard of care for FLT3 mutant patients undergoing induction chemotherapy [1, 2]. ...We observed a correlation between FLT3-ITD mutations and midostaurin sensitivity as expected and observed KRAS …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.,Cancer Chemother Pharmacol. 2020 Sep;86(3):325-337. doi: 10.1007/s00280-020-04114-z. Epub 2020 Aug 3.,"The effect of FLT3i (quizartinib, midostaurin, sorafenib) on cell proliferation and cell cycle kinetics was assessed in AML cell lines with differing FLT3 status; HEL (negligible expression of wild-type FLT3), EOL1 (wild-type FLT3), MV4-11 (FLT3-ITD resulting in constituti …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Management of Acute Myeloid Leukemia (AML) in Older Patients.,Curr Oncol Rep. 2020 Jul 28;22(10):103. doi: 10.1007/s11912-020-00964-1.,"We focus on multiple newly approved medications, including venetoclax, midostaurin, CPX-351, gemtuzumab, glasdegib, enasidenib, and ivosidenib, and their specific indications. ..."
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.,Biomedicines. 2020 Jul 24;8(8):245. doi: 10.3390/biomedicines8080245.,"FLT3 inhibitors such as midostaurin, gilteritinib and quizartinib show excellent response rates in patients with FLT3-mutated AML, but its duration of response may not be sufficient yet. ...On-target mutations (i.e., FLT3-TKD) such as D835Y keep the TK domain in its active …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,The Time Has Come for Targeted Therapies for AML: Lights and Shadows.,Oncol Ther. 2020 Jun;8(1):13-32. doi: 10.1007/s40487-019-00108-x. Epub 2020 Jan 24.,"These therapies include FLT3 inhibitors midostaurin and gilteritinib, CPX-351 (liposomal cytarabine and daunorubicin), gemtuzumab ozogamicin (GO, anti-CD33 monoclonal antibody conjugated with calicheamicin), IDH1/IDH2 inhibitors ivosidenib and enasidenib, Hedgehog inhibito …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.,Ann Hematol. 2020 Sep;99(9):1989-2007. doi: 10.1007/s00277-020-04186-0. Epub 2020 Jul 18.,"In this systematic review, we analyze DDIs of glasdegib, venetoclax, midostaurin, quizartinib, gilteritinib, enasidenib, and ivosidenib. CYP3A4 is the main enzyme responsible for SMIs metabolism, and strong CYP3A4 inhibitors, such azoles, could increase drug exposure and t …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity.,Haematologica. 2020 Jul 2:haematol.2019.231944. doi: 10.3324/haematol.2019.231944. Online ahead of print.,CD44-induced VLA-4 activation could be inhibited by the Src family kinase inhibitor PP2 and the multikinase inhibitor midostaurin. ...
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.,Cancer Treat Rev. 2020 Aug;88:102026. doi: 10.1016/j.ctrv.2020.102026. Epub 2020 May 16.,"Targeted drugs already changed the clinical practice in treatment of leukemias, such as imatinib (BCR/ABL inhibitor) in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), ibrutinib (Bruton's tyrosine kinase inhibitor) in chronic lymphocytic leukemia (CL …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.,Br J Haematol. 2020 Aug;190(3):467-470. doi: 10.1111/bjh.16800. Epub 2020 Jun 21.,
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Fentanyl inhibits acute myeloid leukemia differentiated cells and committed progenitors via opioid receptor-independent suppression of Ras and STAT5 pathways.,Fundam Clin Pharmacol. 2020 Jun 21. doi: 10.1111/fcp.12581. Online ahead of print.,Fentanyl significantly augmented the efficacy of cytarabine but not midostaurin in AML differentiated cells and committed progenitors. ...
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia.,Cancers (Basel). 2020 Jun 14;12(6):1574. doi: 10.3390/cancers12061574.,"The FLT3-ITD mutation is targetable with approved FLT3 small molecule inhibitors, including midostaurin and gilteritinib. However, outside of patients receiving allogeneic transplant, most patients fail to respond or relapse, suggesting alternative approaches of therapy wi …"
2020-09-23T05:53:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIDOSTAURIN&sort=date&size=20,Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma.,Ann Hematol. 2020 Jul;99(7):1429-1440. doi: 10.1007/s00277-020-04107-1. Epub 2020 Jun 8.,Midostaurin is a novel agent for FLT3-TKD/-ITD(mut)-acute myeloid leukemia (AML) and metabolized via cytochrome P450 3A4 (CYP3A4). ...Concomitant administration of both drugs leads to elevated midostaurin exposure. Both drugs improve overall survival at low numbers …
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,First report of Godronia cassandrae as a major cranberry fruit rot pathogen in Eastern Canada.,Plant Dis. 2020 Sep 15. doi: 10.1094/PDIS-06-20-1193-PDN. Online ahead of print.,"., 2003), it was supposed to amplify with the molecular tool developed from the strain DAOM C216021 (AAFC, Ottawa, ON) identified in 1993 on Vaccinium angustifolium as G. cassandrae. ..."
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Comparative analysis of cadmium uptake and distribution in contrasting canadian flax cultivars.,BMC Res Notes. 2020 Sep 7;13(1):424. doi: 10.1186/s13104-020-05265-1.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Fungal endophyte diversity in table grape berries.,Can J Microbiol. 2020 Aug 11. doi: 10.1139/cjm-2020-0293. Online ahead of print.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,In vitro ruminal fermentation of Fenugreek (Trigonella foenum-graecum L.) produced less methane than that of alfalfa (Medicago sativa).,Asian-Australas J Anim Sci. 2020 May 12. doi: 10.5713/ajas.20.0114. Online ahead of print.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Editorial: Why Livestock Genomics for Developing Countries Offers Opportunities for Success.,Front Genet. 2020 Jun 26;11:626. doi: 10.3389/fgene.2020.00626. eCollection 2020.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Mapping of Major Fusarium Head Blight Resistance from Canadian Wheat cv. AAC Tenacious.,Int J Mol Sci. 2020 Jun 24;21(12):4497. doi: 10.3390/ijms21124497.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Destigmatizing Carbohydrate with Food Labeling: The Use of Non-Mandatory Labelling to Highlight Quality Carbohydrate Foods.,Nutrients. 2020 Jun 9;12(6):1725. doi: 10.3390/nu12061725.,"The existing labelling frameworks discussed here align with established measures of carbohydrate quality, such as 1. dietary fibre nutrient content claims and associated dietary fibre-based health claims; 2. the presence of whole carbohydrate foods and ingredients that are …"
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Local White Matter Fiber Clustering Differentiates Parkinson's Disease Diagnoses.,Neuroscience. 2020 May 21;435:146-160. doi: 10.1016/j.neuroscience.2020.03.049. Epub 2020 Apr 6.,Automatically annotated fibre clustering (AAFC) is a novel clustering method based on diffusion magnetic resonance imaging (dMRI) tractography that enables highly robust reconstruction of white matter tracts that are composed of corresponding clusters. ...We applied AAF …
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Effect of fructose and its epimers on postprandial carbohydrate metabolism: A systematic review and meta-analysis.,Clin Nutr. 2020 Mar 10:S0261-5614(20)30104-7. doi: 10.1016/j.clnu.2020.03.002. Online ahead of print.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Structural genome analysis in cultivated potato taxa.,Theor Appl Genet. 2020 Mar;133(3):951-966. doi: 10.1007/s00122-019-03519-6. Epub 2019 Dec 31.,"Further, the auxin-induced SAUR genes (involved in abiotic stress), disease resistance genes and the 2-oxoglutarate/Fe(II)-dependent oxygenase superfamily proteins, among others, had increased copy numbers in these sequenced genomes relative to the references...."
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Establishment and validation of cell pools using primary muscle cells derived from satellite cells of pig skeletal muscle.,In Vitro Cell Dev Biol Anim. 2020 Mar;56(3):193-199. doi: 10.1007/s11626-019-00428-2. Epub 2019 Dec 23.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Spontaneous Mutations in the Nitrate Reductase Gene napC Drive the Emergence of Eco-friendly Low-N(2)O-Emitting Alfalfa Rhizobia in Regions with Different Climates.,Microb Ecol. 2020 May;79(4):1044-1053. doi: 10.1007/s00248-019-01473-w. Epub 2019 Dec 11.,"., Sinorhizobium meliloti B399), which are closely related to the denitrifier model strain Sinorhizobium meliloti 1021, have conserved nitrate, nitrite, and nitric oxide reductases associated with the production of the greenhouse gas nitrous oxide (N(2)O) from nitrate but …"
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Discerning the effects of phosphate status on the metabolism of hybrid poplar.,Tree Physiol. 2020 Feb 20;40(2):158-169. doi: 10.1093/treephys/tpz114.,"During senescence, the hybrid poplar Tristis had higher sulfate and organic acid resorption, while hybrid willow, AAFC-5, had higher phosphate resorption proficiencies, suggesting differing anion remobilization mechanisms. ..."
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,New Syrphidae (Diptera) of North-eastern North America.,Biodivers Data J. 2019 Sep 3;7:e36673. doi: 10.3897/BDJ.7.e36673. eCollection 2019.,
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Dietary Patterns and Cardiometabolic Outcomes in Diabetes: A Summary of Systematic Reviews and Meta-Analyses.,Nutrients. 2019 Sep 13;11(9):2209. doi: 10.3390/nu11092209.,"The Portfolio dietary pattern improved cardiometabolic risk factors and reduced estimated 10-year coronary heart disease (CHD) risk by 13% (-1.34% (95%CI, -2.19 to -0.49)). ..."
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Identification of Primary Antimicrobial Resistance Drivers in Agricultural Nontyphoidal Salmonella enterica Serovars by Using Machine Learning.,mSystems. 2019 Aug 6;4(4):e00211-19. doi: 10.1128/mSystems.00211-19.,"With our research representing one of the largest studies of a diverse set of NTS isolates from broiler chicken, we can thus confirm that the AmpC-like CMY-2 β-lactamase is a primary driver of β-lactam resistance and that the phosphotransferases APH(6)-Id and APH(3″-Ib) ar …"
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Dueling KRASG12C Inhibitors Achieve Responses.,Cancer Discov. 2020 Jan;10(1):10. doi: 10.1158/2159-8290.CD-ND2019-012. Epub 2019 Dec 10.,"Clinical trials of two KRAS(G12C) inhibitors, MRTX849 and AMG 510, have shown robust efficacy in phase I trials including patients with non-small cell lung cancer. ..."
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Dietary Glycemic Index and Load and the Risk of Type 2 Diabetes: Assessment of Causal Relations.,Nutrients. 2019 Jun 25;11(6):1436. doi: 10.3390/nu11061436.,"While dietary factors are important modifiable risk factors for type 2 diabetes (T2D), the causal role of carbohydrate quality in nutrition remains controversial. ...Here, the results of our recent meta-analyses of prospective cohort studies of 4 to 26-y follow-up are inte …"
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Soil respiration response to alterations in precipitation and nitrogen addition in a desert steppe in northern China.,Sci Total Environ. 2019 Oct 20;688:231-242. doi: 10.1016/j.scitotenv.2019.05.419. Epub 2019 Jun 1.,"There was a significant increase in soil respiration under N addition at 11.5%. Statistical assessment of their interactions demonstrated that N supplementation strengthened the stimulation of soil respiration under increased precipitation, whereas decreased precipitation …"
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Dietary Glycemic Index and Load and the Risk of Type 2 Diabetes: A Systematic Review and Updated Meta-Analyses of Prospective Cohort Studies.,Nutrients. 2019 Jun 5;11(6):1280. doi: 10.3390/nu11061280.,"Published meta-analyses indicate significant but inconsistent incident type-2 diabetes(T2D)-dietary glycemic index (GI) and glycemic load (GL) risk ratios or risk relations (RR). ...Thecombined T2D-GI RR was 1.27 (1.15-1.40) (p < 0.001, n = 10 studies) per 10 units GI, …"
2020-09-23T05:53:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=AAFC&sort=date&size=20,Effects of wild blueberry (Vaccinium angustifolium) pomace feeding on gut microbiota and blood metabolites in free-range pastured broiler chickens.,Poult Sci. 2019 Sep 1;98(9):3739-3755. doi: 10.3382/ps/pez062.,"Slow-growing broiler chickens were reared on pasture up to 64 D for sampling after 2 wk of treatment during brooding with 0, 1, and 2% LBBP in feed. ..."
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Pharmacological depletion of serotonin and norepinephrine with para-chlorophenylalanine and alpha-methyl-p-tyrosine reverses the antidepressant-like effects of adolescent caffeine exposure in the male rat.,Behav Pharmacol. 2020 Sep 3. doi: 10.1097/FBP.0000000000000588. Online ahead of print.,"Caffeine-treated adolescent male rats were exposed to caffeine (0.25 g/L) in their drinking water beginning on P28. A-methyl-p-tyrosine, para-chlorophenylalanine, or saline were administered prior to light-dark, open field, and forced swim testing beginning on P45. ..."
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,"p28 Bacterial Peptide, as an Anticancer Agent.",Front Oncol. 2020 Aug 6;10:1303. doi: 10.3389/fonc.2020.01303. eCollection 2020.,"The peptide, p28, is a post-translational, multi-target anticancer agent that preferentially enters a wide variety of solid tumor cells. ...Here, we review the current basic and clinical evidence suggesting the potential of p28 as a cancer therapeutic peptide...."
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Interleukin-27 Functional Duality Balances Leishmania Infectivity and Pathogenesis.,Front Immunol. 2020 Aug 7;11:1573. doi: 10.3389/fimmu.2020.01573. eCollection 2020.,
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Electrowetting-on-dielectric characteristics of ZnO nanorods.,Sci Rep. 2020 Aug 25;10(1):14194. doi: 10.1038/s41598-020-71017-7.,
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Targeting IL-27 and/or IL-10 in Experimental Murine Visceral Leishmaniasis.,Am J Trop Med Hyg. 2020 Aug 17. doi: 10.4269/ajtmh.20-0531. Online ahead of print.,"In C57BL/6 wild-type mice with established liver infection, a single injection of anti-IL-27 p28 or anti-IL-10R monoclonal antibody enhanced granuloma assembly, enabled macrophage activation, and induced comparable parasite killing (49-56%). However, anti-IL-27 p28 …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Distinct Phases of Postnatal Skeletal Muscle Growth Govern the Progressive Establishment of Muscle Stem Cell Quiescence.,Stem Cell Reports. 2020 Sep 8;15(3):597-611. doi: 10.1016/j.stemcr.2020.07.011. Epub 2020 Aug 6.,"We identified two distinct peaks of myogenic differentiation between P7-P10 and P21-P28, and showed that the quiescent MuSC pool is established between 7 and 8 weeks of age. ..."
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,IL-27 Rα+ cells promoted allorejection via enhancing STAT1/3/5 phosphorylation.,J Cell Mol Med. 2020 Aug 6. doi: 10.1111/jcmm.15700. Online ahead of print.,"IL-27Rα(+) spleen cells accelerated allograft rejection in vivo. rIL-27 significantly promoted proliferation, inhibited apoptosis and increased STAT1/3/5 phosphorylation of alloreactive splenocytes, and these effects of rIL-27 could be almost totally blocked by JAK/ STAT inhibito …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Multiple Ehrlichia chaffeensis Genes Critical for Its Persistent Infection in a Vertebrate Host Are Identified by Random Mutagenesis Coupled with In Vivo Infection Assessment.,Infect Immun. 2020 Sep 18;88(10):e00316-20. doi: 10.1128/IAI.00316-20. Print 2020 Sep 18.,"., two 28-kDa outer membrane proteins (P28/OMP) and a 120-kDa surface protein, were also recognized as necessary for the pathogen's obligate intracellular life cycle. ..."
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,"Calcium repletion to rats with calcipenic rickets fails to recover bone quality: A calcipenic ""memory"".",Bone. 2020 Jul 28;141:115562. doi: 10.1016/j.bone.2020.115562. Online ahead of print.,Female SD rats (postnatal 28 days/P28) were rendered calcipenic by feeding calcium deficient (CaD) diet (0.1% Ca) till P70 while control SD rats were fed Ca sufficient diet (0.8% Ca). ...
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Identifying the key regulators that promote cell-cycle activity in the hearts of early neonatal pigs after myocardial injury.,PLoS One. 2020 Jul 30;15(7):e0232963. doi: 10.1371/journal.pone.0232963. eCollection 2020.,"We identified five pathways (mitogen associated protein kinase [MAPK], Hippo, cyclic [cAMP], Janus kinase/signal transducers and activators of transcription [JAK-STAT], and Ras) which were comprehensively upregulated in cardiac tissues collected on day 7 (P7) and/or P28 of …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Fibroblast growth factor 10 is a negative regulator of postnatal neurogenesis in the mouse hypothalamus.,Development. 2020 Jul 13;147(13):dev180950. doi: 10.1242/dev.180950.,"Quantitative lineage-tracing in vivo revealed that conditional deletion of fibroblast growth factor 10 (Fgf10) from Fgf10-expressing β-tanycytes at postnatal days (P)4-5 results in the generation of significantly more parenchymal cells by P28, composed mostly of ventromedi …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,"Inexpensive NaX (X = I, Br, Cl) as a halogen donor in the practical Ag/Cu-mediated decarboxylative halogenation of aryl carboxylic acids under aerobic conditions.",Org Biomol Chem. 2018 Aug 1;16(30):5416-5421. doi: 10.1039/c8ob01095a.,A gram-scale reaction and a three-step procedure to synthesize iniparib have been performed to evaluate the practicality of this protocol. ...
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and molecular dynamics simulations.,J Biomol Struct Dyn. 2020 Jul 3:1-16. doi: 10.1080/07391102.2020.1787864. Online ahead of print.,"The second azurin derived peptide p28, fared the best among the docked proteins. p28 interacted with all the three viral proteins and the host ACE-2 receptor by forming several electrostatic and hydrogen bonds with the S-protein, 3CL(pro), and PL(pro). MD simulation …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Developmental onset distinguishes three types of spontaneous recognition memory in mice.,Sci Rep. 2020 Jun 30;10(1):10612. doi: 10.1038/s41598-020-67619-w.,"Temporal order recognition was the last to emerge, at P28. Elucidating the developmental expression of recognition memory in mice is critical to improving our understanding of the ontogeny of episodic memory, and establishes a necessary blueprint to apply these tasks to pr …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,"Depletion of microglia in developing cortical circuits reveals its critical role in glutamatergic synapse development, functional connectivity, and critical period plasticity.",J Neurosci Res. 2020 Oct;98(10):1968-1986. doi: 10.1002/jnr.24641. Epub 2020 Jun 28.,"We administered PLX3397, a colony-stimulating factor 1 receptor inhibitor, to mice starting at postnatal day 14 and through P28, which depletes >75% of microglia in the visual cortex (VC). ..."
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,"In silico design of two novel fusion proteins, p28-IL-24 and p28-M4, targeted to breast cancer cells.",Res Pharm Sci. 2020 May 11;15(2):200-208. doi: 10.4103/1735-5362.283820. eCollection 2020 Apr.,"BACKGROUND AND PURPOSE: An anticancer peptide P28, has shown to be cytolethal on various cancer cells including breast cancer. ...In the present study, the impact of different linkers on construction of the two chimeric proteins (p28-IL-24 and p28-M4) was ass …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Bobby sox homolog regulates tooth root formation through modulation of dentin sialophosphoprotein.,J Cell Physiol. 2020 Jun 14. doi: 10.1002/jcp.29875. Online ahead of print.,"Until P28, the crown morphology in Bbx(-/-) mice was not distinctively different from Bbx(+/+) littermates. Meanwhile, the length of the mandibular base in Bbx(-/-) mice was notably less at P28. ...The second molar of Bbx(-/-) mice also showed 10.16% and 6.4% reduct …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Sex differences in dendritic spine density and morphology in auditory and visual cortices in adolescence and adulthood.,Sci Rep. 2020 Jun 10;10(1):9442. doi: 10.1038/s41598-020-65942-w.,"We analyzed dendritic spines in 4-week-old (P28) and 12-week-old (P84) male and female mice and found that DSD is lower in female mice due in part to fewer short stubby, long stubby and short mushroom spines. We found striking layer-specific patterns including a significan …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Serial Passaging of the Human Rotavirus CDC-9 Strain in Cell Culture Leads to Attenuation: Characterization from In Vitro and In Vivo Studies.,J Virol. 2020 Jul 16;94(15):e00889-20. doi: 10.1128/JVI.00889-20. Print 2020 Jul 16.,"Upon adaptation and passages in Vero cells, the strain underwent five amino acid changes at P28 and one additional change at P44/P45 in the VP4 gene. We performed virologic, immunological, and pathogenic characterization of wild-type CDC-9 virus at P11/P12 and its two muta …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,Dynamics of the Transcriptome and Accessible Chromatin Landscapes During Early Goose Ovarian Development.,Front Cell Dev Biol. 2020 Apr 3;8:196. doi: 10.3389/fcell.2020.00196. eCollection 2020.,"Results from hematoxylin-eosin, periodic acid-Schiff, and anti-CVH immunohistochemical stainings demonstrated that programmed oocyte loss, oocyte nest breakdown and primordial follicle formation, and the primordial-to-secondary follicle transition occur during the periods from em …"
2020-09-23T05:53:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=P28&sort=date&size=20,mTOR Suppresses Macroautophagy During Striatal Postnatal Development and Is Hyperactive in Mouse Models of Autism Spectrum Disorders.,Front Cell Neurosci. 2020 Mar 31;14:70. doi: 10.3389/fncel.2020.00070. eCollection 2020.,"We demonstrate that autophagic flux is suppressed during striatal postnatal development, reaching adult levels around postnatal day 28 (P28). ...Finally, we discover that autophagy is downregulated during late striatal postnatal development (P28) in mice with in ute …"
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,"RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.",BMC Cancer. 2020 Sep 15;20(1):886. doi: 10.1186/s12885-020-07388-x.,"METHODS: The RACE trial is a an investigator initiated multicenter, prospective, randomized, stratified phase III clinical trial and seeks to investigate the role of preoperative induction chemotherapy (2 cycles of FLOT: 5-FU, leucovorin, oxaliplatin, docetaxel) with subse …"
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials.,JCO Precis Oncol. 2020 Feb 26;4:PO.19.00237. doi: 10.1200/PO.19.00237. eCollection 2020.,"PATIENTS AND METHODS: Patients with stage III colon cancers were randomly assigned to FOLFOX (leucovorin, fluorouracil, and oxaliplatin) with or without cetuximab in 2 large adjuvant phase III trials (N = 5,577). ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).,Clin Colorectal Cancer. 2020 Jun 12:S1533-0028(20)30088-8. doi: 10.1016/j.clcc.2020.06.003. Online ahead of print.,"BACKGROUND: FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with previously treated metastatic colorectal cancer (mCRC). ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma.,J Gastrointest Cancer. 2020 Sep 12. doi: 10.1007/s12029-020-00516-7. Online ahead of print.,"This study aimed to evaluate the feasibility and efficacy of fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line therapy in patients with relapsed or recurrent GI-NEC after first-line platinum plus etoposide therapy. ..."
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.,Cancer Treat Rev. 2018 Jun;67:34-44. doi: 10.1016/j.ctrv.2018.04.010. Epub 2018 May 2.,
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer.,JCO Precis Oncol. 2019 Aug 23;3:PO.19.00001. doi: 10.1200/PO.19.00001. eCollection 2019.,"We prospectively evaluated fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX)-based treatment and imaging-based biomarkers for borderline resectable PDAC. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).,Invest New Drugs. 2020 Sep 10. doi: 10.1007/s10637-020-01000-6. Online ahead of print.,"Heavily pretreated patients were treated with pegilodecakin (self-administered subcutaneously daily at 2.5, 5, or 10 μg/kg) + 5-flurouracil/leucovorin/oxaliplatin (FOLFOX), dosed per manufacturers prescribing information, until tumor progression. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Case report on 5-fluorouracil induced cerebrovascular accident.,J Oncol Pharm Pract. 2020 Sep 9:1078155220954900. doi: 10.1177/1078155220954900. Online ahead of print.,A 37 years old female patient diagnosed with carcinoma rectum underwent six cycles of chemotherapy with 5- fluorouracil- calcium leucovorin- irinotecan (FOLFIRI regimen). ...
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.,Medicine (Baltimore). 2020 Sep 4;99(36):e22060. doi: 10.1097/MD.0000000000022060.,
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients.,Cancer Gene Ther. 2020 Sep 8. doi: 10.1038/s41417-020-00219-y. Online ahead of print.,"CD-NSCs were given every 2 weeks using an indwelling brain catheter, followed each time by a 7-d course of oral 5-FC (and leucovorin in the final patient cohort). ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder.,Semin Pediatr Neurol. 2020 Oct;35:100835. doi: 10.1016/j.spen.2020.100835. Epub 2020 Jun 25.,"This article reviews one of these treatments, d,l-leucovorin calcium (also known as folinic acid) for treatment of folate pathway abnormalities in children with ASD. ...This article reviews the current evidence for treating core and associated symptoms and underlying patho …"
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,A case of chemotherapy-induced coronary vasospasm in a patient with colorectal cancer.,J Cardiol Cases. 2020 Jun 10;22(3):117-120. doi: 10.1016/j.jccase.2020.05.014. eCollection 2020 Sep.,"Here we present a case of a patient with colorectal cancer without any modifiable cardiovascular risk factors who experienced coronary vasospasm shortly after initiation of therapy with 5-flourouracil, leucovorin, and oxaliplatin with bevacizumab, despite having previously …"
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan.,Ther Adv Med Oncol. 2020 Aug 17;12:1758835920944052. doi: 10.1177/1758835920944052. eCollection 2020.,"This literature review compared the clinical characteristics and outcomes of available real-world evidence (RWE) for liposomal irinotecan in combination with 5-fluorouracil (5-FU) and leucovorin (LV), a treatment regimen indicated for patients with metastatic pancreatic du …"
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.,BMC Cancer. 2020 Sep 1;20(1):832. doi: 10.1186/s12885-020-07347-6.,"Patients received dose-dense TPF (ddTPF) with cisplatin and docetaxel 50 mg/m2 on day 1, leucovorin 250 mg/m2 on day1, followed by 48-h continuous infusion of 2500 mg/m2 of 5-fluorouracil on day 1 and 2, every 2 weeks for 6 cycles followed by radiotherapy. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Prognostic Role of the Platelet-to-Lymphocyte Ratio for Patients With Metastatic Colorectal Cancer Treated With Aflibercept.,In Vivo. 2020 Sep-Oct;34(5):2667-2673. doi: 10.21873/invivo.12086.,"BACKGROUND/AIM: The efficacy of aflibercept plus 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) therapy has been demonstrated in patients with metastatic colorectal cancer (mCRC) in global and Japanese clinical trials. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).,BMC Cancer. 2020 Aug 31;20(1):822. doi: 10.1186/s12885-020-07268-4.,"BACKGROUND: FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens in first line with the highest activity in patients (pts.) with metastatic colorectal cancer (mCRC) unselected for biomolecular al …"
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,5-Fluorouracil Rechallenge After Cardiotoxicity.,Am J Case Rep. 2020 Aug 29;21:e924446. doi: 10.12659/AJCR.924446.,"After comprehensive risk-benefit discussions, the decision was made for palliative chemotherapy using 5-FU/leucovorin. A pre-treatment regimen including isosorbide dinitrate, diltiazem, and metoprolol was used. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.,Gut Liver. 2020 Aug 26. doi: 10.5009/gnl20070. Online ahead of print.,"The current study compared clinical outcomes between gemcitabine and FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) in patients with BRPC. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Systemic treatment of advanced or recurrent biliary tract cancer.,Biosci Trends. 2020 Aug 24. doi: 10.5582/bst.2020.03240. Online ahead of print.,"Chemotherapy, and especially a triplet regimen based on gemcitabine/cisplatin/nab-paclitaxel, has had the most significant effect, and fluorouracil, leucovorin, irinotecan plus oxaliplatin (FOLFIRINOX) combined with bevacizumab is promising. ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,"Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials.",J Clin Med. 2020 Aug 16;9(8):2654. doi: 10.3390/jcm9082654.,"BACKGROUND: The 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) protocol provides superior oncologic results compared to other perioperative chemotherapeutic protocols for the treatment of non-metastatic esophagogastric cancer (EGAC). ..."
2020-09-23T05:54:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEUCOVORIN&sort=date&size=20,Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.,J Clin Oncol. 2020 Aug 20:JCO2001225. doi: 10.1200/JCO.20.01225. Online ahead of print.,"PURPOSE: A proper estimation of the magnitude of the overall survival (OS) benefit from infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab versus doublets + bevacizumab is lacking because all trials that have investigated this reg …"
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,"Letter to Editor Regarding ""Comparing Efficacy, Safety, and Pre-Infusion Period of Axicabtagene Ciloleucel vs Tisagenlecleucel in Relapsed/Refractory Large B-Cell Lymphoma"".",Biol Blood Marrow Transplant. 2020 Sep 17:S1083-8791(20)30597-8. doi: 10.1016/j.bbmt.2020.08.032. Online ahead of print.,
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,"Response to Letter to Editor Regarding ""Comparing Efficacy, Safety, and Pre-Infusion Period of Axicabtagene Ciloleucel vs Tisagenlecleucel in Relapsed/Refractory Large B-Cell Lymphoma"".",Biol Blood Marrow Transplant. 2020 Sep 17:S1083-8791(20)30598-X. doi: 10.1016/j.bbmt.2020.09.009. Online ahead of print.,
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.,Oncoimmunology. 2020 Jun 10;9(1):1777064. doi: 10.1080/2162402X.2020.1777064.,"Recently two CAR T-cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) were approved by the US Food and Drug Administration and by the European Medicines Agency. ..."
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Advances in chimeric antigen receptor T cells.,Curr Opin Hematol. 2020 Sep 10. doi: 10.1097/MOH.0000000000000614. Online ahead of print.,"In the United States, the Food and Drug Administration (FDA) approved Tisagenlecleucel for the treatment of relapsed/refractory B-ALL and Axicabtagene Ciloleucel, for adults with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) in 2017. ..."
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,[Advances in antibody therapy for B cell lymphoma].,Rinsho Ketsueki. 2020;61(8):901-911. doi: 10.11406/rinketsu.61.901.,"In this review, molecular mechanisms of the second/third generation anti-CD20 antibodies (ofatumumab and obinutuzumab), anti-CD19 chimeric antigen-receptor T-cells (CAR-T-CD19; tisagenlecleucel, axicabtagene ciloleucel), and the anti-PD-1 antibodies (nivolumab and p …"
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,[The care process of patient receiving CAR T-cell therapy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].,Bull Cancer. 2020 Sep 2:S0007-4551(20)30315-5. doi: 10.1016/j.bulcan.2020.05.014. Online ahead of print.,"In Europe, two CAR T-cell products, tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), were approved in 2018. ..."
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors.,Expert Opin Biol Ther. 2020 Sep 21:1-16. doi: 10.1080/14712598.2020.1819978. Online ahead of print.,Cancer immunotherapy witnessed a major breakthrough with the US FDA approval of the first chimeric antigen receptor (CAR) T-cell therapy Kymriah(TM) (tisagenlecleucel) for relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) in August 2017 followed by approval of Yesca …
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.,Blood Adv. 2020 Aug 25;4(16):3943-3951. doi: 10.1182/bloodadvances.2020002228.,We conducted a cohort analysis of 100 consecutive patients with relapsed or refractory large B-cell lymphoma (LBCL) treated with standard of care axicabtagene ciloleucel (axi-cel). ...
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials.,Curr Res Transl Med. 2020 Aug 15:S2452-3186(20)30038-6. doi: 10.1016/j.retram.2020.05.005. Online ahead of print.,"Two CAR T products, namely axicabtagene ciloleucel and tisagenlecleucel, are commercially available and represent genetically engineered T cells expressing chimeric receptors for CD19. ..."
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Neurological adverse events following CAR T-cell therapy: a real-world analysis.,Immunotherapy. 2020 Aug 18. doi: 10.2217/imt-2020-0161. Online ahead of print.,Materials & methods: Postmarketing case reports from the US FDA AEs reporting system involving axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for large B-cell lymphomas were analyzed. ...
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Real-world adverse events associated with CAR T-cell therapy among adults age ≥ 65 years.,J Geriatr Oncol. 2020 Aug 11:S1879-4068(20)30145-4. doi: 10.1016/j.jgo.2020.07.006. Online ahead of print.,INTRODUCTION: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for relapsed or refractory large B-cell lymphoma (LBCL) with the Food and Drug Administration (FDA) approvals of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel …
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.,Bone Marrow Transplant. 2020 Aug 11. doi: 10.1038/s41409-020-01029-4. Online ahead of print.,
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.,Blood Adv. 2020 Aug 11;4(15):3776-3787. doi: 10.1182/bloodadvances.2020002509.,"We included patients who received axicabtagene ciloleucel (n = 30) or tisagenlecleucel (n = 10) for B-cell lymphoma, CD19-28z CAR T therapy for B-cell acute lymphoblastic leukemia (NCT01044069; n = 37), or B-cell maturation antigen targeting CAR T cells for multiple …"
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.,JAMA Neurol. 2020 Aug 10:e202703. doi: 10.1001/jamaneurol.2020.2703. Online ahead of print.,A consecutive sample of all patients undergoing CAR T-cell therapy with axicabtagene ciloleucel for relapsed or refractory lymphoma were assessed for inclusion (n = 213). ...
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.,Pharmacol Res. 2018 Jun;132:47-68. doi: 10.1016/j.phrs.2018.03.021. Epub 2018 Mar 28.,
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Emerging trends in gene-modified-based chimeric antigen receptor-engineered T-cellular therapy for malignant tumors: The lesson from leukemia to pediatric brain tumors.,J Chin Med Assoc. 2020 Aug;83(8):719-724. doi: 10.1097/JCMA.0000000000000358.,"In 2017 and 2018, Food and Drug Administration has approved YESCARTA (axicabtagene ciloleucel) and KYMRIAH (tisagenlecleucel), two chimeric antigen receptor (CAR)-engineered T-cell products, for B-cell malignancies. ..."
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.,J Allergy Clin Immunol. 2020 Aug 6:S0091-6749(20)31099-X. doi: 10.1016/j.jaci.2020.07.025. Online ahead of print.,
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes.,Neuro Oncol. 2020 Aug 5:noaa183. doi: 10.1093/neuonc/noaa183. Online ahead of print.,"METHODS: Patients (n=45) with R/R LBCL treated with axicabtagene ciloleucel (axi-cel) were identified. Data regarding treatment course, clinical outcomes, and correlative studies were collected. ..."
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.,Am J Hematol. 2020 Aug 3. doi: 10.1002/ajh.25951. Online ahead of print.,Two autologous anti-CD19 chimeric antigen receptors (CAR) T cells (axicabtagene ciloleucel [axi-cel] and tisagenlecleucel [tisa-cel]) are commercially approved in Europe for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). ...
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,CD19-directed CAR T-cell therapy in B-cell NHL.,Curr Opin Oncol. 2020 Sep;32(5):408-417. doi: 10.1097/CCO.0000000000000668.,This has led to Food and Drug Administration and European Medicines Agency approval for axicabtagene ciloleucel and tisagenlecleucel and filing of the biologics license application for lisocabtagene maraleucel. ...
2020-09-23T05:54:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=AXICABTAGENECILOLEUCEL&sort=date&size=20,Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma.,Haematologica. 2020 Jul 30:haematol.2020.254045. doi: 10.3324/haematol.2020.254045. Online ahead of print.,"To characterize these late events, we analyzed 31 patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene ciloleucel at our institution on 2 clinical trials, ZUMA-1 (NCT02348216) and ZUMA-9 (NCT03153462). ...These results suggest the nee …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials.,BMC Bioinformatics. 2020 Jul 25;21(1):333. doi: 10.1186/s12859-020-03655-7.,"RESULTS: Focusing on two ""use cases"" of two-arm clinical trials, one for metastatic colorectal cancer (CRC) patients treated with the anti-angiogenic molecule aflibercept, and the other for triple negative breast cancer (TNBC) patients treated with the small molecule iniparib …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium.,Expert Opin Pharmacother. 2020 Apr;21(6):679-686. doi: 10.1080/14656566.2020.1724283. Epub 2020 Feb 19.,
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy.,BMC Vet Res. 2020 Jan 31;16(1):30. doi: 10.1186/s12917-020-2247-4.,Early investigations show tolerability of iniparib in dogs. PARP inhibitors also imply higher therapy costs and consequently are less likely to be accepted by pet owners.We summarized the current evidence of canine BRCA2 gene alterations and their association with mammary …
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.,J Immunother Cancer. 2019 Oct 23;7(1):274. doi: 10.1186/s40425-019-0740-8.,"She developed mTNBC in 2009 and was sequentially treated with capecitabine, gemcitabine-carboplatin-iniparib (GCI), XRT and an experimental vaccine. ..."
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.,Breast Cancer Res Treat. 2019 Sep;177(2):383-393. doi: 10.1007/s10549-019-05305-w. Epub 2019 Jun 6.,"Pharmacokinetics of iniparib and its two metabolites were analyzed. RESULTS: A total of 163 patients were randomized, 82 GC+w-iniparib and 81 GC+tw-iniparib. ...Iniparib plasma concentrations and exposure were two-fold higher with w-iniparib com …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer.,Cancer Med. 2019 Jan;8(1):383-399. doi: 10.1002/cam4.1892. Epub 2018 Dec 7.,"Other targeted agents like iniparib, sorafenib, cetuximab, and ipatasertib combined with CT showed significant superiority in PFS compared with CT alone, and the HRs were 0.75 (0.62-0.90), 0.44 (0.21-0.91), 0.67 (0.47-0.96), and 0.44 (0.24-0.81), respectively, while some o …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Iniparib for newly diagnosed glioblastoma.,Lancet Oncol. 2018 Oct;19(10):e514. doi: 10.1016/S1470-2045(18)30665-X. Epub 2018 Aug 31.,
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.,Clin Cancer Res. 2019 Jan 1;25(1):73-79. doi: 10.1158/1078-0432.CCR-18-0110. Epub 2018 Aug 21.,PURPOSE: Iniparib is a purported prodrug causing cell death through intracellular conversion to nitro radical ions. We assessed the efficacy and safety of iniparib with standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma (GBM). ...A …
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.,Radiat Res. 2018 Nov;190(5):464-472. doi: 10.1667/RR15035.1. Epub 2018 Aug 1.,"For clonogenic assays, STS cell lines were irradiated with or without olaparib, iniparib or veliparib pretreatment. The effect of PARP inhibition on γ-H2AX and Rad51 foci formation, on PARP-1, phospho-ERK and cleaved caspase-3 protein expression and on cell cycle progressi …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.,J Exp Clin Cancer Res. 2009 Feb 14;28(1):18. doi: 10.1186/1756-9966-28-18.,
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.,Medicine (Baltimore). 2017 Nov;96(45):e8389. doi: 10.1097/MD.0000000000008389.,"In the regression analysis, Bevacizumab (odds ratio [OR], 1.71; 95% confidence interval [CI], 1.43-2.05; P Iniparib (OR, 1.51; 95% CI, 1.11-2.07; P = .009) corre …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells.,PLoS One. 2017 Aug 17;12(8):e0183578. doi: 10.1371/journal.pone.0183578. eCollection 2017.,"Myc/MDA-468 cells were resistant to standard chemotherapeutic treatments such as iniparib (PARP inhibitor) plus cisplatin, / iniparib, cisplatin, paclitaxel and docetaxel. However, Myc/MDA-231 cells, which showed EMT changes responded to iniparib with cisplat …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro.,Mol Med Rep. 2017 Jul;16(1):208-214. doi: 10.3892/mmr.2017.6568. Epub 2017 May 10.,
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.,Clin Cancer Res. 2017 Jul 1;23(13):3365-3370. doi: 10.1158/1078-0432.CCR-16-2174. Epub 2017 Jan 13.,"We evaluated this mechanism of resistance in newly diagnosed patients with BRCA1/2-mutant breast cancer with poor response to neoadjuvant platinum-based therapy.Experimental Design: PrECOG 0105 was a phase II neoadjuvant study of gemcitabine, carboplatin, and iniparib in p …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.,Radiology. 2017 Feb;282(2):453-463. doi: 10.1148/radiol.2016161929. Epub 2016 Nov 14.,"The area under the receiver operating characteristic curve (AUC, in g/mL· min) for (18)F-FTT was assessed in normal mouse organs before and after treatment with olaparib (n = 14), a PARP inhibitor, or iniparib (n = 11), which has no PARP inhibitory activity. ...Results In …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.,Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8.,"RESULTS: In a trial of neoadjuvant platinum, gemcitabine, and iniparib, HR deficiency predicted residual cancer burden score of 0 or I (RCB 0/I) and pathologic complete response (pCR; OR = 4.96, P = 0.0036; OR = 6.52, P = 0.0058). ...When restricted to BRCA1/2 nonmutated t …"
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model.,PLoS One. 2016 Feb 11;11(2):e0149194. doi: 10.1371/journal.pone.0149194. eCollection 2016.,Dogs were treated with iniparib alone and in combination with carboplatin chemotherapy. Iniparib doses ranged between 10-70 mg/kg intravenously (IV). ...The maximum tolerated dose (MTD) of iniparib was not identified. Moderate to high variability in plasma ex …
2020-09-23T05:54:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=INIPARIB(BSI-201)&sort=date&size=20,Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.,J Breast Cancer. 2015 Dec;18(4):329-38. doi: 10.4048/jbc.2015.18.4.329. Epub 2015 Dec 23.,"METHODS: We have evaluated the in vitro synergistic effect of combinations of trabectedin and three different PARP inhibitors (veliparib, olaparib, and iniparib) in four breast cancer cell lines, each presenting a different BRCA1 genetic background. ...Synergistic effects …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Tumor Microenvironment Targeting Nano-Bio Emulsion for Synergistic Combinational X-Ray PDT with Oncolytic Bacteria Therapy.,Adv Healthc Mater. 2020 Jul;9(13):e1901812. doi: 10.1002/adhm.201901812. Epub 2020 Jun 11.,"Herein, a nano-bio therapeutic emulsion formulated with multifunctional nanoscintillators and anaerobic Clostridium novyi-NT spores for synergistic image-guided combinational cancer therapy is reported. ...An anaerobic oncolytic bacterium (C. novyi- …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Iron-Oxide Nanocluster Labeling of Clostridium novyi-NT Spores for MR Imaging-Monitored Locoregional Delivery to Liver Tumors in Rat and Rabbit Models.,J Vasc Interv Radiol. 2019 Jul;30(7):1106-1115.e1. doi: 10.1016/j.jvir.2018.11.002. Epub 2019 Apr 2.,PURPOSE: To label Clostridium novyi-NT spores (C. novyi-NT) with iron oxide nanoclusters and track distribution of bacteria during magnetic resonance (MR) imaging-monitored locoregional delivery to liver tumors using intratumoral injection or in …
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Immune response to C. novyi-NT immunotherapy.,Vet Res. 2018 Apr 24;49(1):38. doi: 10.1186/s13567-018-0531-0.,Clostridium novyi-NT (CVN-NT) spores germinate in hypoxic regions of tumors and have successfully cured induced neoplasia in mouse models and resulted in objective tumor responses in naturally developing neoplasia in the dog. ...Intratumoral injection …
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy.,BMC Vet Res. 2018 Apr 2;14(1):119. doi: 10.1186/s12917-018-1424-1.,"BACKGROUND: Clostridium novyi-NT (CNV-NT), has shown promise as a bacterolytic therapy for solid tumors in mouse models and in dogs with naturally developing neoplasia. ...RESULTS: Dogs that developed an inflammatory response to CNV-NT had a hig …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Learning from Clostridium novyi-NT: How to defeat cancer.,J Cancer Res Ther. 2018;14(Supplement):S1-S6. doi: 10.4103/0973-1482.204841.,"Here, we take ""Clostridium novyi"" for the search keyword in the PubMed from 2000 to 2015 and describe that C. novyi-NT spores act as ""Trojan horse"" for bacteriolytic therapy. ...Therefore, C. novyi-NT spores should be an effective and saf …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Branched Gold Nanoparticle Coating of Clostridium novyi-NT Spores for CT-Guided Intratumoral Injection.,Small. 2017 Feb;13(5):10.1002/smll.201602722. doi: 10.1002/smll.201602722. Epub 2016 Nov 15.,Branched gold nanoparticle (BGNP)-coated Clostridium novyi-NT (C. novyi-NT) spores are developed for computed tomography (CT)-guided bacteriolytic tumor therapy. ...
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL).,Leuk Lymphoma. 2020 Feb;61(2):445-449. doi: 10.1080/10428194.2019.1660967. Epub 2019 Sep 30.,
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Clostridium novyi-NT in cancer therapy.,Genes Dis. 2016 Feb 6;3(2):144-152. doi: 10.1016/j.gendis.2016.01.003. eCollection 2016 Jun.,The attenuated anaerobic bacterium Clostridium novyi-NT (C. novyi-NT) is known for its ability to precisely germinate in and eradicate treatment-resistant hypoxic tumors in various experimental animal models and spontaneously occurring canine sa …
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Clostridium to treat cancer: dream or reality?,Ann Transl Med. 2015 May;3(Suppl 1):S21. doi: 10.3978/j.issn.2305-5839.2015.03.39.,"In their paper ""Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses"", Roberts et al. describe the induction of antitumor responses following local spore administration of an attenuated C. novyi strain (C. novyi-N …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats.,Oncotarget. 2015 Mar 20;6(8):5536-46. doi: 10.18632/oncotarget.3627.,"The spore-forming anaerobic bacterium Clostridium novyi-NT(C. novyi-NT) has the ability to propagate in tumor-generated hypoxia, leading to oncolysis. Here, we show that intravenously injected spores of C. novyi-NT led to dramatic …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,MRI-monitored intra-tumoral injection of iron-oxide labeled Clostridium novyi-NT anaerobes in pancreatic carcinoma mouse model.,PLoS One. 2014 Dec 30;9(12):e116204. doi: 10.1371/journal.pone.0116204. eCollection 2014.,OBJECTIVES: To validate the feasibility of labeling Clostridium novyi-NT (C.novyi-NT) anaerobes with iron-oxide nanoparticles for magnetic resonance imaging (MRI) and demonstrate the potential to use MRI to visualize intra-tumoral delivery of th …
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses.,Sci Transl Med. 2014 Aug 13;6(249):249ra111. doi: 10.1126/scitranslmed.3008982.,"Species of Clostridium bacteria are notable for their ability to lyse tumor cells growing in hypoxic environments. We show that an attenuated strain of Clostridium novyi (C. novyi-NT) induces a microscopically precise, tumor-localized response i …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Noninvasive imaging of infection after treatment with tumor-homing bacteria using Chemical Exchange Saturation Transfer (CEST) MRI.,Magn Reson Med. 2013 Dec;70(6):1690-8. doi: 10.1002/mrm.24955. Epub 2013 Oct 7.,"METHODS: The CEST parameters of the anaerobic gram-positive bacterium Clostridium novyi-NT (C. novyi-NT) were first characterized in vitro, then used to detect C. novyi-NT germination and infection in subcutaneous CT26 colorectal t …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors.,Am J Vet Res. 2012 Jan;73(1):112-8. doi: 10.2460/ajvr.73.1.112.,OBJECTIVE: To establish the maximum tolerated dose of Clostridium novyi-NT spores in tumor-bearing dogs and evaluate spore germination within tumors and tumor response. ...Clostridium novyi-NT was cultured from 1 of 6 tumors. Five dogs we …
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Structural characterization of the polar lipids of Clostridium novyi NT. Further evidence for a novel anaerobic biosynthetic pathway to plasmalogens.,Biochim Biophys Acta. 2011 Mar;1811(3):186-93. doi: 10.1016/j.bbalip.2010.12.010. Epub 2010 Dec 30.,"A study of the polar lipids of Clostridium novyi NT has revealed the presence of phosphatidylethanolamine (PE) and cardiolipin as major phospholipids with smaller amounts of phosphatidylglycerol (PG), lysyl-PG and alanyl-PG. ...These findings are consistent w …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Bacteriolytic therapy of experimental pancreatic carcinoma.,World J Gastroenterol. 2010 Jul 28;16(28):3546-52. doi: 10.3748/wjg.v16.i28.3546.,"AIM: To investigate the effectiveness of Clostridium novyi (C. novyi)-NT spores for the treatment of established subcutaneous pancreatic tumor in the syngeneic, immunocompetent Panc02/C57Bl/6 model. METHODS: C. novyi-NT spores were applie …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Combination of a fluorescent dye and a Zn-S cluster and its biological application as a stain for bacteria.,Inorg Chem. 2010 Feb 15;49(4):1319-21. doi: 10.1021/ic9023629.,"An ionic-pair charge-transfer salt [C(15)H(16)N(3)](+)[Zn(8)S(SC(6)H(5))(15).H(2)O](-) (1) featuring a fluorescent dye and a wurtzite-like octanuclear Zn-S cluster shows high stability when staining bacteria Escherichia coli, Salmonella typhimurium, and Clostridium novy …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,"Targeting cancer with bugs and liposomes: ready, aim, fire.",Cancer Res. 2007 Oct 15;67(20):9605-8. doi: 10.1158/0008-5472.CAN-07-1565.,This article will highlight the recent advance in using a novel lipase secreted by the tumor-colonizing anaerobic bacterium Clostridium novyi-NT to induce the targeted release of liposomal payloads within tumors....
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,Spore coat architecture of Clostridium novyi NT spores.,J Bacteriol. 2007 Sep;189(17):6457-68. doi: 10.1128/JB.00757-07. Epub 2007 Jun 22.,"Spores of the anaerobic bacterium Clostridium novyi NT are able to germinate in and destroy hypoxic regions of tumors in experimental animals. ...In addition to their implications for understanding the biology of C. novyi NT, these studies docum …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,A bacterial protein enhances the release and efficacy of liposomal cancer drugs.,Science. 2006 Nov 24;314(5803):1308-11. doi: 10.1126/science.1130651.,"Clostridium novyi-NT is an anaerobic bacterium that can infect hypoxic regions within experimental tumors. Because C. novyi-NT lyses red blood cells, we hypothesized that its membrane-disrupting properties could be exploited to enhance the relea …"
2020-09-23T05:54:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=CLOSTRIDIUMNOVYI-NT&sort=date&size=20,The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT.,Nat Biotechnol. 2006 Dec;24(12):1573-80. doi: 10.1038/nbt1256. Epub 2006 Nov 19.,"Clostridium novyi-NT spores represent one of the most promising of these agents, as they generate potent anti-tumor effects in experimental animals. We have determined the 2.55-Mb genomic sequence of C. novyi-NT, identifying a new type of transp …"
2020-09-23T05:54:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=KTN3379&sort=date&size=20,HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.,Sci Rep. 2019 Jun 24;9(1):9130. doi: 10.1038/s41598-019-45589-y.,"Combination treatment with KTN3379, a monoclonal antibody targeted against HER3, and BYL719 led to enhanced suppression of in vitro and in vivo cancer growth and durable suppression of AKT and S6. Therefore, inhibition of HER3 with KTN3379 enhanced the effects of PI …"
2020-09-23T05:54:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=KTN3379&sort=date&size=20,ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.,PLoS One. 2017 Jul 19;12(7):e0181356. doi: 10.1371/journal.pone.0181356. eCollection 2017.,"Surprisingly, we found that while NRG1 is required for ErbB3 activation, it was not sufficient to fully predict for KTN3379 activity. ...Furthermore, NRG1-positive HNSCC cell lines that secreted high levels of AREG and TGFα or contained high levels of EGFR homodimers (H11D …"
2020-09-23T05:54:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=KTN3379&sort=date&size=20,Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.,Clin Cancer Res. 2017 Jun 15;23(12):3072-3083. doi: 10.1158/1078-0432.CCR-16-2203. Epub 2016 Dec 16.,"The dependency of HPV(+) and HPV(-) HNSCC models on HER3 was evaluated with anti-HER3 siRNAs and the clinical stage anti-HER3 monoclonal antibody KTN3379.Results: HER3 was overexpressed in HPV(+) HNSCC, where it was associated with worse overall survival in patients with p …"
2020-09-23T05:54:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=KTN3379&sort=date&size=20,Effect of treatment of rectal cancer metastasis with intravitreal bevacizumab (Avastin) in patient with subretinal fluid and macular oedema: short-term follow-up.,BMJ Case Rep. 2016 Sep 2;2016:bcr2016216273. doi: 10.1136/bcr-2016-216273.,A patient with grade VI KRAS mutation rectal cancer with metastasis to the lung and cerebellum presented with left eye choroidal metastasis 1 week after being started on the experimental medication KTN3379. ...
2020-09-23T05:54:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=KTN3379&sort=date&size=20,A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.,Mol Cancer Ther. 2016 Apr;15(4):689-701. doi: 10.1158/1535-7163.MCT-15-0555. Epub 2016 Feb 15.,We developed a fully human mAb against HER3 (KTN3379) that efficiently suppressed HER3 activity in both ligand-dependent and independent settings. ...KTN3379 is currently undergoing a phase Ib clinical trial in patients with advanced solid tumors. Our current study …
2020-09-23T05:54:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=KTN3379&sort=date&size=20,Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration.,Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13225-30. doi: 10.1073/pnas.1518361112. Epub 2015 Oct 12.,"Here we describe the crystal structure of the Fab fragment of an antagonistic monoclonal antibody KTN3379, currently in clinical development in human cancer patients, in complex with the ErbB3 extracellular domain. ..."
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.,Exp Hematol Oncol. 2017 Nov 28;6:31. doi: 10.1186/s40164-017-0091-4. eCollection 2017.,"MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic breast cancer. ...Ertumaxomab enhanced the interaction of immune effector cells and tumor c …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors.,BMC Cancer. 2016 Jul 7;16:420. doi: 10.1186/s12885-016-2449-0.,"BACKGROUND: Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells. ..."
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Targeting the HER2 receptor in metastatic breast cancer.,Hematol Oncol Stem Cell Ther. 2012;5(3):127-37. doi: 10.5144/1658-3876.2012.127.,"Several other targeted agents, including T-DM1, pertuzumab, neratinib, afatinib and ertumaxomab, are currently being tested in vivo as well as in clinical studies. ..."
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling.,MAbs. 2012 Sep-Oct;4(5):614-22. doi: 10.4161/mabs.21003. Epub 2012 Jul 23.,"Whether molecular effects, however, might contribute to the cellular antitumor efficiency of ertumaxomab are largely unknown. ...RESULTS: The Kd of ertumaxomab for Her2-binding was determined at 265 nM and the ertumaxomab binding epitope was found to not over …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.,Clin Transl Oncol. 2011 Dec;13(12):889-98. doi: 10.1007/s12094-011-0751-5.,"BACKGROUND Trifunctional antibodies, such as catumaxomab (anti-EpCAM×anti-CD3) and ertumaxomab (anti- HER-2/neu×anti-CD3), transiently link immune effector cells to tumour cells, which results in cellular cytotoxicity towards the tumour cells. ...The potency of catumaxomab …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Targeted therapy in breast cancer: what's new?,Swiss Med Wkly. 2011 Jun 27;141:w13231. doi: 10.4414/smw.2011.13231. eCollection 2011.,"In this review we discuss the major newly developed targeted agents in breast cancer treatment, including the novel anti-HER-2 monoclonal antibody pertuzumab or ertumaxomab, small molecular tyrosine inhibitor lapatinib, selective PARP1 inhibitor olaparib, mTOR inhibitor ra …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Structural and functional characterization of the trifunctional antibody catumaxomab.,MAbs. 2010 May-Jun;2(3):309-19. doi: 10.4161/mabs.2.3.11791. Epub 2010 May 16.,"., EpCAM (catumaxomab), HER2/neu (ertumaxomab), CD20 (FBTA05), gangliosides GD2/GD3 (Ektomun), on appropriate tumor target cells associated with carcinomas, lymphomas or melanomas. ..."
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Evolving novel anti-HER2 strategies.,Lancet Oncol. 2009 Dec;10(12):1179-87. doi: 10.1016/S1470-2045(09)70315-8.,
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.,Cancer Res. 2009 May 15;69(10):4270-6. doi: 10.1158/0008-5472.CAN-08-2861. Epub 2009 May 12.,"The trifunctional antibody ertumaxomab targets HER2/neu, CD3, and activating Fcgamma receptors. In presence of ertumaxomab, tri-cell complexes consisting of tumor cells, T cells, and accessory cells form to cause tumor cell lysis. ...Ertumaxomab-mediated acti …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.,Oncologist. 2009 Apr;14(4):320-68. doi: 10.1634/theoncologist.2008-0230. Epub 2009 Apr 3.,"A series of novel HER-2-targeting agents is also presented, including pertuzumab, ertumaxomab, HER-2 vaccines, and recently discovered tyrosine kinase inhibitors. ..."
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Ertumaxomab: a trifunctional antibody for breast cancer treatment.,Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8. doi: 10.1517/13543784.17.10.1553.,"Ertumaxomab is an intact bispecific antibody targeting HER2/neu and CD3 with preferential binding to activating Fcgamma type I/III-receptors, resulting in the formation of a tri-cell complex among tumour cell, T cell and accessory cell. ...Owing to efficient tumour cell de …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,ErbB-directed immunotherapy: antibodies in current practice and promising new agents.,Immunol Lett. 2008 Mar 15;116(2):126-40. doi: 10.1016/j.imlet.2007.12.001. Epub 2007 Dec 26.,"In this review, we discuss the biological and clinical background of ErbB targeting, and describe the most successful antibodies against ErbB1 (cetuximab, panitumumab, matuzumab, nimotuzumab, ICR62, mAb 528, ch806 and MDX-447) and ErbB2 (trastuzumab, pertuzumab, MDX-H210, 2B1, C6 …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):719-40.,"This issue focuses on the following selection of drugs: 5-Methyltetrahydrofolate, 9-aminocamptothecin; AdPEDF.11, AE-37, albumin interferon alfa, alicaforsen sodium, alvocidib hydrochloride, AMG-706, arginine butyrate, avanafil, axitinib, azimilide hydrochloride; BAY-579352, bela …"
2020-09-23T05:54:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERTUMAXOMAB&sort=date&size=20,Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.,Clin Cancer Res. 2006 May 15;12(10):3085-91. doi: 10.1158/1078-0432.CCR-05-2436.,"EXPERIMENTAL DESIGN: Three ascending doses of ertumaxomab (10-200 microg) were administered i.v. on day 1, 7 +/- 1, and 13 +/- 1. ...DISCUSSION: Treatment with triple infusions of ertumaxomab yields a strong immunologic response. Doses up to 100 microg can be safely …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction.,Pharmacol Res. 2015 Sep;99:202-16. doi: 10.1016/j.phrs.2015.06.007. Epub 2015 Jun 25.,
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer.,PLoS One. 2014 Dec 26;9(12):e115228. doi: 10.1371/journal.pone.0115228. eCollection 2014.,"Therefore, we investigated the molecular mechanism of action of IPI-504 (retaspimycin HCl), a potent and selective inhibitor of HSP90, in combination with the microtubule targeting agent (MTA) docetaxel, in preclinical models of NSCLC. ...Our data provide a p …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,Discontinued in 2013: oncology drugs.,Expert Opin Investig Drugs. 2015 Jan;24(1):95-110. doi: 10.1517/13543784.2015.971154. Epub 2014 Oct 14.,
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models.,J Neurooncol. 2014 Dec;120(3):473-81. doi: 10.1007/s11060-014-1579-y. Epub 2014 Aug 13.,"Retaspimycin hydrochloride (IPI-504), an Hsp90 (heat shock protein 90) inhibitor, has shown activity in multiple preclinical cancer models, such as lung, breast and ovarian cancers. ...The effects of IPI-504 on cell proliferation, apoptosis, mot …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.,Clin Cancer Res. 2013 Nov 1;19(21):6020-9. doi: 10.1158/1078-0432.CCR-13-0953. Epub 2013 Sep 17.,"This phase I study investigated the safety and maximum tolerated dose (MTD) of retaspimycin hydrochloride (IPI-504), a novel potent and selective HSP90 inhibitor, in patients with metastatic and/or unresectable GIST or other soft-tissue sarcomas (STS). ...Exp …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,Hsp90 inhibitors in breast cancer: a systematic review.,Breast. 2013 Oct;22(5):569-78. doi: 10.1016/j.breast.2013.06.003. Epub 2013 Jul 17.,
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.,Breast Cancer Res Treat. 2013 May;139(1):107-13. doi: 10.1007/s10549-013-2510-5. Epub 2013 Apr 12.,"Retaspimycin HCl at 300 mg/m² weekly in combination with trastuzumab was well tolerated and without significant toxicities. Modest clinical activity was observed, but did not meet criteria for trial expansion. The safety profile for patients on study raises the possibility …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,Geldanamycin and its derivatives as Hsp90 inhibitors.,Front Biosci (Landmark Ed). 2012 Jun 1;17:2269-77. doi: 10.2741/4050.,"Therefore, its analogues, including 17AAG, 17DMAG, Tanespimycin and Retaspimycin hydrochloride, with improved pharmacokinetic profiles, have been developed...."
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.,Leuk Lymphoma. 2011 Dec;52(12):2308-15. doi: 10.3109/10428194.2011.600481. Epub 2011 Aug 18.,"Abstract A phase 1 study of IPI-504 (retaspimycin hydrochloride) administered intravenously twice weekly for 2 weeks at 22.5, 45, 90, 150, 225, 300 or 400 mg/m(2) followed by 10 days off-treatment was conducted to determine the safety and maximum tolerated do …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,"The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.",Mol Cancer Ther. 2011 Oct;10(10):1897-908. doi: 10.1158/1535-7163.MCT-11-0148. Epub 2011 Aug 8.,The observation that heat shock protein 90 (HSP90) inhibition results in KIT degradation prompted us to assess the efficacy of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) alone or in combination with imatinib or sunitinib in two GIST xenografts w …
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,"Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.",Urology. 2011 Sep;78(3):626-30. doi: 10.1016/j.urology.2011.04.041. Epub 2011 Jul 18.,OBJECTIVE: To evaluate clinical activity and safety of retaspimycin hydrochloride (IPI-504) in patients with castration-resistant prostate cancer (CRPC). ...IPI-504 is being investigated at less-intensive doses and schedules in other tumor types …
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy.,Curr Top Med Chem. 2009;9(15):1386-418. doi: 10.2174/156802609789895719.,"Infinity Pharmaceuticals is developing IPI-504 or retaspimycin hydrochloride as an intravenous product, which is in several Phase 2 clinical trials; IPI-504 is the hydroquinone hydrochloride salt of 17-AAG. More recently, Infinity Pharmaceutical …"
2020-09-23T05:54:29Z,https://pubmed.ncbi.nlm.nih.gov/?term=RETASPIMYCIN(IPI-504)&sort=date&size=20,Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.,Expert Opin Investig Drugs. 2009 Sep;18(9):1375-83. doi: 10.1517/13543780903158934.,"In contrast, retaspimycin, or IPI-504, a derivative of geldanamycin and 17-AAG, is highly soluble in water and generally well tolerated. ...This article reviews IPI-504 and its utility in a wide variety of cancer phenotypes...."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Current treatment options for HCC: from pharmacokinetics to efficacy and adverse events in liver cirrhosis.,Curr Drug Metab. 2020 Sep 18. doi: 10.2174/1389200221999200918141239. Online ahead of print.,"Currently, however, other first or second line therapeutic options have also shown efficacy against HCC, such as multikinase inhibitors (Regorafenib, Lenvatinib, and Cabozantinib), a monoclonal antibody against the vascular endothelial growth factor receptor 2 (Ramucirumab …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report.,Medicine (Baltimore). 2020 Sep 18;99(38):e22312. doi: 10.1097/MD.0000000000022312.,"INTERVENTIONS: After failed transarterial chemoembolization therapy, he was initially treated with immunotherapy pembrolizumab plus angiogenesis inhibitor lenvatinib, and after 3 months of treatment, the condition improved. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT.,Oncol Rep. 2020 Aug 7. doi: 10.3892/or.2020.7720. Online ahead of print.,"The increase observed in tumor volume was 26.9‑ and 12.2‑fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. Furthermore, the increase in FDG uptake was 1.8 and 1.6‑fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. . …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis.,Hepatol Res. 2020 Sep 13. doi: 10.1111/hepr.13567. Online ahead of print.,"RESULTS: A total of 291 and 54 patients received sorafenib and lenvatinib as first-line TKI therapy, respectively. The median OS of patients treated with TKI were significantly stratified by ALBI grade (grade 1, 20.1 months; grade 2a, 16.3 months; grades 2b and 3, 9.8 mont …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma.,Pharmacol Res. 2020 Sep 8;160:105195. doi: 10.1016/j.phrs.2020.105195. Online ahead of print.,
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Safety and quality of life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer.,Thyroid. 2020 Sep 10. doi: 10.1089/thy.2020.0276. Online ahead of print.,"BACKGROUND: Lenvatinib, a multikinase inhibitor, is for progressive radioiodine-refractory-differentiated thyroid cancer (RR-DTC) patients. ...The aims of this study were a) to evaluate, and compared to other series, the safety of lenvatinib used in RR-DTC patients …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Primary undifferentiated carcinoma with osteoclast-like giant cells in liver and rapidly developing multiple metastases after curative hepatectomy: a case report.,Int Cancer Conf J. 2020 Aug 18;9(4):244-248. doi: 10.1007/s13691-020-00436-0. eCollection 2020 Oct.,"Thereafter, the patient was prescribed the molecularly targeted drug, lenvatinib (12 mg/day). However, lenvatinib was not effective, as evident by the extension of several metastases. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Optimizing Survival by Changing the Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.,J Natl Cancer Inst. 2020 Sep 8:djaa119. doi: 10.1093/jnci/djaa119. Online ahead of print.,"In the first-line, atezolizumab plus bevacizumab statistically significantly improved overall survival (OS) and patient-reported outcomes (PROs) compared with sorafenib, while lenvatinib demonstrated non-inferior OS. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Branched-chain amino acid to tyrosine ratio is an essential pre-treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma.,J Hepatobiliary Pancreat Sci. 2020 Sep 7. doi: 10.1002/jhbp.821. Online ahead of print.,We aimed to identify essential factors contributing to achieve sufficient treatment intensity of lenvatinib. METHODS: Seventy-one patients who received treatment with lenvatinib were included in this study. ...CONCLUSIONS: Maintaining high 2M-DBR of lenvatinib …
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.,Endocrine. 2020 Sep 3. doi: 10.1007/s12020-020-02477-0. Online ahead of print.,PURPOSE: Lenvatinib (LEN) has been approved for the treatment of patients with progressive radioiodine-refractory differentiated thyroid cancer (RAI-R DTC). ...
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,"Targeting angiogenesis for liver cancer: Past, present, and future.",Genes Dis. 2020 Apr 7;7(3):328-335. doi: 10.1016/j.gendis.2020.03.010. eCollection 2020 Sep.,"Sorafenib and lenvatinib are the first-line treatment, and regorafenib, ramucirumab, and cabozantinib are second-line treatment options. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.,Oncology. 2020 Sep 3:1-11. doi: 10.1159/000509387. Online ahead of print.,"BACKGROUND: Although a strong antitumor effect of lenvatinib (LEN) has been noted for patients with unresectable hepatocellular carcinoma (HCC), there are still no reports on the prognosis for patients with disease progression after first-line LEN therapy. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.,Anticancer Res. 2020 Sep;40(9):5271-5276. doi: 10.21873/anticanres.14531.,BACKGROUND/AIM: Hepatic encephalopathy is an adverse event resulting from lenvatinib use in patients with hepatocellular carcinoma (HCC). ...CONCLUSION: Lenvatinib might directly disturb hepatocyte metabolism to result in increased serum ammonia concentration....
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.,Oncology. 2020 Sep 2:1-8. doi: 10.1159/000509005. Online ahead of print.,BACKGROUND AND AIMS: Lenvatinib is an oral anticancer drug for patients with unresectable advanced hepatocellular carcinoma (HCC). ...CONCLUSION: Reduction in tumor stain at 2 weeks after lenvatinib treatment may be an early biomarker of efficacy at 12 weeks in pati …
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,"Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China.",World J Gastroenterol. 2020 Aug 14;26(30):4465-4478. doi: 10.3748/wjg.v26.i30.4465.,"BACKGROUND: Lenvatinib has become an indispensable part of treatment regimens for patients with advanced hepatocellular carcinoma (aHCC). ...This necessitates further real-world studies of lenvatinib across diverse populations, such as in China. AIM: To investigate …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib.,In Vivo. 2020 Sep-Oct;34(5):2859-2864. doi: 10.21873/invivo.12113.,"BACKGROUND/AIM: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer (ATC). However, tumor markers for ATC treated with lenvatinib is lacking. ...PATIENTS AND METHODS: We retrospectively analyzed the prognostic significance of the NLR in …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Targeted Molecular Therapeutic Options for Hepatocellular Carcinoma.,Crit Rev Oncog. 2020;25(1):47-55. doi: 10.1615/CritRevOncog.2020034985.,"Kinase inhibitors that modulate growth signals, such as sorafenib and lenvatinib, are commonly employed in targeted molecular therapy for HCC patients. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,"Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma.",PLoS One. 2020 Aug 28;15(8):e0237370. doi: 10.1371/journal.pone.0237370. eCollection 2020.,"Moreover, we treated 12 HCC patients with lenvatinib and investigated the changes in MT during lenvatinib therapy. RESULTS: The serum level of Cu was positively correlated with alanine aminotransferase and the BCLC stage. ...MT levels increased in HCC patients recei …"
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea.,PLoS One. 2020 Aug 25;15(8):e0238207. doi: 10.1371/journal.pone.0238207. eCollection 2020.,"Among 5 patients treated with tyrosine kinase inhibitors, 4 treated with lenvatinib showed stable disease or a partial response at the first treatment response. ..."
2020-09-23T05:54:33Z,https://pubmed.ncbi.nlm.nih.gov/?term=LENVATINIB&sort=date&size=20,2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights.,Hepatobiliary Surg Nutr. 2020 Aug;9(4):452-463. doi: 10.21037/hbsn-20-480.,"The systemic treatments for HCC have evolved considerably since lenvatinib, regorafenib, carbozantinib, ramucirumab and immune checkpoint inhibitors (ICIs)were first prescribed as first-line or second-line agents. ..."
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Novel Recurrent COL5A1 Genetic Variant Is Associated With a Dysplasia-Associated Arterial Disease Exhibiting Dissections and Fibromuscular Dysplasia.,Arterioscler Thromb Vasc Biol. 2020 Sep 17:ATVBAHA119313885. doi: 10.1161/ATVBAHA.119.313885. Online ahead of print.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Downregulation of G3BP2 reduces atherosclerotic lesions in ApoE-/- mice.,Atherosclerosis. 2020 Aug 27;310:64-74. doi: 10.1016/j.atherosclerosis.2020.08.003. Online ahead of print.,"Then, using a repetitive multiple site strategy, the mice were immunized with a Keyhole limpet haemocyanin (KLH) conjugated G3BP2 peptide for 2 weeks from weeks 16 to 18. ..."
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for Darunavir.,Molecules. 2020 Sep 7;25(18):E4075. doi: 10.3390/molecules25184075.,These immunogens were the DRV conjugates with keyhole limpet hemocyanin (KLH) protein. The first immunogen (DRV-KLH) was prepared by zero-length direct linking of DRV via its aromatic amino group with the tyrosine amino acid residues of KLH by diazotization/c …
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Identification of a protective epitope in Japanese encephalitis virus NS1 protein.,Antiviral Res. 2020 Sep 6;182:104930. doi: 10.1016/j.antiviral.2020.104930. Online ahead of print.,"Furthermore, mice immunized with KLH-polypeptide ((225)PETHTLWGD(233)) showed reduced mortality following JEV challenge. Collectively, we found a new protective epitope in the JEV NS1 protein. ..."
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,"Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases' by Giollo et al.",Ann Rheum Dis. 2020 Sep 7:annrheumdis-2020-218910. doi: 10.1136/annrheumdis-2020-218910. Online ahead of print.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Intranasal delivery of a nicotine vaccine candidate induces antibodies in mouse blood and lung mucosal secretions that specifically neutralize nicotine.,Drug Dev Ind Pharm. 2020 Sep 15:1-9. doi: 10.1080/03639045.2020.1820033. Online ahead of print.,METHODS: Nicotine-keyhole limpet hemocyanin conjugate (Nic-KLH) was prepared and mixed with monophosphoryl lipid A (MPL) as an adjuvant. ...The nicotine-specific IgG level in mice nasally immunized with Nic-KLH/MPL was lower than in mice subcutaneously immunized wit …
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Bone mineral density and fracture risk in adult patients with hypophosphatasia.,Osteoporos Int. 2020 Sep 2. doi: 10.1007/s00198-020-05612-9. Online ahead of print.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Fit-for-Purpose Validation and Establishment of Assay Acceptance and Reporting Criteria of Dendritic Cell Activation Assay Contributing to the Assessment of Immunogenicity Risk.,AAPS J. 2020 Aug 24;22(5):114. doi: 10.1208/s12248-020-00491-8.,"., background control (BC)), keyhole limpet hemocyanin (KLH) as system positive control (SPC), and 2 therapeutic monoclonal antibodies (mAbs) with known clinical immunogenicity profiles (bococizumab and TAM163) as therapeutic controls (TCs). ..."
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Methodological considerations for assessing immune defense in reproductive females.,Integr Comp Biol. 2020 Aug 20:icaa098. doi: 10.1093/icb/icaa098. Online ahead of print.,"Previous work within pharmacological research has reported that the response to the commonly-used antigen keyhole limpet hemocyanin (KLH) varies among individuals and between females and males. In this heuristic analysis, we characterize antibody responses to KLH in …"
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,"COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience' by Khan et al, 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al' by Andreica et al and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin et al.",Ann Rheum Dis. 2020 Aug 12:annrheumdis-2020-218713. doi: 10.1136/annrheumdis-2020-218713. Online ahead of print.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,"Letter by Helgestad et al Regarding Article, ""The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support"".",Circulation. 2020 Aug 11;142(6):e72-e73. doi: 10.1161/CIRCULATIONAHA.119.045133. Epub 2020 Aug 10.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,[Knee revision arthroplasty-a increasing challenge].,Oper Orthop Traumatol. 2020 Aug;32(4):271-272. doi: 10.1007/s00064-020-00670-y.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.,Neurology. 2020 Jul 29:10.1212/WNL.0000000000010380. doi: 10.1212/WNL.0000000000010380. Online ahead of print.,"All received tetanus toxoid (TT)-containing vaccine, Pneumovax® (23-PPV) and keyhole limpet hemocyanin (KLH). Group OCR was subdivided into OCR1 (n=33) and OCR2 (n=35) at randomization. ...Humoral response to KLH was decreased in OCR vs Control. Seroprotection rates …"
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,"Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study.",J Immunother Cancer. 2020 Jul;8(2):e000342. doi: 10.1136/jitc-2019-000342.,"PURPOSE: This randomized, double-blind, placebo-controlled, parallel-group, phase II trial assessed the efficacy and safety of adagloxad simolenin (OBI-822; a Globo H epitope covalently linked to keyhole limpet hemocyanin (KLH)) with adjuvant OBI-821 in metastatic breast c …"
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Generation of a Peptide Vaccine Candidate against Falciparum Placental Malaria Based on a Discontinuous Epitope.,Vaccines (Basel). 2020 Jul 18;8(3):E392. doi: 10.3390/vaccines8030392.,We overcame this using a synthetic scaffold to conformationally constrain the SD1 peptide and coupled it to keyhole limpet hemocyanin (KLH). The SD1-KLH conjugate elicited antibodies in mice that cross-reacted with VAR2CSA. This strategy successfully recapitulated a …
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Electrochemical nucleation and growth of Pt nanoflower particles on reduced graphite oxide with electrooxidation of glucose.,Anal Methods. 2020 Jul 23;12(28):3617-3625. doi: 10.1039/d0ay00021c.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Immunostimulatory efficacy and protective potential of putative TgERK7 protein in mice experimentally infected by Toxoplasma gondii.,Int J Med Microbiol. 2020 Jul;310(5):151432. doi: 10.1016/j.ijmm.2020.151432. Epub 2020 May 30.,Five predicted peptides of TgERK7 were synthesized and conjugated with KLH and used to analyze the antibody specificity in the sera of immunized mice. ...
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Characterization of natural antigen-specific antibodies from naïve sturgeon serum.,Dev Comp Immunol. 2020 Nov;112:103770. doi: 10.1016/j.dci.2020.103770. Epub 2020 Jul 4.,"Natural antibodies specifically detected hen egg lysozyme (HEL), keyhole limpet hemocyanin (KLH), and several species of pathogenic bacteria. ...Antigen-specific antibodies against KLH, Aeromonas hydrophila and Streptococcus iniae were affinity-fractionated from nai …"
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Obesity and COVID-19 in New York City: A Retrospective Cohort Study.,Ann Intern Med. 2020 Jul 6:M20-2730. doi: 10.7326/M20-2730. Online ahead of print.,
2020-09-23T05:54:40Z,https://pubmed.ncbi.nlm.nih.gov/?term=LEWISY-MMCCH/KLH&sort=date&size=20,Rational Design of Hypoallergenic Vaccines: Blocking IgE-binding to Polcalcin Using Allergen-specific IgG Antibodies.,Iran J Allergy Asthma Immunol. 2020 Jun 23;19(3):276-288. doi: 10.18502/ijaai.v19i3.3455.,"The first was a mosaic peptide derivative computationally identified in Che a 3 which was coupled to keyhole limpet hemocyanin (KLH). The second one was a mutant Che a 3, and the other two derivatives included N- and C-terminal halves of Che a 3 that both coupled to KLH …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation.,Med Oncol. 2020 Jul 21;37(8):66. doi: 10.1007/s12032-020-01390-w.,There is still no research evaluating the immunoregulatory effects of AZD1775 plus high-dose irradiation (IR) in vivo. T cell killing and CD8+ T cell depletion assays demonstrated that the combination of AZD1775 and IR delayed tumour growth in breast cancer mouse mo …
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.,Elife. 2020 Jul 6;9:e57894. doi: 10.7554/eLife.57894.,"Inhibition of WEE1 kinase by AZD1775 has shown promising results in clinical cancer trials, but markers predicting AZD1775 response are lacking. Here we analysed AZD1775 response in a panel of human breast cancer (BC) cell lines by global proteome/transcripto …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Targeting ATRX Loss through Inhibition of the Cell-Cycle Checkpoint Mediator WEE1.,Cancer Res. 2020 Feb 1;80(3):375-376. doi: 10.1158/0008-5472.CAN-19-3587.,"Because ATRX mutations are frequently mutated across a variety of pediatric and adult malignancies, this work may contribute to the preclinical rationale for a precision medicine trial of the WEE1 inhibitor AZD1775 (adavosertib) for patients whose tumors demonstrate …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,"A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.",Clin Cancer Res. 2020 Sep 15;26(18):4767-4776. doi: 10.1158/1078-0432.CCR-20-0219. Epub 2020 Jul 1.,"PURPOSE: Preclinical studies show that adavosertib, a WEE1 kinase inhibitor, sensitizes TP53-mutant cells to chemotherapy. We hypothesized that adavosertib, plus chemotherapy, would enhance efficacy versus placebo in TP53-mutated ovarian cancer. ...Future studies sh …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.,Cancer. 2020 Sep 1;126(17):4002-4012. doi: 10.1002/cncr.33048. Epub 2020 Jun 25.,"Patients with MYC amplification or CDKN2A and TP53 co-alterations were allocated to adavosertib (SUKSES protocol C [SUKSES-C]; 7 patients) and those with RICTOR amplification were allocated to vistusertib (SUKSES-D; 4 patients). Alternatively, patients who were without any …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model.,Cancer Cell Int. 2020 Jun 17;20:253. doi: 10.1186/s12935-020-01337-1. eCollection 2020.,"Exploiting this acquired vulnerability; resistant cells exhibited collateral sensitivity for the Wee-1 inhibitor, adavosertib (AZD1775). The combination of ribociclib and adavosertib achieved additional antiproliferative effect exclusively in the cocultures c …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.,Cancer Chemother Pharmacol. 2020 Jul;86(1):97-108. doi: 10.1007/s00280-020-04101-4. Epub 2020 Jun 16.,"METHODS: In this Phase I, open-label, randomized, two-period, two-sequence crossover study, the pharmacokinetics of a single 300 mg adavosertib dose were investigated in fed versus fasted states. ...CONCLUSION: A high-fat meal did not have a clinically relevant effect on t …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer.,Sci Rep. 2020 Jun 18;10(1):9930. doi: 10.1038/s41598-020-66018-5.,"This study was conducted to investigate the anti-tumor effects of the WEE1 inhibitor, AZD1775, and the mechanism responsible for its potentiation of sensitivity to olaparib (a PARP inhibitor) via the modulation of DDR in TNBC cells. Our results suggest that AZD1775 …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells.,Cancers (Basel). 2020 Jun 9;12(6):1503. doi: 10.3390/cancers12061503.,"Growth of all olaparib-resistant clones isolated could be controlled by WEE1 kinase inhibitor AZD1775, which inactivates the G2 checkpoint. ..."
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.,Cancer Res Treat. 2020 Jul;52(3):945-956. doi: 10.4143/crt.2020.080. Epub 2020 Apr 17.,"RESULTS: AZD1775 blocked the phosphorylation of CDC2 and CDC25C in all cell lines, but significantly increased apoptosis and S phase arrest in sensitive cells. ...In addition, in vitro and in vivo data illustrated that AZD1775 combined with AZD6738 exerted more pote …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.,Clin Cancer Res. 2020 Jul 15;26(14):3740-3750. doi: 10.1158/1078-0432.CCR-19-3373. Epub 2020 Mar 27.,Human esophageal cancer xenografts were generated to explore the radiosensitizing effect of AZD1775 in vivo. RESULTS: The IC(50) concentrations of AZD1775 on esophageal cancer cell lines were between 300 and 600 nmol/L. ...AZD1775 significantly abrogated radi …
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer.,Cancers (Basel). 2020 Mar 19;12(3):719. doi: 10.3390/cancers12030719.,"Adavosertib (AZD1775) is a potent, small-molecule, ATP-competitive inhibitor of the Wee1 kinase that potentiates the activity of many DNA-damaging chemotherapeutics and is currently in clinical development for multiple indications. ...(TNBC012, p < 0.05 combo vs. …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia.,Front Oncol. 2020 Mar 5;10:296. doi: 10.3389/fonc.2020.00296. eCollection 2020.,"We found that AZD1775 resistant cell lines are dependent upon increased HDAC activity for their survival, in part due to increased KDM5A activity. ...Overexpression of c-MYC confers resistance to AZD1775 in cell lines with low baseline expression. Pharmacologic inhi …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,"Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol.",BMJ Open. 2020 Mar 16;10(3):e033009. doi: 10.1136/bmjopen-2019-033009.,"This trial explores the associated effect of WEE1 kinase inhibitor adavosertib (AZD1775). METHODS AND ANALYSIS: This phase I dose-finding, open-label, multicentre trial aims to determine the highest safe dose of AZD1775 in combination with cisplatin chemother …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine.,J Neurooncol. 2020 May;147(3):531-545. doi: 10.1007/s11060-020-03457-0. Epub 2020 Mar 16.,"The WEE1 inhibitor AZD1775 synergized with inhibitors of nucleotide synthesis, including gemcitabine. AZD1775 with gemcitabine suppressed proliferation and induced apoptosis. Ex vivo modeling demonstrated efficacy in Group 3 medulloblastoma patients, and in vivo mod …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition.,Sci Rep. 2020 Feb 11;10(1):2330. doi: 10.1038/s41598-020-58509-2.,"All four precancerous cell lines were highly sensitive to Wee1 inhibition by Adavosertib (AZD1775), while primary keratinocytes tolerated this inhibitor. ..."
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,"Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.",Target Oncol. 2020 Feb;15(1):75-84. doi: 10.1007/s11523-020-00701-5.,"BACKGROUND: The WEE1 inhibitor adavosertib (AZD1775) has been investigated in Western patients. OBJECTIVE: This open-label Phase Ib study (NCT02341456) investigated the safety, pharmacokinetics, and clinical activity of adavosertib in combination with carbopl …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer.,Cancers (Basel). 2020 Jan 28;12(2):306. doi: 10.3390/cancers12020306.,"Subsequent analyses demonstrated potent combination activity between the CHK1/2 inhibitor LY2606268 (prexasertib), which eliminates a G2 checkpoint, and the WEE1 inhibitor AZD1775 (adavosertib), which promotes M-phase entry, in induction of DNA damage, mitotic catas …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma.,Ther Adv Hematol. 2020 Jan 20;11:2040620719898373. doi: 10.1177/2040620719898373. eCollection 2020.,"RESULTS: Treatment with either RT or CHOP led to enhanced sensitivity to AZD1775 in several DLBCL cell lines. Treatment of cells with AZD1775 induced unscheduled mitotic progression, resulting in abnormal cell cycle distribution in combination with RT or CHOP treatm …"
2020-09-23T05:54:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD1775&sort=date&size=20,Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.,Pediatr Blood Cancer. 2020 May;67(5):e28098. doi: 10.1002/pbc.28098. Epub 2020 Jan 23.,AZD1775 is a WEE1 inhibitor that is in clinical development for children and adults with cancer. METHODS: AZD1775 was tested using a dose of 120 mg/kg administered orally for days 1 to 5. Irinotecan was administered intraperitoneally at a dose of 2.5 mg/kg for days …
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,"Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia.",Cancers (Basel). 2020 Aug 17;12(8):2312. doi: 10.3390/cancers12082312.,"Trabectedin (ET743) and lurbinectedin (PM01183) limit the production of inflammatory cytokines that are elevated during cancer cachexia. ...Since PM01183 extended the animal survival more than ET743, we analyzed PM01183 further. In tibialis anterior of …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.",Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27.,"Lurbinectedin is a selective inhibitor of oncogenic transcription. In this phase 2 study, we evaluated the acti and safety of lurbinectedin in patients with SCLC after failure of platinum-based chemotherapy. ...Treatment consisted of 3·2 mg/m(2) lurbinectedin …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer.,Lancet Oncol. 2020 May;21(5):605-607. doi: 10.1016/S1470-2045(20)30097-8. Epub 2020 Mar 27.,
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia.,Cancer Immunol Immunother. 2020 May;69(5):813-824. doi: 10.1007/s00262-020-02513-y. Epub 2020 Feb 13.,"In this study, we aimed to evaluate the activity of Lurbinectedin on circulating mononuclear cells from CLL patients and to determine whether Lurbinectedin could affect the cross-talk between B-CLL cells and the tumor microenvironment. ...Our findings encourage furt …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.,Eur J Cancer. 2020 Feb;126:21-32. doi: 10.1016/j.ejca.2019.10.021. Epub 2019 Dec 31.,"Lurbinectedin is a new anticancer agent under investigation. The primary objective of this three-arm, phase II study was to determine the disease control rate (DCR = ORR + stable disease [SD]) at 24 weeks of lurbinectedin alone or with chemotherapy in STS. ...Study …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.,Br J Cancer. 2019 Sep;121(6):464-473. doi: 10.1038/s41416-019-0550-2. Epub 2019 Aug 14.,
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,A Scalable Total Synthesis of the Antitumor Agents Et-743 and Lurbinectedin.,Angew Chem Int Ed Engl. 2019 Mar 18;58(12):3972-3975. doi: 10.1002/anie.201900035. Epub 2019 Feb 14.,
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability.,Mol Cancer Res. 2019 Mar;17(3):773-782. doi: 10.1158/1541-7786.MCR-18-0575. Epub 2018 Dec 14.,"Here we show that R-loops play an important role in the cellular response to trabectedin (ET743), an anticancer drug from marine origin and its derivative lurbinectedin (PM01183). ...In yeast, trabectedin and lurbinectedin increased the presence of Rad52 foci …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,"Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer.",Invest New Drugs. 2019 Oct;37(5):818-827. doi: 10.1007/s10637-018-0686-6. Epub 2018 Oct 30.,Mouse xenografts of cervical cancer revealed that lurbinectedin significantly inhibits tumor growth. The growth-inhibitory effect of lurbinectedin was greater than that of cisplatin and paclitaxel. ...Conclusions Lurbinectedin is highly effective on uterine c …
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.,Future Oncol. 2019 Jan;15(3):231-239. doi: 10.2217/fon-2018-0597. Epub 2018 Oct 26.,"Lurbinectedin is an inhibitor of active transcription of protein-coding genes, causing DNA-break accumulation, apoptosis and modulation of the tumor microenvironment. Early-phase clinical trials indicate promising activity of lurbinectedin in small-cell lung cancer. …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Lurbinectedin for BRCA-mutated advanced breast cancer.,Lancet Oncol. 2018 Nov;19(11):e582. doi: 10.1016/S1470-2045(18)30737-X. Epub 2018 Sep 27.,
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.,J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21.,"PURPOSE: This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with metastatic breast cancer. ...In vivo, sensitivity to cisplatin and lurbinectedin was evidenced …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.,Hematol Oncol. 2019 Feb;37(1):96-102. doi: 10.1002/hon.2557. Epub 2018 Dec 5.,"Forty-two patients with relapsed/refractory AML/MDS received lurbinectedin administered as a 1-hour intravenous infusion in a 3 + 3 study design. ...Overall, lurbinectedin was safe and tolerated using the schedules and dose levels tested. While no sustained remissio …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,"Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer.",Clin Pharmacokinet. 2019 Mar;58(3):363-374. doi: 10.1007/s40262-018-0701-2.,"The potential influence of demographic, co-treatment, and laboratory characteristics on lurbinectedin pharmacokinetics was evaluated. ...Co-administration of cytochrome P450 3A inhibitors increased lurbinectedin exposure...."
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.,J Pharm Biomed Anal. 2018 Sep 5;158:160-165. doi: 10.1016/j.jpba.2018.05.053. Epub 2018 Jun 1.,Lurbinectedin was eluted from the columns using tert-butyl methyl ether (TBME). Urine was first diluted in plasma and lurbinectedin was extracted from this matrix by liquid-liquid extraction using TBME. ...The method was developed to support a mass balance study in …
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Targeting DNA damage in SCLC.,Lung Cancer. 2017 Dec;114:12-22. doi: 10.1016/j.lungcan.2017.10.006. Epub 2017 Oct 16.,
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.,Ann Oncol. 2017 Oct 1;28(10):2559-2566. doi: 10.1093/annonc/mdx357.,"BACKGROUND: Lurbinectedin (PM01183) has synergistic antitumor activity when combined with doxorubicin in mice with xenografted tumors. ...RESULTS: Doxorubicin 50 mg/m2 and PM01183 4.0 mg flat dose was the RD. In relapsed SCLC, treatment tolerance at the RD wa …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.,Immunotherapy. 2017 Sep;9(10):805-817. doi: 10.2217/imt-2017-0046.,"AIM: To evaluate the ability of PM01183 to eliminate myeloid-derived suppressor cells (MDSCs). MATERIALS & METHODS: The effect of PM01183 on MDSCs, NK cells and CD8(+) T cells was examined in vitro and in vivo. ...CONCLUSION: PM01183 exhibits strong inhib …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.,Biochem Pharmacol. 2017 Nov 15;144:52-62. doi: 10.1016/j.bcp.2017.08.001. Epub 2017 Aug 4.,"Ascites completely abolished the activity of lurbinectedin at up to 10nM (in regular medium corresponds to the IC90), strongly reduced that of trabectedin, inhibited the cellular uptake of lurbinectedin and, to a lesser extent, that of trabectedin. ...KD values are …"
2020-09-23T05:54:49Z,https://pubmed.ncbi.nlm.nih.gov/?term=LURBINECTEDIN(PM01183)&sort=date&size=20,Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.,Br J Cancer. 2017 Aug 22;117(5):628-638. doi: 10.1038/bjc.2017.205. Epub 2017 Jul 6.,"Similar findings were observed when a lurbinectedin-resistant tumour variant was used, indicating a direct effect of lurbinectedin on the tumour microenviroment. ...These findings were supported by the strong inhibition of genes of the Rho-GTPase family in lurbin …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.,Leukemia. 2020 Aug 20. doi: 10.1038/s41375-020-01010-6. Online ahead of print.,"Duvelisib is a delta/gamma PI3K inhibitor approved for relapsed/refractory CLL. We conducted an investigator-initiated, phase 1b/2 study of duvelisib + FCR (DFCR) as initial treatment for CLL patients aged ≤65. A standard 3 + 3 design included two dose levels of  …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.,Expert Opin Drug Saf. 2020 Aug 25:1-16. doi: 10.1080/14740338.2020.1802424. Online ahead of print.,
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Copanlisib in the treatment of non-Hodgkin lymphoma.,Future Oncol. 2020 Sep;16(26):1947-1955. doi: 10.2217/fon-2020-0195. Epub 2020 Jul 13.,"The two other PI3k inhibitors approved by the US FDA in this setting are idelalisib and duvelisib. In this review, we compare the efficacy and adverse event profile of these different PI3K inhibitors and discuss the advantages and challenges of using copanlisib along with …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.,Blood Adv. 2020 Jul 14;4(13):3072-3084. doi: 10.1182/bloodadvances.2020001800.,"The in-clinic phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have demonstrated high rates of response and progression-free survival in clinical trials of B-cell malignancies, such as chronic lymphocytic leukemia (CLL). ...Here, …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma.,Int J Hematol. 2020 Jul 1. doi: 10.1007/s12185-020-02929-3. Online ahead of print.,"Duvelisib was administered orally twice daily at 25 mg in 28-day cycles. Seven patients, comprising 4 with follicular lymphoma (FL), 2 with diffuse large B-cell lymphoma, and 1 with mantle cell lymphoma (MCL) were enrolled. ...Duvelisib was well tolerated in Japanes …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.,Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16808. Online ahead of print.,"In the relapsed or Cy-refractory setting, alemtuzumab (n = 4) and pentostatin (n = 3) had an ORR of 50% and 66%, respectively, while duvelisib induced a long-term response in one patient. ...Prospective studies evaluating pentostatin, alemtuzumab and novel agents, such as …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.,Sci Rep. 2020 Jun 1;10(1):8867. doi: 10.1038/s41598-020-65637-2.,"Here, we found that both PI3K-α and -δ isoforms are abundantly expressed in our MCC cell lines and clinical samples; we therefore examined antitumor efficacy across a panel of five PI3K inhibitors with distinctive isoform-specificities, including idelalisib (PI3K-δ), copanlisib ( …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,"The regulation and function of CD20: an ""enigma"" of B-cell biology and targeted therapy.",Haematologica. 2020 Jun;105(6):1494-1506. doi: 10.3324/haematol.2019.243543.,"Current efforts to combine anti-CD20 monoclonal antibodies with BCR signaling inhibitors targeting BTK or PI3K (ibrutinib, acalabrutinib, idelalisib, duvelisib) or BH3-mimetics (venetoclax) lead to the necessity to better understand both the mechanisms of regulation and th …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Development of a novel and quick UPLC-MS/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs.,J Pharm Biomed Anal. 2020 Aug 5;187:113355. doi: 10.1016/j.jpba.2020.113355. Epub 2020 May 11.,"Selected reaction monitoring (SRM) mode was employed to detect the parent-to-daughter ion transitions as follows: m/z 416.88 → 281.88 for duvelisib, and m/z 553.09 → 436.01 for IS, respectively. The assay was successfully established in the calibration range from 0.5 to 30 …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation.,J Immunol. 2020 Jul 1;205(1):78-89. doi: 10.4049/jimmunol.2000043. Epub 2020 May 15.,"Idelalisib (PI3Kδ), alpelisib (PI3Kα), duvelisib (PI3Kδ/γ), and copanlisib (pan-PI3K) have recently been approved for use in cancer treatment. ..."
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma.,Curr Treat Options Oncol. 2020 Apr 30;21(6):51. doi: 10.1007/s11864-020-00746-8.,"With three agents now FDA approved for the treatment of relapsed and refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), idelalisib, copanlisib, and duvelisib, we aim to review the pivotal trials leading to their approval as well as their clinical applications according …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,[Reaserch Advance on Inhibitor Targeting at the B-Cell Receptor Pathway in Chronic Lymphocytic Leukemia --Review].,Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Apr;28(2):708-712. doi: 10.19746/j.cnki.issn.1009-2137.2020.02.060.,"To date, the BTK inhibitor Ibrutinib, PI3K inhibitors Idelalisib and Duvelisib have been approved for CLL treatment, and some novel inhibitors are still in clinical trials. ..."
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Duvelisib for the treatment of chronic lymphocytic leukemia.,Expert Opin Pharmacother. 2020 Aug;21(11):1299-1309. doi: 10.1080/14656566.2020.1751123. Epub 2020 Apr 15.,"AREAS COVERED: This review provides analysis of the mechanism of action of duvelisib and includes the rationale for the use of double inhibition. The authors also give their clinical experience with duvelisib. Overall, despite the high efficacy of the drug, some con …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.,Curr Treat Options Oncol. 2020 Mar 13;21(4):24. doi: 10.1007/s11864-020-0715-5.,"Treatment landscape of chronic lymphocytic leukemia (CLL) has changed since 2014 after the introduction of inhibitors of B-cell receptor signaling pathway (ibrutinib, acalabrutinib, idelalisib and duvelisib) and the inhibitor of the anti-apoptotic protein BCL-2 (venetoclax …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Biomarkers of genome instability in normal mammalian genomes following drug-induced replication stress.,Environ Mol Mutagen. 2020 Feb 20. doi: 10.1002/em.22364. Online ahead of print.,"Here, we show that drug-induced replication stress leads to increased genome instability in vitro using proliferating primary human cells as well as in vivo in rat bone marrow (BM) and duodenum (DD). p53-binding protein 1 (53BP1, biomarker of DNA damage repair) nuclear bodies wer …"
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.,Clin Cancer Res. 2020 May 1;26(9):2096-2103. doi: 10.1158/1078-0432.CCR-19-3061. Epub 2020 Jan 21.,We report results from patients with progressive disease (PD) after ofatumumab who crossed over to duvelisib in the DUO trial. PATIENTS AND METHODS: Patients with radiographically confirmed PD after ofatumumab received duvelisib 25 mg twice daily in 28-day cycles un …
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Isoform-Selective PI3K Inhibitors for Various Diseases.,Curr Top Med Chem. 2020;20(12):1074-1092. doi: 10.2174/1568026620666200106141717.,"Idelalisib, Copanlisib, Duvelisib, and Alpelisib were approved by the FDA for the treatment of different types of cancer and several other PI3K inhibitors are currently under active clinical development. ..."
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia.,Cancer J. 2019 Nov/Dec;25(6):428-435. doi: 10.1097/PPO.0000000000000406.,"These 4 agents include the Bruton tyrosine kinase inhibitor ibrutinib, the B-cell leukemia/lymphoma-2 inhibitor venetoclax, and the phosphatidylinositol-3 kinase inhibitors idelalisib and duvelisib. ..."
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,"INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ).",ACS Med Chem Lett. 2019 Oct 17;10(11):1554-1560. doi: 10.1021/acsmedchemlett.9b00334. eCollection 2019 Nov 14.,"The unique structure of 20 contains a pyrazolopyrimidine hinge-binder in place of a purine motif that is present in other PI3Kδ inhibitors, such as idelalisib (1), duvelisib (2), and INCB040093 (3, dezapelisib). ..."
2020-09-23T05:54:53Z,https://pubmed.ncbi.nlm.nih.gov/?term=DUVELISIB&sort=date&size=20,Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.,Science. 2019 Nov 8;366(6466):714-723. doi: 10.1126/science.aaw9032.,
2020-09-23T05:54:56Z,https://pubmed.ncbi.nlm.nih.gov/?term=BAY1895344&sort=date&size=20,"Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.",Pharmacol Ther. 2020 Jun;210:107518. doi: 10.1016/j.pharmthera.2020.107518. Epub 2020 Feb 26.,"We also outline the transition from preclinical to clinical studies, as well as its relationships with other clinical candidates (AZD6738, VX-803 [M4344], and BAY1895344). ..."
2020-09-23T05:54:56Z,https://pubmed.ncbi.nlm.nih.gov/?term=BAY1895344&sort=date&size=20,Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?,Pharmacol Ther. 2020 Mar;207:107450. doi: 10.1016/j.pharmthera.2019.107450. Epub 2019 Dec 11.,"Targeting ATR is the focus of many oncology drug pipelines with a number of potent, selective ATR inhibitors developed, four (M6620, M4344, AZD6738 and BAY1895344) are currently in clinical development. ..."
2020-09-23T05:54:56Z,https://pubmed.ncbi.nlm.nih.gov/?term=BAY1895344&sort=date&size=20,Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.,J Hematol Oncol. 2019 Apr 24;12(1):43. doi: 10.1186/s13045-019-0733-6.,"Preclinical and clinical data from early-phase trials on three ATR inhibitors (M6620, AZD6738, and BAY1895344), either as monotherapy or in combination, were reviewed. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Tocilizumab for severe COVID-19 related illness - A community academic medical center experience.,Cytokine X. 2020 Dec;2(4):100035. doi: 10.1016/j.cytox.2020.100035. Epub 2020 Sep 2.,"We sought to describe outcomes in a series of severely ill patients with COVID-19 CRS following treatment with anti-IL-6/IL-6-Receptor (anti-IL-6/IL-6-R) therapy, including tocilizumab or siltuximab. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.,Am J Hematol. 2020 Sep 7. doi: 10.1002/ajh.25992. Online ahead of print.,Anti-IL-6 therapy with siltuximab is the only FDA- or EMA-approved treatment based on efficacy and safety in multiple studies. ...NCCN currently recommends siltuximab first-line for iMCD except for patients considered to have HV histopathology. We investigated wheth …
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Effects of IL-6 Signaling Pathway Inhibition on Weight and BMI: A Systematic Review and Meta-Analysis.,Int J Mol Sci. 2020 Aug 31;21(17):E6290. doi: 10.3390/ijms21176290.,
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,The Interplay Between Coagulation and Inflammation Pathways in COVID-19-Associated Respiratory Failure: A Narrative Review.,Pulm Ther. 2020 Aug 25:1-17. doi: 10.1007/s41030-020-00126-5. Online ahead of print.,"., tocilizumab, anakinra, siltuximab) and non-steroidal anti-inflammatory drugs are showing early promising results. Potential newer agents (e.g., Janus kinase inhibitor such as ruxolitinib, baricitinib, fedratinib) are likely to be investigated in clinical trials. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19.,Infect Dis Ther. 2020 Aug 12. doi: 10.1007/s40121-020-00326-1. Online ahead of print.,"In an effort to reduce the severity of organ dysfunction, including respiratory insufficiency, monoclonal antibodies (Mabs) that block the interleukin-6 receptor, such as tocilizumab, sarilumab, and siltuximab, are under investigation for the treatment of COVID-19. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.,Cureus. 2020 Jul 2;12(7):e8967. doi: 10.7759/cureus.8967.,"Therefore, treatment with agents that bind to IL-6 (such as siltuximab) or block the IL-6 receptor (such as tocilizumab) has been used. ...We postulate that her siltuximab therapy blocked the IL-6-associated fever and constitutional symptoms that normally are a hall …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2.,J Pharm Pharm Sci. 2020;23:259-277. doi: 10.18433/jpps31346.,"., the use of remdesivir, lopinavir, ritonavir, umifenovir (arbidol), oseltamivir, ganciclovir, favipiravir, darunavir, hydroxychloroquine, chloroquine, colchicine, azithromycin, anakinra, canakinumab, tocilizumab, siltuximab, sarilumab, Type 1 interferon, interferon β-1a, …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients.,Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7475-7484. doi: 10.26355/eurrev_202007_21916.,"A search has been performed for studies using IL-6 blocking drugs (tocilizumab, siltuximab, and sarilumab) in PubMed, Web of Science, and Scopus. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Pharmaco-Immunomodulatory Therapy in COVID-19.,Drugs. 2020 Sep;80(13):1267-1292. doi: 10.1007/s40265-020-01367-z.,"Specific immune modulators include anti-cytokines such as interleukin (IL)-1 and IL-6 receptor antagonists (e.g. anakinra, tocilizumab, sarilumab, siltuximab), Janus kinase (JAK) inhibitors (e.g. baricitinib, ruxolitinib), anti-tumor necrosis factor-α (e.g. adalimumab, inf …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Siltuximab.,2020 Jul 20. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–.,"No information is available on the clinical use of siltuximab during breastfeeding. Because siltuximab is a large protein molecule with a molecular weight of about 145,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is proba …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,"COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study.",Lancet Child Adolesc Health. 2020 Sep;4(9):653-661. doi: 10.1016/S2352-4642(20)30177-2. Epub 2020 Jun 25.,"Immunomodulatory medication used included corticosteroids (22 [4%] patients), intravenous immunoglobulin (seven [1%] patients), tocilizumab (four [1%] patients), anakinra (three [1%] patients), and siltuximab (one [<1%] patient). ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report.,Eur J Haematol. 2020 Jun 21. doi: 10.1111/ejh.13473. Online ahead of print.,
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,"Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.",BioDrugs. 2020 Aug;34(4):415-422. doi: 10.1007/s40259-020-00430-1.,"It is important to critically analyze the available evidence concerning the use of the available anti-IL-6 (siltuximab) and anti-IL-6R (tocilizumab and sarilumab) agents in COVID-19 patients, in terms of both benefit and risk. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?,Pharmaceut Med. 2020 Aug;34(4):223-231. doi: 10.1007/s40290-020-00342-z.,"Considering the proven role of cytokine dysregulation in causing this hyperinflammation in the lungs with IL-6 being a key driver, particularly in seriously ill COVID-19 patients, it is crucial to further explore selective cytokine blockade with drugs like the IL-6 inhibitors toc …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Additive treatment considerations in COVID-19-The clinician's perspective on extracorporeal adjunctive purification techniques.,Artif Organs. 2020 Jun 9:10.1111/aor.13748. doi: 10.1111/aor.13748. Online ahead of print.,"Multiple therapeutic strategies, including antibody therapies (such as Tocilizumab, Sarilumab, Siltuximab), therapeutic plasma exchange (TPE), and blood purification techniques for direct removal of cytokines, including filtration, dialysis (diffusion), and adsorption are …"
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,[Long-Term Survival of a Patient with Metastatic Ovarian Cancer and Local Recurrence of Rectal Cancer].,Gan To Kagaku Ryoho. 2020 Jan;47(1):162-164.,"She received adjuvant therapy with UFT. Three years after the primary resection, metastasis to the right ovary and local recurrence were diagnosed. ..."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.,Eur J Hosp Pharm. 2020 Sep;27(5):297-298. doi: 10.1136/ejhpharm-2020-002322. Epub 2020 Jun 4.,"The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. ...Blockers of this cytokine (tocilizumab, sarilumab and siltuximab) are being studied as …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.,Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.,"The experimental arms consist of Anakinra alone (anti-IL-1 binding the IL-1 receptor), Siltuximab alone (anti-IL-6 chimeric antibody), a combination of Siltuximab and Anakinra, Tocilizumab alone (humanised anti-IL-6 receptor antibody) or a combination of Anakinra wi …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?,Br J Pharmacol. 2020 Aug;177(16):3635-3645. doi: 10.1111/bph.15137. Epub 2020 Jul 5.,"PARPi may potentiate the effectiveness of tocilizumab, anakinra, sarilumab, adalimumab, canakinumab or siltuximab therapy. The evidence suggests that PARPi would benefit COVID-19 patients and trials should be undertaken...."
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.,J Med Virol. 2020 May 21:10.1002/jmv.26038. doi: 10.1002/jmv.26038. Online ahead of print.,"METHODS: We performed a systematic search of PubMed, Embase, and Medline from 22nd April 2020 and again on 27th April 2020 using the following search terms alone or in combination: ""COVID-19,"" ""coronavirus,"" ""SARS-CoV-2,"" ""COVID,"" ""anti-interleukin-6 receptor antibodies,"" ""anti-I …"
2020-09-23T05:55:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=SILTUXIMAB&sort=date&size=20,The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.,J Immunother Cancer. 2020 May;8(1):e000930. doi: 10.1136/jitc-2020-000930.,
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,"Advances in urologic oncology ""OncoForum"": The best of 2019.",Actas Urol Esp. 2020 Sep 15:S0210-4806(20)30153-4. doi: 10.1016/j.acuro.2020.06.007. Online ahead of print.,"Cabazitaxel has demonstrated a survival benefit in patients with metastatic CRPC, while olaparib showed anti-tumor activity after chemotherapy in those tumors with mutations in DNA repair genes. ...In metastatic CRPC, cabazitaxel and olaparib (targeting mutations) a …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,"Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.",Lancet Oncol. 2020 Sep 11:S1470-2045(20)30449-6. doi: 10.1016/S1470-2045(20)30449-6. Online ahead of print.,"FINDINGS: Between Nov 17, 2015, and Nov 28, 2018, of 303 patients screened, 255 were randomly assigned to cabazitaxel (n=129) or abiraterone or enzalutamide (n=126). ...Pain response was observed in 51 (46%) of 111 patients with cabazitaxel and 21 (19%) of 109 patie …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,A surfactant-stripped cabazitaxel micelle formulation optimized with accelerated storage stability.,Pharm Dev Technol. 2020 Sep 16:1-8. doi: 10.1080/10837450.2020.1818780. Online ahead of print.,"Pluronic (Poloxomer) micelles can solubilize cabazitaxel (CTX), a second-generation taxane, and then be subjected to low-temperature ""surfactant-stripping"" to selectively remove loose and free surfactant, thereby increasing the drug-to-surfactant ratio. We previously found …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Taxanes.,2020 Sep 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.,"Three taxanes are in clinical use, paclitaxel (Taxol: 1992), docetaxel (Taxotere: 1996) and cabazitaxel (Jevtana: 2010). Paclitaxel was the first compound in this chemical group to be introduced into clinical use and was initially isolated from the bark of the Western yew …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Cabazitaxel.,2020 Sep 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.,"Cabazitaxel is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after failure of docetaxel. Therapy with cabazitaxel has been associated with a low rate of serum enzyme elevations, but has no …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Photosensitizer-stabilized self-assembling nanoparticles potentiate chemo/photodynamic efficacy of patient-derived melanoma.,J Control Release. 2020 Sep 1;328:325-338. doi: 10.1016/j.jconrel.2020.08.062. Online ahead of print.,"Ligation of anticancer cabazitaxel (CTX) drugs via a reactive oxygen species-activatable thioketal linkage generates a dimeric TKdC prodrug, and subsequent coassembly with a photosensitizer, chlorin e6 (Ce6), forms colloidal-stable nanoassemblies (termed psTKdC NAs). ..."
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Molecular docking analysis of docetaxel analogues as duel lipocalin 2 inhibitors.,Bioinformation. 2020 Jun 30;16(6):438-443. doi: 10.6026/97320630016438. eCollection 2020.,"We document 10 analogues (4Deacetyltaxol, 7Acetyltaxol, Cabazitaxel, Cephalomannine, Docetaxal, Deacetyltaxol, Docetaxeltrihydrate, Ortataxel, Paclitaxel, Taxoline) having optimal binding with Lipocalin 2 in comparison with Docetaxel. ..."
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer.,Anticancer Res. 2020 Sep;40(9):5255-5261. doi: 10.21873/anticanres.14529.,"RESULTS: The median number of cabazitaxel infusions was 4 (range=1-18). In general, cabazitaxel was well-tolerated. The fraction of patients alive and without progression after 3 months of treatment was 54% (14/26). ...CONCLUSION: Cabazitaxel holds promise as …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,YM155 Reverses Cabazitaxel Resistance in Castration-resistant Prostate Cancer by Reducing Survivin Expression.,Anticancer Res. 2020 Sep;40(9):5091-5095. doi: 10.21873/anticanres.14512.,"MATERIALS AND METHODS: Cabazitaxel resistance was induced in the castration-resistant prostate cancer cell line, 22Rv1-CR. In vitro and in vivo models were used to test the efficacy of YM155 and cabazitaxel. ...CONCLUSION: Inhibition of survivin by YM155 overcomes …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Improved antitumor activity and tolerability of cabazitaxel derived remote-loading liposomes.,Int J Pharm. 2020 Aug 30;589:119814. doi: 10.1016/j.ijpharm.2020.119814. Online ahead of print.,"Two weak-base cabazitaxel derivatives were synthesized, and named CN and CN2. CN exhibited higher cytotoxic effects compared to CN2, and was selected for further study. ...When compared to the commercial formulation of cabazitaxel, JEVTANA®, CN-LPs showed less syste …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer.,Sci Adv. 2020 Jul 15;6(29):eabb0616. doi: 10.1126/sciadv.abb0616. eCollection 2020 Jul.,"Here, we report a hybrid nanocomplex to co-deliver the IKBKE siRNA and cabazitaxel to TNBC to achieve an optimal antitumor effect. ...Encapsulation of cabazitaxel in the nanocomplex enhances the activity of the IKBKE siRNA. The hybrid nanocomplex provides a novel an …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer.,Int J Nanomedicine. 2020 Jul 29;15:5333-5344. doi: 10.2147/IJN.S258856. eCollection 2020.,"PURPOSE: Cabazitaxel (CBZ) is a new taxane-based antitumor drug approved by the FDA for the treatment of prostate cancer, especially for patients with advanced prostate cancer for whom docetaxel is ineffective or causes aggravation. ..."
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Ultrasound-Mediated Delivery of Chemotherapy into the Transgenic Adenocarcinoma of the Mouse Prostate Model.,Ultrasound Med Biol. 2020 Aug 12:S0301-5629(20)30296-9. doi: 10.1016/j.ultrasmedbio.2020.07.004. Online ahead of print.,We used two phenotypes of the spontaneous transgenic adenocarcinoma of the mouse prostate (TRAMP) model to evaluate if US + MB could enhance the therapeutic efficacy of cabazitaxel (Cab). ...
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Aurora A inhibitor TAS-119 enhances antitumor efficacy of taxanes in vitro and in vivo: preclinical studies as guidance for clinical development and trial design.,Mol Cancer Ther. 2020 Aug 11:molcanther.0036.2020. doi: 10.1158/1535-7163.MCT-20-0036. Online ahead of print.,"The same TAS-119 concentration enhanced the cell growth inhibitory activity of three clinically approved taxanes, paclitaxel, docetaxel, and cabazitaxel. ..."
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Microfluidic self-assembly of high cabazitaxel loading albumin nanoparticles.,Nanoscale. 2020 Aug 28;12(32):16928-16933. doi: 10.1039/c9nr10941b. Epub 2020 Aug 10.,"Cabazitaxel (CTX) is a promising anticancer drug. In this study, CTX-loaded human serum albumin (HSA) nanoparticles (MF-NPs-CTX) were prepared by a microfluidic (MF) method and were evaluated for tumor inhibition in PC-3 and HeLa cells in vitro and in vivo. ..."
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).,Eur Urol Oncol. 2020 Aug 2:S2588-9311(20)30093-6. doi: 10.1016/j.euo.2020.07.002. Online ahead of print.,"DESIGN, SETTING, AND PARTICIPANTS: Thirty-two men with progressive mCRPC previously treated with taxane-based chemotherapy (91% treated with both docetaxel and cabazitaxel) and abiraterone and/or enzalutamide were enrolled in this phase I dose escalation study with phase I …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Pembrolizumab for a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high.,IJU Case Rep. 2020 Feb 14;3(2):62-64. doi: 10.1002/iju5.12144. eCollection 2020 Mar.,INTRODUCTION: We report the case of a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high who was treated with pembrolizumab after cabazitaxel administration. ...
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.,Prostate. 2020 Jul 31. doi: 10.1002/pros.24048. Online ahead of print.,"After failing second HT, 90 patients were assigned for docetaxel-alone (group A), 33 patients received carboplatin plus docetaxel (group B), while 27 patients received cabazitaxel-alone (Group C). ...We report a Hazard Ratio of 3.1 (95% CI, 1.31-7.35; P = .0037) between pa …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Nursing Implications of Recent Changes in Management Practices for Metastatic Prostate Cancer.,Semin Oncol Nurs. 2020 Aug;36(4):151047. doi: 10.1016/j.soncn.2020.151047. Epub 2020 Jul 22.,"Since then, drugs such as docetaxel, abiraterone, enzalutamide, cabazitaxel, radium-223 dichloride, and (not available in Australia) sipuleucel-T have all demonstrated efficacy in prolongation of survival in castrate-resistant prostate cancer, and improvement in cancer-rel …"
2020-09-23T05:55:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=CABAZITAXEL&sort=date&size=20,Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m(2)) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study.,BMC Cancer. 2020 Jul 13;20(1):649. doi: 10.1186/s12885-020-07131-6.,BACKGROUND: The recommended starting dose of cabazitaxel for castration-resistant prostate cancer (CRPC) is 25 mg/m(2) in Japan and Europe. ...METHODS: We compared the safety and efficacy of cabazitaxel between patients who received cabazitaxel at starting do …
2020-09-23T05:55:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=GD2L-KLH/QS-21&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44.,"This issue focuses on the following selection of drugs: ABI-007, adalimumab, adefovir dipivoxil, alefacept, alemtuzumab, 3-AP, AP-12009, APC-8015, L-Arginine hydrochloride, aripiprazole, arundic acid, avasimibe; Bevacizumab, bivatuzumab, BMS-181176, BMS-184476, BMS-188797, bortez …"
2020-09-23T05:55:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=GD2L-KLH/QS-21&sort=date&size=20,Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.,Clin Cancer Res. 2003 Nov 1;9(14):5214-20.,"Groups of 6 patients were entered at three dose levels (3, 10, or 30 micro g) of GD2 lactone (GD2L) in vaccines containing GD2L-KLH plus the immunological adjuvant QS-21. ...CONCLUSIONS: GD2L-KLH conjugate vaccine plus adjuvant …"
2020-09-23T05:55:19Z,https://pubmed.ncbi.nlm.nih.gov/?term=RGX-104&sort=date&size=20,LXR activation radiosensitizes non-small cell lung cancer by restricting myeloid-derived suppressor cells.,Biochem Biophys Res Commun. 2020 Jul 23;528(2):330-335. doi: 10.1016/j.bbrc.2020.04.137. Epub 2020 May 22.,"Here, we report for the first time that LXR agonists, GW3965 and RGX-104, radiosensitized NSCLC in a subcutaneous homograft murine model. ...Treatment with RGX-104 greatly promoted MDSC apoptosis in vitro. Depleting MDSC activated cytotoxic T lymphocyt …"
2020-09-23T05:55:19Z,https://pubmed.ncbi.nlm.nih.gov/?term=RGX-104&sort=date&size=20,Sequential depletion of myeloid-derived suppressor cells and tumor cells with a dual-pH-sensitive conjugated micelle system for cancer chemoimmunotherapy.,J Control Release. 2020 Jan 10;317:43-56. doi: 10.1016/j.jconrel.2019.11.011. Epub 2019 Nov 20.,"Here we have designed a dual-pH-sensitivity conjugated micelle system (PAH/RGX-104@PDM/PTX) that could deliver liver-X nuclear receptor (LXR) agonist RGX-104 and paclitaxel (PTX) to the perivascular region and tumor cells, respectively. Upon arrival at …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells.,Anticancer Res. 2020 Sep;40(9):5141-5149. doi: 10.21873/anticanres.14517.,"RESULTS: Both TMZ and AZD7762 induced concentration- and time-dependent cytotoxic effects, and combined TMZ and AZD7762 (TMZ+AZD) caused synergistic cytotoxic effects in glioma cells (p<0.05). AZD7762 suppressed the O(6)-methylguanine-DNA-methyltransferase …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,"Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin.",Radiat Environ Biophys. 2020 Aug 28. doi: 10.1007/s00411-020-00867-6. Online ahead of print.,"Cells pretreated with the CHK1/CHK2 inhibitor AZD7762, Honokiol or Tunicamycin were irradiated with low-LET X-rays and high-LET carbon ions. ...Our results revealed that AZD7762, Honokiol and Tunicamycin demonstrated low cytotoxicity to NSCLC cells and a pronounced …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts.,Cancers (Basel). 2020 Jun 29;12(7):1726. doi: 10.3390/cancers12071726.,"The antitumor efficacy of CHK1 inhibitors (PF477736, AZD7762, LY2606368) and PI3K inhibitors (BYL719, GDC0941, GSK1059615) was investigated in OSCC cell lines and PDX models. ..."
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation.,Oncogene. 2020 May;39(22):4344-4357. doi: 10.1038/s41388-020-1300-x. Epub 2020 Apr 25.,"The Chk1/2 inhibitor AZD7762 is used to abrogate radiation therapy (RT)-induced G2/M cell cycle arrest in multiple cell lines and, we find that this therapeutic combination promotes increased micronuclei formation in vitro and subsequently drives increased type I in …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors.,Biomaterials. 2020 Jul;248:120032. doi: 10.1016/j.biomaterials.2020.120032. Epub 2020 Apr 11.,Antibody drug conjugates honed in on tumor overexpressed cell surface receptors with high specificity but lacked efficacy when conjugated to the DNA damage checkpoint kinase inhibitor AZD7762. ...
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells.,Cancer Cell Int. 2019 Jul 27;19:195. doi: 10.1186/s12935-019-0896-9. eCollection 2019.,"BACKGROUND: AZD7762 is a checkpoint kinase 1 (Chk 1) inhibitor, which has been reported to sensitize many tumor cells to DNA damage. ...The clinical application of AZD7762 as an adjuvant in the chemotherapy of osteosarcoma should be further explored...."
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Fbxo6 confers drug-sensitization to cisplatin via inhibiting the activation of Chk1 in non-small cell lung cancer.,FEBS Lett. 2019 Jul;593(14):1827-1836. doi: 10.1002/1873-3468.13461. Epub 2019 Jun 7.,
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas.,Mol Cancer Ther. 2019 Jul;18(7):1255-1264. doi: 10.1158/1535-7163.MCT-18-0919. Epub 2019 May 7.,"AZD6738 exerted a strong synergistic cytotoxic effect in combination with both AZD7762 and AZD1775 in the 2 lymphoma subtypes regardless of their TP53, MYC, and ATM mutational status. ..."
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.,J Thorac Oncol. 2019 Jun;14(6):1032-1045. doi: 10.1016/j.jtho.2019.01.028. Epub 2019 Feb 14.,"The effect was regulated in part through activation of caspase 2 and downregulation of E2F transcription factor 1 (E2F1). Furthermore, Chk1 inhibitors prexasertib and AZD7762 enhanced cisplatin antitumor activity and overcame cisplatin resistance in SCLC preclinical …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762.,Toxicol Appl Pharmacol. 2019 Feb 15;365:71-83. doi: 10.1016/j.taap.2019.01.005. Epub 2019 Jan 8.,"The ROS scavenger N-acetylcysteine (NAC) and the specific p38 inhibitor SB203580 reversed the effects of A-macB on the p38 network and thus rescued ESCC cells from apoptosis. ...Taken together, A-macB is a promising lead compound for ESCC and exerts synergistic anti-cancer …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target.,Clin Cancer Res. 2019 Jan 15;25(2):856-867. doi: 10.1158/1078-0432.CCR-18-1469. Epub 2018 Oct 23.,"We assessed abiraterone acetate and Chk1 inhibitors (GDC-0575 and AZD7762) efficacies, either alone or in combination, on cell lines grown in vitro and in vivo. ..."
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Extending Remission and Reversing New-Onset Type 1 Diabetes by Targeted Ablation of Autoreactive T Cells.,Diabetes. 2018 Nov;67(11):2319-2328. doi: 10.2337/db18-0204. Epub 2018 Aug 13.,
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Identification of Novel Mycobacterial Inhibitors Against Mycobacterial Protein Kinase G.,Front Microbiol. 2018 Jul 12;9:1517. doi: 10.3389/fmicb.2018.01517. eCollection 2018.,"We found that four compounds, namely AZD7762, R406, R406-free base, and CYC116, inhibited PknG activities. AZD7762, R406, and R406-free base promoted transfer of mycobacteria to lysosomes. ..."
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,"Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling.",Int J Oncol. 2018 Sep;53(3):1001-1012. doi: 10.3892/ijo.2018.4481. Epub 2018 Jul 13.,"Using AZD7762, an inhibitor of checkpoint kinase (Chk) 1 and 2, the present study examined its effect on mammary tumor cells in addition to bone cells (osteoclasts, osteoblasts and osteocytes), using monolayer cell cultures and three-dimensional (3D) cell spheroids. …"
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines.,Oncotarget. 2018 May 25;9(40):26064-26071. doi: 10.18632/oncotarget.25436. eCollection 2018 May 25.,
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,"Repositioning of anti-cancer drug candidate, AZD7762, to an anti-allergic drug suppressing IgE-mediated mast cells and allergic responses via the inhibition of Lyn and Fyn.",Biochem Pharmacol. 2018 Aug;154:270-277. doi: 10.1016/j.bcp.2018.05.012. Epub 2018 May 17.,The aim of this study was to investigate the anti-allergic effects of 3-[(aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-thiophenecarboxamide (AZD7762) in vitro and in vivo. AZD7762 inhibited the antig …
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.,Cancer Lett. 2018 Aug 28;430:34-46. doi: 10.1016/j.canlet.2018.05.011. Epub 2018 May 16.,Targeting of oncogene-driven replicative stress as therapeutic option for high-risk medullobastoma was assessed using a panel of medulloblastoma cells differing in their c-Myc expression [i.e. group SHH (c-Myc low) vs. group 3 (c-Myc high)]. ...The enhanced sensitivity of …
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.,Cancer Lett. 2018 Aug 1;428:104-116. doi: 10.1016/j.canlet.2018.04.029. Epub 2018 Apr 26.,"Moreover, using qHTCS we identified two Chk1 inhibitors (PF-477736 and AZD7762) that re-sensitize resistant cells to cisplatin. ..."
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,Small molecules promote CRISPR-Cpf1-mediated genome editing in human pluripotent stem cells.,Nat Commun. 2018 Apr 3;9(1):1303. doi: 10.1038/s41467-018-03760-5.,
2020-09-23T05:55:23Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD7762&sort=date&size=20,"Acetyl-macrocalin B, an ent-kaurane diterpenoid, initiates apoptosis through the ROS-p38-caspase 9-dependent pathway and induces G2/M phase arrest via the Chk1/2-Cdc25C-Cdc2/cyclin B axis in non-small cell lung cancer.",Cancer Biol Ther. 2018 Jul 3;19(7):609-621. doi: 10.1080/15384047.2018.1449613. Epub 2018 May 8.,"A-macB activated the Chk1/2-Cdc25C-Cdc2/cyclin B1 axis to induce G2/M phase arrest. AZD7762 abrogated the function of Chk1/2, abolished the G2/M delay and enhanced the cytotoxicity of A-macB. ..."
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions.,Pharmacol Res. 2020 Aug 3;161:105092. doi: 10.1016/j.phrs.2020.105092. Online ahead of print.,"It is therefore of great interest to investigate CXCR4/CXCR7/CXCL12 modulators in clinical development, with several CXCR4 and CXCL12 modulators such as plerixafor, ulocuplumab, balixafortide, and olaptesed pegol having already reached this stage. ..."
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.,Clin Cancer Res. 2020 Jan 15;26(2):344-353. doi: 10.1158/1078-0432.CCR-19-0647. Epub 2019 Oct 31.,"PURPOSE: Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12. ...Using a 3+3 design on both arms of the trial, ulocuplumab's dose was escalated to a maximum of 10 mg/ …"
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,What is new in the treatment of Waldenstrom macroglobulinemia?,Leukemia. 2019 Nov;33(11):2555-2562. doi: 10.1038/s41375-019-0592-8. Epub 2019 Oct 7.,"., ulocuplumab), among others. It is certainly an exciting time for WM therapy development with novel and promising treatment options in the horizon...."
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,Immunotherapy for small-cell lung cancer: emerging evidence.,Future Oncol. 2016 Apr;12(7):931-43. doi: 10.2217/fon-2015-0012. Epub 2016 Feb 17.,"Immune checkpoint inhibitors such as ipilimumab, nivolumab, pembrolizumab, durvalumab, tremelimumab and ulocuplumab are at the forefront of immunotherapy and have achieved approvals for certain cancer types, including melanoma (ipilimumab, nivolumab and pembrolizumab), non …"
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.,Oncotarget. 2016 Jan 19;7(3):2809-22. doi: 10.18632/oncotarget.6465.,"We found that Ulocuplumab (BMS-936564) inhibited CXCL12 mediated CXCR4 activation-migration of CLL cells at nanomolar concentrations. ...However, Ulocuplumab (BMS-936564) but not AMD3100 induced apoptosis in CLL at nanomolar concentration …"
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.,Cell Rep. 2015 Jul 28;12(4):622-35. doi: 10.1016/j.celrep.2015.06.059. Epub 2015 Jul 16.,"Ulocuplumab, a monoclonal anti-CXCR4 antibody, inhibited MM cell dissemination, supported by suppression of the CXCR4-driven EMT-like phenotype. ..."
2020-09-23T05:55:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=ULOCUPLUMAB(BMS-936564)&sort=date&size=20,BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.,Clin Cancer Res. 2013 Jan 15;19(2):357-66. doi: 10.1158/1078-0432.CCR-12-2333. Epub 2012 Dec 4.,"RESULTS: BMS-936564/MDX-1338 is a fully human IgG(4) monoclonal antibody that specifically recognizes human CXCR4. In vitro studies show that MDX-1338 binds to CXCR4-expressing cells with low nanomolar affinity, blocks CXCL12 binding to CXCR4-expressing cells, and i …"
2020-09-23T05:55:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=SGN-LIV1A&sort=date&size=20,Antibody-drug conjugates in triple negative breast cancer.,Future Oncol. 2018 Oct;14(25):2651-2661. doi: 10.2217/fon-2018-0131. Epub 2018 Sep 3.,"This review will highlight three antibody-drug conjugates currently being evaluated in TNBC (CDX-011, SGN-LIV1a, IMMU-132), including one that has been given Breakthrough Therapy designation from the US FDA...."
2020-09-23T05:55:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=SGN-LIV1A&sort=date&size=20,SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer.,Mol Cancer Ther. 2014 Dec;13(12):2991-3000. doi: 10.1158/1535-7163.MCT-13-0896. Epub 2014 Sep 24.,"In this article, we describe a novel antibody-drug conjugate (ADC; SGN-LIV1A), targeting the zinc transporter LIV-1 (SLC39A6) for the treatment of metastatic breast cancer. ...These results support the clinical evaluation of SGN-LIV1A as a novel therap …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer.,Urol Oncol. 2020 Sep 18:S1078-1439(20)30370-7. doi: 10.1016/j.urolonc.2020.08.003. Online ahead of print.,"The phase 3 PROSPER, SPARTAN, and ARAMIS trials for enzalutamide, apalutamide, and darolutamide, the 3 approved androgen receptor inhibitors for men with nmCRPC, were all associated with increased metastasis-free survival in patients with metastatic castration-resistant pr …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,"Advances in urologic oncology ""OncoForum"": The best of 2019.",Actas Urol Esp. 2020 Sep 15:S0210-4806(20)30153-4. doi: 10.1016/j.acuro.2020.06.007. Online ahead of print.,"The benefit of enzalutamide and apalutamide associated with castration has been confirmed in M1 PCa patients, regardless of disease volume. ...The arrival of new agents for advanced urothelial carcinoma should be highlighted, and the efficacy of enzalutamide and apaluta …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer.,Drugs. 2020 Sep 15. doi: 10.1007/s40265-020-01401-0. Online ahead of print.,"Apalutamide (Erleada(®)) is an oral selective androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. ...Although mature OS data are awaited with interest, the addition of apalutamide to ADT extends the treatment options availabl …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,"Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.",Int J Clin Oncol. 2020 Sep 14. doi: 10.1007/s10147-020-01777-9. Online ahead of print.,"For MFS, apalutamide, darolutamide, and enzalutamide were significantly more effective than placebo, and apalutamide emerged as the best option (P score: 0.8809). ...For PSA-PFS, all three agents were statistically superior to placebo, and apalutamide emerged …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review.,Cancers (Basel). 2020 Sep 9;12(9):E2568. doi: 10.3390/cancers12092568.,"The aim of this systematic review is to describe the evidence about cognitive function in all the randomized trials (RCTs) testing NGHT (abiraterone, enzalutamide, apalutamide, darolutamide). ..."
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Apalutamide and Overall Survival in Prostate Cancer.,Eur Urol. 2020 Sep 6:S0302-2838(20)30628-X. doi: 10.1016/j.eururo.2020.08.011. Online ahead of print.,Subsequent life-prolonging therapy was received by 371 (46%) patients in the apalutamide arm and by 338 (84%) patients in the placebo arm including 59 patients who received apalutamide after crossover. ...CONCLUSIONS: Extension of OS with apalutamide compared …
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.,Cancer Cell. 2020 Aug 25:S1535-6108(20)30414-1. doi: 10.1016/j.ccell.2020.08.003. Online ahead of print.,
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.,Future Oncol. 2020 Sep 4. doi: 10.2217/fon-2020-0557. Online ahead of print.,"Apalutamide, a next-generation androgen receptor inhibitor, has recently been shown to provide an added survival benefit in the treatment of mCSPC and consequently approved for this indication. This review summarizes the body of evidence with regards to the preclinical act …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.,BMC Urol. 2020 Sep 2;20(1):139. doi: 10.1186/s12894-020-00689-0.,"Most (85.7%) skin rash occurred within 4 months of apalutamide initiation and resolved in a median time of 1 month following the use of antihistamines, topical or systemic corticosteroids, with/without apalutamide dose interruptions/reductions. ...There is a potenti …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair.,Cancers (Basel). 2020 Aug 31;12(9):E2467. doi: 10.3390/cancers12092467.,"Here, we evaluated the potential radiosensitizing effect of the second-generation antiandrogens abiraterone acetate, apalutamide and enzalutamide. (2) Methods: Cell proliferation and agarose-colony forming assay were used to measure the effect on survival. ...These finding …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Inferences about drug safety in phase 3 trials in oncology: Examples from advanced prostate cancer.,J Natl Cancer Inst. 2020 Aug 28:djaa134. doi: 10.1093/jnci/djaa134. Online ahead of print.,"METHODS: We assessed consistency in AE reporting, AE risk in placebo arms, and methodology used for risk estimates and quantification of statistical uncertainty in randomized placebo-controlled phase 3 trials of apalutamide, enzalutamide and darolutamide in advanced prosta …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists.,Can Urol Assoc J. 2020 Aug 18. doi: 10.5489/cuaj.6779. Online ahead of print.,"Radiation to the prostate for low-volume mCSPC was identified as a treatment practice by 27% of community physicians, and 35% indicated docetaxel as the next line of treatment after use of apalutamide. ..."
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients.,Radiol Med. 2020 Aug 27. doi: 10.1007/s11547-020-01264-1. Online ahead of print.,"CONCLUSION: Our survey established the prescription attitude of ADT and new hormonal agents (abiraterone, enzalutamide, apalutamide) by Italian Radiation Oncologists and highlighted the importance of expertise in global PC management...."
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,"Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.",Cancer Treat Res Commun. 2020 Aug 12;25:100205. doi: 10.1016/j.ctarc.2020.100205. Online ahead of print.,"Since 2018, apalutamide, darolutamide, and enzalutamide have been approved for the treatment of men with non-metastatic castration-resistant prostate cancer (M0CRPC). ...Based on these results, apalutamide, darolutamide, and enzalutamide can now be considered the st …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Linked Entity Attribute Pair (LEAP): A Harmonization Framework for Data Pooling.,JCO Clin Cancer Inform. 2020 Aug;4:691-699. doi: 10.1200/CCI.20.00037.,
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,The evolving options in metastatic castration-sensitive prostate cancer.,Curr Opin Support Palliat Care. 2020 Sep;14(3):270-275. doi: 10.1097/SPC.0000000000000507.,"RECENT FINDINGS: Two recent combinations, enzalutamide with ADT and apalutamide with ADT were tested in metastatic castration-sensitive prostate cancer in three randomized controlled trials. ..."
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting.,Oncol Ther. 2020 Jun 15. doi: 10.1007/s40487-020-00119-z. Online ahead of print.,"This changed when studies showed that the addition of docetaxel chemotherapy or abiraterone acetate to ADT significantly increases overall survival of patients with mHSPC, followed by more recent evidence showing the efficacy of androgen receptor antagonists, such as enzalutamide …"
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.,Cancer Cell. 2020 Aug 10;38(2):279-296.e9. doi: 10.1016/j.ccell.2020.06.005. Epub 2020 Jul 16.,
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Recent developments in the treatment of non-metastatic castration resistant prostate cancer.,Cancer Treat Res Commun. 2020;24:100181. doi: 10.1016/j.ctarc.2020.100181. Epub 2020 May 22.,"Recently enzalutamide, apalutamide, and darolutamide respectively, were tested in this disease setting with metastasis free survival (MFS) as the primary endpoint for each trial. ..."
2020-09-23T05:55:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=APALUTAMIDE&sort=date&size=20,Treating De Novo Metastatic Castration-Sensitive Prostate Cancer With Visceral Metastases: An Evolving Issue.,Clin Genitourin Cancer. 2020 Jun 10:S1558-7673(20)30140-3. doi: 10.1016/j.clgc.2020.06.001. Online ahead of print.,
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer.,Expert Opin Investig Drugs. 2019 Aug;28(8):667-673. doi: 10.1080/13543784.2019.1648430. Epub 2019 Jul 30.,"This novel agent is known as Etirinotecan Pegol (EP). EP, like irinotecan, exerts its action through its principal metabolite SN-38. ..."
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.,Future Oncol. 2019 Jul;15(19):2211-2225. doi: 10.2217/fon-2019-0180. Epub 2019 May 10.,"The long-acting topoisomerase-1 inhibitor, etirinotecan pegol, was designed to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels. Motivated by improved survival findings from subgroup analyses from the Ph …"
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,"Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent.",Eur J Med Chem. 2018 Oct 5;158:82-90. doi: 10.1016/j.ejmech.2018.08.091. Epub 2018 Aug 31.,"Antitumor activity screening assay indicated that BGC0222 exhibited better in vitro antiproliferation activity than irinotecan and NKTR-102 against HT29, MIA PaCa-2 and MCF-7 tumor cell lines, with IC(50) of 1.83 ± 0.09 μM, 3.95 ± 0.16 μM and 0.68 ± 0.04 μM, respect …"
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.,Clin Cancer Res. 2018 Jul 15;24(14):3348-3357. doi: 10.1158/1078-0432.CCR-17-3059. Epub 2018 Apr 4.,Purpose: Preplanned exploratory analyses were performed to identify biomarkers in circulating tumor cells (CTC) predictive of response to the topoisomerase 1 inhibitor etirinotecan pegol (EP).Experimental Design: The BEACON trial treated patients with metastatic bre …
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.,Pharmacol Res. 2018 Jun;132:47-68. doi: 10.1016/j.phrs.2018.03.021. Epub 2018 Mar 28.,
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.,Cancer Chemother Pharmacol. 2018 May;81(5):897-909. doi: 10.1007/s00280-018-3562-3. Epub 2018 Mar 21.,"PURPOSE: Etirinotecan pegol (EP), a long-acting topoisomerase-1 inhibitor, is a polyethylene glycol conjugate of irinotecan, with an intended indication for treatment of breast cancer with brain metastases. ..."
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study.,Clin Lung Cancer. 2018 Mar;19(2):157-162. doi: 10.1016/j.cllc.2017.10.007. Epub 2017 Oct 19.,Etirinotecan pegol (NKTR-102) is a long-acting topoisomerase-I inhibitor. We conducted a single-arm phase II trial to evaluate its efficacy in third-line treatment. ...CONCLUSIONS: Etirinotecan pegol was well tolerated and led to 2 partia …
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.,Cancer Chemother Pharmacol. 2017 Dec;80(6):1161-1169. doi: 10.1007/s00280-017-3438-y. Epub 2017 Oct 17.,PURPOSE: Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor designed to provide sustained exposure to SN-38 (active metabolite of irinotecan). ...
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,"A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.",Gynecol Oncol. 2017 Nov;147(2):276-282. doi: 10.1016/j.ygyno.2017.08.026. Epub 2017 Sep 19.,OBJECTIVE: Etirinotecan pegol (EP) is a novel polyethylene glycol conjugated form of irinotecan with documented activity in platinum-resistant ovarian cancer (PROC). ...
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.,Breast Cancer Res Treat. 2017 Sep;165(2):329-341. doi: 10.1007/s10549-017-4304-7. Epub 2017 Jun 13.,"Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 inhibitor, was designed using advanced polymer technology to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels. ..."
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.,Eur J Cancer. 2017 May;76:205-215. doi: 10.1016/j.ejca.2017.02.011. Epub 2017 Mar 27.,"Although the primary end-point was not achieved, the BEACON (BrEAst Cancer Outcomes with NKTR-102) trial established etirinotecan pegol, a long-acting topoisomerase-1 (TOP1) inhibitor, as a promising therapeutic for patients with advanced/metastatic br …"
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.,Cancer Chemother Pharmacol. 2017 Jan;79(1):57-67. doi: 10.1007/s00280-016-3192-6. Epub 2016 Nov 30.,PURPOSE: The relationship between incidences of neutropenia and 10-hydroxy-7-ethyl camptothecin (SN38) exposure was explored using SN38 pharmacokinetic and neutrophil count data from toxicology studies of etirinotecan pegol (EP) and irinotecan in beagle dogs. ...
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,"Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.",Springerplus. 2016 Jul 8;5(1):1033. doi: 10.1186/s40064-016-2446-4. eCollection 2016.,Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor with a unique toxicity profile. The randomized phase 3 BEACON study that compared EP to treatment of physician's choice (TPC) demonstrated its clinical activity. ...
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Etirinotecan pegol for the treatment of breast cancer.,Expert Opin Pharmacother. 2016;17(5):727-34. doi: 10.1517/14656566.2016.1154537. Epub 2016 Mar 10.,AREAS COVERED: This review examines etirinotecan pegol as a promising new agent for the treatment of refractory metastatic breast cancer. ...Etirinotecan pegol pharmacology is reviewed in this paper along with safety and efficacy data from preclinical …
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer.,Crit Rev Oncol Hematol. 2016 Apr;100:74-87. doi: 10.1016/j.critrevonc.2016.01.021. Epub 2016 Jan 23.,"Etirinotecan pegol, comprising irinotecan bound to polyethylene glycol by a biodegradable linker, is a new cytotoxic agent for patients with MBC that has achieved encouraging response rates in phase II studies; it has been further evaluated in the phase III BEACON t …"
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,"Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.",Lancet Oncol. 2015 Nov;16(15):1556-1568. doi: 10.1016/S1470-2045(15)00332-0. Epub 2015 Oct 22.,"Etirinotecan pegol is a long-acting topoisomerase-I inhibitor that prolongs exposure to, but reduces the toxicity of, SN38 (the active metabolite of irinotecan). ...METHODS: In this open-label, multicentre, randomised phase 3 study (BEACON; BrEAst Cancer Outcomes wi …"
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.,BMC Cancer. 2015 Oct 13;15:685. doi: 10.1186/s12885-015-1672-4.,Treatment with NKTR-102 extended survival time (from 35 days to 74 days) and increased overall survival for NKTR-102 low dose (30 % mice) and NKTR-102 high dose (50 % mice). Tumor burden decreased (37 % with 10 mg/kg NKTR-102 …
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer.,Future Oncol. 2015;11(12):1775-89. doi: 10.2217/fon.15.80.,"Thereafter, the potential role and safety profile of etirinotecan pegol is discussed given the results recently released of a Phase III trial comparing this agent to Treatment of Physician's Choice...."
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.,J Med Case Rep. 2015 Feb 12;9:5. doi: 10.1186/1752-1947-9-5.,"To the best of our knowledge, this is the first case report of an impressive iterative response to pegylated irinotecan NKTR-102 in metastatic breast cancer. ...The results of the current phase III trials of pegylated irinotecan NKTR-102 are eagerly aw …"
2020-09-23T05:55:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=ETIRINOTECANPEGOL(NKTR-102)&sort=date&size=20,Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.,J Neurooncol. 2015 Jun;123(2):277-82. doi: 10.1007/s11060-015-1795-0. Epub 2015 May 3.,Etirinotecan pegol (EP) is the first long-acting topoisomerase-I inhibitor designed to concentrate in and provide continuous tumor exposure throughout the entire chemotherapy cycle. ...
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.,PLoS One. 2020 Sep 22;15(9):e0238807. doi: 10.1371/journal.pone.0238807. eCollection 2020.,"METHODS: Between April 2001 and November 2018, 120 patients with complete remission following rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy were retrospectively reviewed. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.,Blood. 2020 Sep 21:blood.2020006578. doi: 10.1182/blood.2020006578. Online ahead of print.,"The phase II CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective, B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L) diffuse large B-cell lymphoma ( …"
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,"A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.",Medicine (Baltimore). 2020 Sep 18;99(38):e22238. doi: 10.1097/MD.0000000000022238.,"BACKGROUND: Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma. ...CONCLUSION: Evidently, the conclusion of this study will provide an assessment on whether combined procarbazi …"
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.,Int J Hematol. 2020 Sep 19. doi: 10.1007/s12185-020-03006-5. Online ahead of print.,"Because her ALL had been identified as BCR-ABL1-like ALL with CCDC88C-PDGFRB fusion, she was treated with imatinib for 2 months accompanied by 2 intrathecal methotrexate therapies, and 1 course of L-asparaginase, vincristine, and prednisolone in an outpatient setting. ..."
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Radiosensitization by kinase inhibition revealed by phosphoproteomic analysis of pancreatic cancer cells.,Mol Cell Proteomics. 2020 Jul 10:mcp.RA120.002046. doi: 10.1074/mcp.RA120.002046. Online ahead of print.,Pharmacological inhibition of the kinases FAK by Defactinib and of CHEK1 by Rabusertib showed a statistically significant sensitization to radiation in radioresistant PDAC cells. ...
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,"Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.",Clin Lymphoma Myeloma Leuk. 2020 Aug 27:S2152-2650(20)30436-5. doi: 10.1016/j.clml.2020.08.018. Online ahead of print.,"Fifty-four percent of patients were men; 45.6% had advanced stage disease; 82% were treated with ABVD (doxorubicin hydrochloride [adriamycin], bleomycin sulfate, vincristine, and dacarbazine) as frontline therapy; and 70% achieved complete response. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments.,BMC Med Genomics. 2020 Sep 18;13(Suppl 8):111. doi: 10.1186/s12920-020-00759-0.,"Chemotherapeutics included taxanes, bortezomib, vincristine, trastuzumab, letrozole, tipifarnib, temozolomide, busulfan and cyclophosphamide...."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Gene Expression Signature of Acquired Chemoresistance in Neuroblastoma Cells.,Int J Mol Sci. 2020 Sep 16;21(18):E6811. doi: 10.3390/ijms21186811.,"In the present study, we aimed to identify chemoresistance gene expression signatures in vincristine resistant neuroblastoma cells. We found that vincristine-resistant neuroblastoma cells formed larger clones and survived under reduced serum conditions as compared w …"
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Prognostic Models Integrating Quantitative Parameters from Baseline and Interim Positron Emission Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma: Post-Hoc Analysis from the SAKK38/07 Clinical Trial.,Hematol Oncol. 2020 Sep 18. doi: 10.1002/hon.2805. Online ahead of print.,"We centrally reviewed baseline and interim PET/CT scans of 138 patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone given every 14 days (R-CHOP14) in the SAKK38/07 trial (ClinicalTrial.gov identifier: NCT00544219). ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,"Discovery of a cobalt (III) salen complex that induces apoptosis in Burkitt like lymphoma and leukemia cells, overcoming multidrug resistance in vitro.",Bioorg Chem. 2020 Sep 1;104:104193. doi: 10.1016/j.bioorg.2020.104193. Online ahead of print.,"MBR-60 displays synergistic effects with daunorubicin and vincristine and has a selectivity to tumor cells. In comparison to the apoptotic effects of MBR-60 in BJAB lymphoma cells, the cobalt-free ligand 5 does not influence these cells. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Detection of chemotherapy-resistant patient-derived acute lymphoblastic leukemia clones in murine xenografts using cellular barcodes.,Exp Hematol. 2020 Sep 15:S0301-472X(20)30553-1. doi: 10.1016/j.exphem.2020.09.188. Online ahead of print.,"We transplanted Nod/Scid/Il2Rγ(-/-) (NSG) mice with barcoded patient-derived or SupB15 acute lymphoblastic leukemia (ALL) cells, and assessed clonal responses to dexamethasone, methotrexate and vincristine, longitudinally and across nine anatomical locations. ...At end-sta …"
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Tumor Supernatant Derived from Hepatocellular Carcinoma Cells Treated with Vincristine Sulfate have Therapeutic Activity.,Eur J Pharm Sci. 2020 Sep 15:105557. doi: 10.1016/j.ejps.2020.105557. Online ahead of print.,"Vincristine sulfate (VCR), a commonly used chemotherapeutic agent, kills cancer cells as well as the normal cells for its cytotoxicity. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,"Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy.",Br J Haematol. 2020 Sep 18. doi: 10.1111/bjh.17103. Online ahead of print.,"Of all 80 patients, 54 (68%) pregnant patients received chemotherapy; mostly (89%) CHOP-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,"CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUP‑B15 cells.",Mol Med Rep. 2020 Jul 20. doi: 10.3892/mmr.2020.11350. Online ahead of print.,"In addition, CD9 knockdown could suppress cell proliferation, adhesion, migration and invasion, and promote apoptosis and the efficacy of chemotherapeutic drugs (such as vincristine, daunorubicin, cyclophosphamide and dexamethasone) and the tyrosine kinase inhibitor imatin …"
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells.,Mol Med Rep. 2020 Jul 17. doi: 10.3892/mmr.2020.11347. Online ahead of print.,"Downregulation of CREBBP increased the IC50 value of daunorubicin; however, no significant affects were observed on the IC50 values of vincristine and L‑asparaginase. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.,Clin Transl Oncol. 2020 Sep 17. doi: 10.1007/s12094-020-02483-8. Online ahead of print.,"Three databases (Medline via PUBMED, SCOPUS, and Cochrane Library) were searched for studies featuring males aged 13-51-years who underwent chemotherapy for HL using ABVD (Adriamycin® (doxorubicin), bleomycin, vinblastine, and dacarbazine) or BEACOPP (bleomycin, etoposide, doxoru …"
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.,Blood Adv. 2020 Sep 22;4(18):4451-4462. doi: 10.1182/bloodadvances.2020002546.,"We report survival analyses of 431 patients who received frontline rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for advanced FL, and were randomized to receive consolidative HDT/ASCT. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis.,Blood Adv. 2020 Sep 22;4(18):4442-4450. doi: 10.1182/bloodadvances.2020002293.,"Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOP-like regimens with or without rituximab (n = 48) were the most common primary treatments. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy.,Cancer Med. 2020 Sep 14. doi: 10.1002/cam4.3448. Online ahead of print.,"All were treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), plus rituximab for CD20-positive lymphomas. ..."
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Sticking it to KRAS: Covalent Inhibitors Enter the Clinic.,Cancer Cell. 2020 Jan 13;37(1):3-4. doi: 10.1016/j.ccell.2019.12.009.,"Drugs that target KRAS 12C covalently, AMG 510 and MRTX849, are now in the clinic. Recent papers describe development of these compounds, their selectivity and properties, early clinical data, and potential combination therapies. ..."
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,A Case of Resolved Vincristine-Induced Constipation Following Osteopathic Medicine in a Patient With Infantile Fibrosarcoma.,J Am Osteopath Assoc. 2020 Oct 1;120(10):691-695. doi: 10.7556/jaoa.2020.102.,Vincristine-induced constipation is a common side effect in pediatric oncology patients. We report the case of an infant with histologic diagnosis of infantile fibrosarcoma who developed significant constipation because of ongoing vincristine administration. ...
2020-09-23T05:55:45Z,https://pubmed.ncbi.nlm.nih.gov/?term=VINCRISTINE&sort=date&size=20,Primary Pancreatic Large B-Cell Lymphoma Presenting as Acute Pancreatitis.,Cureus. 2020 Aug 6;12(8):e9583. doi: 10.7759/cureus.9583.,"The patient achieved remission after six cycles of rituximab-cyclophosphamide, doxorubicin (hydroxydaunomycin), vincristine (oncovin), prednisolone (R-CHOP) chemotherapy...."
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Early-stage sugar beet taproot development is characterized by three distinct physiological phases.,Plant Direct. 2020 Aug 1;4(7):e00221. doi: 10.1002/pld3.221. eCollection 2020 Jul.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Emotional Well-Being and Cognitive Function Have Robust Relationship With Physical Frailty in Institutionalized Older Women.,Front Psychol. 2020 Jul 16;11:1568. doi: 10.3389/fpsyg.2020.01568. eCollection 2020.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Immunogenicity of HLA-DR1 and HLA-A2 peptides derived from Leishmania major Gp63 in golden hamsters.,Parasite Immunol. 2020 Aug 1:e12780. doi: 10.1111/pim.12780. Online ahead of print.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Herb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review.,Chin Med. 2020 Jul 25;15:75. doi: 10.1186/s13020-020-00356-4. eCollection 2020.,"In clinical practice, the most commonly used cytotoxic drugs with Lingzhi were cisplatin, 5-fluorouracil (5-FU) and paclitaxel, whereas Tegafur/uracil (UFT)/Tegafur, 5-FU, and mitomycin were the ones used more often with Yunzhi. ..."
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,[Bevacizumab plus UFT Regimen for Four Patients with Stage Ⅳ Colorectal Cancer Receiving Hemodialysis].,Gan To Kagaku Ryoho. 2020 Jul;47(7):1117-1119.,We present case reports of 4 patients on hemodialysis with Stage Ⅳ colorectal cancer who received regular dose bevacizumab( twice per week)plus a daily dose of UFT chemotherapy. ...It is possible that the bevacizumab plus UFT regimen may be acceptable in patients wi …
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Methodologies for assessing the household food availability in the context of food (in)security: a systematic review.,Cien Saude Colet. 2020 Jul 8;25(7):2677-2685. doi: 10.1590/1413-81232020257.29342018.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Hydrolysis of sweet potato (Ipomoea batatas (L.) Lam.) flour by Candida homilentoma strains: effects of pH and temperature using Central Composite Rotatable Design.,An Acad Bras Cienc. 2020;92(2):e20180410. doi: 10.1590/0001-3765202020180410. Epub 2020 Jul 13.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,A case of an enlarged rectal adenoma while achieving a clinical complete response with chemotherapy for advanced rectal cancer.,Clin J Gastroenterol. 2020 Jun 29. doi: 10.1007/s12328-020-01169-6. Online ahead of print.,"The rectal adenocarcinoma was treated with chemotherapy, including 1 cycle of capecitabin plus oxaliplatin (CapeOX), 22 cycles of tegafur/gimeracil/oteracil (S-1) plus irinotecan (IRIS), and 1 cycle of tegafur (UFT) plus calcium folinate (LV). ..."
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,"Sulfidation of sea urchin-like zinc oxide nanospheres: Kinetics, mechanisms, and impacts on growth of Escherichia coli.",Sci Total Environ. 2020 Nov 1;741:140415. doi: 10.1016/j.scitotenv.2020.140415. Epub 2020 Jun 22.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Weight Loss After RYGB Is Associated with an Increase in Serum Vitamin D in a Population with Low Prevalence of Hypovitaminosis D at Low Latitude.,Obes Surg. 2020 Jun 18. doi: 10.1007/s11695-020-04780-1. Online ahead of print.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Lethal and sublethal effects of the saline stressor sodium chloride on Chironomus xanthus and Girardia tigrina.,Environ Sci Pollut Res Int. 2020 Sep;27(27):34223-34233. doi: 10.1007/s11356-020-09556-9. Epub 2020 Jun 16.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,The Preoperative Dietary Inflammatory Index Predicts Changes in Cardiometabolic Risk Factors After 12 Months of Roux-en-Y Gastric Bypass.,Obes Surg. 2020 Oct;30(10):3932-3939. doi: 10.1007/s11695-020-04756-1.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,A meta-analysis to assess long-term spatiotemporal changes of benthic coral and macroalgae cover in the Mexican Caribbean.,Sci Rep. 2020 Jun 1;10(1):8897. doi: 10.1038/s41598-020-65801-8.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Discoid Lupus Erythematosus Lesions Associated with Systemic Fluorouracil Agents: A Case Report and Review.,Cureus. 2020 Apr 25;12(4):e7828. doi: 10.7759/cureus.7828.,"Systemic fluorouracil agents include not only 5-fluorouracil (5FU), but also capecitabine, tegafur, and uracil/tegafur (UFT). ...Fluorouracil agent-induced DLE lesions occurring after initiating treatment with either systemic 5FU or its prodrugs have been described in 19 i …"
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,The risk of COVID-19 transmission in favelas and slums in Brazil.,Public Health. 2020 Jun;183:42-43. doi: 10.1016/j.puhe.2020.04.042. Epub 2020 May 8.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,Comments on the Classification of Neotropical Scionini (Tabanidae) with a Description of a New Genus.,Neotrop Entomol. 2020 Jun;49(3):412-419. doi: 10.1007/s13744-020-00767-w. Epub 2020 May 12.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,[A Case of Duodenal Cancer with Advanced Lymph Node Metastasis Treated with mFOLFOX6 Preoperative Chemotherapy].,Gan To Kagaku Ryoho. 2020 Apr;47(4):625-627.,"UFT/UZEL supplemental postoperative chemotherapy was administered for 6 months. The patient remained alive, with no remissions 3 years post-surgery...."
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,"Yeast in plant phytotelmata: Is there a ""core"" community in different localities of rupestrian savannas of Brazil?",Braz J Microbiol. 2020 Sep;51(3):1209-1218. doi: 10.1007/s42770-020-00286-1. Epub 2020 May 8.,
2020-09-23T05:55:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=UFT&sort=date&size=20,[Locally Advanced Rectal Cancer Curatively Resected after Modified FOLFOXIRI plus Bevacizumab Chemotherapy-A Case Report].,Gan To Kagaku Ryoho. 2020 Mar;47(3):453-455.,The patient has been receiving adjuvant chemotherapy with oral UFT/UZEL for 6months. No recurrence has been observed for the past 4 months....
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Defactinib attenuates osteoarthritis by inhibiting positive feedback loop between H-type vessels and MSCs in subchondral bone.,J Orthop Translat. 2020 May 19;24:12-22. doi: 10.1016/j.jot.2020.04.008. eCollection 2020 Sep.,RESULTS: This study demonstrated that inhibition of H-type vessels with defactinib alleviated OA by inhibiting H-type vessel-linked MSCs in subchondral bone. ...THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE: Our results provide a mechanistic rationale for the use of defac …
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype.,Apoptosis. 2020 Aug;25(7-8):535-547. doi: 10.1007/s10495-020-01612-6.,"Combination of CP-31398 and defactinib, a FAK inhibitor, also achieved synergistic inhibitory effects and increased p53 with FAK dephosphorylation levels greater than the single treatment. ..."
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,"Feed‑back loops integrating RELA, SOX18 and FAK mediate the break‑down of the lymph‑endothelial barrier that is triggered by 12(S)‑HETE.",Int J Oncol. 2020 Apr;56(4):1034-1044. doi: 10.3892/ijo.2020.4985. Epub 2020 Feb 13.,"The silencing of a combination of these signalling and executing molecules using siRNA, or pharmacological inhibition with defactinib and Bay11‑7082, extended the mono‑culture experiments to co‑culture settings using HCT116 colon cancer cell spheroids that were placed on t …"
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,"Mesothelioma: Hippo pathway as a target, lessons from COMMAND.",Oncotarget. 2019 Jun 18;10(40):3996-3997. doi: 10.18632/oncotarget.27018. eCollection 2019 Jun 18.,
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.,Respir Res. 2019 Dec 2;20(1):270. doi: 10.1186/s12931-019-1244-2.,Oral defactinib and osimertinib were administered in mice bearing subcutaneous xenografts to evaluate the efficacy of the treatment combination in vivo. ...Combination of PTK2 inhibitor and EGFR-TKI (defactinib and osimertinib) recovered EGFR-TKI sensitivity in the …
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.,Lung Cancer. 2020 Jan;139:60-67. doi: 10.1016/j.lungcan.2019.10.033. Epub 2019 Nov 4.,Defactinib (VS-6063) is a selective oral inhibitor of FAK. MATERIALS AND METHODS: Patients with previously treated advanced KRAS mutant NSCLC were prospectively assigned to one of four molecularly defined cohorts based on the presence or absence of TP53 or CD …
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Questions Regarding the Randomized Phase II Trial of Defactinib as Maintenance Therapy in Malignant Pleural Mesothelioma.,J Clin Oncol. 2019 Sep 1;37(25):2293-2294. doi: 10.1200/JCO.19.00891. Epub 2019 Jul 22.,
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Reply to K. Masuda et al.,J Clin Oncol. 2019 Sep 1;37(25):2294-2295. doi: 10.1200/JCO.19.01208. Epub 2019 Jul 22.,
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,"Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.",J Clin Oncol. 2019 Apr 1;37(10):790-798. doi: 10.1200/JCO.2018.79.0543. Epub 2019 Feb 20.,RESULTS: Three hundred forty-four patients were randomly assigned to receive either defactinib (n = 173) or placebo (n = 171). ...CONCLUSION: Neither PFS nor OS was improved by defactinib after first-line chemotherapy in patients with merlin-low MPM. Defactinib …
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.,Haematologica. 2019 Jul;104(7):e310-e313. doi: 10.3324/haematol.2018.194688. Epub 2019 Jan 17.,
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.,Lung Cancer. 2018 Dec;126:15-24. doi: 10.1016/j.lungcan.2018.10.015. Epub 2018 Oct 16.,"Three inhibitors were more efficient than cisplatin, the drug used as first-line chemotherapy in patients with MPM: verteporfin, a putative YAP inhibitor, defactinib, a FAK inhibitor and NSC668394, an Ezrin inhibitor. ..."
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation.,J Am Chem Soc. 2018 Dec 12;140(49):17019-17026. doi: 10.1021/jacs.8b08008. Epub 2018 Nov 28.,"Here, we report the development of a selective and potent Fak degrader, PROTAC-3, which outperforms a clinical candidate, defactinib, with respect to Fak activation as well as Fak-mediated cell migration and invasion. ..."
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.,PLoS One. 2018 Jun 21;13(6):e0199361. doi: 10.1371/journal.pone.0199361. eCollection 2018.,"Similarly, our new anti-CD133 antibody enabled detection and quantitation of drug-induced reductions in CD133-positive tumor cells following treatment of SUM149PT triple-negative breast cancer xenograft models with the CSC/focal adhesion kinase (FAK) inhibitor VS-6063 …"
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,β1 integrin-mediated multicellular resistance in hepatocellular carcinoma through activation of the FAK/Akt pathway.,J Int Med Res. 2018 Apr;46(4):1311-1325. doi: 10.1177/0300060517740807. Epub 2018 Jan 14.,
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.,Prostate. 2018 Mar;78(4):308-317. doi: 10.1002/pros.23476. Epub 2018 Jan 5.,The aim of this study was to investigate the effect of the second generation FAK inhibitor VS-6063 on docetaxel efficacy in pre-clinical CRPC and CSPC models. ...Patient-derived prostate tumor explants cultured with both docetaxel and VS-6063 displayed …
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.,Cancer Biol Ther. 2018 Apr 3;19(4):316-327. doi: 10.1080/15384047.2017.1416937. Epub 2018 Feb 22.,"Then we analyze effects of two small molecule inhibitors PF-573228, and PF-431396, which are dual specificity inhibitors of FAK and proline rich tyrosine kinase 2 (PYK2), as well as VS-6063, another small molecule inhibitor that specifically inhibits FAK but not PYK …"
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,"LC-ESI-MS/MS determination of defactinib, a novel FAK inhibitor in mice plasma and its application to a pharmacokinetic study in mice.",J Pharm Biomed Anal. 2018 Feb 5;149:358-364. doi: 10.1016/j.jpba.2017.11.022. Epub 2017 Nov 10.,"A sensitive, specific, selective and rapid LC-ESI-MS/MS method has been developed and validated for the quantification of defactinib in mice plasma using (13)C(3,)(15)N-tofacitinib as an internal standard (I.S.). ...Defactinib was found to be stable under various st …"
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.,Oncotarget. 2017 May 23;8(32):53068-53083. doi: 10.18632/oncotarget.18087. eCollection 2017 Aug 8.,"Prompted by our observation of a correlation between PTEN loss and FAK phosphorylation in a cohort of patients with stage IV SCC, we evaluated the relevance of PTEN loss in cancer progression as well as the efficacy of a new combined treatment with the pan PI3K inhibitor buparlis …"
2020-09-23T05:55:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=DEFACTINIB(VS-6063)&sort=date&size=20,Stem Cell Factor-Based Identification and Functional Properties of In Vitro-Selected Subpopulations of Malignant Mesothelioma Cells.,Stem Cell Reports. 2017 Apr 11;8(4):1005-1017. doi: 10.1016/j.stemcr.2017.02.005. Epub 2017 Mar 9.,"CSC-enriched MM cell subpopulations were identified by an OCT4/SOX2 reporter approach and were characterized by (1) increased resistance to cisplatin, (2) increased sensitivity toward the FAK inhibitor VS-6063 in vitro, and (3) a higher tumor-initiating capacity in …"
2020-09-23T05:56:03Z,https://pubmed.ncbi.nlm.nih.gov/?term=CDX-1401&sort=date&size=20,NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.,Clin Cancer Res. 2018 Mar 1;24(5):1019-1029. doi: 10.1158/1078-0432.CCR-17-1792. Epub 2017 Sep 25.,We hypothesized that vaccinating against NY-ESO-1 in patients with MDS receiving decitabine would capitalize upon induced NY-ESO-1 expression in malignant myeloid cells to provoke an NY-ESO-1-specific MDS-directed cytotoxic T-cell immune response.Experimental Design: In a phase I …
2020-09-23T05:56:03Z,https://pubmed.ncbi.nlm.nih.gov/?term=CDX-1401&sort=date&size=20,Cancer vaccine shows benefit in solid tumors.,Cancer Discov. 2014 Jul;4(7):OF4. doi: 10.1158/2159-8290.CD-NB2014-072. Epub 2014 May 15.,"In a phase I clinical trial, the cancer vaccine CDX-1401 was well tolerated in 45 patients with solid tumors and produced some immune responses...."
2020-09-23T05:56:03Z,https://pubmed.ncbi.nlm.nih.gov/?term=CDX-1401&sort=date&size=20,Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.,Sci Transl Med. 2014 Apr 16;6(232):232ra51. doi: 10.1126/scitranslmed.3008068.,"CDX-1401 is a vaccine composed of a human mAb specific for DEC-205 fused to the full-length tumor antigen NY-ESO-1. This phase 1 trial assessed the safety, immunogenicity, and clinical activity of escalating doses of CDX-1401 with the Toll-like recepto …"
2020-09-23T05:56:03Z,https://pubmed.ncbi.nlm.nih.gov/?term=CDX-1401&sort=date&size=20,CDX-1401 combined with TLR agonist: positive phase 1 results.,Hum Vaccin Immunother. 2012 Dec 1;8(12):1742.,
2020-09-23T05:56:03Z,https://pubmed.ncbi.nlm.nih.gov/?term=CDX-1401&sort=date&size=20,Two therapeutic HPV vaccine candidates successful in phase 1.,Hum Vaccin Immunother. 2012 Dec 1;8(12):1741. doi: 10.4161/hv.23373.,Two therapeutic HPV vaccine candidates successful in phase 1 Flu shot may prevent heart attacks and stroke CDX-1401 combined with TLR agonist: Positive phase 1 results Three MRSA vaccines in early clincial trials Ovarian cancer vaccine candidate DPX-Survivac: Positi …
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.",EBioMedicine. 2020 Jul 7:102844. doi: 10.1016/j.ebiom.2020.102844. Online ahead of print.,"Patients were randomised (1:1:1) to aldesleukin 2 MIU, 1 MIU, or placebo once daily for 5 days every 4 weeks for 3 cycles. Primary outcome was change from baseline in Treg percentage of CD4(+) T cells (%Tregs) following a first cycle. ..."
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial.",Wellcome Open Res. 2020 Mar 20;5:49. doi: 10.12688/wellcomeopenres.15697.1. eCollection 2020.,"A total of 45 participants will be randomised in a 2:1 ratio to receive either ultra-low dose IL-2 (aldesleukin), at a dose of 0.2 x 10 (6) IU/m (2) twice-weekly, given subcutaneously, or placebo, for 6 months. ...The secondary objectives are: 1) to assess the efficacy of …"
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,Systemic Therapies for Advanced Melanoma.,Dermatol Clin. 2019 Oct;37(4):409-423. doi: 10.1016/j.det.2019.05.001. Epub 2019 Jul 10.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study.",J Clin Oncol. 2019 Oct 20;37(30):2759-2768. doi: 10.1200/JCO.18.02424. Epub 2019 Aug 13.,"Treatment consisted of autologous genetically engineered T cells expressing a T-cell receptor directed against HPV16 E6 (E6 T-cell receptor T cells), a conditioning regimen, and systemic aldesleukin. ..."
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort.,Eur J Cancer. 2019 Jul;115:61-67. doi: 10.1016/j.ejca.2019.03.023. Epub 2019 May 17.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"GOF/LOF knowledge inference with tensor decomposition in support of high order link discovery for gene, mutation and disease.",Math Biosci Eng. 2019 Feb 20;16(3):1376-1391. doi: 10.3934/mbe.2019067.,"At the end, a case study reproducing two disease-gene-drug links(Myelodysplatic Syndromes-IL2RA-Aldesleukin, Lymphoma- IL2RA-Aldesleukin) presented the feasibility of our prediction model for drug repurposing...."
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.,J Immunother Cancer. 2019 Mar 27;7(1):84. doi: 10.1186/s40425-019-0567-3.,METHODS: Survival of 810 mRCC patients treated from 2006 to 2017 with high dose IL-2 (aldesleukin) and enrolled in the PROCLAIM(SM) registry data base was assessed utilizing the International Metastatic RCC Database Consortium (IMDC) risk criteria. ...
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond.,Cancer Discov. 2020 Jan;10(1):20-22. doi: 10.1158/2159-8290.CD-19-1255.,Hallin and colleagues demonstrate the preclinical activity of the KRAS(G12C)-specific inhibitor MRTX849 in a series of in vitro and in vivo studies with supporting pilot clinical efficacy. ...
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.,Clin Cancer Res. 2019 Mar 1;25(5):1486-1493. doi: 10.1158/1078-0432.CCR-18-2722. Epub 2018 Dec 5.,Cell infusion was preceded by a lymphocyte-depleting conditioning regimen and followed by systemic high-dose aldesleukin. RESULTS: Objective tumor responses occurred in 5 of 18 (28%) patients in the cervical cancer cohort and 2 of 11 (18%) patients in the noncervical cance …
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.,JCI Insight. 2018 Oct 4;3(19):e99306. doi: 10.1172/jci.insight.99306.,"Using a response-adaptive design, we aimed to determine the optimal regimen of aldesleukin (recombinant human IL-2) to physiologically enhance Tregs while limiting expansion of Teffs. ...CONCLUSIONS: Using a response-adaptive design, aldesleukin treatment can be opt …"
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial.",BMJ Open. 2018 Sep 17;8(9):e022452. doi: 10.1136/bmjopen-2018-022452.,"Aldesleukin is a human recombinant form of IL-2 that has been used therapeutically in several autoimmune diseases. However, its safety and efficacy is unknown in the setting of coronary artery disease. ...The primary endpoint is safety and tolerability of aldesleukin …"
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,Aldesleukin.,2018 May 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.,"Aldesleukin is a recombinant form of human interleukin-2, a cytokine that stimulates the proliferation and maturation of T cells, which is used in immune therapy of renal cell cancer and malignant melanoma. ..."
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.,Oncoimmunology. 2018 Feb 1;7(5):e1423172. doi: 10.1080/2162402X.2017.1423172. eCollection 2018.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.,Acta Oncol. 2018 May;57(5):589-594. doi: 10.1080/0284186X.2018.1433324. Epub 2018 Feb 2.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer.,Gynecol Oncol Rep. 2017 Sep 25;22:43-44. doi: 10.1016/j.gore.2017.09.009. eCollection 2017 Nov.,•A case report of a 14 year remission of recurrent ovarian cancer with intraperitoneal aldesleukin (IL-2) is presented.•Intraperitoneal IL-2 was given with little toxicity....
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.,Wellcome Open Res. 2017 Oct 5;2:28. doi: 10.12688/wellcomeopenres.11300.3. eCollection 2017.,"To differentiate between the immune response to norovirus and to control for the administration of a single dose of aldesleukin (recombinant interleukin-2, rIL-2) alone, samples from five non-infected participants administered similar doses were analysed in parallel. ..."
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.",Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,"Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases.",Clin Exp Immunol. 2017 Jun;188(3):394-411. doi: 10.1111/cei.12940. Epub 2017 Mar 20.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,[Clinical Significance of the Balanceshift of Th1 and Th2 Type Cytokines in Patients with Primary Immune Thrombocytopenic Purpura Detected by Cytometric Bead Array].,Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Dec;24(6):1846-1849. doi: 10.7534/j.issn.1009-2137.2016.06.042.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.,Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29.,
2020-09-23T05:56:07Z,https://pubmed.ncbi.nlm.nih.gov/?term=ALDESLEUKIN&sort=date&size=20,FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.,Clin Cancer Res. 2017 May 1;23(9):2159-2168. doi: 10.1158/1078-0432.CCR-16-1874. Epub 2016 Oct 14.,"The previously published ""SELECT"" trial of high-dose aldesleukin (HD-IL2) for metastatic renal cell carcinoma resulted in an objective response rate of 25%. ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Novel approach to accurately predict bond strength and ligand lability in platinum-based anticancer drugs.,Dalton Trans. 2020 Sep 22;49(36):12632-12642. doi: 10.1039/d0dt02552f.,"In a second stage, we apply the IBSI score to a panel of eleven case studies, comprising mostly antineoplastic agents, such as cisplatin, carboplatin, lobaplatin etc., in order to quantify the coordinate bond strength of the ligands, providing insights about the hydrolysis …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,A comparative study on etoposide combined with lobaplatin or cisplatin in the first-line treatment of extensive-stage small cell lung cancer.,J BUON. 2020 May-Jun;25(3):1490-1496.,PURPOSE: To compare the efficacy and safety of etoposide combined with lobaplatin or cisplatin in the first-line treatment of extensive-stage small cell lung cancer (SCLC). METHODS: A total of 98 extensive-stage SCLC patients treated at the Oncology Department from March 2 …
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Enhanced therapeutic effect of transcatheter arterial chemoembolization combined with radioactive I-125 seed implantation on liver cancer.,Oncol Lett. 2020 Sep;20(3):2493-2498. doi: 10.3892/ol.2020.11765. Epub 2020 Jun 24.,"A total of 38 liver cancer patients in the combined treatment group were treated with lobaplatin-TACE combined with radioactive I-125 seed implantation, while 45 patients in the TACE group were treated only with lobaplatin-TACE. ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles.,Cancer Manag Res. 2020 Jun 29;12:5141-5146. doi: 10.2147/CMAR.S249838. eCollection 2020.,OBJECTIVE: This study aims to evaluate the safety and efficacy of lobaplatin in prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer. ...CONCLUSION: Lobaplatin in prophylactic HIPEC is safe for advanced gastric cancer patients a …
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Combination of computed tomography-guided iodine-125 brachytherapy and bronchial arterial chemoembolization for locally advanced stage III non-small cell lung cancer after failure of concurrent chemoradiotherapy.,Lung Cancer. 2020 Aug;146:290-296. doi: 10.1016/j.lungcan.2020.06.010. Epub 2020 Jun 20.,"The tumor-feeding arteries were detected on angiography, and chemotherapeutic agents (gemcitabine 1000 mg/m(2) + lobaplatin 30 mg/m(2)) were then administered via arterial infusion. ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo.,Int J Oncol. 2020 Sep;57(3):697-706. doi: 10.3892/ijo.2020.5085. Epub 2020 Jun 22.,"High concentrations of carboplatin and lobaplatin markedly inhibited Y79 RB cell proliferation in vitro. In addition, the lobaplatin group exhibited higher proportions of early‑stage apoptotic cells than the carboplatin group, while no significant differences in the …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Uninfluenced alpha-fetoprotein and treatment of liver primary carcinoma by lobaplatin in combination with 5-fluorouracil and doxorubicin via chemoembolization and transarterial chemoembolization.,Cell Mol Biol (Noisy-le-grand). 2020 Jun 5;66(3):48-51.,"Patients in the research group adopted the TACE in combination with lobaplatin, while those in the control group took cisplatin instead in combination with TACE. ...TACE is a promising strategy for the treatment of primary carcinoma of the liver, while lobaplatin, a …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,"Lobaplatin induces pyroptosis through regulating cIAP1/2, Ripoptosome and ROS in nasopharyngeal carcinoma.",Biochem Pharmacol. 2020 Jul;177:114023. doi: 10.1016/j.bcp.2020.114023. Epub 2020 May 13.,"However, the anti-NPC mechanism of lobaplatin remains largely unknown. In present study, 50% inhibiting concentration (IC50) of lobaplatin for NPC cells is found to be similar to that of cisplatin. 10 μM and 20 μM lobaplatin caused obvious gasdermin-E (GSDME) …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.,Front Pharmacol. 2020 Mar 20;11:343. doi: 10.3389/fphar.2020.00343. eCollection 2020.,"Platinum-based anticancer drugs, including cisplatin, carboplatin, oxaliplatin, nedaplatin, and lobaplatin, are heavily applied in chemotherapy regimens. ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Pharmacokinetics and tissue distribution in rats of a novel anticancer platinum compound LLC-1903.,Xenobiotica. 2020 Aug;50(8):980-987. doi: 10.1080/00498254.2020.1728421. Epub 2020 Feb 19.,"LLC-1903, a novel anticancer compound, was synthesized by optimizing the structure, which was derived from altering the leaving group of lobaplatin. ...The plasma level of LLC-1903 is only half of that of lobaplatin (p < 0.01) which could be the direct result of …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,[Risk factor analysis for perineal incision complications after abdominoperineal resection in elderly patients with rectal cancer].,Zhonghua Zhong Liu Za Zhi. 2020 Jan 23;42(1):65-69. doi: 10.3760/cma.j.issn.0253-3766.2020.01.010.,"The result of univariate analysis showed that, the occurrence of perineal incision complications was associated with serum albumin level < 35g/L (χ(2)=4.860, P=0.027), intraperitoneal chemotherapy with fluorouracil sustained release/lobaplatin rinse (χ(2)=8.827, P=0.003 …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Retrospective study of TACE in the treatment of lobaplatin-induced thrombocytopenia in primary hepatocellular carcinoma.,J BUON. 2019 Nov-Dec;24(6):2385-2393.,"The number of first-time users of lobaplatin reached 128, the second-time users reached 417, the third-time and above users 239. ...The level of post-intervention thrombocytopenia was not correlated with the cycles of lobaplatin use. The initial thrombocytopenia was …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer.,Medicine (Baltimore). 2019 Dec;98(52):e18513. doi: 10.1097/MD.0000000000018513.,"METHODS: Patients with rMBC received ≥2 cycles (21 days each) of either docetaxel and lobaplatin (DL; n = 21), or docetaxel and gemcitabine (DG; n = 22). ...Patients in DL and DG were also given, respectively, 35 mg/m intravenous lobaplatin (day 2) or 1000 mg/m intr …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,"Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report.",Thorac Cancer. 2020 Feb;11(2):456-460. doi: 10.1111/1759-7714.13286. Epub 2019 Dec 22.,"The efficacy was significantly improved after lobaplatin combined with pemetrexed, temozolomide and bevacizumab. This is the first report of a novel mutation type EGFR-ANXA2, as well as double EGFR fusion mutations in advanced lung adenocarcinoma. ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,"Corrigendum to ""Lobaplatin arrests cell cycle progression, induces apoptosis and impairs migration and invasion in B16-F10 melanoma cell line in vitro"" [Biomed. Pharmacother. 69 (2015) 402-408].",Biomed Pharmacother. 2019 Dec;120:109511. doi: 10.1016/j.biopha.2019.109511. Epub 2019 Oct 16.,
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Endometrial carcinoma complicated by malignant pericardial effusion: A case report on the therapeutic regimen.,Medicine (Baltimore). 2019 Oct;98(42):e17584. doi: 10.1097/MD.0000000000017584.,"INTERVENTIONS: In addition to cisplatin instilled into the pericardial space, for systemic chemotherapy, we chose that gemcitabine and lobaplatin regimen be preferred. ...When this happens, we recommend ultrasound-guided pericardial puncture and the pericardial injection o …"
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Lobaplatin promotes (125)I-induced apoptosis and inhibition of proliferation in hepatocellular carcinoma by upregulating PERK-eIF2α-ATF4-CHOP pathway.,Cell Death Dis. 2019 Oct 3;10(10):744. doi: 10.1038/s41419-019-1918-1.,We investigated the mechanism underlying the effect of a combination treatment of (125)I radioactive seed implantation and lobaplatin (LBP) in hepatocellular carcinoma. ...
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,"Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.",Int J Hyperthermia. 2019;36(1):841-853. doi: 10.1080/02656736.2019.1646927.,"Results: TACE procedures were performed using lobaplatin (20-50 mg), epirubicin (30-60 mg), lipiodol (5-25 mL) and gelatin sponge particles (350-560 μm). ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Lobaplatin-Induced Apoptosis Requires p53-Mediated p38MAPK Activation Through ROS Generation in Non-Small-Cell Lung Cancer.,Front Oncol. 2019 Jul 24;9:538. doi: 10.3389/fonc.2019.00538. eCollection 2019.,"Lobaplatin (LBP), a third-generation platinum anti-neoplastic agent, has shown an improved efficacy. This study is aimed to investigate the mechanisms of LBP-induced apoptosis in the A549 p53 wild-type cell line. ..."
2020-09-23T05:56:10Z,https://pubmed.ncbi.nlm.nih.gov/?term=LOBAPLATIN&sort=date&size=20,Retrospective study of the efficacy and toxicity of lobaplatin in combined chemotherapy for metastatic breast cancer.,Onco Targets Ther. 2019 Jun 21;12:4849-4857. doi: 10.2147/OTT.S192373. eCollection 2019.,OBJECTIVE: To study the efficacy and adverse reactions of lobaplatin combined with other chemotherapy drugs in the treatment of metastatic breast cancer. ...CONCLUSION: Lobaplatin-based regimen chemotherapy for advanced metastatic breast cancer patients is effective …
2020-09-23T05:56:19Z,https://pubmed.ncbi.nlm.nih.gov/?term=ARQ501&sort=date&size=20,Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.,J Control Release. 2015 Feb 28;200:201-11. doi: 10.1016/j.jconrel.2014.12.027. Epub 2014 Dec 24.,"Pre-clinical and clinical use of β-lap (clinical form, ARQ501 or 761) is hampered by poor pharmacokinetics and toxicity due to hemolytic anemia. ..."
2020-09-23T05:56:19Z,https://pubmed.ncbi.nlm.nih.gov/?term=ARQ501&sort=date&size=20,Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.,Mol Cancer Ther. 2013 Oct;12(10):2110-20. doi: 10.1158/1535-7163.MCT-12-0962. Epub 2013 Jul 24.,"Improving patient outcome by personalized therapy involves a thorough understanding of an agent's mechanism of action. β-Lapachone (clinical forms, Arq501/Arq761) has been developed to exploit dramatic cancer-specific elevations in the phase II detoxifying enzyme NAD(P)H:q …"
2020-09-23T05:56:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=TYROSINASE/GP100/HSP70&sort=date&size=20,HSP70i is a critical component of the immune response leading to vitiligo.,Pigment Cell Melanoma Res. 2012 Jan;25(1):88-98. doi: 10.1111/j.1755-148X.2011.00916.x. Epub 2011 Nov 14.,"HSP70i and other stress proteins have been used in anti-tumor vaccines. This begs the question whether HSP70i plays a unique role in immune activation. ...By contrast, depigmentation proceeded without interruption in mice lacking a tissue-specific constitutive isoform of …"
2020-09-23T05:56:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=TYROSINASE/GP100/HSP70&sort=date&size=20,Superior antitumor response induced by large stress protein chaperoned protein antigen compared with peptide antigen.,J Immunol. 2010 Jun 1;184(11):6309-19. doi: 10.4049/jimmunol.0903891. Epub 2010 May 3.,"., gp100) and large stress proteins (e.g., hsp110 and grp170) with exceptional Ag-holding capabilities augment potent tumor protective immunity. ...Both hsp110 and grp170 readily formed complexes with antigenic peptides under physiologic conditions, and the peptide …"
2020-09-23T05:56:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=TYROSINASE/GP100/HSP70&sort=date&size=20,Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.,Cancer Res. 2005 Mar 1;65(5):2009-17. doi: 10.1158/0008-5472.CAN-04-3216.,"We have reported that i.d. injection of plasmids encoding hsp70 and a suicide gene transcriptionally targeted to melanocytes generates specific proinflammatory killing of melanocytes. ...In suboptimal protocols, the T cell response selected B16 variants, which grow extreme …"
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs.,ACS Cent Sci. 2020 Aug 26;6(8):1367-1375. doi: 10.1021/acscentsci.0c00411. Epub 2020 Jul 8.,"LC-2 covalently binds KRAS(G12C) with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS(G12C) degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS(G12C) cell lines. ..."
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Inhibition of RAS: proven and potential vulnerabilities.,Biochem Soc Trans. 2020 Sep 1:BST20190023. doi: 10.1042/BST20190023. Online ahead of print.,"Building on this success, several groups have developed similar compounds that selectively target KRAS(G12C), with AMG510 and MRTX849 the first to advance to clinical trials. ..."
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,KRAS: From undruggable to a druggable Cancer Target.,Cancer Treat Rev. 2020 Sep;89:102070. doi: 10.1016/j.ctrv.2020.102070. Epub 2020 Jul 15.,"Recently, several small molecules (AMG510, MRTX849, JNJ-74699157, and LY3499446) have been developed to specifically target K-RAS G12C. ..."
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Hitting KRAS When It's Down.,J Med Chem. 2020 Jul 9;63(13):6677-6678. doi: 10.1021/acs.jmedchem.0c00785. Epub 2020 Jun 22.,"MRTX849 is one such clinical candidate with promising initial results in patients harboring the mutation. The impressive optimization story of MRTX849 highlights challenges and solutions in the development of covalent drugs, including the use of an α-fluoroacrylamid …"
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS(G12C) Inhibitor for the Treatment of Cancer.",J Med Chem. 2020 Jul 9;63(13):6679-6693. doi: 10.1021/acs.jmedchem.9b02052. Epub 2020 Apr 6.,"The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRAS(G12C) is described...."
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,Targeting Krasg12c -mutant cancer with a mutation-specific inhibitor.,J Intern Med. 2020 Aug;288(2):183-191. doi: 10.1111/joim.13057. Epub 2020 Apr 7.,"MRTX849 was recently identified as a potent, selective and covalent KRAS(G12C) inhibitor that possesses favourable drug-like properties. MRTX849 selectively modifies the mutant cysteine residue in GDP-bound KRAS(G12C) and inhibits GTP-loading and downstream KRAS-dep …"
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,"KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?",Cancer Treat Rev. 2020 Mar;84:101974. doi: 10.1016/j.ctrv.2020.101974. Epub 2020 Jan 23.,"Both AMG 510 from Amgen and MRTX849 from Mirati Therapeutics covalently binds to KRAS(G12C) at the cysteine at residue 12, keeping KRAS(G12C) in its inactive GDP-bound state and inhibiting KRAS-dependent signaling. ..."
2020-09-23T05:56:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=MRTX849&sort=date&size=20,The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.,Cancer Discov. 2020 Jan;10(1):54-71. doi: 10.1158/2159-8290.CD-19-1167. Epub 2019 Oct 28.,"MRTX849 was identified as a potent, selective, and covalent KRAS(G12C) inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRAS(G12C), and inhibits KRAS-dependent signaling. ...Combinations of MRTX849 with age …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,[The importance of efflux systems in antibiotic resistance and efflux pump inhibitors in the management of resistance].,Mikrobiyol Bul. 2015 Apr;49(2):278-91. doi: 10.5578/mb.8964.,"There are some compounds known to inhibit bacterial pump systems, such as phenyl-arginine beta naphthylamide (PAβN), INF271, INF55, carbonyl cyanide m-chlorophenyl hydrazone (CCCP), reserpine, 1-(1-naphthylmethyl)-piperazine (NMP), biricodar, timcodar, verapamil, milbemyci …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.,Biochem Pharmacol. 2013 Apr 15;85(8):1057-65. doi: 10.1016/j.bcp.2013.01.015. Epub 2013 Jan 24.,"The addition of either tamoxifen, VX-710, verapamil, or cyclosporin A, antagonists of P-gp, enhanced C6-ceramide cytotoxicity in all cell lines. ..."
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.,Exp Cell Res. 2011 Jul 15;317(12):1736-45. doi: 10.1016/j.yexcr.2011.03.004. Epub 2011 Mar 21.,"For example, C6-cer, VX-710 (Biricodar), and cyclosporin A (cyc A) exposure resulted in viabilities of ~90% of control; however, C6-cer/VX-710 and C6-cer/cyc A additions were synergistic and resulted in viabilities of 22% and 17%, respectively. …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux.,Recent Pat Antiinfect Drug Discov. 2006 Jun;1(2):157-75. doi: 10.2174/157489106777452692.,"Apart from (i) a peptidomimetic inhibitor of Mex pumps in Pseudomonas aeruginosa (MC-04,124), for which efficacy was evaluated in animal models, and (ii) a piperidinecarboxylic acid inhibitor of fluoroquinolone efflux in Gram-positive (VX-710), which was safely admi …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2007 Jul-Aug;29(6):427-37.,"[111In]-DOTA-cG250, [131I]-Metuximab injection, [177Lu]-DOTA-cG250; Anatumomab mafenatox, AP-12009; BIBW-2992, Biricodar dicitrate; Cediranib, Cilengitide, Clevidipine, CNTO-528, CNTO-95, CP-870893; Disufenton sodium, DNK-333A; Ecallantide, Enzastaurin hydrochloride, Etrav …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.,Cancer. 2007 Mar 1;109(5):924-32. doi: 10.1002/cncr.22492.,MDR represents an obstacle to successful chemotherapy treatment and is reversible in Pgp- or MRP-1-expressing cells by the inhibitor VX-710. ...No correlative (99m)Tc-sestamibi uptake in tumor tissue was observed with the addition of VX-710 in this stu …
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Pharmacological strategies for overcoming multidrug resistance.,Curr Drug Targets. 2006 Jul;7(7):861-79. doi: 10.2174/138945006777709593.,"Clinical trials with third generation modulators (e.g. biricodar, zosuquidar, and laniquidar) specifically developed for MDR reversal are ongoing. ..."
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Approaches to multidrug resistance reversal.,Expert Opin Investig Drugs. 1998 Jun;7(6):929-39. doi: 10.1517/13543784.7.6.929.,"Drugs that have clearly shown a potential for sensitisation of resistant cancers with acceptable toxicity include dexverapamil one of the two enantiomers constituting verapamil, valspodar (PSC-833), an analogue of cyclosporine A, and original compounds, named VX-710 …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Immunosuppressors and reversion of multidrug-resistance.,Crit Rev Oncol Hematol. 2005 Oct;56(1):61-70. doi: 10.1016/j.critrevonc.2004.12.010.,
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Thyroid hormone export from cells: contribution of P-glycoprotein.,J Endocrinol. 2005 Apr;185(1):93-8. doi: 10.1677/joe.1.06096.,"We compared the transport of 125I-T3 in MDCKII cells that had been transfected with mdr1 cDNA (MDCKII-MDR) versus wild-type MDCKII cells (MDCKII), and examined the effect of conventional (verapamil and nitrendipine) and specific MDR inhibitors (VX 853 and VX 710 …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853).,Antimicrob Agents Chemother. 2004 Nov;48(11):4171-6. doi: 10.1128/AAC.48.11.4171-4176.2004.,"Based on this precedent, two novel mammalian multiple drug resistance inhibitors, biricodar (VX-710) and timcodar (VX-853), were evaluated for activity in a variety of bacteria. ...Similar to reserpine, VX-710 and VX-853 directly b …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,"VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.",Clin Cancer Res. 2004 Mar 1;10(5):1826-34. doi: 10.1158/1078-0432.ccr-0914-3.,PURPOSE: The pipecolinate derivative VX-710 (biricodar; Incel) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1); we studied its activity against the third multidrug resistance (MDR)-associated drug efflux p …
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2003 May;25(4):317-40.,"This issue focuses on the following selection of drugs: 2F5, 2G12, abetimus sodium, ABI-007, adalimumab, adefovir dipivoxil, AE-941, alefacept, altropane, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, aminopterin, anakinra, aprinocarsen sodium, atazanavir, …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide.,Cancer Res. 2003 May 15;63(10):2492-8.,"Treating the cells with leukotriene D4, a known MRP1 substrate, or VX-710, an MRP1 modulator, restored flutamide and hydroxyflutamide accumulation. ..."
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.,Eur J Med Chem. 2020 May 1;193:112232. doi: 10.1016/j.ejmech.2020.112232. Epub 2020 Mar 13.,Methanone 16 and its carbamate derivative 17b inhibit FLT3-ITD at least as potently as the TKi AC220 (quizartinib). Models indicate corresponding interactions of 16 and quizartinib with FLT3. ...
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,"Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.",Cancer Chemother Pharmacol. 2003 Apr;51(4):297-305. doi: 10.1007/s00280-003-0573-4. Epub 2003 Mar 13.,"PURPOSE: VX-710 (biricodar, Incel) restores drug sensitivity to cells expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP1). ...VX-710 blood concentration at the time of mitoxantrone administration averaged 4.52 mic …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.,Cancer Control. 2003 Mar-Apr;10(2):159-65. doi: 10.1177/107327480301000207.,"RESULTS: First-generation agents (eg, cyclosporin, verapamil) were limited by unacceptable toxicity, whereas second-generation agents (eg, valspodar, biricodar) had better tolerability but were confounded by unpredictable pharmacokinetic interactions and interactions with …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Multidrug resistance: can new drugs help chemotherapy score against cancer?,J Natl Cancer Inst. 2003 Feb 19;95(4):255-7. doi: 10.1093/jnci/95.4.255.,
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,"A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.",Gynecol Oncol. 2002 Sep;86(3):302-10. doi: 10.1006/gyno.2002.6762.,"PURPOSE: Incel (biricodar, VX-710) restores drug sensitivity to P-glycoprotein (MDR1) and multidrug-resistance-associated protein (MRP1) expressing cells. ...Patients received 80 mg/m(2) paclitaxel over 3 h starting 4 h after initiation of a 24-h continuous i …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Biricodar. Vertex Pharmaceuticals.,Curr Opin Investig Drugs. 2002 May;3(5):818-23.,"By March 2000, Vertex was the sole developer of biricodar, as an agreement made in 1996 with BioChem Pharma (now Shire Pharmaceuticals), for the development and marketing of biricodar in Canada was terminated. Biricodar is the free base compound, which also h …"
2020-09-23T05:56:30Z,https://pubmed.ncbi.nlm.nih.gov/?term=VX-710&sort=date&size=20,Reversal of multidrug resistance: lessons from clinical oncology.,"Novartis Found Symp. 2002;243:83-96; discussion 96-102, 180-5.",
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Development of Recombinant Immunotoxins for Hairy Cell Leukemia.,Biomolecules. 2020 Aug 3;10(8):1140. doi: 10.3390/biom10081140.,"Hairy cell leukemia (HCL) is an indolent B-cell malignancy with excellent initial response to purine analogs pentostatin or cladribine, but patients are rarely, if ever, cured. ..."
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902.,Transfusion. 2020 Jul 12. doi: 10.1111/trf.15798. Online ahead of print.,"STUDY DESIGN AND METHODS: Patients received 2 days of ECP followed by pentostatin 4 mg/m2 /day for two consecutive days, followed by 600 cGy of total body irradiation prior to stem cell infusion. ...CONCLUSIONS: These studies demonstrate that ECP/pentostatin/TBI is …"
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Simultaneous Quantification of Adenosine and Deoxyadenosine Isomers in Foods with High Sensitivity.,Anal Methods. 2019 Oct 14;11(38):4946-4950. doi: 10.1039/c9ay01735f. Epub 2019 Sep 3.,
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Bioactive Metabolites and Potential Mycotoxins Produced by Cordyceps Fungi: A Review of Safety.,Toxins (Basel). 2020 Jun 19;12(6):410. doi: 10.3390/toxins12060410.,"On the one hand, the known compounds from these fungi such as adenosine analogs cordycepin and pentostatin have demonstrated different beneficial or pharmaceutical activities but also dose-dependent cytotoxicities, neurological toxicities and or toxicological effects in hu …"
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,A BRAF Negative Classic Hairy Cell Leukemia Patient in Long Lasting Complete Remission after Rituximab and Pentostatin.,Turk J Haematol. 2020 Jun 16. doi: 10.4274/tjh.galenos.2020.2020.0204. Online ahead of print.,
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.,Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16808. Online ahead of print.,"In the relapsed or Cy-refractory setting, alemtuzumab (n = 4) and pentostatin (n = 3) had an ORR of 50% and 66%, respectively, while duvelisib induced a long-term response in one patient. ...Prospective studies evaluating pentostatin, alemtuzumab and novel agents, s …"
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Characterization of the coformycin biosynthetic gene cluster in Streptomyces kaniharaensis.,Proc Natl Acad Sci U S A. 2020 May 12;117(19):10265-10270. doi: 10.1073/pnas.2000111117. Epub 2020 Apr 29.,"Coformycin and pentostatin are structurally related N-nucleoside inhibitors of adenosine deaminase characterized by an unusual 1,3-diazepine nucleobase. ..."
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Hairy Cell Leukaemia.,Curr Oncol Rep. 2020 Apr 16;22(5):42. doi: 10.1007/s11912-020-00911-0.,
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Intensive Induction Therapy Compared With CHOP for Hepatosplenic T-cell Lymphoma.,Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):431-437.e2. doi: 10.1016/j.clml.2019.10.007. Epub 2019 Oct 21.,"We also review additional regimens including alemtuzumab and pentostatin, and assessed the role of consolidation with hematopoietic stem-cell transplantation (HSCT). ..."
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis.,Orphanet J Rare Dis. 2020 Feb 13;15(1):47. doi: 10.1186/s13023-020-1325-9.,Included patients had ≥1 claim for HCL therapy (cladribine ± rituximab or pentostatin ± rituximab [index date: first claim date]) and continuous enrollment for a ≥ 6-month baseline and ≥ 12-month follow-up period. ...
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Persistent Mixed Donor Chimerism following Double Umbilical Cord Transplantation in a Patient with T-Cell Prolymphocytic Leukemia.,Case Rep Hematol. 2019 Sep 11;2019:8437805. doi: 10.1155/2019/8437805. eCollection 2019.,"After 16 months, the patient had relapse of the disease, unfortunately, prompting treatment with alemtuzumab and pentostatin, which resulted in remission once again. ..."
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Coupled biosynthesis of cordycepin and pentostatin in Cordyceps militaris: implications for fungal biology and medicinal natural products.,Ann Transl Med. 2019 Jul;7(Suppl 3):S85. doi: 10.21037/atm.2019.04.25.,
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Immune recovery uveitis in a patient with herpes retinitis as a complication of hairy cell leukaemia.,Arch Soc Esp Oftalmol. 2019 Nov;94(11):545-550. doi: 10.1016/j.oftal.2019.07.012. Epub 2019 Sep 7.,"A 51 year-old man with hairy cell leukaemia was treated with pentostatin. While receiving the treatment, he was diagnosed with herpes retinitis in his right eye. After the last cycle of pentostatin the patient developed a mild vitritis and cystoid macular oedema. Th …"
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,"Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases.",Biol Blood Marrow Transplant. 2020 Jan;26(1):94-106. doi: 10.1016/j.bbmt.2019.08.018. Epub 2019 Sep 4.,"Twenty PID patients, ranging in age from 4 to 58 years, were treated on a prospective clinical trial of a novel, radiation-free and serotherapy-free RIC, T-cell-replete BMT approach using pentostatin, low-dose cyclophosphamide, and busulfan for conditioning with post-trans …"
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,"Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).",Acta Haematol. 2019;142(4):224-232. doi: 10.1159/000500164. Epub 2019 Jul 23.,"To explore further the use of CIT in the pre-novel agent era, ECOG-ACRIN undertook a phase 2 trial (E2903) for R/R CLL utilizing pentostatin, cyclophosphamide, and rituximab (PCR) followed by a consolidation course of alemtuzumab. ..."
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Activation of 6-Alkoxy-Substituted Methylenecyclopropane Nucleoside Analogs Requires Enzymatic Modification by Adenosine Deaminase-Like Protein 1.,Antimicrob Agents Chemother. 2019 Sep 23;63(10):e01301-19. doi: 10.1128/AAC.01301-19. Print 2019 Oct.,"To test this hypothesis, pentostatin (deoxycoformycin [dCF]), an adenosine deaminase-like protein 1 (ADAL-1) inhibitor, was coincubated with MBX-2168. ..."
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Hairy cell leukemia: present and future directions.,Leuk Lymphoma. 2019 Dec;60(12):2869-2879. doi: 10.1080/10428194.2019.1608536. Epub 2019 May 9.,
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,Moxetumomab pasudotox for the treatment of hairy cell leukemia.,Expert Opin Biol Ther. 2019 Jun;19(6):501-508. doi: 10.1080/14712598.2019.1614558. Epub 2019 May 10.,"Introduction: Cladribine and pentostatin are the drugs of choice in the treatment of hairy cell leukemia (HCL). Recently, immunotoxin moxetumomab pasudotox has been introduced to improve the prognosis in relapsed and refractory HCL. ..."
2020-09-23T06:01:50Z,https://pubmed.ncbi.nlm.nih.gov/?term=PENTOSTATIN&sort=date&size=20,No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.,Ann Pharmacother. 2019 Sep;53(9):922-932. doi: 10.1177/1060028019836775. Epub 2019 Mar 6.,"An electronic literature search of PubMed (January 1958 to January 2019) was conducted in PubMed using the MESH terms hairy cell leukemia, hairy cell leukemia variant, cladribine, pentostatin, rituximab, interferon, vemurafenib, moxetumomab pasudotox. ..."
2020-09-23T06:01:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=ARQ092&sort=date&size=20,Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.,Angiogenesis. 2020 Aug;23(3):425-442. doi: 10.1007/s10456-020-09722-0. Epub 2020 Apr 30.,Inhibitors of PIK3CA (BYL719) and AKT (ARQ092) attenuated the proliferation of CLVM EC in a dose-dependent manner. A xenograft model of CLVM was developed by injecting patient-derived EC into the flanks of immunocompromised mice. ...
2020-09-23T06:01:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=ARQ092&sort=date&size=20,Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells.,Cancers (Basel). 2019 Sep 13;11(9):1359. doi: 10.3390/cancers11091359.,
2020-09-23T06:01:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=ARQ092&sort=date&size=20,Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms.,PLoS One. 2019 Jun 19;14(6):e0218537. doi: 10.1371/journal.pone.0218537. eCollection 2019.,
2020-09-23T06:01:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=ARQ092&sort=date&size=20,Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.,Pediatr Blood Cancer. 2019 Aug;66(8):e27790. doi: 10.1002/pbc.27790. Epub 2019 May 2.,"Cell proliferation studies assessed PI3K inhibitors (LY294002; BYL719), AKT inhibitor ARQ092, mTOR inhibitor rapamycin, and MAPK inhibitor U0126. ..."
2020-09-23T06:01:54Z,https://pubmed.ncbi.nlm.nih.gov/?term=ARQ092&sort=date&size=20,CK2 inhibition confers functional protection to young and aging axons against ischemia by differentially regulating the CDK5 and AKT signaling pathways.,Neurobiol Dis. 2019 Jun;126:47-61. doi: 10.1016/j.nbd.2018.05.011. Epub 2018 Jun 23.,
2020-09-23T06:01:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=XL844&sort=date&size=20,A key genomic signature associated with lymphovascular invasion in head and neck squamous cell carcinoma.,BMC Cancer. 2020 Mar 30;20(1):266. doi: 10.1186/s12885-020-06728-1.,"Eight small molecular agents, namely XL844, AT7519, AT9283, alvocidib, nelarabine, benzamidine, L-glutamine, and zinc, were identified as novel candidates for controlling LOI in HNSCC (P < 0.05). ..."
2020-09-23T06:01:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=XL844&sort=date&size=20,"A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe.",Invest New Drugs. 2011 Jun;29(3):514-22. doi: 10.1007/s10637-009-9361-2. Epub 2009 Dec 22.,
2020-09-23T06:01:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=XL844&sort=date&size=20,Keeping checkpoint kinases in line: new selective inhibitors in clinical trials.,Expert Opin Investig Drugs. 2008 Sep;17(9):1331-40. doi: 10.1517/13543784.17.9.1331.,
2020-09-23T06:01:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=XL844&sort=date&size=20,Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.,Cell Cycle. 2007 Jan 1;6(1):104-10. doi: 10.4161/cc.6.1.3699. Epub 2007 Jan 7.,"We studied the in vitro and in vivo effects of EXEL-9844 (XL844), a potent, orally available, and specific inhibitor of Chk1 and Chk2, in combination with gemcitabine. ..."
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,Quizartinib for the treatment of acute myeloid leukemia.,Expert Opin Pharmacother. 2020 Aug 9:1-14. doi: 10.1080/14656566.2020.1801637. Online ahead of print.,"This article reviews the mechanism of action, pharmacology, clinical efficacy, and safety of quizartinib, a FLT3 inhibitor, for the treatment of acute myeloid leukemia. ...Quizartinib yielded an improvement in OS and complete remission (CR) rates in a phase 3 trial …"
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,"Discovery of DS-6930, a potent selective PPARγ modulator. Part I: Lead identification.",Bioorg Med Chem. 2018 Oct 1;26(18):5079-5098. doi: 10.1016/j.bmc.2018.09.006. Epub 2018 Sep 8.,"Because the TZD group is known to interact with helix 12, the TZD in efatutazone (CS-7017) was replaced to discover novel PPARγ intermediate partial agonist 8i. ..."
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia.,Pharmacol Res. 2020 Jan;151:104556. doi: 10.1016/j.phrs.2019.104556. Epub 2019 Nov 25.,Treatment of pediatric acute leukemia might involve combined therapies targeting the FMS-like tyrosine kinase 3 (FLT3) receptor (i.e. quizartinib - AC220) and nucleotide metabolism (cytarabine - AraC). ...FLT3 inhibition using AC220 promoted the expression of …
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,Quizartinib (AC220): a promising option for acute myeloid leukemia.,Drug Des Devel Ther. 2019 Apr 8;13:1117-1125. doi: 10.2147/DDDT.S198950. eCollection 2019.,"In this review, we focus on the characteristics of FLT3/ITD mutations, the mechanism and pharmacokinetics of quizartinib, and the mechanisms of resistance to quizartinib. We also summarize clinical experiences and adverse effects with quizartinib and recommen …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,FLT3 inhibitor quizartinib (AC220).,Leuk Lymphoma. 2019 Aug;60(8):1866-1876. doi: 10.1080/10428194.2019.1602263. Epub 2019 Apr 18.,"Besides the complex nature of AML itself, resistance mechanisms blunting the efficacy of quizartinib have been identified and are being investigated including TKD mutations, alternate signaling pathways and the bone marrow microenvironment. Strategies using combination of …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia.,J Cell Physiol. 2019 Feb 15:10.1002/jcp.28294. doi: 10.1002/jcp.28294. Online ahead of print.,"Finally, we determined that combined treatment of NSG mice engrafted with FLT3-ITD (+) MV4-11 AML cells with 8-Cl-Ado and the FLT3 inhibitor AC220 (quizartinib) synergistically enhanced survival, compared with that of mice treated with the individual drugs, suggesti …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,Flt3 inhibition alleviates chronic kidney disease by suppressing CD103+ dendritic cell-mediated T cell activation.,Nephrol Dial Transplant. 2019 Nov 1;34(11):1853-1863. doi: 10.1093/ndt/gfy385.,"The number of kidney CD103+ DCs, but not CD103- DCs or plasmacytoid DCs, was significantly decreased in AN mice after AC220 administration. ...The protective effect of AC220 was associated with its suppression of CD103+ DCs-mediated CD8 T cell proliferation and acti …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.,Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21.,"PARP1i, olaparib, and BMN673 caused accumulation of lethal DSBs and cell death in AC220-treated FLT3(ITD)-positive leukemia cells, thus mimicking synthetic lethality. ...Notably, the combination of AC220 and BMN673 significantly delayed disease onset and effectively …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death.,Cell Death Dis. 2018 Jan 26;9(2):138. doi: 10.1038/s41419-017-0170-9.,"AC220 (Quizartinib), an FLT3 receptor tyrosine kinase inhibitor, developed for the treatment of AML, has been tested in phase II human clinical trials. However, AC220 as a monotherapy is not efficacious enough. In this study, we performed a small-molecule scr …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies.,Oncotarget. 2017 Sep 16;8(55):93785-93799. doi: 10.18632/oncotarget.21078. eCollection 2017 Nov 7.,"Quizartinib (AC220), a potent class III receptor tyrosine kinase inhibitor (TKI), was synthesized to selectively inhibit FMS-like tyrosine kinase-3 (FLT3), a target in the treatment of acute myeloid leukemia (AML). ...These findings may be useful in clinical practic …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.,Exp Hematol. 2018 Feb;58:52-58. doi: 10.1016/j.exphem.2017.09.007. Epub 2017 Sep 22.,"We found that the FLT3 inhibitor AC220 inhibited glutamine flux into the antioxidant factor glutathione profoundly due to defective glutamine import. ...In vivo, glutaminase inhibition with CB-839 facilitated leukemic cell elimination by AC220 and improved survival …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.,Cancer Res. 2017 Aug 15;77(16):4402-4413. doi: 10.1158/0008-5472.CAN-16-1627. Epub 2017 Jun 16.,Quizartinib (AC220) is a potent and selective second-generation inhibitor of FLT3. It is in clinical trials for the treatment of relapsed or refractory FLT3-ITD-positive and -negative AML patients and as maintenance therapy. ...Expression of SPRY3 and GSK3A was dram …
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.,Cancer Res. 2016 Nov 15;76(22):6471-6482. doi: 10.1158/0008-5472.CAN-15-3569. Epub 2016 Sep 26.,"Potent FLT3 inhibitors, such as quizartinib (AC220), have shown promise in treating acute myeloid leukemia (AML) containing FLT3 internal tandem duplication (ITD) mutations. ...FLT3-ITD AML patients treated with AC220 developed increased FGF2 expression in ma …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,"AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes.",Exp Hematol. 2017 Jan;45:36-44.e2. doi: 10.1016/j.exphem.2016.09.004. Epub 2016 Sep 23.,"Treatment with FLT3 TKI (AC220) caused complete remission in peripheral blood, spleen, and bone, along with relief of symptoms and extended life, hinting that FLT3-ITD may be a key leukemogenic driver maintaining the disease. Interestingly, withdrawal of AC220 (high …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.,Oncogene. 2017 Mar;36(11):1516-1524. doi: 10.1038/onc.2016.318. Epub 2016 Sep 12.,"To define the role of Flt3 in AML with high Hoxa9/Meis1, we treated mice with Hoxa9/Meis1-induced AML with the Flt3 inhibitor AC220, used an Flt3-ligand (FL-/-) knockout model, and investigated whether overexpression of Flt3 could induce leukemia together with overexpressi …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,Internal Tandem Duplication in FLT3 Attenuates Proliferation and Regulates Resistance to the FLT3 Inhibitor AC220 by Modulating p21Cdkn1a and Pbx1 in Hematopoietic Cells.,PLoS One. 2016 Jul 7;11(7):e0158290. doi: 10.1371/journal.pone.0158290. eCollection 2016.,"When FLT3-ITD was antagonized with AC220, a selective inhibitor of FLT3-ITD, p21 expression was decreased coincident with Pbx1 mRNA up-regulation and a rapid decline in the number of viable FLT3-ITD+ Ba/F3 cells; however, the cells eventually became refractory to AC220 …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.,Clin Cancer Res. 2016 Aug 15;22(16):4014-22. doi: 10.1158/1078-0432.CCR-15-1998. Epub 2016 Feb 26.,"PURPOSE: To determine a safe and biologically active dose of quizartinib (AC220), a potent and selective class III receptor tyrosine kinase (RTK) FLT3 inhibitor, in combination with salvage chemotherapy in children with relapsed acute leukemia. ...The favorable toxi …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,Leukemogenic potency of the novel FLT3-N676K mutant.,Ann Hematol. 2016 Apr;95(5):783-91. doi: 10.1007/s00277-016-2616-z. Epub 2016 Feb 19.,"Importantly, leukemic cells carrying the FLT3-N676K mutant in the absence of an ITD mutation were highly sensitive to FLT3 inhibitors AC220 and crenolanib, and crenolanib even retained activity against the AC220-resistant FLT3-ITD-N676K mutant. ..."
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.,Int J Hematol. 2016 Jan;103(1):95-106. doi: 10.1007/s12185-015-1908-8. Epub 2015 Nov 21.,"Although the number of FLT3/ITD(+) 32D cells declined after incubation with the FLT3/ITD inhibitor AC220, the cells became refractory to AC220, concomitant with up-regulation of RUNX1. Silencing of RUNX1 abrogated the emergence and proliferation of AC220-resi …"
2020-09-23T06:02:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB(AC220)&sort=date&size=20,Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors.,Bioorg Med Chem Lett. 2015 Sep 1;25(17):3436-41. doi: 10.1016/j.bmcl.2015.07.023. Epub 2015 Jul 14.,"Based on a putative binding mode of quizartinib (AC220, 1), a potent FMS-like tyrosine kinase 3 (FLT3) inhibitor in Phase III clinical development, we have designed de novo a simpler aminopyridine-based hinge binding motif. ..."
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,Exosome mediated growth effect on the non-growing pre-B acute lymphoblastic leukemia cells at low starting cell density.,Am J Transl Res. 2016 Sep 15;8(9):3614-3629. eCollection 2016.,"ALL3 cells are very sensitive to potent tyrosine kinase inhibitors (TKIs) such as Dasatinib and PD166325, but less sensitive to AMN 107, Imatinib, and BMS 214662 (a farnesyl transferase inhibitor). ..."
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.,Eur J Med Chem. 2017 Jan 5;125:299-314. doi: 10.1016/j.ejmech.2016.09.049. Epub 2016 Sep 16.,"Some peptidomimetics and bi-substrate inhibitors like FTI 276, FTI 277, B956, B1086, L731, L735, L739, L750, BMS-214662, L778123, and L778123 are under clinical trials. ..."
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.,Curr Med Chem. 2013;20(38):4888-923. doi: 10.2174/09298673113206660262.,"The structural analysis of those developed FTIs by various researchers suggested that the presence of a heterocycle or a polar group in place of the thiol group is required for interaction with the Zn(2+) ion. ...Other important FTIs such as BMS-214662, LB429 …"
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients.,Proteomics. 2013 Jan;13(1):153-68. doi: 10.1002/pmic.201200022.,"We found that expression of Ebp1, a negative regulator of proliferation, was upregulated in the nucleus of BMS-214662-treated cells. Furthermore, proteins showing altered levels in the cytosol, such as histones, were predominantly derived from the nucleus and BMS …"
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.,Leuk Res. 2012 Feb;36(2):212-8. doi: 10.1016/j.leukres.2011.09.011. Epub 2011 Oct 5.,To study the cellular basis of this resistance we have generated a MM cell line displaying enhanced (5-6-fold) resistance to bortezomib by serial cultivation of RPMI 8226 cells with increasing concentrations of this drug. ...Bortezomib-resistant cells were roughly as sensi …
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.,J Mol Med (Berl). 2012 Feb;90(2):149-61. doi: 10.1007/s00109-011-0814-7. Epub 2011 Sep 14.,"Myeloid leukemia cell lines were screened for idarubicin-induced apoptosis, cell-cycle progression, cell-cycle-dependent MAP kinase kinase (MEK-1/2) activation, and Top2 expression. ...Idarubicin caused a G2/M cell-cycle arrest characterized by elevated diphosphoryl …"
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,CoMFA and CoMSIA analysis of tetrahydroquinolines as potential antimalarial agents.,SAR QSAR Environ Res. 2011 Jul-Sep;22(5-6):473-88. doi: 10.1080/1062936X.2011.569945. Epub 2011 May 23.,"The co-crystal structure of the lead molecule, BMS-214662 bound to Rat-PFT was used as a template. CoMFA yielded a good model, with r²(ncv) = 0.909, r²(cv) = 0.617 and was validated using an external set r²(pred) = 0.748). ..."
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells.,Leukemia. 2011 Jul;25(7):1159-67. doi: 10.1038/leu.2011.67. Epub 2011 Apr 12.,"PD184352 increased the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. Compared with BMS-214662, after combination treatment we observed inhibition of ERK phosphorylation, increased An …"
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,Chronic myelogenous leukemia stem cells: What's new?,Curr Hematol Malig Rep. 2009 Apr;4(2):66-73. doi: 10.1007/s11899-009-0010-9.,
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.,Anticancer Agents Med Chem. 2010 Feb;10(2):111-5. doi: 10.2174/187152010790909326.,"Recently, several new targets or drugs have been reported to inhibit LSCs in cultured human CD34+ CML cells or in mouse model of BCR-ABL induced CML, including an Alox5 pathway inhibitor, Hsp90 inhibitors, omacetaxine, hedgehog inhibitor and BMS-214662. ..."
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,"Ethyl methanesulphonate in a parenteral formulation of BMS-214662 mesylate, a selective farnesyltransferase inhibitor: formation and rate of hydrolysis.",Pharm Dev Technol. 2009;14(6):672-7. doi: 10.3109/10837450902980262.,The objectives of the present study were to investigate the formation and rate of hydrolysis of ethyl methanesulphonate (EMS) in BMS-214662 mesylate drug substance and parenteral formulation by a gas chromatographic/mass spectrometric (GC/MS) method. ...The rates of …
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,"BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.",Blood. 2009 Nov 5;114(19):4186-96. doi: 10.1182/blood-2009-05-219550. Epub 2009 Sep 8.,"BMS-214662 significantly and selectively induced apoptosis in primitive CD34(+)38(-) CML compared with normal cells. Apoptosis proceeded via the intrinsic pathway: Bax conformational changes, loss of mitochondrial membrane potential, generation of reactive oxygen sp …"
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,QSAR study on tetrahydroquinoline analogues as plasmodium protein farnesyltransferase inhibitors: a comparison of rationales of malarial and mammalian enzyme inhibitory activities for selectivity.,Eur J Med Chem. 2008 Dec;43(12):2751-67. doi: 10.1016/j.ejmech.2008.01.025. Epub 2008 Feb 1.,"The quantitative structure-activity relationships of Plasmodium falciparum and Rat protein farnesyltransferase (PFT) inhibitory activities of 6-cyano-1-(3-methyl-3H-imidazoly-4-ylmethyl)-3-substituted-1,2,3,4-t …"
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.,Blood. 2008 Mar 1;111(5):2843-53. doi: 10.1182/blood-2007-09-112573. Epub 2007 Dec 21.,"In contrast, BMS-214662, alone or in combination with IM or dasatinib, potently induced apoptosis of both proliferating and quiescent CML stem/progenitor cells with less than 1% recovery of Philadelphia-positive long-term culture-initiating cells. ...The abil …"
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,Characterization of cancer stem cells in chronic myeloid leukaemia.,Biochem Soc Trans. 2007 Nov;35(Pt 5):1347-51. doi: 10.1042/BST0351347.,"Furthermore, BMS-214662 synergizes with MEK1/2 [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase 1/2] inhibitors, suggesting a second mechanism other that RAS inhibition for induction of apoptosis. Our i …"
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.,Clin Cancer Res. 2007 Jun 15;13(12):3623-9. doi: 10.1158/1078-0432.CCR-07-0158. Epub 2007 May 17.,"DLTs observed at or near the MTD (200 mg/m(2)/wk) were grade 4 febrile neutropenia with sepsis occurring on day 2 of course 1 (245 mg/m(2)/wk), reversible grade 3 to 4 serum transaminase increases on day 2, and grade 3 …"
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2006 Oct;28(8):533-91.,"This issues focuses on the following selection of drugs: (-)-Epigallocatechin gallate, (-)-gossypol, 2-deoxyglucose, 3,4-DAP, 7-monohydroxyethylrutoside; Ad5CMV-p53, adalimumab, adefovir dipivoxil, ADH-1, alemtuzumab, aliskiren fumarate, alvocid …"
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.,Cancer Chemother Pharmacol. 2006 Jul;58(1):107-16. doi: 10.1007/s00280-005-0134-0. Epub 2005 Dec 13.,"PATIENTS AND METHODS: Infusion of BMS-214662 was prolonged from 2, 4, 8, 16, 24 h in single patient cohorts and repeated weekly for 3 out of 4 weeks. ...CONCLUSION: Administering BMS-214662 as a weekly 24 h continuous i.v. i …"
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2005 Oct;27(8):569-612.,"This issue focuses on the following selection of drugs: (-)-Epigallocatechin gallate, (Z)-4-hydroxytamoxifen; Ad.muIFN-beta AD-237, adalimumab, adefovir dipivoxil, agalsidase alfa, alemtuzumab, almotriptan, ALVAC vCP1452, alvimopan hydrate, ambrisentan, anakinra, anti-IFN- …"
2020-09-23T06:02:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=BMS-214662&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2005 Sep;27(7):505-22.,"This issue focuses on the following selection of drugs: AAV-NGFbeta, aprepitant, aripiprazole, atomoxetine hydrochloride; beta-Methyl-6-chloromelatonin, BMS-214662, bortezomib, bosentan; Calcipotriol/betamethasone dipropionate, CEA-TRICOM, cetuximab, ciclesonide, cl …"
2020-09-23T06:02:12Z,https://pubmed.ncbi.nlm.nih.gov/?term=CERGUTUZUMABAMUNALEUKIN(RO6895882)&sort=date&size=20,89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding.,Oncotarget. 2018 May 15;9(37):24737-24749. doi: 10.18632/oncotarget.25343. eCollection 2018 May 15.,Cergutuzumab amunaleukin (CEA-IL2v) is an immunocytokine directed against carcinoembryonic antigen (CEA) containing an IL2v-moiety with abolished IL-2 receptor (IL-2R) α binding. ...
2020-09-23T06:02:12Z,https://pubmed.ncbi.nlm.nih.gov/?term=CERGUTUZUMABAMUNALEUKIN(RO6895882)&sort=date&size=20,Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy.,Clin Cancer Res. 2018 Jul 15;24(14):3325-3333. doi: 10.1158/1078-0432.CCR-17-2953. Epub 2018 Feb 20.,Cergutuzumab amunaleukin (CEA-IL2v) is a novel CEA-targeted immunocytokine. We set out to develop a mathematical model to predict intratumoral CEA-IL2v concentrations following various systemic dosing intensities.Experimental Design: Sequential measurements of CEA-I …
2020-09-23T06:02:12Z,https://pubmed.ncbi.nlm.nih.gov/?term=CERGUTUZUMABAMUNALEUKIN(RO6895882)&sort=date&size=20,"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.",Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.,"We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic antigen (CE …"
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,[Study of cone-beam CT in evaluating the electrode array of cochlear implantation postoperatively].,Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018 Sep;32(18):1371-1373. doi: 10.13201/j.issn.1001-1781.2018.18.002.,"There are four ways of evaluating the morphological information of electrode in cochlea post-operatively, including mode of Panorex, mode of MPR, mode of 3D-Ceph and 3D-Bone. ..."
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Impact of primary tumor side on the outcomes of patients with non-metastatic colon cancer; a patient-level pooled analysis of two clinical trials.,Expert Rev Gastroenterol Hepatol. 2018 Aug;12(8):843-848. doi: 10.1080/17474124.2018.1495075. Epub 2018 Jul 10.,"When the analysis was repeated among different treatment strata (observation, adjuvant 5FU/LCV, adjuvant edrecolomab), right-sided colon cancer has longer disease-free survival among observation-treated patients only (p = 0.020). ...The left side of the primary tumor was p …"
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition.,Stem Cells Transl Med. 2018 Jun;7(6):495-501. doi: 10.1002/sctm.17-0289. Epub 2018 Apr 17.,"Furthermore, an EpCAM-specific antibody (edrecolomab) has the merit of having launched the era of monoclonal antibody treatment in oncology in the 1990s. ..."
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Radiological Evaluation of the Dimensions of Lower Molar Alveoli.,Implant Dent. 2018 Jun;27(3):271-275. doi: 10.1097/ID.0000000000000757.,"Axial, paraxial, and Panorex sections were analyzed using a dedicated software. Precise reference points were encoded to make the bone measurements clear and repeatable. ..."
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Outcomes After Open Reduction With Internal Fixation of Mandible Fractures.,J Craniofac Surg. 2018 Jul;29(5):1237-1240. doi: 10.1097/SCS.0000000000004551.,"Preoperative face CT scans were performed in 49 patients (96%) and Panorex in 2 patients (4%). Eight patients (16%) had both modalities, with CT face identifying fractures in 5 patients not seen on Panorex, resulting in a change in operative approach. Postreduction …"
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs.,Cancers (Basel). 2018 Jan 12;10(1):19. doi: 10.3390/cancers10010019.,"In the last forty years, this biomarker has been investigated for use in personalized cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled in humans more than thirty years ago. ..."
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Effect of Surgery First Orthognathic Approach on the Temporomandibular Joint.,J Craniofac Surg. 2018 May;29(3):671-675. doi: 10.1097/SCS.0000000000004227.,A radiological follow-up was performed at 1 week and at 1 year after the operation with a panorex and a latero-lateral teleradiograph. ...
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,"Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update.",Curr Cancer Drug Targets. 2018;18(9):857-868. doi: 10.2174/1568009618666180102102311.,"Based on literatures, Edrecolomab showed limited efficacy in the phase III studies. The wholly human monoclonal antibody Adecatumumab is dose- and target-dependent in metastatic breast cancer patients expressing EpCAM. ..."
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,The use of Synthes MatrixWAVE bone anchored arch bars for closed treatment of multiple concurrent mandibular fractures.,J Oral Biol Craniofac Res. 2017 Sep-Dec;7(3):153-157. doi: 10.1016/j.jobcr.2017.08.006. Epub 2017 Sep 1.,Post-operative Panorex scans did not reveal any evidence of damage to tooth roots. None of the screws became overly embedded in the mucosa secondary to overgrowth; the arch bars were successfully removed in an outpatient setting without local anesthesia. ...
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Predictive factors for resorption of teeth adjacent to impacted maxillary canines.,Int Orthod. 2017 Mar;15(1):54-68. doi: 10.1016/j.ortho.2016.12.011. Epub 2017 Jan 31.,"MATERIAL AND METHODS: This was a retrospective study concerning all patients with impacted maxillary canines who consulted the orthodontics department at the Center for dental care, teaching and research (CSERD) in Montpellier between 2010 and 2015, with a full radiological file …"
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Demirjian approach of dental age estimation: Abridged for operator ease.,J Forensic Dent Sci. 2016 Sep-Dec;8(3):177. doi: 10.4103/0975-1475.195103.,"The second stage assessed the applicability of the ease of DAE by DAE(CC), whereby fifty 2(nd) year BDS students were asked to trace the calcification stages of the seven permanent left mandibular teeth on a panorex, identify the correct stage, assign the corresponding sco …"
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Is Cone-Beam Computed Tomography Always Necessary for Dental Implant Placement?,J Oral Maxillofac Surg. 2017 Feb;75(2):285-289. doi: 10.1016/j.joms.2016.11.005. Epub 2016 Nov 15.,"RESULTS: The Panorex method and the CBCT method accurately predicted implant width to within 1.5 mm of the implant actually placed in 100% of cases and length to within 1.5 mm in more than 95% of cases. For bone graft prediction, the results indicated that neither the P …"
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).,J Clin Oncol. 2016 Sep 1;34(25):3047-53. doi: 10.1200/JCO.2015.65.4699. Epub 2016 Jul 18.,PATIENTS AND METHODS: C9581 evaluated edrecolomab versus observation in patients with stage II CC and reported no survival benefit. ...
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Fusobacterium Nucleatum: Atypical Organism of Pyogenic Liver Abscess Might be Related to Sigmoid Diverticulitis.,N Am J Med Sci. 2016 Apr;8(4):197-9. doi: 10.4103/1947-2714.179961.,Dental examination and Panorex x-ray were normal. Imaging of the liver with abdominal computed tomography demonstrated a 5.5 cm abscess in the right lobe of the liver. ...
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Fast and Early Mandibular Osteodistraction: The Long-Term Follow-Up of Mandibular Distraction Osteogenesis on Teeth Position.,J Craniofac Surg. 2015 Nov;26(8):2325-8. doi: 10.1097/SCS.0000000000001997.,"All patients underwent fast and early mandibular osteodistraction; two years follow up computed tomography and panorex reconstructions showed bone consolidation, 33 of 35 teeth analyzed before ostedistraction are present after distraction protocol; no positional changes we …"
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,The mandibular permanent second molars and their risk of impaction: a retrospective study.,Eur J Paediatr Dent. 2015 Sep;16(3):246-50.,"STUDY DESIGN: 478 patients of the Orthodontic School of ""La Sapienza"" University of Rome (Italy) were studied to assess the eruption of teeth 37 and 47 on at least two good-quality panorex using angular measurements and Nolla's index from January 2008 to December 2013. ..."
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Maxillary Sinus Septa and Anatomic Correlation With the Schneiderian Membrane.,J Craniofac Surg. 2015 Jun;26(4):1394-8. doi: 10.1097/SCS.0000000000001725.,"Septa were identified using ""panorex"" reconstructions and axial scans of cone-beam computed tomography using the software ""eXamVision."" ..."
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,Long-term survival with eribulin monotherapy after whole brain radiation therapy in a patient with brain metastasis from breast cancer.,Asian J Surg. 2020 Jul 3:S1015-9584(20)30131-7. doi: 10.1016/j.asjsur.2020.05.002. Online ahead of print.,
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Evaluation of bone height of the free fibula flap in mandible reconstruction.,J Craniofac Surg. 2015 May;26(3):673-6. doi: 10.1097/SCS.0000000000001509.,"Postoperative Panorex examinations were used to evaluate fibular height, and 7 factors with a potential influence on long-term fibular height were evaluated: age, gender, length of the mandible defect, number of segmental osteotomies, preservation of a direct nutrient arte …"
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Exposure to ionizing radiation during dental X-rays is not associated with risk of developing meningioma: a meta-analysis based on seven case-control studies.,PLoS One. 2015 Feb 6;10(2):e0113210. doi: 10.1371/journal.pone.0113210. eCollection 2015.,"Neither exposure to dental X-rays nor performance of full-mouth panorex X-rays was associated with an increased risk of development of meningioma (overall: OR, 0.97; 95% CI, 0.70-1.32; dental X-rays: OR, 1.05; 95% CI, 0.89-1.25; panorex X-rays: OR, 1.01; 95% CI, 0.7 …"
2020-09-23T06:02:16Z,https://pubmed.ncbi.nlm.nih.gov/?term=MOAB17-1A(PANOREX)&sort=date&size=20,Bayesian Multiscale Modeling of Closed Curves in Point Clouds.,J Am Stat Assoc. 2014 Oct;109(508):1481-1494. doi: 10.1080/01621459.2014.934825.,"Theoretical properties of our prior are studied in specific cases and efficient Markov chain Monte Carlo methods are developed, evaluated through simulation examples and applied to panorex teeth images for modeling teeth contours and also to a brain tumor contour detection …"
2020-09-23T06:02:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=CA-4948&sort=date&size=20,Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis.,Expert Opin Investig Drugs. 2020 May;29(5):475-482. doi: 10.1080/13543784.2020.1752660. Epub 2020 Apr 17.,
2020-09-23T06:02:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=CA-4948&sort=date&size=20,Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).,Expert Opin Ther Pat. 2019 Apr;29(4):243-259. doi: 10.1080/13543776.2019.1597850. Epub 2019 Mar 29.,
2020-09-23T06:02:32Z,https://pubmed.ncbi.nlm.nih.gov/?term=MDX-060&sort=date&size=20,TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.,Leukemia. 2010 Jan;24(1):51-7. doi: 10.1038/leu.2009.230. Epub 2009 Nov 5.,"Consequently, shedding inhibition substantially improved the synergistic antitumor efficacy of the human anti-CD30 Ab, MDX-060, and bortezomib. ..."
2020-09-23T06:02:32Z,https://pubmed.ncbi.nlm.nih.gov/?term=MDX-060&sort=date&size=20,In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.,Clin Cancer Res. 2009 May 15;15(10):3376-83. doi: 10.1158/1078-0432.CCR-08-3222. Epub 2009 Apr 28.,"RESULTS: The binding of MDX-1401 to CD30 antigen was identical to fucose-containing parental anti-CD30 antibody (MDX-060). In contrast, MDX-1401 showed increased binding affinity to FcgammaRIIIa-transfected cells resulting in increased effector functio …"
2020-09-23T06:02:32Z,https://pubmed.ncbi.nlm.nih.gov/?term=MDX-060&sort=date&size=20,Newer monoclonal antibodies for hematological malignancies.,Exp Hematol. 2008 Jul;36(7):755-68. doi: 10.1016/j.exphem.2008.04.018.,"This review will focus on three major aspects of monoclonal antibody therapy: 1) new therapeutic approaches with currently approved agents; 2) preclinical and clinical experience accumulated on new agents in the last few years; discussion will include available phase I, II, and I …"
2020-09-23T06:02:32Z,https://pubmed.ncbi.nlm.nih.gov/?term=MDX-060&sort=date&size=20,Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.,J Clin Oncol. 2007 Jul 1;25(19):2764-9. doi: 10.1200/JCO.2006.07.8972. Epub 2007 May 21.,PURPOSE: MDX-060 is a human anti-CD30 immunoglobulin (Ig) G1kappa monoclonal antibody that inhibits growth of CD30-expressing tumor cells in preclinical models. ...CONCLUSION: MDX-060 was well tolerated at doses up to 15 mg/kg. MDX-060 ha …
2020-09-23T06:02:32Z,https://pubmed.ncbi.nlm.nih.gov/?term=MDX-060&sort=date&size=20,Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.,Drugs. 2007;67(3):333-50. doi: 10.2165/00003495-200767030-00002.,Further clinical evaluation of antibodies has been based largely on our knowledge of antigen expression on the surface of lymphoma cells and has led to the development of antibodies against CD22 (unconjugated epratuzumab and calicheamicin conjugated CMC-544 [inotuzumab ozogamicin …
2020-09-23T06:02:32Z,https://pubmed.ncbi.nlm.nih.gov/?term=MDX-060&sort=date&size=20,MDX-060. Medarex.,Curr Opin Investig Drugs. 2005 Dec;6(12):1266-71.,"Medarex is developing the antibody MDX-060 for the potential treatment of CD30+ lymphomas, such as Hodgkin's disease and anaplastic large cell lymphomas. ..."
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,Combretastatin A4 nanodrug combined plerixafor for inhibiting tumor growth and metastasis simultaneously.,Biomater Sci. 2019 Dec 1;7(12):5283-5291. doi: 10.1039/c9bm01418g. Epub 2019 Oct 11.,"Combretastatin A4 nanodrug (CA4-NPs), a neogenesis blood vascular disrupting agent, can accumulate around blood vessels and disrupt tumor neogenesis of blood vessels more efficaciously than typical small molecular drug combretastatin A4 phosphate (CA4P). ..."
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,"Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate.",Cancer Chemother Pharmacol. 2019 Dec;84(6):1187-1194. doi: 10.1007/s00280-019-03953-9. Epub 2019 Sep 13.,"Nab-paclitaxel in combination with CA4P inhibited tumor growth significantly more potently compared with the CA4P group, nab-paclitaxel group and PBS group. Our results demonstrate that co-administration of CA4P increased the intratumoral accumulation of nab- …"
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,Biological and anti-vascular activity evaluation of ethoxy-erianin phosphate as a vascular disrupting agent.,J Cell Biochem. 2019 Oct;120(10):16978-16989. doi: 10.1002/jcb.28959. Epub 2019 May 20.,The results showed that EBTP possessed antiproliferative activity in the micromole range and was relatively less toxic than CA4P. ...EBTP is an effective vascular disrupting agent that is superior to CA4P and may prevent and treat malignancy by inhibiting the expres …
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,"Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects.",Int J Nanomedicine. 2019 Mar 8;14:1789-1804. doi: 10.2147/IJN.S188971. eCollection 2019.,"RESULTS: Compared with unmodified LPs (Cur-CA4P LPs), Cur-CA4P/GA LPs were taken up effectively by human hepatocellular carcinoma cells (BEL-7402) and showed higher cytotoxicity than free drugs. ...Moreover, Cur-CA4P/GA LPs showed stronger inhibition of tumor …"
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,Autophagy as a molecular target for cancer treatment.,Eur J Pharm Sci. 2019 Jun 15;134:116-137. doi: 10.1016/j.ejps.2019.04.011. Epub 2019 Apr 11.,
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,Enhanced local cancer therapy using a CA4P and CDDP co-loaded polypeptide gel depot.,Biomater Sci. 2019 Feb 26;7(3):860-866. doi: 10.1039/c8bm01442f.,"In this work, a new strategy through co-delivery of combretastatin A4 disodium phosphate (CA4P) and cisplatin (CDDP) was developed for the local treatment of colon cancer, through an in situ thermo-gelling hydrogel (mPEG-b-PELG). ...Also, the drug loaded gel could regulate …"
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,Evaluation of Sydnone-Based Analogues of Combretastatin A-4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer Therapy.,ChemMedChem. 2018 Dec 20;13(24):2618-2626. doi: 10.1002/cmdc.201800567. Epub 2018 Nov 8.,
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.,World J Gastroenterol. 2018 Jul 7;24(25):2710-2721. doi: 10.3748/wjg.v24.i25.2710.,"RESULTS: On CE-T1WIs, unlike the negative response in all tumors of control animals, in treatment group CA4P caused rapid extensive vascular shutdown in all R1-tumors, but mildly or spottily in HCCs at 1 h. ...CONCLUSION: This study suggests superior performance of CA4P …"
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.,Vet Comp Oncol. 2018 Dec;16(4):467-477. doi: 10.1111/vco.12402. Epub 2018 May 24.,"Combretastatin A4-phosphate (CA4P) is an anti-tumour vascular targeting agent which selectively blocks tumour blood flow. Research on CA4P in rodent tumour models is extensive; however, knowledge of its effect on spontaneous cancer is scarce. ...The goal was to asse …"
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.,Int J Cancer. 2018 Oct 1;143(7):1817-1828. doi: 10.1002/ijc.31567. Epub 2018 Jul 3.,"Multi-parametric MRI revealed rapid CA4P-induced tumor vascular shutdown within 1 hr, followed by variable intratumoral necrosis at 12 hr. ...Ordinal-logistic-regression helped to predict early tumor responses to CA4P in terms of tumoral differentiation and vascular …"
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,Preclinical Evaluation of Radioiodinated Hoechst 33258 for Early Prediction of Tumor Response to Treatment of Vascular-Disrupting Agents.,Contrast Media Mol Imaging. 2018 Feb 26;2018:5237950. doi: 10.1155/2018/5237950. eCollection 2018.,"This study aimed to explore the use of (131)I-Hoechst 33258 ((131)I-H33258) for early prediction of tumor response to vascular-disrupting agents (VDAs) with combretastatin-A4 phosphate (CA4P) as a representative. ...SPECT/CT imaging demonstrated that an obvious ""hot spot"" …"
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,Photoacoustic microscopy for evaluating combretastatin A4 phosphate induced vascular disruption in orthotopic glioma.,J Biophotonics. 2018 Oct;11(10):e201700327. doi: 10.1002/jbio.201700327. Epub 2018 May 9.,The use of an optical resolution photoacoustic microscopy (OR-PAM) system to evaluate the vascular disruptive effect of combretastatin A4 Phosphate (CA4P) on a murine orthotopic glioma with intact skull is described here. ...Longitudinal imaging of the brain pre- and post- …
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,Quantitative Evaluation of Combretastatin A4 Phosphate Early Efficacy in a Tumor Model with Dynamic Contrast-Enhanced Ultrasound.,Ultrasound Med Biol. 2018 Apr;44(4):840-852. doi: 10.1016/j.ultrasmedbio.2017.12.002. Epub 2018 Feb 1.,"Central and peripheral perfusion of tumors was detected by CEUS pre-treatment (0 h) and 2, 12 and 48 h after CA4P injection. ...After CEUS, the efficacy of CA4P was immediately confirmed by immunofluorescence assay and hematoxylin and eosin, Hoechst 33342 and fluore …"
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,"Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.",Gynecol Oncol Res Pract. 2018 Jan 5;5:1. doi: 10.1186/s40661-017-0058-5. eCollection 2018.,Combretastatin A4-phosphate (CA4P) is a vascular-disrupting agent (VDA) in clinical development for the treatment of ovarian and other cancers. ...The clinical trial experience with CA4P suggests that cardiovascular assessment of patients prior to CA4P treatm …
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,"Vascular disrupting agent in pancreatic and hepatic tumour allografts: observations of location-dependent efficacy by MRI, microangiography and histomorphology.",Br J Cancer. 2017 Nov 7;117(10):1529-1536. doi: 10.1038/bjc.2017.324. Epub 2017 Sep 14.,This study was aimed to identify in vivo imaging biomarkers for evaluation of pancreatic and hepatic tumours and comparison of their responses to a VDA Combretastatin A4 Phosphate (CA4P) using multiparametric MRI. ...Therapeutic intervention using CA4P was investiga …
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,"Design, Synthesis, and Biological Evaluation of Novel Selenium-Containing Isocombretastatins and Phenstatins as Antitumor Agents.",J Med Chem. 2017 Sep 14;60(17):7300-7314. doi: 10.1021/acs.jmedchem.7b00480. Epub 2017 Aug 23.,
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,A dose-escalation study of combretastatin A4-phosphate in healthy dogs.,Vet Comp Oncol. 2018 Mar;16(1):E16-E22. doi: 10.1111/vco.12327. Epub 2017 Jun 16.,Combretastatin A4-Phosphate (CA4P) is a vascular disrupting agent revealing promising results in cancer treatments for humans. The aim of this study was to investigate the safety and adverse events of CA4P in healthy dogs as a prerequisite to application of CA4P …
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,Water-Soluble Combretastatin A4 Phosphate Orally Delivered via Composite Nanoparticles With Improved Inhibition Effect Toward S180 Tumors.,J Pharm Sci. 2017 Oct;106(10):3076-3083. doi: 10.1016/j.xphs.2017.05.031. Epub 2017 Jun 13.,The highest entrapment efficiency of CA4P-NPs was achieved when the weight ratio of PELA to PLGA was optimized to 1:1. The apparent permeability coefficient of CA4P-NPs was found to be 2.08-fold higher than that of free CA4P in transport study. CA4P-NP …
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,Effects of combretastatin A-4 phosphate on canine normal and tumor tissue-derived endothelial cells.,Res Vet Sci. 2017 Jun;112:222-228. doi: 10.1016/j.rvsc.2017.05.017. Epub 2017 May 13.,"Combretastatin A-4 phosphate (CA4P) selectively blocks tumor blood flow. However, the detailed mechanisms through which CA4P specifically affects tumor blood vessels are not well understood. ...Thus, abnormalities in TECs may be involved in the selective vascular bl …"
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,Monitoring Tumor Response to Antivascular Therapy Using Non-Contrast Intravoxel Incoherent Motion Diffusion-Weighted MRI.,Cancer Res. 2017 Jul 1;77(13):3491-3501. doi: 10.1158/0008-5472.CAN-16-2499. Epub 2017 May 9.,"In this study, we sought to investigate the feasibility of using intravoxel incoherent motion (IVIM) diffusion MRI to quantitatively assess the efficacy of the treatments of a vascular-disrupting agent CA4P or its combination with bevacizumab on experimental NSCLC tumors. …"
2020-09-23T06:02:36Z,https://pubmed.ncbi.nlm.nih.gov/?term=FOSBRETABULIN(CA4P)&sort=date&size=20,Identification of novel 1-indolyl acetate-5-nitroimidazole derivatives of combretastatin A-4 as potential tubulin polymerization inhibitors.,Biochem Pharmacol. 2017 Aug 1;137:10-28. doi: 10.1016/j.bcp.2017.04.026. Epub 2017 Apr 27.,
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Risk-based Approaches for Optimizing Treatment in HER2-Positive Early Stage Breast Cancer.,Semin Oncol. 2020 Aug 20:S0093-7754(20)30084-1. doi: 10.1053/j.seminoncol.2020.07.007. Online ahead of print.,"In addition to trastuzumab, pertuzumab, neratinib, and ado-trastuzumab emtansine have been approved in recent years for the treatment of high-risk early stage HER2-positive breast cancer. ..."
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.",Lancet Oncol. 2020 Sep 10:S1470-2045(20)30444-7. doi: 10.1016/S1470-2045(20)30444-7. Online ahead of print.,Patients were recruited into four parallel treatment cohorts matched to mutations identified in ctDNA: cohort A comprised patients with ESR1 mutations (treated with intramuscular extended-dose fulvestrant 500 mg); cohort B comprised patients with HER2 mutations (treated with oral …
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Tyrosine kinase inhibitor neratinib attenuates liver fibrosis by targeting activated hepatic stellate cells.,Sci Rep. 2020 Sep 8;10(1):14756. doi: 10.1038/s41598-020-71688-2.,"We elucidated the anti-fibrotic effects of neratinib in hepatic stellate cells (HSCs) and in vivo models of CCl(4)-induced liver fibrosis. ...Moreover, the anti-fibrotic effects of neratinib were not associated with the HER2 signaling pathways. Neratinib inhi …"
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Systemic therapy for metastatic HER2-positive breast cancer.,Semin Oncol. 2020 Aug 18:S0093-7754(20)30085-3. doi: 10.1053/j.seminoncol.2020.07.008. Online ahead of print.,"Recent studies of small molecule oral tyrosine kinase inhibitors such as tucatinib and neratinib, and antibody drug conjugates such as trastuzumab deruxtecan further improve outcomes. ..."
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer.,Curr Opin Oncol. 2020 Sep 2. doi: 10.1097/CCO.0000000000000682. Online ahead of print.,"Neratinib, has shown that it was able to delay brain metastases progression. Finally, tucatinib, has demonstrated benefit in progression-free survival and overall survival in combination with trastuzumab and capecitabine over trastuzumab and capecitabine for patients with …"
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Management of brain metastases according to molecular subtypes.,Nat Rev Neurol. 2020 Sep 1. doi: 10.1038/s41582-020-0391-x. Online ahead of print.,"HER2-targeted therapies (lapatinib, neratinib, tucatinib and trastuzumab emtansine), alone or in combination, yield a number of intracranial responses in patients with HER2-positive breast cancer brain metastases. ..."
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer.,Expert Rev Anticancer Ther. 2020 Aug 30:1-11. doi: 10.1080/14737140.2020.1807947. Online ahead of print.,"Neratinib is an irreversible pan-HER (EGFR, ERBB2, and ERBB4) TKI being tested in early and advanced HER2-positive breast cancer. ...The main adverse event in the neratinib arm was diarrhea, which mandates for prophylactic treatment with loperamide. AREAS COVERED: I …"
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins.,Drug Metab Pharmacokinet. 2020 Jul 24:S1347-4367(20)30399-2. doi: 10.1016/j.dmpk.2020.07.002. Online ahead of print.,"In addition to the reports on neratinib and pyrotinib, osimertinib, alflutinib, AST5902, and ibrutinib were confirmed to covalently bind to the Lys-190 of human serum albumin (HSA). ..."
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Trastuzumab Targeted Neratinib Loaded Poly-Amidoamine Dendrimer Nanocapsules for Breast Cancer Therapy.,Int J Nanomedicine. 2020 Jul 30;15:5433-5443. doi: 10.2147/IJN.S256898. eCollection 2020.,RESULTS: The G4 PAMAM dendrimer showed successful encapsulation of neratinib and a sustained release profile. Comparative in vitro studies revealed that these TZ-targeted dendrimers loaded with neratinib were more selective and have higher antiproliferation activity …
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib.,Saudi Pharm J. 2020 Aug;28(8):963-970. doi: 10.1016/j.jsps.2020.06.017. Epub 2020 Jun 30.,"Neratinib, an irreversible tyrosine kinase inhibitor is used to treat HER2 positive cancers. Neratinib targets HER2 and blocks its signal transduction resulting in inhibition of cell proliferation and induction of apoptosis without any information about the molecula …"
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,"Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.",Breast Cancer Res. 2020 Aug 11;22(1):85. doi: 10.1186/s13058-020-01324-4.,Activating mutations amenable to HER2-directed therapy with neratinib were identified using existing functional data from in vitro cell line and xenograft experiments. ...Differential gene expression analyses by ERBB2 mutation and amplification status was performed using w …
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Differential mutation spectrum and immune landscape in African Americans versus Whites: A possible determinant to health disparity in head and neck cancer.,Cancer Lett. 2020 Jul 29;492:44-53. doi: 10.1016/j.canlet.2020.07.029. Online ahead of print.,Connectivity map analysis identified drugs (Neratinib and Selumetinib) that target aberrant PI3K/RAS/MEK signaling and may reduce racial disparity in therapy response....
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,WNT5A augments cell invasiveness by inducing CXCL8 in HER2-positive breast cancer cells.,Cytokine. 2020 Nov;135:155213. doi: 10.1016/j.cyto.2020.155213. Epub 2020 Jul 28.,"WNT5A expression was also decreased by pan-HER inhibitor neratinib but not by trastuzumab. In addition, WNT5A augmented cell invasiveness of HER2+ breast-cancer cells. ..."
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,"Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.",Gynecol Oncol. 2020 Jul 25:S0090-8258(20)33660-X. doi: 10.1016/j.ygyno.2020.07.025. Online ahead of print.,"Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is active in multiple HER2-mutant cancers. SUMMIT is a phase II basket trial investigating the efficacy and safety of neratinib in solid tumors. ...CONCLUSIONS: Neratinib monotherapy showed evidenc …"
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.,Cancer. 2020 Jul 28. doi: 10.1002/cncr.33102. Online ahead of print.,"Food and Drug Administration approvals of trastuzumab deruxtecan (DS-8201), neratinib, and tucatinib in combination with trastuzumab and capecitabine. ..."
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.,Breast Cancer. 2020 Jul 18. doi: 10.1007/s12282-020-01133-9. Online ahead of print.,"In this study, we developed a reproducible model for neratinib-induced diarrhea in male and female rats. METHODS: At first, male rats were treated with neratinib at 15, 30 or 50 mg/kg or vehicle control via oral gavage for 28 days (total n = 12). ...Male rats treate …"
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.,J Clin Oncol. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17.,"PURPOSE: NALA (ClinicalTrials.gov identifier: NCT01808573) is a randomized, active-controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), plus capecitabine (N+C) against lapatinib, a reversible dual TKI, plus capecitabine …"
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Strategy for Determining the Free Fraction of Labile Covalent Modulators in Plasma Using Equilibrium Dialysis.,J Pharm Sci. 2020 Oct;109(10):3181-3189. doi: 10.1016/j.xphs.2020.06.029. Epub 2020 Jul 12.,"Two approaches using diluted plasma and low temperature (4 & 20 °C) for equilibrium dialysis (ED) have been investigated using covalent modulators including osimertinib, ibrutinib, rociletinib, afatinib, neratinib and acalabrutinib. ..."
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,Neratinib-Induced Duodenal Ulcer: A Case Report.,Breast Cancer (Auckl). 2020 Jun 23;14:1178223420935871. doi: 10.1177/1178223420935871. eCollection 2020.,"Given this unexpected serious adverse event and only modest benefit of neratinib in the adjuvant setting, the decision was made to forgo further treatment with neratinib. Physicians should be aware of the gastrointestinal (GI) side effects associated with neratin …"
2020-09-23T06:02:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=NERATINIB&sort=date&size=20,"In silico structure prediction, molecular docking and dynamic simulation studies on G Protein-Coupled Receptor 116: a novel insight into breast cancer therapy.",J Biomol Struct Dyn. 2020 Jun 25:1-9. doi: 10.1080/07391102.2020.1783365. Online ahead of print.,"The results have shown that Doxorubicin, Neratinib maleate, Epirubicin, and Lapatinib Ditosylate have good interaction with GPR116 binding site. ..."
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients.,J Neuroimmunol. 2020 Sep 15;348:577383. doi: 10.1016/j.jneuroim.2020.577383. Online ahead of print.,Two potentially related microRNAs (miRNAs; miR-150-5p and miR-146a-5p) were examined after low-dose rituximab (RTX) treatment in patients with acetylcholine receptor antibody (AChR)-positive refractory myasthenia gravis (MG). ...
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.,PLoS One. 2020 Sep 22;15(9):e0238807. doi: 10.1371/journal.pone.0238807. eCollection 2020.,"METHODS: Between April 2001 and November 2018, 120 patients with complete remission following rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy were retrospectively reviewed. ..."
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus.,Drugs R D. 2020 Sep 22. doi: 10.1007/s40268-020-00320-5. Online ahead of print.,"Of the licensed mAbs, adalimumab, denosumab, rituximab, etanercept and infliximab were calculated to have the highest relative number of yearly users based on global sales data. ..."
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Synchronous duodenal mucosa-associated lymphoid tissue lymphoma and gastric cancer.,Clin J Gastroenterol. 2020 Sep 21. doi: 10.1007/s12328-020-01241-1. Online ahead of print.,"After operation, four courses of systemic rituximab treatment were administered for the MALT lymphoma, followed by adjuvant S-1 (tegafur/gimeracil/oteracil) chemotherapy for the gastric cancer. ..."
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.,Blood. 2020 Sep 21:blood.2020006578. doi: 10.1182/blood.2020006578. Online ahead of print.,"The phase II CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective, B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L) diffuse large B-cell lymphoma ( …"
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell targeted therapies.,Blood. 2020 Sep 21:blood.2020007092. doi: 10.1182/blood.2020007092. Online ahead of print.,"Intravenous immunoglobulins (IVIg) and rituximab-based regimens were the most effective therapies with respectively 53 and 52% of partial or better clinical responses. ...Although more studies are warranted to better define the optimal therapeutic sequence, IVIg should be …"
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,An atypical presentation of primary central nervous system lymphoma: A case report.,Medicine (Baltimore). 2020 Sep 18;99(38):e22062. doi: 10.1097/MD.0000000000022062.,"OUTCOMES: The patient underwent induction therapy with high-dose methotrexate, temozolomide, and rituximab, which resulted in complete resolution of the enhancing lesions. ..."
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.,Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07018-4. Online ahead of print.,"CD123 (the α-subunit of interleukin (IL)-3 receptor) is over-expressed on BPDCN cells surface and seems to be the ideal marker to develop antibody-based therapies. Tagraxofusp (Elzonris), a recombinant immunotoxin consisting of human interleukin-3 fuse …"
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia.,Mult Scler Relat Disord. 2020 Sep 16;46:102516. doi: 10.1016/j.msard.2020.102516. Online ahead of print.,We aimed to evaluate patient perspectives regarding the use of Natalizumab and anti-CD20 therapies (Rituximab and Ocrelizumab) in the context of the COVID-19 pandemic. ...More than half of the cohort were self-isolating more stringently than general government advice and g …
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Isolated opsoclonus heralding neuromyelitis optica spectrum disorder.,J Neuroimmunol. 2020 Sep 14;348:577394. doi: 10.1016/j.jneuroim.2020.577394. Online ahead of print.,"After one-and-a-half-year follow-up, the patient was maintaining well on rituximab as secondary prophylaxis without any further attack. ..."
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,"Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma.",Future Oncol. 2020 Sep 21. doi: 10.2217/fon-2020-0675. Online ahead of print.,"This drug was US FDA approved in 2019 in combination with bendamustine and rituximab for the treatment of refractory/relapsed diffuse large B-cell lymphoma in third line and more, after demonstrating relevant efficacy and acceptable safety in a pivotal randomized Phase II …"
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,A dermatopathic Juvenile Dermatomyositis; An Unexpected Case in Childhood.,Iran J Child Neurol. 2020 Summer;14(3):89-92.,"The patient was treated with intravenous immunoglobulin, corticosteroids, methotrexate, hydroxychloroquine, pamidronate, and rituximab. ..."
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans Health Administration.,Fed Pract. 2020 May;37(Suppl 2):S44-S49.,"RESULTS: From 2010 to 2014, 2,796 patients were diagnosed and received care for CLL within the VHA, of whom 172 patients received ibrutinib and 291 received bendamustine + rituximab (BR). ..."
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Do immunosuppressive agents hamper the vaccination response in patients with rheumatic diseases? A review of the literature.,Therapie. 2020 Sep 3:S0040-5957(20)30148-7. doi: 10.1016/j.therap.2020.08.002. Online ahead of print.,"We found that the majority of studies confirms that neither the use of corticosteroids and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) nor the use of biological agents, except rituximab, reduce the efficacy of inactivated vaccines such as pneumo …"
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Preemptive HLA Antibody Screening Prior to Episodic Transplant Renal Biopsy Enables Early Diagnosis and Therapeutic Response in Asymptomatic Chronically Active Antibody-Related Rejection: A Case Report.,Transplant Proc. 2020 Sep 17:S0041-1345(20)32705-6. doi: 10.1016/j.transproceed.2020.08.034. Online ahead of print.,"Intravenous steroid pulse, deoxyspagarin, antithymocyte globulin, rituximab, and oral everolimus were administrated. The treatment resulted in a gradual decrease in the DSA, which became negative 1 year later. The patient's serum creatinine remains around 1.0 mg/dL, …"
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis.,Pediatr Neurol. 2020 Oct;111:40-43. doi: 10.1016/j.pediatrneurol.2020.07.002. Epub 2020 Jul 6.,The objective of our study was to assess the tolerability and efficacy of rituximab use in children with refractory juvenile myasthenia gravis. ...CONCLUSION: Rituximab was well-tolerated and efficacious in this juvenile myasthenia gravis cohort. The beneficial effe …
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Biosimilars in oncology: Effects on economy and therapeutic innovations.,Eur J Cancer. 2020 Sep 17;139:10-19. doi: 10.1016/j.ejca.2020.07.037. Online ahead of print.,"METHODS: Based on available health-economic analyses, the actual prescription and cost containment potential of biosimilars compared to the originator were calculated exemplarily for the cost-intensive therapies trastuzumab in breast cancer, rituximab in follicular lymphom …"
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Ex-vivo delivery of monoclonal antibody (Rituximab) to treat human donor lungs prior to transplantation.,EBioMedicine. 2020 Sep 15;60:102994. doi: 10.1016/j.ebiom.2020.102994. Online ahead of print.,"In this study, we demonstrate an extension of its utility by administering the anti-CD20 monoclonal antibody, Rituximab, during EVLP. ...In lung tissue, Rituximab resulted in an 8.75 fold-reduction in CD20+ staining relative to controls (p = 0.0002). This decrease i …"
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Chylomicronemia from GPIHBP1 autoantibodies.,J Lipid Res. 2020 Sep 18:jlr.R120001116. doi: 10.1194/jlr.R120001116. Online ahead of print.,"Recently, several GPIHBP1 autoantibody syndrome patients were treated successfully with rituximab, resulting in the disappearance of GPIHBP1 autoantibodies and normalization of both plasma triglyceride and LPL levels. ..."
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,Prognostic Models Integrating Quantitative Parameters from Baseline and Interim Positron Emission Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma: Post-Hoc Analysis from the SAKK38/07 Clinical Trial.,Hematol Oncol. 2020 Sep 18. doi: 10.1002/hon.2805. Online ahead of print.,"We centrally reviewed baseline and interim PET/CT scans of 138 patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone given every 14 days (R-CHOP14) in the SAKK38/07 trial (ClinicalTrial.gov identifier: NCT00544219). ..."
2020-09-23T06:02:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=RITUXIMAB&sort=date&size=20,The safety of available chemo-free treatments for mantle cell lymphoma.,Expert Opin Drug Saf. 2020 Sep 18. doi: 10.1080/14740338.2020.1826435. Online ahead of print.,"INTRODUCTION: Conventional treatment for mantle cell lymphoma (MCL) patients includes regimens combining rituximab with other cytotoxic drugs, followed or not by consolidation with autologous stem cell transplantation and rituximab maintenance. ..."
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,"JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs.",Blood Adv. 2020 Sep 22;4(18):4554-4559. doi: 10.1182/bloodadvances.2019001283.,"Consistent with the genetic and clinical data, expression of JAK2S523L causes interleukin-3-independent growth in Ba/F3 cells transduced with the erythropoietin receptor by constitutively active Jak2/Stat5 signaling...."
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,Novel treatments for anaplastic thyroid carcinoma.,Gland Surg. 2020 Jan;9(Suppl 1):S28-S42. doi: 10.21037/gs.2019.10.18.,".); EGFR (gefitinib, docetaxel); BRAF (dabrafenib/trametinib, vemurafenib); PPARγ agonists (rosiglitazone, pioglitazone, efatutazone); PD-1 and PD-L1 (pembrolizumab); TERT. ..."
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Interleukin 3-induced GITR promotes the activation of human basophils.,Cytokine. 2020 Sep 1;136:155268. doi: 10.1016/j.cyto.2020.155268. Online ahead of print.,"Human basophils regulate allergic reactions by secreting histamine, interleukin 4 (IL-4) and IL-13 through key surface receptors FcεRI as well as IL-3R, which are constitutively expressed on basophils. IL-3/IL-3R signaling axis plays key roles in regulating the deve …"
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,"Nfil3, a target of the NACA transcriptional coregulator, affects osteoblast and osteocyte gene expression differentially.",Bone. 2020 Aug 30:115624. doi: 10.1016/j.bone.2020.115624. Online ahead of print.,Our approach identified Nuclear factor interleukin-3-regulated (Nfil3) as a target promoter of this pathway. Knockdown of Naca reduced the response of Nfil3 to PTH(1-34) stimulation. ...
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.,Blood Adv. 2020 Aug 25;4(16):4020-4027. doi: 10.1182/bloodadvances.2019000173.,"The major scientific breakthrough in this field was the recognition of overexpression of a surface receptor, CD123/interleukin 3 (IL-3) receptor α, in all patients. Importantly, a novel therapeutic agent consisting of a truncated diphtheria toxin (DT) payload …"
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,[Methodology of Differentiation of Bone Marrow Cells into Megakaryocytes in Vitro].,Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Aug;28(4):1357-1362. doi: 10.19746/j.cnki.issn.1009-2137.2020.04.047.,
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Molecular modeling and co-expression analysis of human stem cell factor as fusion partner to granulocyte colony stimulating factor for improving their bioactivity.,J Biomol Struct Dyn. 2020 Jul 28:1-15. doi: 10.1080/07391102.2020.1796792. Online ahead of print.,"Here, through a computational biology approach, we show that human stem cell factor (hSCF) could be a better fusion partner than human thyroid peroxidase (hTPO), human erythropoietin (hEPO) and human interleukin-3 (hIL3) for co-expression with hG-CSF. ..."
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Effect of simulated microgravity conditions of hindlimb unloading on mice hematopoietic and mesenchymal stromal cells.,Cell Biol Int. 2020 Jul 27. doi: 10.1002/cbin.11432. Online ahead of print.,"The expression levels of hematopoietic-related genes, such as fms-like tyrosine kinase-3 ligand, granulocyte-macrophage colony stimulating factor, interleukin-3, and adipogenic differentiation associated genes, leptin and proliferator-activated receptor γ typ …"
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Rhubarb-Aconite Decoction (RAD) Drug-Containing Serum Alleviated Endotoxin-Induced Oxidative Stress Injury and Inflammatory Response in Caco-2 Cells In Vitro.,Evid Based Complement Alternat Med. 2020 Jul 4;2020:5834502. doi: 10.1155/2020/5834502. eCollection 2020.,"Lipid peroxide malondialdehyde (MDA), lactate dehydrogenase (LDH), caspase-11, tumor necrosis factor-α(TNF-α), interleukin-3(IL-3), and cytokeratin (CK)18, adenosine triphosphate (ATP) activity, and intracellular free calcium ion levels were measured. ...More …"
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,The autocrine regulation of Interleukin-3 on the activity of regulatory T cells and its effectiveness in the pathophysiology of sepsis.,J Infect Dis. 2020 Jul 23:jiaa441. doi: 10.1093/infdis/jiaa441. Online ahead of print.,"Here, we verified the simultaneous expression of IL-3 and its receptor (IL-3R) on Tregs. Then, by modulation of IL-3 expression via lentiviral transduction mediated siRNA, we demonstrated that IL-3 negatively regulated Tregs activity via an autocrine mechanis …"
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Value Added Impact of Both Point-of-Care and Laboratory Lactic Acid Analysis When Emergently Evaluating Cancer Patients.,Oncol Ther. 2020 Jun 2. doi: 10.1007/s40487-020-00118-0. Online ahead of print.,"Therefore, in subsequent decision-making, we recommend that if sepsis is suspected and BLAC determined by POCT is normal, nucleic acids, proteins, circulating cells, and interleukin-3 levels should also be obtained by POCT to confirm sepsis and/or rule out tumor lys …"
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Biochemical Markers of Colorectal Cancer - Present and Future.,Cancer Manag Res. 2020 Jun 22;12:4789-4797. doi: 10.2147/CMAR.S253369. eCollection 2020.,"These include macrophage-colony stimulating factor (M-CSF) and granulocyte-macrophage-colony stimulating factor (GM-CSF), interleukin-3, interleukin-6 and enzymes (alcohol dehydrogenase and lysosomal exoglycosidases). ..."
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.,Onco Targets Ther. 2020 Jun 9;13:5199-5205. doi: 10.2147/OTT.S228342. eCollection 2020.,"CD123, the α-subunit of interleukin (IL)-3 receptor, is constantly overexpressed at the surface of tumoral cells. Tagraxofusp (or SL-401) is a recombinant cytotoxin which consists of human interleukin-3 fused to a truncated diphtheria toxin. ..."
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,FACS-Based Functional Protein Screening via Microfluidic Co-encapsulation of Yeast Secretor and Mammalian Reporter Cells.,Sci Rep. 2020 Jun 23;10(1):10182. doi: 10.1038/s41598-020-66927-5.,"In a model study we co-encapsulated murine interleukin 3 (mIL-3)-secreting S. cerevisiae cells with murine Ba/F3 reporter cells, which express green fluorescent protein (GFP) upon stimulation with mIL-3, and could observe specific and robust induction …"
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Modified plasma cytokine profile in occupational dermatitis.,Endocr Metab Immune Disord Drug Targets. 2020 Jun 7. doi: 10.2174/1871530320666200607194021. Online ahead of print.,"RESULTS: A 1.5-fold increase was noticed for interleukin 3, interleukin 10 and leptin in cases, as compared to controls. Fibroblast growth factor-7 and growth/differentiation factor-15 showed a 1.4- fold increase, while interleukin 19, interleukin …"
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice.,Blood Adv. 2020 Jun 9;4(11):2477-2488. doi: 10.1182/bloodadvances.2019001364.,"We hypothesized that the physiological expression of human cytokines (macrophage colony-stimulating factor, interleukin-3, granulocyte-macrophage colony-stimulating factor, and thrombopoietin) combined with human signal regulatory protein α expression in Rag2-/-Il2r …"
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,Differential efatutazone's impact on mammary neoplasia dependent upon Brca1 dose.,Endocr Relat Cancer. 2018 Dec 1;25(12):L53-L57. doi: 10.1530/ERC-18-0299.,
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Radiation Exposure-Induced Changes in the Immune Cells and Immune Factors of Mice With or Without Primary Lung Tumor.,Dose Response. 2020 May 19;18(2):1559325820926744. doi: 10.1177/1559325820926744. eCollection 2020 Apr-Jun.,"Interleukin-3 (IL-3), IL-6, regulated upon activation, normally T-expressed, and presumably secreted factor (RANTES), and vascular endothelial growth factor (VEGF) were found to be decreased after tumor formation, and the similar results have also been observ …"
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.,Expert Rev Anticancer Ther. 2020 Jul;20(7):543-550. doi: 10.1080/14737140.2020.1776120. Epub 2020 Jun 24.,"CD123 (interleukin-3 receptor alpha unit) is highly expressed in many hematologic malignancies, including BPDCN. Tagraxofusp-ezrs (tagraxofusp from herein) is an agent that consists of interleukin-3 fused to a truncated diphtheria toxin, targeting CD12 …"
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Signal transducer and activator of transcription 5a (STAT5a) represses mitochondrial gene expression through direct binding to mitochondrial DNA.,Biochem Biophys Res Commun. 2020 Jul 5;527(4):974-978. doi: 10.1016/j.bbrc.2020.04.152. Epub 2020 May 20.,"Our previous study showed that interleukin-3 (IL-3) induced STAT5 translocation to mitochondria and binding to mitochondrial DNA (mtDNA) in vitro. In this report, we further demonstrated in vivo binding of endogenous STAT5a to mtDNA transcriptional control re …"
2020-09-23T06:02:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=INTERLEUKIN-3&sort=date&size=20,Lupus Erythematosus Tumidus with Pseudolymphomatous Infiltrates: A Case Report.,J Nippon Med Sch. 2020;87(2):100-103. doi: 10.1272/jnms.JNMS.2020_87-208.,"The nodular infiltrates consisted of CD3+ T cell clusters and CD20+ B cell clusters (ratio, approximately 3:1) and included numerous CD123+ cells, indicative of plasmacytoid dendritic cells. ..."
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for stage IV non-small cell lung cancer: a meta-analysis based on randomized controlled trials.,Ann Palliat Med. 2020 Sep 15:apm-19-365. doi: 10.21037/apm-19-365. Online ahead of print.,BACKGROUND: Whether necitumumab combined with platinum-based chemotherapy (NC) for treating stage IV non-small cell lung cancer (NSCLC) as a first-line treatment could enhance antitumor effectiveness compared with platinum-based chemotherapy alone (CA) treatment is still c …
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells.,Front Oncol. 2020 Jul 24;10:1249. doi: 10.3389/fonc.2020.01249. eCollection 2020.,"Four EGFR monoclonal antibody drugs (cetuximab, panitumumab, nimotuzumab, and necitumumab) are already on the market, and a dozen other EGFR monoclonal antibodies are in clinical trials. ..."
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,Necitumumab.,2020 Jul 20. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–.,"No information is available on the clinical use of necitumumab during breastfeeding. Because necitumumab is a large protein molecule with a molecular weight of 145,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably …"
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.,Lung Cancer. 2020 Apr;142:63-69. doi: 10.1016/j.lungcan.2020.02.003. Epub 2020 Feb 19.,No dose-limiting toxicities were recorded and the combination of necitumumab 800 mg with pembrolizumab 200 mg was considered tolerable. CONCLUSION: Results suggest modest benefits of second-line necitumumab and pembrolizumab combination therapy in patients with Stag …
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,Effects of adding necitumumab to first-line chemotherapy in patients with stage IV non-small-cell lung cancer: Meta-analysis.,J Oncol Pharm Pract. 2020 Sep;26(6):1331-1342. doi: 10.1177/1078155219891631. Epub 2019 Dec 10.,Our aim was to assess the effects of adding necitumumab to chemotherapy in patients with stage IV NSCLC. MATERIAL AND METHODS: A comprehensive literature search was performed according to pre-specified inclusion and exclusion criteria. ...The pooled results showed signific …
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.,Lung Cancer. 2019 Nov;137:136-143. doi: 10.1016/j.lungcan.2019.09.002. Epub 2019 Sep 3.,"OBJECTIVES: Necitumumab, an anti-EGFR antibody, and abemaciclib, a CDK4/6 inhibitor, have shown activity in patients with non-small cell lung cancer (NSCLC) and have non-overlapping toxicities. ...CONCLUSIONS: Abemaciclib 150 mg Q12H with necitumumab 800 mg did not …"
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.,Lung Cancer. 2019 Oct;136:52-56. doi: 10.1016/j.lungcan.2019.08.009. Epub 2019 Aug 14.,"MATERIALS AND METHODS: The treatment regimen comprised triplet induction with necitumumab (800 mg) with nab-paclitaxel (100 mg/m(2)) and carboplatin (AUC 6 mg*min/mL) for 4 cycles, followed by doublet maintenance with necitumumab and nab-paclitaxel with a 3-weekly s …"
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,The effects of somatic mutations on EGFR interaction with anti-EGFR monoclonal antibodies: Implication for acquired resistance.,Proteins. 2020 Jan;88(1):3-14. doi: 10.1002/prot.25762. Epub 2019 Jul 2.,"The aim of the current study was to perform computational analysis to investigate the structural implications of the EGFR somatic mutations on its complexes with the four anti-EGFR mAbs (Cetuximab, Panitumumab, Necitumumab, and Matuzumab). ...We found that EGFR(S492R) and …"
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,"Corrigendum to ""Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan"" [Lung Cancer, 129 (March) (2019) 55-62].",Lung Cancer. 2019 Jun;132:157-158. doi: 10.1016/j.lungcan.2019.04.010. Epub 2019 Apr 20.,
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma.,Neuro Oncol. 2019 Apr 19;21(8):1016-27. doi: 10.1093/neuonc/noz073. Online ahead of print.,"RESULTS: The EGFR domain III-targeting antibodies, cetuximab, necitumumab, nimotuzumab and matuzumab did not neutralize EGFRvIII activation. ..."
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.",Lung Cancer. 2019 Mar;129:55-62. doi: 10.1016/j.lungcan.2019.01.005. Epub 2019 Jan 16.,"OBJECTIVES: This open-label, multicenter, phase 1b/2 study assessed necitumumab plus gemcitabine and cisplatin (GC + N) in patients with previously untreated squamous non-small cell lung cancer in Japan. ..."
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis.,J Thorac Dis. 2018 Dec;10(12):6677-6694. doi: 10.21037/jtd.2018.11.87.,Carboplatin + S-1 and necitumumab in combination with gemcitabine and cisplatin were associated with lower HRs for OS versus all other comparators. Nine studies connected to the network for the PFS analysis in which necitumumab in combination with gemcitabine and ci …
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,The people behind the papers - Elena Popa and Abigail Tucker.,Development. 2019 Feb 8;146(3):dev176313. doi: 10.1242/dev.176313.,
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,Necitumumab for the treatment of advanced non-small-cell lung cancer.,Future Oncol. 2019 Mar;15(7):705-716. doi: 10.2217/fon-2018-0594. Epub 2018 Dec 3.,"The EGFR pathway has been explored as a druggable target with monoclonal antibodies such as cetuximab or necitumumab. Necitumumab is a humanized IgG1 anti-EGFR. ...Thus, necitumumab is now a new first-line treatment option in squamous NSCLC. However, further …"
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,Immune Effector Functions of Human IgG2 Antibodies against EGFR.,Mol Cancer Ther. 2019 Jan;18(1):75-88. doi: 10.1158/1535-7163.MCT-18-0341. Epub 2018 Oct 3.,"Three FDA-approved epidermal growth factor receptor (EGFR) antibodies (cetuximab, panitumumab, necitumumab) are clinically available to treat patients with different types of cancers. ..."
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.,Expert Opin Biol Ther. 2018 Sep;18(9):937-945. doi: 10.1080/14712598.2018.1508445. Epub 2018 Aug 9.,"Necitumumab is a fully humanized IgG1 monoclonal antibody directed against the binding domain of EGFR, approved in combination with cisplatin-gemcitabine for the first-line treatment of squamous NSCLC. Areas covered: The purpose of this manuscript is to systematically revi …"
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,Necitumumab: a new option for first-line treatment of squamous cell lung cancer.,Expert Opin Drug Metab Toxicol. 2018 Aug;14(8):765-772. doi: 10.1080/17425255.2018.1498839. Epub 2018 Jul 31.,"Areas covered: Necitumumab is a human IgG1 anti-EGFR antibody that binds to the receptor and inhibits further pathway activation, thereby inhibiting cell differentiation, proliferation and migration. The phase III SQUIRE trial was a randomized study of gemcitabine-cisplati …"
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview.,Curr Oncol. 2018 Jun;25(Suppl 1):S77-S85. doi: 10.3747/co.25.3792. Epub 2018 Jun 13.,"Targeted agents include ramucirumab, an inhibitor of vascular endothelial growth factor receptor 2, and necitumumab, a monoclonal antibody against epithelial growth factor receptor. ..."
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.,Ann Oncol. 2018 Aug 1;29(8):1701-1709. doi: 10.1093/annonc/mdy196.,"DESIGN: Randomized trials of EGFR-directed mAbs cetuximab and necitumumab in combination with chemotherapy, immunotherapy, or antiangiogenic therapy in patients with advanced NSCLC, including SqCLC, were searched in the literature. ..."
2020-09-23T06:02:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=NECITUMUMAB&sort=date&size=20,Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?,Ann Transl Med. 2018 Apr;6(8):143. doi: 10.21037/atm.2018.02.18.,"Although the majority of these advances took place in the non-squamous histological subtype, therapeutic options for patients diagnosed with advanced squamous cell lung cancer (SqCLC) have been also enriched significantly with the addition of nab-paclitaxel in the conventional ch …"
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,Natural Product as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases.,Curr Protein Pept Sci. 2020 Sep 18. doi: 10.2174/1389203721666200918152511. Online ahead of print.,"Subsequently, several other inhibitors of Topo II such as doxorubicin, mitoxantrone, and teniposide were developed. These drugs have been reported to cause accumulation of cytotoxic non-reversible DNA double-strand breaks (cleavable complex). ..."
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy.,Nat Prod Rep. 2020 Sep 8. doi: 10.1039/d0np00041h. Online ahead of print.,"Almost all podophyllotoxin derivatives, including the FDA-approved drugs VP-16 and teniposide, were seriously limited in clinical therapy due to systemic toxicity, drug resistance, and low bioavailability. ..."
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,Survivin silencing improved the cytotoxicity of carboplatin and melphalan in Y79 and primary retinoblastoma cells.,Int J Pharm. 2020 Aug 27;589:119824. doi: 10.1016/j.ijpharm.2020.119824. Online ahead of print.,"Subsequently, we selected retinoblastoma (RB) as our model to screen four chemotherapeutic agents: carboplatin, topotecan, melphalan or teniposide. ..."
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.,Comput Biol Chem. 2020 Jul 31;88:107351. doi: 10.1016/j.compbiolchem.2020.107351. Online ahead of print.,"Several known drugs, e.g. oxytetracycline, doxorubicin, kanamycin, cefpiramide, teniposide, proanthocyanidin and salvianolic acid B, but also not-approved active compounds from the ZINC15 library were identified as new potential inhibitors of 3CL(pro) by using different co …"
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,Subtribe Hyptidinae (Lamiaceae): A promising source of bioactive metabolites.,J Ethnopharmacol. 2020 Aug 5;264:113225. doi: 10.1016/j.jep.2020.113225. Online ahead of print.,"In addition, the species of the subtribe appear to be very promising as alternative sources of podophyllotoxin-like lignans which are the lead compounds for the semi-synthesis of teniposide and etoposide, important antineoplastic agents. ..."
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,Impact of Systemic Chemotherapy and Delayed Enucleation on Survival of Children with Advanced Intraocular Retinoblastoma.,Ophthalmol Retina. 2020 Jun;4(6):630-639. doi: 10.1016/j.oret.2020.02.015. Epub 2020 Mar 4.,"METHODS: Data reviewed included clinical staging, time from diagnosis to enucleation, numbers of cycles of carboplatin, etoposide/teniposide and vincristine chemotherapy, disease-specific survival (DSS), histopathology, and follow-up. ..."
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,Screening and Matching Polymers with Drugs to Improve Drug Incorporation and Retention in Nanoparticles.,Mol Pharm. 2020 Jun 1;17(6):2083-2098. doi: 10.1021/acs.molpharmaceut.0c00236. Epub 2020 May 15.,"Etoposide, etoposide phosphate, and teniposide were screened against modified poly(glycerol) adipate (PGA) based polymers by monitoring drug release from 40% drug in polymer films and using Fourier transform infrared spectroscopy (FTIR) and contact angle measurements to he …"
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,Ototoxicity after platinum-based chemotherapy in the treatment of melanotic neuroectodermal tumour of infancy.,Oncol Lett. 2020 May;19(5):3411-3416. doi: 10.3892/ol.2020.11447. Epub 2020 Mar 5.,"The present study evaluated the long-term effects of ototoxicity following chemotherapy with cisplatin, vincristine, cyclophosphamide, teniposide and adriamycin in a 10-year-old patient after surgical removal of a MNTI tumor at the age of 8 months. ..."
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma.,Oncol Lett. 2020 Mar;19(3):2097-2106. doi: 10.3892/ol.2020.11328. Epub 2020 Jan 22.,The present study aimed to investigate the curative effect of high-dose methotrexate (HD-MTX) combined with teniposide (Vm26) vs. ...
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,"The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study.",Neurosurg Rev. 2020 Mar 18. doi: 10.1007/s10143-020-01285-4. Online ahead of print.,"Treatments included surgery (GTR, 63 patients; STR, 39 patients; biopsy, 1 patient), radiotherapy (adjuvant, 76 patients; exclusive treatment, 1 patient), and chemotherapy (adjuvant temozolomide, 52 patients; adjuvant nimustine/teniposide, 19 patients; adjuvant bevacizumab …"
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,lncRNA CCAT2 Enhanced Resistance of Glioma Cells Against Chemodrugs by Disturbing the Normal Function of miR-424.,Onco Targets Ther. 2020 Feb 17;13:1431-1445. doi: 10.2147/OTT.S227831. eCollection 2020.,"Among the glioma cell lines, the SHG44 cell line showed the strongest resistance against teniposide, temozolomide and cisplatin (P<0.05), whereas the U251 cell line was more sensitive to teniposide, temozolomide, vincristine and cisplatin than any other cell line …"
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,"Discovery of 4,6-O-Thenylidene-β-d-glucopyranoside-(2″-acetamido, 3″-acetyl-di-S-5-fluorobenzothizole/5-fluorobenzoxazole)-4'-demethylepipodophyllotoxin as Potential Less Toxic Antitumor Candidate Drugs by Reducing DNA Damage and Less Inhibition of PI3K.",J Med Chem. 2020 Mar 26;63(6):2877-2893. doi: 10.1021/acs.jmedchem.9b01354. Epub 2020 Mar 10.,"As an FDA-approved drug, teniposide, was utilized in cancer treatment but was accompanied by a strong side effect in long-term clinical trials. This work discovered potential candidate drugs with low toxicity by modifying the molecule structure of teniposide through …"
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,SCFβ-TrCP-mediated degradation of TOP2β promotes cancer cell survival in response to chemotherapeutic drugs targeting topoisomerase II.,Oncogenesis. 2020 Feb 3;9(2):8. doi: 10.1038/s41389-020-0196-1.,"Specifically, DNA damage signal, triggered by teniposide (VM-26) treatment, activates ATM, cooperating with CK1 to phosphorylate TOP2β on Ser1134 and Ser1130, respectively, in a canonical degron motif to facilitate β-TrCP binding and subsequent degradation. ..."
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,De novo transcriptome analysis of needles of Thujopsis dolabrata var. hondae.,Plant Biotechnol (Tokyo). 2019;36(2):113-118. doi: 10.5511/plantbiotechnology.19.0220a.,"Podophyllotoxin is a starting material of the semisynthetic anticancer medicines etoposide, teniposide, and etopophos. The major plant source of podophyllotoxin is rhizomes of Podophyllum hexandrum, which is a Himalayan endangered species; therefore, alternative sources of …"
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour.,Anticancer Drugs. 2019 Oct;30(9):959-963. doi: 10.1097/CAD.0000000000000806.,"To the best of our knowledge, we describe for the first time, the case of a young woman with a diagnosis of metastatic gastrointestinal neuroectodermal tumour arising from ileum, who had a childhood adrenal neuroblastoma with liver, bone and lymph nodes metastasis, treated with f …"
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,Concurrent Bronchial Artery and Posterior Inferior Cerebellar Artery Microcatheter Interventional Chemotherapy for Adenocarcinoma of the Lung with Solitary Cerebellar Metastasis.,Med Sci Monit. 2019 Aug 30;25:6504-6511. doi: 10.12659/MSM.915470.,"Two cycles of treatment with teniposide (VM-26), carmustine (BCNU), carboplatin (CBP), and pirarubicin (THP) were performed every four weeks. ..."
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity.,J Clin Invest. 2019 Aug 13;129(11):4850-4862. doi: 10.1172/JCI127471.,"We identified that teniposide, a DNA topoisomerase II inhibitor, could induce high mobility group box 1 (HMGB1) release and type I interferon signaling in tumor cells, and teniposide-treated tumor cells could activate antitumor T cell response both in vitro and in v …"
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,Toxic effects of VCD on kidneys and liver tissues: a histopathological and biochemical study.,BMC Res Notes. 2019 Jul 22;12(1):446. doi: 10.1186/s13104-019-4490-y.,
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,"Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL).",Leuk Lymphoma. 2019 Dec;60(12):2890-2898. doi: 10.1080/10428194.2019.1608529. Epub 2019 Jul 8.,
2020-09-23T06:03:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=TENIPOSIDE&sort=date&size=20,Design and synthesis of 4β-Acetamidobenzofuranone-podophyllotoxin hybrids and their anti-cancer evaluation.,Bioorg Med Chem Lett. 2019 Aug 15;29(16):2153-2156. doi: 10.1016/j.bmcl.2019.06.060. Epub 2019 Jun 29.,
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,Novel treatment options for anaplastic thyroid cancer.,Expert Rev Endocrinol Metab. 2017 Jul;12(4):279-288. doi: 10.1080/17446651.2017.1340155. Epub 2017 Jun 15.,"Interesting results have been reported with molecules targeting different pathways, as: a-BRAF (dabrafenib/trametinib, vemurafenib); b-angiogenesis (sorafenib, combretastatin, vandetanib, sunitinib, lenvatinib, CLM3, etc); c-EGFR (gefitinib); d- PPARγ agonists (rosiglitazone, pio …"
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,Biotinylation enhances the anticancer effects of 15d‑PGJ2 against breast cancer cells.,Int J Oncol. 2018 Jun;52(6):1991-2000. doi: 10.3892/ijo.2018.4338. Epub 2018 Mar 28.,"In the present study, we examined the effects of a biotinylated form of 15d‑PGJ2 (b‑15d‑PGJ2) on hormone-dependent MCF‑7 and triple‑negative MDA‑MB‑231 breast cancer cell lines. b‑15d‑PGJ2 inhibited cell proliferation more efficiently than 15d‑PGJ2 or the synthetic PPARγ agonist, …"
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells.,Cancer Med. 2018 May;7(5):1955-1966. doi: 10.1002/cam4.1440. Epub 2018 Mar 23.,"However, it remains not clear whether efatutazone has similar roles in lung adenocarcinoma cells of gefitinib resistant such as HCC827-GR and PC9-GR. ...In the presence of GW9662 (a specific antagonist of PPARγ) or GGPP (a specific antagonist of LXRα), efatutazone ( …"
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ.,Breast Cancer Res Treat. 2018 May;169(1):47-57. doi: 10.1007/s10549-017-4649-y. Epub 2018 Jan 19.,We studied the effects of activated PPARγ on DCIS progression in MCFDCIS xenograft and C3(1)/Tag transgenic mice treated with 30 mg/kg of efatutazone. ...Similar trends in gene expression changes consistent with lactational and luminal cell differentiation were observed in …
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.,Exp Cell Res. 2017 Dec 15;361(2):246-256. doi: 10.1016/j.yexcr.2017.10.024. Epub 2017 Oct 26.,"Efatutazone, a novel later generation PPARγ agonist, selectively activates PPARγ target genes and has antiproliferative effects in a range of malignancies. ...Our results suggested that efatutazone, alone or in combination with gefitinib, might offer therapeutic eff …"
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.,Nat Rev Endocrinol. 2017 Nov;13(11):644-660. doi: 10.1038/nrendo.2017.76. Epub 2017 Jul 14.,
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy.,Clin Colorectal Cancer. 2016 Mar;15(1):7-15. doi: 10.1016/j.clcc.2015.08.002. Epub 2015 Aug 22.,
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,Discontinued in 2013: oncology drugs.,Expert Opin Investig Drugs. 2015 Jan;24(1):95-110. doi: 10.1517/13543784.2015.971154. Epub 2014 Oct 14.,
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,"Phase I study of Efatutazone, an oral PPARγ agonist, in patients with metastatic solid tumors.",Anticancer Res. 2014 Sep;34(9):5133-41.,"BACKGROUND: Efatutazone is a highly selective agonist of peroxisome proliferator-activated receptor gamma (PPARγ), a therapeutic target for carcinogenesis. ...RESULTS: A total of 13 patients were enrolled and received efatutazone at doses of 0.25 mg, 0.50 mg, and 0. …"
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.,Cancer Sci. 2014 Jun;105(6):683-9. doi: 10.1111/cas.12411. Epub 2014 May 10.,"The present study investigated the effects of efatutazone in EGFR-TKI-resistant NSCLC cells, while focusing on cell motility. ...Efatutazone plus erlotinib treatment provided greater inhibition of PC-9ER cell migration than efatutazone or erlotinib alone. ..."
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,Genetically engineered ERα-positive breast cancer mouse models.,Endocr Relat Cancer. 2014 May 6;21(3):R195-208. doi: 10.1530/ERC-13-0512. Print 2014 Jun.,"Treatment with the PPARγ agonist efatutazone in a mouse with Brca1 and p53 deficiency and 7,12-dimethylbenz(a)anthracene exposure in combination with an activated myristoylated form of AKT1 also induce ER+ mammary cancer. ..."
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,"Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.",Invest New Drugs. 2014 Jun;32(3):473-80. doi: 10.1007/s10637-013-0056-3. Epub 2013 Dec 15.,METHODS: Dose-limiting toxicities (DLTs) were evaluated at 2 efatutazone dose levels of 0.25 and 0.50 mg (the recommended dose [RD] of efatutazone monotherapy) twice daily in combination with FOLFIRI in a 3-9 patient cohort. ...The RD for efatutazone monother …
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,Small molecule agonists of PPAR-γ exert therapeutic effects in esophageal cancer.,Cancer Res. 2014 Jan 15;74(2):575-85. doi: 10.1158/0008-5472.CAN-13-1836. Epub 2013 Nov 22.,"In this study, we investigated PPAR-γ status in esophageal squamous cell carcinoma (ESCC) and investigated the antiproliferative effects of efatutazone. ...Together, our results suggest that efatutazone, alone or in combination with cetuximab, may offer therapeutic …"
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.,Am J Pathol. 2013 Jun;182(6):1976-85. doi: 10.1016/j.ajpath.2013.02.006. Epub 2013 May 8.,We examined the impact of the selective PPARγ agonist efatutazone on mammary cancer pathogenesis in a mouse model of BRCA1 mutation. ...Expression levels of phosphorylated AKT and CDK6 were significantly reduced in the cancers developing in efatutazone-treated mice. …
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,Anticancer activities of PPARγ in breast cancer are context-dependent.,Am J Pathol. 2013 Jun;182(6):1972-5. doi: 10.1016/j.ajpath.2013.03.005. Epub 2013 Apr 22.,
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,"Newer-generation Metallic Stents: Design, Performance Characteristics, and Outcomes.",Interv Cardiol Clin. 2019 Apr;8(2):95-109. doi: 10.1016/j.iccl.2018.11.001.,
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,"Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.",J Clin Endocrinol Metab. 2013 Jun;98(6):2392-400. doi: 10.1210/jc.2013-1106. Epub 2013 Apr 15.,"Median times to progression were 48 and 68 days in patients receiving 0.15 mg of efatutazone and 0.3 mg of efatutazone, respectively; corresponding median survival was 98 vs 138 days. ...Angiopoietin-like 4 was induced by efatutazone in tissue biopsy samples …"
2020-09-23T06:03:05Z,https://pubmed.ncbi.nlm.nih.gov/?term=EFATUTAZONE(CS-7017)&sort=date&size=20,"A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.",Cancer. 2012 Nov 1;118(21):5403-13. doi: 10.1002/cncr.27526. Epub 2012 May 8.,"BACKGROUND: Efatutazone (CS-7017), a novel peroxisome proliferator-activated receptor gamma (PPARγ) agonist, exerts anticancer activity in preclinical models. ...Efatutazone dosing continued until disease progression or unacceptable toxicity, with meas …"
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,Anti-Cancer Compounds from Terrestrial and Marine Resources - in silico and Experimental Studies.,Curr Comput Aided Drug Des. 2020 Sep 10. doi: 10.2174/1573409916666200910140801. Online ahead of print.,"Taxol, vincristine, vinblastine, cytarabine, eribulin mesylate and trabectidine are some of the anticancer compounds isolated from terrestrial and marine sources. ..."
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,Eribulin and Confusion: A Previously Unknown Drug Side-Effect.,Eur J Case Rep Intern Med. 2020 Jun 9;7(9):001708. doi: 10.12890/2020_001708. eCollection 2020.,Eribulin is an antineoplastic agent used in advanced breast cancer refractory to anthracycline and taxane treatment regimens. ...LEARNING POINTS: Eribulin-induced encephalopathy is a diagnosis of exclusion and should be included in the differential diagnosis of pati …
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,"Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.",JAMA Oncol. 2020 Sep 3. doi: 10.1001/jamaoncol.2020.3524. Online ahead of print.,"OBJECTIVE: To compare the efficacy of eribulin plus pembrolizumab vs eribulin alone in patients with HR-positive, ERBB2 (formerly HER2)-negative MBC. ...INTERVENTIONS: Patients were randomized 1:1 to eribulin, 1.4 mg/m2 intravenously, on days 1 and 8 plus pem …"
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,A case of Stewart-Treves syndrome occurring in the abdominal wall successfully treated with eribulin: A case report.,Mol Clin Oncol. 2020 Nov;13(5):49. doi: 10.3892/mco.2020.2119. Epub 2020 Aug 20.,Eribulin mesylate (eribulin) is a non-taxane microtubule inhibitor that has been approved in Japan for treating soft tissue sarcoma. ...The results reveal that eribulin may serve as a potential therapeutic option for the treatment of STS....
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.,Breast Cancer. 2020 Aug 28. doi: 10.1007/s12282-020-01150-8. Online ahead of print.,"Both resistant cells were cross-resistant to the other CDK4/6 inhibitor but almost as equally sensitive to different chemotherapeutic agents (5-fluorouracil, gemcitabine, paclitaxel, docetaxel, doxorubicin and eribulin) as the parental cells. ..."
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,"Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).",Invest New Drugs. 2020 Aug 24. doi: 10.1007/s10637-020-00991-6. Online ahead of print.,"The treatment comprised eribulin on days 1 and 8 of a 21-day cycle and trastuzumabplus pertuzumab once every 3 weeks, all administered intravenously. ...Hence, we have started a randomized phase III study comparing eribulin and a taxane in combination with pertuzuma …"
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,"Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.",Breast Cancer Res Treat. 2020 Aug 17. doi: 10.1007/s10549-020-05867-0. Online ahead of print.,"RESULTS: 443 patients with liver or lung metastases received third-line therapy with eribulin (n = 229), gemcitabine (n = 134), or capecitabine (n = 80). ...Median survival times showed that overall, and within the TNBC and HR+/HER2- subtype, patients receiving eribulin …"
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,"Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.",Breast Cancer Res Treat. 2020 Aug 12. doi: 10.1007/s10549-020-05838-5. Online ahead of print.,"The chemotherapies included in the cohort were single-agent capecitabine, gemcitabine, eribulin, or vinorelbine. Results were adjusted for baseline demographics and clinical differences using Mahalanobis distance matching (primary analysis) and entropy balancing (sensitivi …"
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies.,Oncogene. 2020 Sep;39(36):5867-5875. doi: 10.1038/s41388-020-01404-x. Epub 2020 Jul 28.,"For in vivo preclinical treatments, trastuzumab, lapatinib, docetaxel, or eribulin were administered to patient-derived xenograft (PDX) models. ...Also, cytotoxic agents (docetaxel and eribulin) were effective against the xenografted tumors. This PDX model (EMPD-PDX …"
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,Eribulin for recurrent cutaneous angiosarcoma.,Br J Dermatol. 2020 Jul 27. doi: 10.1111/bjd.19333. Online ahead of print.,
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium.,Pediatr Blood Cancer. 2020 Jul 24:e28606. doi: 10.1002/pbc.28606. Online ahead of print.,The pediatric preclinical testing program previously demonstrated activity of eribulin in osteosarcoma patient-derived xenograft (PDX) models. ...Eribulin was evaluated in the original and an expanded set of PDX models and tested at multiple dose levels and schedule …
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis.,Sci Rep. 2020 Jul 8;10(1):11203. doi: 10.1038/s41598-020-66980-0.,Prior pooled analysis of eribulin studies (301 and 305) indicated eribulin prolonged overall survival (OS) in patients with locally advanced/metastatic breast cancer (MBC) regardless of visceral or nonvisceral disease. ...Eribulin appeared efficacious in pati …
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin.,Anticancer Res. 2020 Jul;40(7):4147-4156. doi: 10.21873/anticanres.14414.,"BACKGROUND/AIM: We investigated the efficacy of neutrophil-to-lymphocyte ratio (NLR), absolute lymphocyte count (ALC), and C-reactive protein (CRP) in predicting overall survival of metastatic breast cancer patients treated with eribulin. PATIENTS AND METHODS: Overall, 74 …"
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,Giant paratesticular liposarcoma with lung metastases: a case report and review of the literature.,J Med Case Rep. 2020 Jul 2;14(1):86. doi: 10.1186/s13256-020-02420-x.,Eribulin was used for second-line chemotherapy. He had a relapse at 5 months after eliburin and died at 22 months after diagnosis. ...
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.,Cancer Genomics Proteomics. 2020 Jul-Aug;17(4):351-358. doi: 10.21873/cgp.20194.,"MATERIALS AND METHODS: We randomized DDLPS PDOX models into 8 treatment groups when tumor volume became approximately 100 mm(3): control, no treatment; G2, doxorubicin (DOX); G3, pazopanib (PAZ); G4, gemcitabine (GEM) combined with docetaxel (DOC); G5, trabectedin (YON); G6, temo …"
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry.,Acta Oncol. 2020 Sep;59(9):1123-1130. doi: 10.1080/0284186X.2020.1775289. Epub 2020 Jun 16.,"Incremental cost-effectiveness ratio (ICER) between the eribulin and matched non-eribulin chemotherapy was estimated. Deterministic and probabilistic sensitivity analyses and scenario analyses were performed. The financial risk (i.e., the expected value of perfect i …"
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study.,J BUON. 2020 Mar-Apr;25(2):641-647.,METHODS: A total of 80 patients treated with eribulin in 12 medical oncology centers in Turkey between 2013-2017 were retrospectively evaluated. ...CONCLUSIONS: Eribulin treatment line was identified as indepedent prognostic factor for PFS in MBC patients....
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,"Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).",Trials. 2020 Jun 8;21(1):503. doi: 10.1186/s13063-020-04408-w.,
2020-09-23T06:03:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN&sort=date&size=20,Validation of Systemic and Local Tumour Immune Response to Eribulin Chemotherapy in the Treatment of Breast Cancer.,Anticancer Res. 2020 Jun;40(6):3345-3354. doi: 10.21873/anticanres.14317.,"BACKGROUND/AIM: In addition to its cytocidal effects as a microtubule dynamics inhibitor, eribulin mesylate (eribulin) regulates the tumour microenvironment. ...RESULTS: The response to eribulin was significantly associated with ALC (p=0.007). The expression …"
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,Ridaforolimus eluting stent for the treatment of Japanese patients with coronary disease: 1 year outcomes of the JNIR study.,Cardiovasc Interv Ther. 2020 Jun 26. doi: 10.1007/s12928-020-00680-4. Online ahead of print.,Outcomes with the ridaforolimus-eluting EluNIR stent in Japanese patients are unknown. METHODS AND RESULTS: This was a multi-center trial in Japanese patients undergoing PCI with the ridaforolimus eluting EluNIR stent. ...
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,Outcomes of Patients With Coronary Arterial Bifurcation Narrowings Undergoing Provisional 1-Stent Treatment (from the BIONICS Trial).,Am J Cardiol. 2020 Jul 1;126:8-15. doi: 10.1016/j.amjcard.2020.04.002. Epub 2020 Apr 14.,"We sought to evaluate the clinical and angiographic outcomes of patients who underwent bifurcation lesion provisional treatment in the BioNIR Ridaforolimus Eluting Coronary Stent System in Coronary Stenosis trial. A prospective, multicenter, 1:1 randomized trial was conduc …"
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,Comparison of Acute Thrombogenicity and Albumin Adsorption in Three Different Durable Polymer Coronary Drug-Eluting Stents.,EuroIntervention. 2020 Mar 10:EIJ-D-19-00938. doi: 10.4244/EIJ-D-19-00938. Online ahead of print.,"METHODS AND RESULTS: In an ex vivo swine arterio-venous shunt model, fluoropolymer everolimus-eluting stent (FP-EES) (n=14) was compared with two durable polymer DES (BioLinx polymer coated zotarolimus-eluting stent (BL-ZES)(n=9) and a CarboSil® elastomer polymer coated ridafo …"
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,Looking for a Hidden Superiority in Noninferiority DES Studies.,JACC Cardiovasc Interv. 2020 Jan 13;13(1):94-96. doi: 10.1016/j.jcin.2019.09.003.,
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials.,JACC Cardiovasc Interv. 2020 Jan 13;13(1):86-93. doi: 10.1016/j.jcin.2019.08.019.,BACKGROUND: The safety and efficacy of a ridaforolimus-eluting stent (RES) was evaluated in the BIONICS (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis) and NIREUS (BioNIR Ridaforolimus Eluting Coronary Stent System [BioNIR] European …
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,Short-Term Environmental Conditioning Enhances Tumorigenic Potential of Triple-Negative Breast Cancer Cells.,Tomography. 2019 Dec;5(4):346-357. doi: 10.18383/j.tom.2019.00019.,Epidermal growth factor and the mTORC1 inhibitor ridaforolimus produced similar but relatively reduced effects on tumorigenic potential. ...
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,Percutaneous Coronary Intervention Does Not Lower Cardiovascular Outcomes in Patients with Chronic Kidney Disease.,Am J Nephrol. 2019;50(6):465-472. doi: 10.1159/000503916. Epub 2019 Oct 25.,"METHODS: Patient level data were pooled from 2 multicenter randomized trials (BIONICS and NIREUS trials) with a near ""all-comers"" design, comparing PCI with ridaforolimus-eluting stents vs. zotarolimus-eluting stents in patients with CAD. ..."
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.,Cochrane Database Syst Rev. 2019 Oct 7;10(10):CD012160. doi: 10.1002/14651858.CD012160.pub2. Online ahead of print.,The second study compared the mTOR inhibitor ridaforolimus alone versus progestin or investigator choice of chemotherapy in women who had received prior treatment for metastatic or recurrent endometrial cancer. ...
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial.,JACC Cardiovasc Interv. 2018 Dec 24;11(24):2467-2476. doi: 10.1016/j.jcin.2018.09.033.,OBJECTIVES: The authors sought to investigate the impact of diabetes mellitus (DM) on outcomes following contemporary drug-eluting stent (DES) implantation in the BIONICS (BioNIR Ridaforolimus Eluting Coronary Stent System in Coronary Stenosis) trial. ...Clinical and angio …
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,The EluNIR(TM) Ridaforolimus Eluting Coronary Stent System.,Expert Rev Med Devices. 2019 Jan;16(1):71-76. doi: 10.1080/17434440.2018.1549986. Epub 2018 Dec 1.,"Area covered: The EluNIR(TM) (Medinol, Tel Aviv, Israel) Ridaforolimus Eluting Coronary Stent System is a new DES with unique properties. ...Expert commentary: The newly FDA-approved EluNIR(TM) stent features an elastomeric durable polymer which elutes a novel drug, Rid …"
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial.,EuroIntervention. 2018 May 20;14(1):86-93. doi: 10.4244/EIJ-D-17-00890.,
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,"Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.",Oral Dis. 2018 Mar;24(1-2):144-171. doi: 10.1111/odi.12795.,"Of the included studies, 95 referred to everolimus use, 16 to ridaforolimus, and 26 to temsirolimus (two studies referred to both everolimus and temsirolimus). ...CONCLUSIONS: Analysis of the reports with patients treated with everolimus, temsirolimus, and ridaforolimus …"
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis).,Circulation. 2017 Oct 3;136(14):1304-1314. doi: 10.1161/CIRCULATIONAHA.117.028885. Epub 2017 Aug 9.,"BACKGROUND: The safety and efficacy of a novel cobalt alloy-based coronary stent with a durable elastomeric polymer eluting the antiproliferative agent ridaforolimus for treatment of patients with coronary artery disease is undetermined. METHODS: A prospective, internation …"
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,"A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.",Breast Cancer Res Treat. 2017 Oct;165(3):601-609. doi: 10.1007/s10549-017-4375-5. Epub 2017 Jul 5.,"Randomly assigned patients were given oral ridaforolimus 10 mg QD 5 ×/week, intravenous dalotuzumab 10 mg/kg/week, and oral exemestane 25 mg/day (R/D/E, n = 40), or ridaforolimus 30 mg QD 5 ×/week and exemestane 25 mg/day (R/E; n = 40). ...Because the PFS reported f …"
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.,BMC Cancer. 2017 Jun 8;17(1):407. doi: 10.1186/s12885-017-3394-2.,BACKGROUND: Ridaforolimus is a mammalian target of rapamycin inhibitor that has activity in solid tumors. Paclitaxel and carboplatin have broad antineoplastic activity in many cancers. ...CONCLUSIONS: Treatment with ridaforolimus combined with paclitaxel and carbopl …
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.,Breast Cancer Res Treat. 2017 Jun;163(3):535-544. doi: 10.1007/s10549-017-4199-3. Epub 2017 Mar 21.,"Due to a high incidence of stomatitis in the ridaforolimus-dalotuzumab group, two sequential, nonrandomized, reduced-dose cohorts were explored with ridaforolimus 20 and 10 mg qd × 5 days/week. ...The incidence of drug-related, nonserious, and serious adverse events …"
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.,Adv Biol Regul. 2017 May;64:39-48. doi: 10.1016/j.jbior.2016.12.001. Epub 2017 Jan 4.,
2020-09-23T06:03:13Z,https://pubmed.ncbi.nlm.nih.gov/?term=RIDAFOROLIMUS(MK-8669)&sort=date&size=20,m-TOR inhibitors and their potential role in haematological malignancies.,Br J Haematol. 2017 Jun;177(5):684-702. doi: 10.1111/bjh.14529. Epub 2017 Feb 1.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients.,Cancer Immunol Immunother. 2020 May;69(5):703-716. doi: 10.1007/s00262-020-02503-0. Epub 2020 Feb 7.,"The MAG-Tn3 vaccine was formulated with the GSK-proprietary immunostimulant AS15, composed of CpG7909, MPL, and QS21, which has been shown to stimulate both innate and humoral responses, in addition to being well tolerated. ..."
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,Repeat-Dose Toxicity Study of a Lyophilized Recombinant Protective Antigen-Based Anthrax Vaccine Adjuvanted With CpG 7909.,Int J Toxicol. 2019 May/Jun;38(3):163-172. doi: 10.1177/1091581819848722.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.,Mol Ther. 2018 Mar 7;26(3):695-707. doi: 10.1016/j.ymthe.2018.01.007. Epub 2018 Jan 17.,"Here, we describe a dual-function molecule consisting of a clinically relevant TLR9 agonist (CpG7909) and a STAT3 inhibitor in the form of a high-affinity decoy oligodeoxynucleotide (dODN). ...Both TLR9 stimulation and concurrent STAT3 inhibition were critical for immune-m …"
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.,Clin Cancer Res. 2017 Oct 1;23(19):5679-5686. doi: 10.1158/1078-0432.CCR-17-0944.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,"Signal management in pharmacovigilance and human risk assessment of CpG 7909, integrating embryo-fetal and post-natal developmental toxicity studies in rats and rabbits.",Reprod Toxicol. 2018 Jan;75:110-120. doi: 10.1016/j.reprotox.2017.09.006. Epub 2017 Sep 23.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,DOCK8 and STAT3 dependent inhibition of IgE isotype switching by TLR9 ligation in human B cells.,Clin Immunol. 2017 Oct;183:263-265. doi: 10.1016/j.clim.2017.08.020. Epub 2017 Sep 4.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,IRAK-M alters the polarity of macrophages to facilitate the survival of Mycobacterium tuberculosis.,BMC Microbiol. 2017 Aug 23;17(1):185. doi: 10.1186/s12866-017-1095-2.,"U937 cells were stimulated with immunostimulant CpG7909 into M1 status and then infected with M. tb H37Rv. Expression of IRAK-M, IRAK-4 and iNOS was detected with immunofluorescence staining and Western blot, to evaluate the effect of IRAK-M to CpG directed M1-type polariz …"
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context.,Immun Inflamm Dis. 2016 Oct 18;4(4):446-462. doi: 10.1002/iid3.126. eCollection 2016 Dec.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,Human effector B lymphocytes express ARID3a and secrete interferon alpha.,J Autoimmun. 2016 Dec;75:130-140. doi: 10.1016/j.jaut.2016.08.003. Epub 2016 Aug 10.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.,Clin Cancer Res. 2017 Feb 1;23(3):717-725. doi: 10.1158/1078-0432.CCR-16-1189. Epub 2016 Aug 12.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,"Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.",Vaccine. 2016 Apr 19;34(18):2096-105. doi: 10.1016/j.vaccine.2016.03.006. Epub 2016 Mar 12.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,"Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.",Lancet Haematol. 2016 Feb;3(2):e87-98. doi: 10.1016/S2352-3026(15)00246-X. Epub 2015 Dec 24.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.,Vaccine. 2015 Nov 27;33(48):6719-26. doi: 10.1016/j.vaccine.2015.10.072. Epub 2015 Oct 26.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,CpG-DNA enhances the tight junction integrity of the bronchial epithelial cell barrier.,J Allergy Clin Immunol. 2015 Nov;136(5):1413-6.e1-8. doi: 10.1016/j.jaci.2015.05.006. Epub 2015 Jun 19.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.,Cancer Immunol Res. 2015 May;3(5):495-505. doi: 10.1158/2326-6066.CIR-14-0165. Epub 2015 Jan 29.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,"Phenotypic, ultra-structural, and functional characterization of bovine peripheral blood dendritic cell subsets.",PLoS One. 2014 Oct 8;9(10):e109273. doi: 10.1371/journal.pone.0109273. eCollection 2014.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.,Mol Ther. 2014 Dec;22(12):2142-2154. doi: 10.1038/mt.2014.157. Epub 2014 Aug 26.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,Trial Watch: Toll-like receptor agonists in oncological indications.,Oncoimmunology. 2014 Aug 1;3:e29179. doi: 10.4161/onci.29179. eCollection 2014.,
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses.,PLoS One. 2014 May 15;9(5):e94883. doi: 10.1371/journal.pone.0094883. eCollection 2014.,"In the present study, different aspects of the murine anti-tumor immune responses induced by a recombinant MAGE-A3 protein (recMAGE-A3) in combination with different immunostimulants (AS01, AS02, CpG7909 or AS15) were investigated. ..."
2020-09-23T06:03:17Z,https://pubmed.ncbi.nlm.nih.gov/?term=CPG7909&sort=date&size=20,Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).,Vaccine. 2014 Nov 28;32(50):6847-54. doi: 10.1016/j.vaccine.2014.01.096. Epub 2014 Feb 13.,
2020-09-23T06:03:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=UTOMILUMAB(PF-05082566)&sort=date&size=20,"First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20(+) Non-Hodgkin Lymphomas.",Clin Cancer Res. 2020 Jun 1;26(11):2524-2534. doi: 10.1158/1078-0432.CCR-19-2973. Epub 2020 Mar 6.,RESULTS: Sixty-seven patients received utomilumab (0.03-10.0 mg/kg every 4 weeks) and rituximab (375 mg/m(2) weekly) in the dose-escalation groups or utomilumab (1.2 mg/kg every 4 weeks) plus rituximab in the dose-expansion cohort. ...The pharmacokinetics of utom …
2020-09-23T06:03:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=UTOMILUMAB(PF-05082566)&sort=date&size=20,"Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity.",Mol Cancer Ther. 2020 Apr;19(4):1040-1051. doi: 10.1158/1535-7163.MCT-19-0608. Epub 2020 Jan 23.,"In clinical trials, the degrees of liver toxicity of anti-CD137 vary from grade 4 transaminitis (urelumab) to nonexistent (utomilumab). ..."
2020-09-23T06:03:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=UTOMILUMAB(PF-05082566)&sort=date&size=20,A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.,J Immunother Cancer. 2019 Dec 4;7(1):342. doi: 10.1186/s40425-019-0815-6.,"This phase Ib, open-label study in patients with advanced solid tumors assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of utomilumab (PF-05082566), a human monoclonal antibody (mAb) agonist of the T-cell costimulatory receptor 4-1BB/CD13 …"
2020-09-23T06:03:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=UTOMILUMAB(PF-05082566)&sort=date&size=20,Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.,Nat Commun. 2019 May 20;10(1):2141. doi: 10.1038/s41467-019-10088-1.,"Costimulation of T cell responses with monoclonal antibody agonists (mAb-AG) targeting 4-1BB showed robust anti-tumor activity in preclinical models, but their clinical development was hampered by low efficacy (Utomilumab) or severe liver toxicity (Urelumab). ..."
2020-09-23T06:03:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=UTOMILUMAB(PF-05082566)&sort=date&size=20,Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.,Nat Commun. 2018 Nov 8;9(1):4679. doi: 10.1038/s41467-018-07136-7.,"Clinical trials of two agonist antibodies, utomilumab (PF-05082566) and urelumab (BMS-663513), are ongoing in multiple cancer indications, and both antibodies demonstrate distinct activities in the clinic. ...Utomilumab, a ligand-blocking antibody, bin …"
2020-09-23T06:03:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=UTOMILUMAB(PF-05082566)&sort=date&size=20,Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab.,Cell Rep. 2018 Oct 23;25(4):909-920.e4. doi: 10.1016/j.celrep.2018.09.073.,The structure of utomilumab/4-1BB complex shows that utomilumab binds to dimeric 4-1BB with a distinct but partially overlapping binding area with 4-1BBL. ...The binding profiles of 4-1BBL and utomilumab to monomeric or dimeric 4-1BB indicate limited cross-li …
2020-09-23T06:03:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=UTOMILUMAB(PF-05082566)&sort=date&size=20,"Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.",Clin Cancer Res. 2018 Apr 15;24(8):1816-1823. doi: 10.1158/1078-0432.CCR-17-1922. Epub 2018 Mar 16.,"Purpose: Utomilumab (PF-05082566) is an agonistic mAb that engages the immune costimulatory molecule 4-1BB/CD137. In this first-in-human, phase I, open-label, multicenter, multiple-dose study (NCT01307267) we evaluated safety, tolerability, pharmacokinetics, …"
2020-09-23T06:03:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=UTOMILUMAB(PF-05082566)&sort=date&size=20,"Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.",Blood. 2018 Jan 4;131(1):49-57. doi: 10.1182/blood-2017-06-741041. Epub 2017 Nov 8.,"Clinical trials of 2 agonist antibodies, urelumab and utomilumab, are ongoing. Despite initial signs of efficacy, clinical development of urelumab has been hampered by inflammatory liver toxicity at doses >1 mg/kg. Utomilumab has a superior safety profile, but is …"
2020-09-23T06:03:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=UTOMILUMAB(PF-05082566)&sort=date&size=20,Combination avelumab and utomilumab immunotherapy can induce diabetic ketoacidosis.,Diabetes Metab. 2018 Dec;44(6):514-515. doi: 10.1016/j.diabet.2017.05.005. Epub 2017 Jun 23.,
2020-09-23T06:03:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=UTOMILUMAB(PF-05082566)&sort=date&size=20,"Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.",Clin Cancer Res. 2017 Sep 15;23(18):5349-5357. doi: 10.1158/1078-0432.CCR-17-1243. Epub 2017 Jun 20.,"Purpose: This phase Ib study (NCT02179918) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of utomilumab, a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137 in combination with the humanized, PD-1-blocking IgG4 …"
2020-09-23T06:03:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=UTOMILUMAB(PF-05082566)&sort=date&size=20,Enhancing PD-1 Blockade in Solid Tumors.,Cancer Discov. 2016 Aug;6(8):OF2. doi: 10.1158/2159-8290.CD-NB2016-086. Epub 2016 Jul 1.,"A phase I study indicates that the combination of utomilumab, an investigational antibody that binds CD137, plus pembrolizumab is safe and well tolerated, yielding sustained responses in patients with various solid cancers...."
2020-09-23T06:03:27Z,https://pubmed.ncbi.nlm.nih.gov/?term=UTOMILUMAB(PF-05082566)&sort=date&size=20,Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity.,Cancer Immunol Immunother. 2012 Oct;61(10):1721-33. doi: 10.1007/s00262-012-1237-1. Epub 2012 Mar 11.,"PF-05082566 is a fully human IgG2 that binds to the extracellular domain of human 4-1BB with high affinity and specificity. In preclinical studies, this agonist antibody demonstrated its ability to activate NF-κB and induce downstream cytokine production, promote le …"
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,Oncolytic Activity of Targeted Picornaviruses Formulated as Synthetic Infectious RNA.,Mol Ther Oncolytics. 2020 May 19;17:484-495. doi: 10.1016/j.omto.2020.05.003. eCollection 2020 Jun 26.,"This new iRNA (R-CVA21) retained high specific infectivity, rapidly generating replicating miRNA-detargeted viruses following transfection in H1-HeLa cells. ...Moreover, R-CVA21 also exhibited superior miRNA response element stability in vivo. This novel formulation …"
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.,Methods Mol Biol. 2020;2058:249-259. doi: 10.1007/978-1-4939-9794-7_16.,"Coxsackievirus A21 (CVA21) is a novel intercellular adhesion molecule-1 (ICAM-1)-targeted immunotherapeutic virus. We have investigated CVA21-induced cytotoxicity in a panel of human bladder cancer cell lines, revealing a range of sensitivities largely correlating w …"
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.,Clin Cancer Res. 2019 Oct 1;25(19):5818-5831. doi: 10.1158/1078-0432.CCR-18-4022. Epub 2019 Jul 4.,
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.,J Immunother Cancer. 2019 Jul 1;7(1):164. doi: 10.1186/s40425-019-0632-y.,"Combination therapies offer the best chance of disease control; however, the design of successful combination strategies requires a deeper understanding of the mechanisms underpinning CVA21 efficacy, in particular, the role of CVA21 anti-tumor immunity. ...RESULTS: …"
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,Essential Role of Enterovirus 2A Protease in Counteracting Stress Granule Formation and the Induction of Type I Interferon.,J Virol. 2019 May 1;93(10):e00222-19. doi: 10.1128/JVI.00222-19. Print 2019 May 15.,
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?,Expert Opin Biol Ther. 2018 Dec;18(12):1199-1207. doi: 10.1080/14712598.2018.1544614.,
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,"The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.",Cancers (Basel). 2018 Sep 26;10(10):356. doi: 10.3390/cancers10100356.,"Various oncolytic viruses (OVs), such as HF10 (Canerpaturev-C-REV) and CVA21 (CAVATAK), are now actively being developed in phase II as monotherapies, or in combination with immune checkpoint inhibitors against melanoma. ..."
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.,Mol Ther Oncolytics. 2018 Feb 14;9:1-12. doi: 10.1016/j.omto.2018.02.001. eCollection 2018 Jun 29.,"CVA21 in combination with low doses of mitomycin-C enhanced CVA21 viral replication and oncolysis by increasing surface expression levels of ICAM-1. ...Such CVA21 immunotherapy could offer a potentially less toxic, more effective option for the treatment of b …"
2020-09-23T06:03:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=KAPANOL&sort=date&size=20,[Care for terminal cancer patients at general practitioner office].,Acta Med Croatica. 2007 Feb;61(1):63-8.,"Physicians prescribed opioid therapy in 55 patients: codeine in 2, tramadol in 46, pentazocine in 7, methadone in 5, Kapanol in 15 and fentanyl in 21 patients. ..."
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,[Oncolytic coxsackievirus therapy as an immunostimulator].,Rinsho Ketsueki. 2017;58(8):977-982. doi: 10.11406/rinketsu.58.977.,"In particular, coxsackievirus A21 (CVA21) is a promising candidate for oncolytic virotherapy, and thus is the focus of many clinical trials. ...In this report, we review recent clinical progress in oncolytic virotherapy of CVA21 and clinical development of our CVB3. …"
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,"Identification and molecular characterization of non-polio enteroviruses from children with acute flaccid paralysis in West Africa, 2013-2014.",Sci Rep. 2017 Jun 19;7(1):3808. doi: 10.1038/s41598-017-03835-1.,"Interestingly, several rarely described types with limited detection worldwide were identified (EVA76, EVA119, EVB75, EVB77, EVB97, EVC99, CVA20, CVA21 and EVD94). ..."
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,A cluster of coxsackievirus A21 associated acute respiratory illness: the evidence of efficient transmission of CVA21.,Arch Virol. 2017 Apr;162(4):1057-1059. doi: 10.1007/s00705-016-3201-4. Epub 2016 Dec 26.,"CVA21 was found in eight of fourteen patients. Phylogenetic analysis suggested that the CVA21 outbreak was most likely caused by transmission of the virus from person to person. This is the first report of an ARI outbreak caused by CVA21, which suggests that …"
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,The Role of Intralesional Therapies in Melanoma.,Oncology (Williston Park). 2016 May;30(5):436-41.,"Several other intralesional therapies (PV-10, interleukin-12 electroporation, coxsackievirus A21 [CVA21]) are entering later-stage testing. ...Studies of PV-10 with pembrolizumab and of CVA21 with pembrolizumab are also being initiated. Preliminary analyses of the r …"
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,"Molecular characterization of coxsackievirus A21 in Shandong, China.",Arch Virol. 2016 Feb;161(2):437-44. doi: 10.1007/s00705-015-2669-7. Epub 2015 Nov 12.,
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,Complete coding regions of the prototypes enterovirus B93 and C95: phylogenetic analyses of the P1 and P3 regions of EV-B and EV-C strains.,J Med Virol. 2015 Mar;87(3):485-97. doi: 10.1002/jmv.24062. Epub 2014 Aug 27.,
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,"Recombination in the evolution of enterovirus C species sub-group that contains types CVA-21, CVA-24, EV-C95, EV-C96 and EV-C99.",PLoS One. 2014 Apr 10;9(4):e94579. doi: 10.1371/journal.pone.0094579. eCollection 2014.,
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,"The evolution of Vp1 gene in enterovirus C species sub-group that contains types CVA-21, CVA-24, EV-C95, EV-C96 and EV-C99.",PLoS One. 2014 Apr 2;9(4):e93737. doi: 10.1371/journal.pone.0093737. eCollection 2014.,
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,Applications of coxsackievirus A21 in oncology.,Oncolytic Virother. 2014 Apr 10;3:47-55. doi: 10.2147/OV.S56322. eCollection 2014.,Characterization of coxsackievirus A21 (CVA21) receptor-based mechanism of virus internalization and lysis in the last decade has suggested promise for CVA21 as a virotherapy against malignancies which overexpress those receptors. ...This review outlines the potenti …
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid.,Mol Ther. 2011 Jun;19(6):1041-7. doi: 10.1038/mt.2011.68. Epub 2011 Apr 19.,"Infectious RNA encoding coxsackievirus A21 (CVA21) was transcribed from plasmid DNA using T7 polymerase. Within 48 hours of injecting this RNA into KAS6/1 myeloma xenografts, high titers of infectious CVA21 virions were detected in the bloodstream. ...At euthanasia, …"
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,"Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18.",Virol J. 2011 Jan 18;8:22. doi: 10.1186/1743-422X-8-22.,"Previously, we reported that the picornavirus Coxsackievirus A21 (CVA21) possessed potent oncolytic activity against cultured malignant melanoma cells and melanoma xenografts in mice. ...Serum neutralization assays revealed that 3 of 21 subjects possessed low levels of ant …"
2020-09-23T06:03:31Z,https://pubmed.ncbi.nlm.nih.gov/?term=CVA21(COXSAKIEVIRUSA21)&sort=date&size=20,Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.,Invest New Drugs. 2012 Apr;30(2):568-81. doi: 10.1007/s10637-010-9614-0. Epub 2010 Dec 21.,"CVA21 specifically targets and lytically infects susceptible cells expressing the CVA21 cellular receptors, intercellular adhesion molecule-1 (ICAM-1) and decay-accelerating factor (DAF). ...When CVA21 was combined with doxorubicin hydrochloride, synergistica …"
2020-09-23T06:03:35Z,https://pubmed.ncbi.nlm.nih.gov/?term=L-778123&sort=date&size=20,Comparison of Cytotoxic Activity of L778123 as a Farnesyltranferase Inhibitor and Doxorubicin against A549 and HT-29 Cell Lines.,Adv Pharm Bull. 2013;3(1):73-7. doi: 10.5681/apb.2013.012. Epub 2013 Feb 7.,
2020-09-23T06:03:35Z,https://pubmed.ncbi.nlm.nih.gov/?term=L-778123&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506.,"This issue focuses on the following selection of drugs: ABT-510, ABX-EGF, acetyldinaline, ACIDFORM, acyline, afeletecan hydrochloride, anecortave acetate, apolizumab, l-arginine hydrochloride, asimadoline, atazanavir sufate, atlizumab; BMS-181176, BMS-188667; CAB-175, carn …"
2020-09-23T06:03:35Z,https://pubmed.ncbi.nlm.nih.gov/?term=L-778123&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2002 Oct;24(8):525-51.,"This issue focuses on the following selection of drugs: Abacavir sulfate, abciximab, acetylcysteine, adefovir dipivoxil, alfuzosin hydrochloride, aliskiren fumarate, alosetron hydrochloride, amlodipine besilate, apomorphine hydrochloride, atazanavir, atorvastatin, atorvastatin ca …"
2020-09-23T06:03:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=KAPANOL&sort=date&size=20,"The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam.",J Palliat Med. 2013 Jul;16(7):741-4. doi: 10.1089/jpm.2012.0505. Epub 2013 Apr 18.,"METHODS: This is a single site, open label phase II study of the addition of regular clonazepam 0.5 mg nocte orally to Kapanol(R) 10 mg (sustained release morphine sulphate) orally mane together with docusate/sennosides in people with modified Medical Research Council Scal …"
2020-09-23T06:03:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=KAPANOL&sort=date&size=20,Comparison of Two Oral Morphine Formulations for Chronic Severe Pain of Malignant and Nonmalignant Origin: Kapanol(trade mark) vs MST((R)).,Clin Drug Investig. 1998;15(1):69-71. doi: 10.2165/00044011-199815010-00010.,
2020-09-23T06:03:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=KAPANOL&sort=date&size=20,Comparison of Two Oral Morphine Formulations for Chronic Severe Pain of Malignant and Nonmalignant Origin: Kapanol(trade mark) vs MST((R)).,Clin Drug Investig. 1998;15(1):69-71. doi: 10.2165/00044011-199815010-00011.,
2020-09-23T06:03:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=KAPANOL&sort=date&size=20,Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence.,Addiction. 2004 Aug;99(8):940-5. doi: 10.1111/j.1360-0443.2004.00764.x.,Intervention Participants were transferred from methadone to SROM (once-daily Kapanol trade mark ) for approximately 6 weeks before resuming methadone maintenance. ...
2020-09-23T06:03:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=KAPANOL&sort=date&size=20,Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence.,Drug Alcohol Depend. 2003 Oct 24;72(1):85-94. doi: 10.1016/s0376-8716(03)00190-x.,"METHODS: In 14 methadone maintenance patients reporting adequate (holders, n=7) or inadequate (non-holders, n=7) withdrawal suppression between doses, plasma drug concentrations and indices of opioid effect (withdrawal severity, pupil diameter, and respiratory rate) were determin …"
2020-09-23T06:03:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=KAPANOL&sort=date&size=20,Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.,Clin Pharmacokinet. 1998 Sep;35(3):173-90. doi: 10.2165/00003088-199835030-00002.,"At steady state, fluctuations in plasma morphine concentrations throughout a 12-hour dosage interval were greatest for MS Contin and least for Kapanol. ...The pharmacokinetic parameters of morphine following Kapanol once daily were similar to MS Contin (12 hours) wi …"
2020-09-23T06:03:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=KAPANOL&sort=date&size=20,Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain.,J Pain Symptom Manage. 1997 Aug;14(2):63-73. doi: 10.1016/s0885-3924(97)00012-2.,Kadian/Kapanol (K) is a capsule formulation of morphine designed for 12- or 24-hourly dosing. This double-blind study compared the efficacy and safety of K every 24 hr to K every 12 hr and MS Contin tablets (MSC) every 12 hr. ...
2020-09-23T06:03:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=KAPANOL&sort=date&size=20,Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain.,Pain. 1997 Feb;69(3):295-302. doi: 10.1016/s0304-3959(96)03269-1.,"Some of these pharmacokinetic differences (e.g., Cmin and fluctuation in plasma morphine concentration) were surprising given that the dosing interval for Kapanol (24 h) was double that of MS Contin (12 h). ...Once a day Kapanol provided the same degree of pain reli …"
2020-09-23T06:03:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=KAPANOL&sort=date&size=20,Managing heroin addiction with a long-acting morphine product (Kapanol).,Med J Aust. 1996 Aug 19;165(4):239.,
2020-09-23T06:03:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=KAPANOL&sort=date&size=20,Kapanol™ capsules : pellet formulation provides alternative methods of administration of sustained-release morphine sulfate.,Clin Drug Investig. 1996 Aug;12(2):88-93. doi: 10.2165/00044011-199612020-00004.,
2020-09-23T06:03:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=M3814(MSC2490484A)&sort=date&size=20,"M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells.",Front Oncol. 2020 May 12;10:674. doi: 10.3389/fonc.2020.00674. eCollection 2020.,"In this study, we demonstrated that M3814 can modulate the function of ABCG2 and overcome ABCG2-mediated MDR. Mechanistic studies showed that M3814 can attenuate the efflux activity of ABCG2 transporter, leading to increased ABCG2 substrate drugs accumulation. ...Ta …"
2020-09-23T06:03:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=M3814(MSC2490484A)&sort=date&size=20,"Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.",Mol Cancer Ther. 2020 May;19(5):1091-1101. doi: 10.1158/1535-7163.MCT-19-0734. Epub 2020 Mar 27.,M3814 potently inhibits DNA-PK catalytic activity and sensitizes multiple cancer cell lines to ionizing radiation (IR) and DSB-inducing agents. ...M3814 is currently under investigation in combination with radiotherapy in clinical trials....
2020-09-23T06:03:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=M3814(MSC2490484A)&sort=date&size=20,"DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia.",Front Oncol. 2020 Feb 13;10:127. doi: 10.3389/fonc.2020.00127. eCollection 2020.,"M3814 is a novel, potent and selective inhibitor of DNA-PK. This compound effectively blocks DSB repair, strongly potentiates the antitumor activity of ionizing radiation and DSB-inducing chemotherapeutics and is currently under clinical investigation. Suppressing DSB repa …"
2020-09-23T06:03:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=M3814(MSC2490484A)&sort=date&size=20,DNA-PKcs chemical inhibition versus genetic mutation: Impact on the junctional repair steps of V(D)J recombination.,Mol Immunol. 2020 Apr;120:93-100. doi: 10.1016/j.molimm.2020.01.018. Epub 2020 Feb 26.,M3814 (also known as Nedisertib) is a potent DNA-PKcs inhibitor. We find here that M3814 causes a quantitative reduction in coding joint formation relative to signal joint formation. ...
2020-09-23T06:03:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=M3814(MSC2490484A)&sort=date&size=20,"Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.",Sci Rep. 2019 Dec 11;9(1):18882. doi: 10.1038/s41598-019-54796-6.,"Mice were treated with vehicle, M3814 alone, topoisomerase II inhibitor alone, and M3814 in combination with topoisomerase II inhibitor, and change in tumor volume over time was documented. The addition of M3814 was well tolerated. We demonstrated that M38 …"
2020-09-23T06:03:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=M3814(MSC2490484A)&sort=date&size=20,Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814.,Mol Cancer Res. 2019 Dec;17(12):2457-2468. doi: 10.1158/1541-7786.MCR-19-0362. Epub 2019 Sep 24.,"Here, we show that M3814 effectively blocks the repair of radiation-induced DSBs and potently enhances p53 phosphorylation and activation. ...Isogenic p53-null/wild-type A549 and HT-1080 cell lines were generated and used to demonstrate that p53 plays a critical role in de …"
2020-09-23T06:03:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=M3814(MSC2490484A)&sort=date&size=20,Simultaneous precise editing of multiple genes in human cells.,Nucleic Acids Res. 2019 Nov 4;47(19):e116. doi: 10.1093/nar/gkz669.,Transient inhibition of DNA-PKcs by the kinase inhibitor M3814 is similarly able to enhance precise genome editing....
2020-09-23T06:03:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=M3814(MSC2490484A)&sort=date&size=20,Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation.,Radiat Oncol. 2017 Dec 29;12(1):208. doi: 10.1186/s13014-017-0939-0.,"Clonogenic survival was studied after dual combinations of radiotherapy with inhibitors of DNA-dependent Protein Kinase (DNAPKi, M3814) and ATM serine/threonine kinase (ATMi). ..."
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,Binding mechanisms of therapeutic antibodies to human CD20.,Science. 2020 Aug 14;369(6505):793-799. doi: 10.1126/science.abb8008.,Here we present 3.7- to 4.7-angstrom cryo-electron microscopy structures of full-length CD20 in complexes with prototypical type I rituximab and ofatumumab and type II obinutuzumab. ...
2020-09-23T06:03:43Z,https://pubmed.ncbi.nlm.nih.gov/?term=M3814(MSC2490484A)&sort=date&size=20,Targeting DNA-Dependent Protein Kinase for Cancer Therapy.,ChemMedChem. 2017 Jun 21;12(12):895-900. doi: 10.1002/cmdc.201700143. Epub 2017 May 29.,"DNA-PK catalytic inhibitors, such as VX-984 (8-[(1S)-2-[[6-(4,6-dideuterio-2-methylpyrimidin-5-yl)pyrimidin-4-yl]amino]-1-methylethyl]quinoline-4-carboxamide) and M3814 ((S)-[2-chloro-4-fluoro-5-(7-morpholinoquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol), have …"
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review.,Cancers (Basel). 2017 Jul 8;9(7):83. doi: 10.3390/cancers9070083.,
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives.,Cancer Cell Int. 2015 Dec 15;15:117. doi: 10.1186/s12935-015-0267-0. eCollection 2015.,"We review the drugs targeting angiogenesis (bevacizumab, sorafenib, and pazopanib), growth factors (gefitinib, erlotinib, lapatinib, trastuzumab, and AMG479), and signaling pathways (temsirolimus, dasatinib, and imatinib), and other drugs (oregovomab, volociximab, and inip …"
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,Membrane proteome analysis of glioblastoma cell invasion.,J Neuropathol Exp Neurol. 2015 May;74(5):425-41. doi: 10.1097/NEN.0000000000000187.,"Thus, invasion-associated proteins, including ITGA5, may prove to be useful anti-invasive targets; volociximab, a therapeutic antibody against integrin α5β1, may be useful for treatment of patients with GBM...."
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.,Expert Opin Investig Drugs. 2013 Sep;22(9):1181-92. doi: 10.1517/13543784.2013.812071. Epub 2013 Jun 20.,"Inhibitors reviewed in this paper include bevacizumab, volociximab, aflibercept, temsirolimus, enzastaurin, trebananib, sunitinib, imatinib, pazopanib, sorafenib and nintedanib. ..."
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,"Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer.",Ann Oncol. 2013 Jan;24(1):90-6. doi: 10.1093/annonc/mds281. Epub 2012 Aug 16.,"In 29 patients who received volociximab, the most common grade≥3 AEs were neutropenia (24%), hyponatremia (17%), and fatigue (10%). ...CONCLUSIONS: Volociximab combined with carboplatin and paclitaxel was generally well-tolerated and showed preliminary evidence of e …"
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,Volociximab in cancer.,Expert Opin Biol Ther. 2012 Feb;12(2):251-7. doi: 10.1517/14712598.2012.646985. Epub 2011 Dec 22.,INTRODUCTION: Volociximab is a first-in-class chimeric monoclonal antibody that targets α5β1 integrin. Preclinical studies have shown the ability of volociximab to inhibit tumor neoangiogenesis by blocking the interaction between α5β1 and fibronectin. ...EXPERT OPIN …
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,β1-integrin: a potential therapeutic target in the battle against cancer recurrence.,Clin Cancer Res. 2011 Dec 1;17(23):7219-23. doi: 10.1158/1078-0432.CCR-11-0642. Epub 2011 Sep 7.,"We also consider possible therapeutic approaches, such as small molecules or antibodies (ATN-161, volociximab, and JSM6427), directed against β1-integrin signaling to target dormant cancer cells and to prevent metastatic recurrence...."
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,"A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.",Gynecol Oncol. 2011 May 1;121(2):273-9. doi: 10.1016/j.ygyno.2010.12.362. Epub 2011 Jan 26.,"Volociximab was administered at 15mg/kg IV qwk until progression of disease or drug intolerability. Tumor response was assessed every 8weeks. ...CONCLUSION: Despite insufficient clinical activity in this refractory patient population to continue the study, weekly voloci …"
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,"Integrins as target: first phase III trial launches, but questions remain.",J Natl Cancer Inst. 2010 May 19;102(10):675-7. doi: 10.1093/jnci/djq186. Epub 2010 May 11.,
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions.,Ther Adv Med Oncol. 2010 Jan;2(1):39-49. doi: 10.1177/1758834009352498.,"The development of new targeted therapies including axitinib, pazopanib, cediranib, volociximab, tivozanib (AV-951), BAY 73-4506, and c-met inhibitors such as GSK1363089 and ARQ197 may potentially expand the list of treatment options. ..."
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2009 Sep;31(7):463-93.,"This issue focuses on the following selection of drugs: AAV1/SERCA2a, Abacavir sulfate/lamivudine, Adalimumab, Aliskiren fumarate, Ambrisentan, Aripiprazole, AT-7519, Atazanavir sulfate, Atomoxetine hydrochloride, Azacitidine, Azelnidipine; Besifloxacin hydrochloride, Bevacizumab …"
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2009 Jul-Aug;31(6):397-417.,"[90Y-DOTA-Tyr3]octreotate, Abatacept, ABT-888, ACE-011, Adefovir dipivoxil, Alosetron hydrochloride, Aminolevulinic acid methyl ester, Amlodipine, Apaziquone, Aripiprazole, AS-101, Atomoxetine hydrochloride, Atrasentan, Azacitidine; Bevacizumab, Biphasic insulin aspart, Bortezomi …"
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,Combination therapy for age-related macular degeneration.,Retina. 2009 Jun;29(6 Suppl):S45-8. doi: 10.1097/IAE.0b013e3181ad22d5.,
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,Gateways to clinical trials.,Methods Find Exp Clin Pharmacol. 2009 May;31(4):263-98. doi: 10.1358/mf.2009.31.4.1373959.,"(-)-Gossypol; Abacavir sulfate/lamivudine, ACAM-1000, ACE-011, Agomelatine, AGS-004, Alemtuzumab, Alvocidib hydrochloride, AMG-317, Amlodipine, Aripiprazole, Atazanavir sulfate, Azacitidine; Becatecarin, Belinostat, Bevacizumab, BMS-387032, BMS-690514, Bortezomib; Casopitant mesy …"
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients.,Cancer Chemother Pharmacol. 2010 Jan;65(2):207-17. doi: 10.1007/s00280-009-1023-8.,"PURPOSE: Volociximab is a chimeric IgG(4) that is being developed as a novel first-in-class anti-angiogenic, α(5)β(1) integrin inhibitor for the treatment of solid tumors. A mechanism-based pharmacokinetic (PK)/pharmacodynamic (PD) model was developed to investigate the dy …"
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,"Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study.",Clin Cancer Res. 2008 Dec 1;14(23):7924-9. doi: 10.1158/1078-0432.CCR-08-0378.,"EXPERIMENTAL DESIGN: Patients with advanced solid malignancies were treated with escalating doses of volociximab i.v. administered over 60 minutes. ...Mild (grade 1 or 2), reversible fatigue was the principal toxicity of volociximab at the highest dose levels of 10 …"
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,Novel drugs for renal cell carcinoma.,Expert Opin Investig Drugs. 2008 Oct;17(10):1501-16. doi: 10.1517/13543784.17.10.1501.,
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,[Report of the 10th Annual Meeting of the Chinese society of Clinical Oncology].,Zhong Xi Yi Jie He Xue Bao. 2008 Mar;6(3):324-30. doi: 10.3736/jcim20080321.,"Several hotspots were particularly highlighted in this report, including innovative radiotherapy and chemotherapy methods, researches on molecular targets and clinical trials of targeted therapy, such as endostatin, volociximab, cetuximab, bevacizumab and temozolomide. ..."
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,"Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.",JOP. 2008 Mar 8;9(2):91-8.,"The studies discussed here include the following: i) a phase I study of a chemotherapy doublet gemcitabine plus capecitabine, combined with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma (abstract #141); ii) a phase II study of …"
2020-09-23T06:03:47Z,https://pubmed.ncbi.nlm.nih.gov/?term=VOLOCIXIMAB&sort=date&size=20,A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.,J Transl Med. 2007 Nov 27;5:61. doi: 10.1186/1479-5876-5-61.,"Although volociximab has already been tested in open label, pilot phase II clinical trials in melanoma, pancreatic and renal cell cancer, evaluation of the mechanism of action of volociximab has been limited because this antibody does not cross-react with murine alp …"
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,"Phase II trial of CHIP for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group Study.",Am J Clin Oncol. 1995 Oct;18(5):400-2. doi: 10.1097/00000421-199510000-00008.,"CHIP, a second generation analogue of cisplatin, was subjected to a Phase II trial for the treatment of advanced, hormonally refractory carcinoma of the prostate. ...While CHIP can be administered on an outpatient basis, its response rate for prostatic carcinoma app …"
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,"Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.",J Clin Oncol. 1994 Aug;12(8):1616-20. doi: 10.1200/JCO.1994.12.8.1616.,PURPOSE: Children less than 1 year of age with metastatic neuroblastoma NB are at high risk of death. The need to identify new and effective chemotherapy agents is clear. ...PATIENTS AND METHODS: One hundred seventy-three eligible patients more than 1 year of age with diss …
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,The influence of platinum drugs on the radiation response of rat kidneys.,Radiother Oncol. 1994 May;31(2):138-50. doi: 10.1016/0167-8140(94)90394-8.,"Drugs employed were cis-diammine-dichloroplatinum(II) (cisplatin, CDDP), cis-diammine-1,1-cyclobutanedicarboxylate platinum(II) (carboplatin, CBDCA) and cis-dichloro,trans- dihydroxy-bis-isopropylamine platinum(IV) (iproplatin, CHIP). ...Those for CBDCA and CHIP …"
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,"The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents.",Biochem Pharmacol. 1993 Jan 7;45(1):253-6. doi: 10.1016/0006-2952(93)90399-h.,"The glutathione contents, glutathione S-transferase activities and metallothionein contents have been measured in a series of L1210 cell lines which show decreased sensitivities to platinum drugs. ...However, depletion of glutathione by buthionine 1-sulphoximine sensitizes …"
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.,Br J Cancer. 1993 Jan;67(1):24-9. doi: 10.1038/bjc.1993.5.,"In vivo models of acquired resistance to the platinum-based agents cisplatin (CDDP), carboplatin (CBDCA), iproplatin (CHIP) and tetraplatin have been established using a panel of six parent human ovarian carcinoma lines, two (HX/110 and PXN/87) being derived from pr …"
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT.,Invest New Drugs. 1992 Nov;10(4):327-30. doi: 10.1007/BF00944190.,"Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated with iproplatin (CHIP). No objective responses were noted in any of the patients treated. ..."
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,Acute leukemia arising from a myelodysplastic syndrome after long-term administration of iproplatin.,Cancer. 1992 Sep 15;70(6):1536-40. doi: 10.1002/1097-0142(19920915)70:6<1536::aid-cncr2820700615>3.0.co;2-w.,BACKGROUND: Iproplatin (cis-dichloro-transdihydroxybis-isopropylamine platinum IV; CHIP) is a second generation cisplatin derivative that was developed to retain the antineoplastic effect of cisplatin with fewer toxic effects. ...CONCLUSIONS: Acute leukemia may repr …
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors. A phase II study (Pediatric Oncology Group).,Invest New Drugs. 1992 Jul;10(2):93-6. doi: 10.1007/BF00873123.,"CHIP (325 mg/M2), a second generation cisplatin derivative, was administered intravenously every 3 weeks to 85 pediatric patients with recurrent sarcomas (19), osteosarcomas (20), neuroblastoma (23), germ cell tumors (10), and other malignant tumors (7). ..."
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,"The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.",Br J Cancer. 1991 Aug;64(2):215-20. doi: 10.1038/bjc.1991.279.,"The role of glutathione (GSH) and GSH-S-transferase (GST) activity in modulating the cytotoxicity of four platinum drugs and melphalan was evaluated in eight human ovarian carcinoma cell lines. ...In contrast, extending the BSO treatment to 24 h after drug exposure potenti …"
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,Phase II trial of carboplatin or iproplatin in cervical cancer.,Cancer Chemother Pharmacol. 1991;28(5):391-6. doi: 10.1007/BF00685695.,"From July 1984 to November 1987, 89 patients with recurrent measurable squamous-cell cancer of the uterine cervix were randomized in a single institution to receive treatment with either carboplatin (CBDCA) or iproplatin (CHIP). ...Analysis of all toxic events yield …"
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology Group.,J Urol. 1990 Nov;144(5):1119-22. doi: 10.1016/s0022-5347(17)39672-6.,Among 17 patients with evaluable but not measurable metastases (10 carboplatin and 7 CHIP recipients) there were no responses. ...A total of 31% of the patients treated with carboplatin and 34% of those who received CHIP experienced severe or life-threatening myelos …
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,Hypersensitivity reactions to CHIP.,J Clin Oncol. 1990 Jun;8(6):1119. doi: 10.1200/JCO.1990.8.6.1119.,
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs.,Anticancer Res. 1990 Mar-Apr;10(2A):447-52.,"The IgM/cDDP cells showed cross-resistance, in vitro and in vivo, to the currently used cis-DDP analogs carboplatin (CBDCA or JM8) and iproplatin (CHIP or JM9). ..."
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tract.,Invest New Drugs. 1990 Feb;8(1):71-5. doi: 10.1007/BF00216927.,"Iproplatin (CHIP) is a second generation cisplatin analogue which has completed its Phase I trials. We studied the efficacy and toxicity of CHIP in 36 previously untreated patients with advanced upper gastrointestinal tract adenocarcinomas (GE junction, cardi …"
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,Cross resistance studies with L1210 leukemia subline single and double resistant to cisplatin and iproplatin (CHIP).,Neoplasma. 1990;37(6):631-8.,Resistance to cisplatin (DDP) and/or iproplatin (CHIP) was induced in vitro in murine L1210 leukemia cells. Double-resistant sublines with combined resistance to both drugs were also developed. ...Lack of cross resistance between DDP and CHIP was found. A hig …
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,The effect of second generation platinum cytostatics on mammalian cell proliferation.,Neoplasma. 1990;37(2):121-9.,Cell proliferation was inhibited least of all by CHIP(IV). The differences observed are discussed from the point of view of the structure and oxidation state of the platinum complexes....
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP.,Cancer Chemother Pharmacol. 1990;25(6):395-404. doi: 10.1007/BF00686049.,The two most promising analogs are CBDCA (carboplatin) and CHIP (iproplatin). The preclinical and early clinical trial results have demonstrated that these two compounds show activity in cisplatin-responsive tumors. ...We suggest a means of screening for each analog …
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,A phase II study of carboplatin and CHIP in patients with metastatic colon carcinoma.,Am J Clin Oncol. 1989 Oct;12(5):416-9. doi: 10.1097/00000421-198910000-00011.,Fifty-six patients were treated in each arm of a study comparing CHIP and carboplatin for the therapy of previously untreated metastatic colorectal carcinoma. There were one partial response (2%) with CHIP and two partial responses (4%) with carboplatin. Side effect …
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,Phase II study of iproplatin (CHIP) in previously treated small-cell lung cancer.,Am J Clin Oncol. 1989 Aug;12(4):355-7. doi: 10.1097/00000421-198908000-00016.,"Eighteen patients with previously treated extensive small-cell carcinoma of the lung were entered into a Phase II study employing iproplatin (CHIP), a cis-platin analog. ...CHIP (225 mg/m2) was administered by intermittent intravenous infusion over 30 min for …"
2020-09-23T06:03:51Z,https://pubmed.ncbi.nlm.nih.gov/?term=CHIP(IPROPLATIN)&sort=date&size=20,"Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow.",In Vivo. 1989 Jul-Aug;3(4):267-70.,"The in vivo toxic actions of cis-dichloro-1, 1-cyclo-butane-dicarboxylate platinum (II): carboplatin (CBDCA), cis-diisopropyl-ammine-transdihydroxy-dichloro platinum (IV) and iproplatin (CHIP) were compared with those of cis-diamminedichloroplatinum (II): cisplatin …"
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,"AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers.",Am J Cancer Res. 2020 Aug 1;10(8):2649-2676. eCollection 2020.,"AMXI-5001 demonstrates comparable IC50 inhibition against PARP and microtubule polymerization as clinical PARP inhibitors (Olaparib, Rucaparib, Niraparib, and Talazoparib) and the potent polymerization inhibitor (Vinblastine), respectively. ..."
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.,Cancer Rep (Hoboken). 2020 Sep 3:e1287. doi: 10.1002/cnr2.1287. Online ahead of print.,"After the FDA approvals of the poly ADP ribose polymerase (PARP) inhibitors, olaparib and talazoparib, for treatment of metastatic breast cancer, carrying germline mutations in BRCA1 and BRCA2 genes, the genetic testing result has become critical in their care. ..."
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.,Oncologist. 2020 Sep 1. doi: 10.1634/theoncologist.2020-0449. Online ahead of print.,"Of the remaining 212 patients, 10.4% (22/212) had a BRCA1/2 mutation, which, if confirmed by germline testing, would allow olaparib plus talazoparib therapy. ..."
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,"PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective.",Oncol Lett. 2020 Oct;20(4):90. doi: 10.3892/ol.2020.11951. Epub 2020 Aug 6.,"Three PARP inhibitors, olaparib, rucaparib and niraparib, have been recently approved by the Food and Drug Administration for clinical use in EOC patients, though with different clinical indications and profiles of toxicity, while two other molecules, veliparib and talazoparib …"
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series.,J Neurosurg. 2020 Sep 4:1-14. doi: 10.3171/2020.5.JNS201116. Online ahead of print.,
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.,Ann Oncol. 2020 Aug 20:S0923-7534(20)42106-4. doi: 10.1016/j.annonc.2020.08.2098. Online ahead of print.,RESULTS: 431 patients were randomized (287 talazoparib/144 chemotherapy) with 412 patients treated (286 talazoparib/126 chemotherapy). ...PRO continued to favor talazoparib....
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer.,Clin Cancer Res. 2020 Aug 14. doi: 10.1158/1078-0432.CCR-20-1439. Online ahead of print.,RESULTS: We found that biallelic inactivation of BRCA1/BRCA2 is associated with genomic hallmarks of HRD and required for cisplatin and talazoparib (PARPi) sensitivity. ...We identified tumor polyploidy and a low Ki67 index as predictors of poor cisplatin and talazopari …
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts.,BMC Cancer. 2020 Aug 18;20(1):775. doi: 10.1186/s12885-020-07190-9.,BACKGROUND: PARP inhibitors niraparib and talazoparib are FDA approved for special cases of breast cancer. PARP is an interesting repair protein which is frequently affected in cancer cells. We studied the combined action of talazoparib or niraparib with ionizing ra …
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.,Eur J Cancer. 2020 Sep;137:204-213. doi: 10.1016/j.ejca.2020.06.014. Epub 2020 Aug 11.,"BACKGROUND: Talazoparib combined with irinotecan and temozolomide demonstrated efficacy in a murine Ewing sarcoma model. Based on these data, we conducted a phase I trial of talazoparib and irinotecan with/without temozolomide in paediatric patients with recurrent/r …"
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,The emerging role of PARP inhibitors in prostate cancer.,Expert Rev Anticancer Ther. 2020 Aug;20(8):715-726. doi: 10.1080/14737140.2020.1797497. Epub 2020 Aug 6.,"Several PARP inhibitors (PARPi) are under development, such as olaparib, talazoparib, niraparib, rucaparib, and veliparib. In metastatic castration resistant prostate cancer (mCRPC), olaparib has been the most studied and its clinical efficacy has been validated in a phase …"
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.,Eur J Med Chem. 2020 Oct 1;203:112570. doi: 10.1016/j.ejmech.2020.112570. Epub 2020 Jul 15.,"To date, four PARP1 inhibitors namely olaparib, rucaparib, niraparib and talazoparib, have been approved by Food and Drug Administration (FDA) for treating ovarian cancer and breast cancer with BRCA1/2 mutation. ..."
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,DNA Repair and Prostate Cancer: A Field Ripe for Harvest.,Eur Urol. 2020 Oct;78(4):486-488. doi: 10.1016/j.eururo.2020.06.020. Epub 2020 Jul 5.,"Additional clinical trials are in progress for talazoparib, veliparib, and niraparib. More progress can be anticipated in the near future...."
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma.,Oncotarget. 2020 Jun 9;11(23):2141-2159. doi: 10.18632/oncotarget.27329. eCollection 2020 Jun 9.,"In a panel of neuroblastoma cell lines, MYCN amplification or MYCN expression resulted in increased cell death in response to a range of PARP inhibitors (niraparib, veliparib, talazoparib and olaparib) compared to the response seen in non-expressing/amplified cells. ..."
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.,Sci Rep. 2020 Jun 23;10(1):10196. doi: 10.1038/s41598-020-67199-9.,"In vitro studies using the SSTR2 expressing AR42J model demonstrate that the combination of LuTate and the small molecule Poly(ADP-ribose) polymerase-1 (PARP) inhibitor, talazoparib led to increased DNA double strand breaks, as assessed by γ-H2AX foci formation, as compare …"
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,PARP inhibitors in prostate cancer: time to narrow patient selection?,Expert Rev Anticancer Ther. 2020 Jul;20(7):523-526. doi: 10.1080/14737140.2020.1781622. Epub 2020 Jul 7.,
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.,Blood Rev. 2020 May 7:100696. doi: 10.1016/j.blre.2020.100696. Online ahead of print.,
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?,Cancers (Basel). 2020 May 27;12(6):1378. doi: 10.3390/cancers12061378.,"Yet, neoadjuvant talazoparib, administered as a single-agent in patients with HER2-negative breast cancer and germline BRCA1/2 mutation, achieved an impressive pathological complete response rate of nearly 50%. ..."
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.,J Clin Pharmacol. 2020 Oct;60(10):1334-1343. doi: 10.1002/jcph.1626. Epub 2020 May 28.,"Poly(ADP-ribose) polymerase inhibitors, such as talazoparib, may affect hematopoiesis. This analysis characterized the relationship between talazoparib exposure and the most common grade ≥ 3 hematopoietic adverse events (AEs) leading to dose modification in the phas …"
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.,J Clin Pharmacol. 2020 Oct;60(10):1324-1333. doi: 10.1002/jcph.1623. Epub 2020 May 28.,We conducted an exposure-efficacy analysis using EMBRACA data from 285 patients who were treated with talazoparib and had available pharmacokinetic parameters to evaluate the effect of talazoparib exposure (time-varying average talazoparib concentration [C(av …
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,'PARP'ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors.,Drug Discov Today. 2020 Jul;25(7):1253-1261. doi: 10.1016/j.drudis.2020.04.019. Epub 2020 May 1.,"The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) recently approved several PARP inhibitors, such as olaparib, niraparib, talazoparib, and rucaparib, for the treatment of ovarian and germline BRCA-mutant breast cancers. ..."
2020-09-23T06:03:55Z,https://pubmed.ncbi.nlm.nih.gov/?term=TALAZOPARIB&sort=date&size=20,PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.,Prostate Cancer Prostatic Dis. 2020 May 4. doi: 10.1038/s41391-020-0233-3. Online ahead of print.,"On-going clinical trials with olaparib, niraparib, talazoparib, veliparib, and rucaparib in mCRPC were searched on the clinicalTrials.gov website. ...Other phase-III clinical trials are evaluating niraparib and talazoparib, alone or in combination with AR signaling …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice.,Virol Sin. 2020 Aug 5. doi: 10.1007/s12250-020-00261-y. Online ahead of print.,"The subunit herpes zoster vaccine Shingrix is superior to attenuated vaccine Zostavax in both safety and efficacy, yet its unlyophilizable liposome delivery system and the limited supply of naturally sourced immunological adjuvant QS-21 still need to be improved. .. …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,"VaxiPatch™, a novel vaccination system comprised of subunit antigens, adjuvants and microneedle skin delivery: An application to influenza B/Colorado/06/2017.",Vaccine. 2020 Jul 31:S0264-410X(20)30958-0. doi: 10.1016/j.vaccine.2020.07.040. Online ahead of print.,"For this study, rHA of influenza virus B/Colorado/06/2017 was incorporated into synthetic virosomes, and adjuvant liposomes were formed with QS-21 from Saponaria quillaja, with or without the synthetic TLR4 agonist 3D - (6-acyl) PHAD. ...In this study, Sprague Dawle …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,In vitro Notch-mediated adjuvant immunogenic potency is induced by combining QS-21 and MPL in a co-culture model of PBMC and HUVEC cells.,Toxicol In Vitro. 2020 Oct;68:104947. doi: 10.1016/j.tiv.2020.104947. Epub 2020 Jul 15.,"MPL is a toll-like receptor agonist able to trigger a high and persistent antibody response via-TLR-4 while QS-21 activates the NLRP3 inflammasome. ...Both MPL and QS-21 by themselves were able to generate significant NF-κB activation. However, this ef …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,In vitro evaluation and molecular docking of QS-21 and quillaic acid from Quillaja saponaria Molina as gastric cancer agents.,Sci Rep. 2020 Jun 29;10(1):10534. doi: 10.1038/s41598-020-67442-3.,The cytotoxic mechanism of the saponin QS-21 and its aglycone quillaic acid (QA) was studied on human gastric cancer cells (SNU1 and KATO III). Both compounds showed in vitro cytotoxic activity with IC(50) values: 7.1 μM (QS-21) and 13.6 …
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,Investigation of the combination of anti-PD-L1 mAb with HER2/neu-loaded dendritic cells and QS-21 saponin adjuvant: effect against HER2 positive breast cancer in mice.,Immunopharmacol Immunotoxicol. 2020 Aug;42(4):346-357. doi: 10.1080/08923973.2020.1775644. Epub 2020 Jun 9.,"The vaccine combination was further supported using a QS-21 saponin adjuvant and the immune response was evaluated. RESULTS: Mice treated with HER2/neu-loaded BM-DCs, combined with QS-21 and anti-PD-L1 mAb had significantly decreased tumor sizes …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,Impact of C28 Oligosaccharide on Adjuvant Activity of QS-7 Analogues.,J Org Chem. 2020 May 28. doi: 10.1021/acs.joc.0c00359. Online ahead of print.,"We have synthesized a number of Quillaja saponaria Molina (QS) saponin analogues with a different C28 sugar unit, which features either 3,4-diacetyl groups or a 3,4-cyclic carbonate group at the reducing end fucoside to mimic the naturally occurring saponin a …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,A systematic comparison of triterpenoid biosynthetic enzymes for the production of oleanolic acid in Saccharomyces cerevisiae.,PLoS One. 2020 May 1;15(5):e0231980. doi: 10.1371/journal.pone.0231980. eCollection 2020.,"An important triterpenoid is oleanolic acid because it is the precursor to many bioactive triterpenoids of commercial interest, such as QS-21 which is being evaluated as a vaccine adjuvant in clinical trials against HIV and malaria. ..."
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,Army Liposome Formulation (ALF) family of vaccine adjuvants.,Expert Rev Vaccines. 2020 Mar;19(3):279-292. doi: 10.1080/14760584.2020.1745636. Epub 2020 Mar 31.,Improvements based on ALF include: ALF adsorbed to aluminum hydroxide (ALFA); ALF containing QS21 saponin (ALFQ); and ALFQ adsorbed to aluminum hydroxide (ALFQA). ...
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,Exploiting structure-activity relationships of QS-21 in the design and synthesis of streamlined saponin vaccine adjuvants.,Chem Commun (Camb). 2020 Jan 16;56(5):719-722. doi: 10.1039/c9cc07781b.,"We report the design, synthesis, immunological evaluation, and conformational analysis of new saponin variants as promising vaccine adjuvants. These studies have provided expedient synthetic access to streamlined adjuvant-active saponins and yielded molecular-level insight …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,Impact of Th1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques.,J Virol. 2020 Feb 28;94(6):e01737-19. doi: 10.1128/JVI.01737-19. Print 2020 Feb 28.,"Utilizing a novel interferon-induced protein 10 (IP-10)-adjuvanted HIV-1 DNA prime followed by a monophosphoryl lipid A and QS-21 (MPLA+QS-21)-adjuvanted Env protein boost (D(IP-10) P(ALFQ)) in macaques, we observed higher anti-Env serum IgG titers wit …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins.,Vaccines (Basel). 2019 Dec 3;7(4):204. doi: 10.3390/vaccines7040204.,"Herein, we evaluated two different semi-synthetic archaeosome formulations as an adjuvant to the E1/E2 HCV envelope protein in a murine model and compared antigen-specific humoral (levels of anti-E1/E2 IgG and HCV pseudoparticle neutralization) and cellular responses (numbers of …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,"Microprojection arrays applied to skin generate mechanical stress, induce an inflammatory transcriptome and cell death, and improve vaccine-induced immune responses.",NPJ Vaccines. 2019 Oct 11;4:41. doi: 10.1038/s41541-019-0134-4. eCollection 2019.,Increasing the microprojection array application energy and the addition of QS-21 adjuvant were each associated with enhanced antibody response to delivered antigen and with induction of gene transcriptions associated with TNF and NF-κB signalling pathways. ...
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,Electrocardiographic predictors of cardiovascular events in patients at high cardiovascular risk: a multicenter study.,J Geriatr Cardiol. 2019 Aug;16(8):630-638. doi: 10.11909/j.issn.1671-5411.2019.08.004.,"ECG abnormalities included atrial fibrillation (6.7%), premature ventricular contraction (5.4%), pathological Q-wave (Q/QS) (21.3%), T-wave inversion (20.0%), intraventricular ventricular conduction delay (IVCD) (7.3%), left ventricular hypertrophy (LVH) (12.2%), an …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,Foamy matters: an update on Quillaja saponins and their use as immunoadjuvants.,Future Med Chem. 2019 Jun;11(12):1485-1499. doi: 10.4155/fmc-2018-0438. Epub 2019 Jul 15.,"Saponin chemistry affords characteristic interactions with cell membranes, which are essential for its mechanism of action. Natural sources include Quillaja saponaria barks and, more recently, Quillaja brasiliensis leaves. ...Quillaja genomic studies will most likely buttr …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,"Erratum for Ramakrishnan et al., ""Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21"".",mSphere. 2019 Jun 26;4(3):e00440-19. doi: 10.1128/mSphere.00440-19.,
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.,Phytomedicine. 2019 Jul;60:152905. doi: 10.1016/j.phymed.2019.152905. Epub 2019 Mar 30.,"The limitations of the use of aluminium salts that are unable to elicite cell responses against intracellular pathogens such as those causing malaria, tuberculosis, or AIDS, have driven the development of new alternative adjuvants such as QS-21, a triterpene sapo …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,"Correction for Ramakrishnan et al., ""Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21"".",mSphere. 2019 May 22;4(3):e00351-19. doi: 10.1128/mSphere.00351-19.,
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21.,mSphere. 2019 May 1;4(3):e00101-19. doi: 10.1128/mSphere.00101-19.,"To enhance immunogenicity, two novel liposome-based adjuvant systems, the Army Liposome Formulation (ALF), containing synthetic monophosphoryl lipid A, and ALF plus QS-21 (ALFQ), were evaluated with CPS-CRM in this study. ...Here, we report enhanced immunogenicity o …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,"Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.",Infect Immun. 2019 May 21;87(6):e00911-18. doi: 10.1128/IAI.00911-18. Print 2019 Jun.,"As recombinant purified proteins are normally poor immunogens, they require to be admixed with an adjuvant(s); therefore, the objective of the present study was to evaluate the capacity of different vaccine adjuvants, monophosphoryl lipid A (MPL), CpG, and Quillaja saponaria Moli …"
2020-09-23T06:03:58Z,https://pubmed.ncbi.nlm.nih.gov/?term=MUC-2KLH/QS-21&sort=date&size=20,Immunotherapeutic Potential of Mollusk Hemocyanins in Combination with Human Vaccine Adjuvants in Murine Models of Oral Cancer.,J Immunol Res. 2019 Jan 20;2019:7076942. doi: 10.1155/2019/7076942. eCollection 2019.,"The KLH- and FLH-QS-21 formulations showed reduced tumor development and greater overall survival. Hemocyanins, as opposed to QS-21, had no cytotoxic effect on either oral cancer cell line cultured in vitro, supporting the idea that the antitumor effec …"
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,"Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.",Cancer Discov. 2020 Sep 21:CD-20-0553. doi: 10.1158/2159-8290.CD-20-0553. Online ahead of print.,"We conducted a phase Ib trial investigating safety and efficacy of doublet CDK4/6 inhibitor palbociclib plus selective PI3K inhibitor taselisib in advanced solid tumors, and triplet palbociclib plus taselisib plus fulvestrant in 25 patients with PIK3CA mutant, ER-po …"
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,"A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.",Gynecol Oncol. 2020 Sep 18:S0090-8258(20)33905-6. doi: 10.1016/j.ygyno.2020.09.012. Online ahead of print.,"MATERIALS AND METHOD: Anti-proliferative activity and mechanistic investigations for CDDD2-94, employing palbociclib as comparator, were evaluated by MTT assay, cell cycle and apoptosis analysis, western blotting as well as senescence and colony formation assay. ...Importa …"
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,Management of ER positive metastatic breast cancer.,Semin Oncol. 2020 Aug 29:S0093-7754(20)30082-8. doi: 10.1053/j.seminoncol.2020.07.005. Online ahead of print.,"The first of these to receive FDA approval was the mTOR inhibitor everolimus (2012) [4], followed by the approval of 3 cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors [palbociclib (2015) [5], ribociclib (2018) [6], and abemaciclib (2018) [7]], and more recently the PI …"
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,"Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.",Breast. 2020 Aug 29;54:88-95. doi: 10.1016/j.breast.2020.08.011. Online ahead of print.,
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,Palbociclib in the treatment of recurrent ovarian cancer.,Gynecol Oncol Rep. 2020 Sep 1;34:100626. doi: 10.1016/j.gore.2020.100626. eCollection 2020 Nov.,"This case describes the use of palbociclib after multiple lines of cytotoxic chemotherapy and hormonal therapy. At 30 months upon commencement of palbociclib and letrozole, this patient continues to respond to the treatment radiologically and in the suppression of C …"
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer.,Onco Targets Ther. 2020 Aug 5;13:7785-7792. doi: 10.2147/OTT.S253333. eCollection 2020.,"Palbociclib in combination with an aromatase inhibitor (AI) was used, but the metastatic lesion at the sixth left rib increased than before. ...Herein, we reported a pseudoprogression in the breast cancer patient after treatment with palbociclib plus AI...."
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.,J Natl Cancer Inst. 2020 Jun 17:djaa087. doi: 10.1093/jnci/djaa087. Online ahead of print.,"We aimed to determine whether genomic markers in circulating tumor DNA (ctDNA) can identify patients at higher risk of early progression on fulvestrant therapy with or without palbociclib, a CDK4/6i. METHODS: PALOMA-3 was a phase III, multicenter, double-blind randomized c …"
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,"Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.",Value Health. 2020 Sep;23(9):1128-1136. doi: 10.1016/j.jval.2020.04.002.,Recent examples include the approval of palbociclib in combination with endocrine therapy for male breast cancer and the inclusion of RWE in the label of paliperidone palmitate for schizophrenia. ...
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial.,Clin Cancer Res. 2020 Sep 16:clincanres.0844.2020. doi: 10.1158/1078-0432.CCR-20-0844. Online ahead of print.,PURPOSE: To assess palbociclib in combination with trastuzumab with or without endocrine therapy in patients with HER2-positive advanced breast cancer. ...CONCLUSION: Palbociclib in combination with trastuzumab is safe and exhibits promising survival outcomes in tra …
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis.,Cell Death Dis. 2020 Sep 15;11(9):760. doi: 10.1038/s41419-020-02980-2.,"To determine potential biomarkers of palbociclib sensitivity to assist in patient selection and clinical development, we investigated the effects of palbociclib in a panel of molecularly characterized breast cancer cell lines. ...We found non-TNBC subtypes were more …"
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.,Breast Cancer Res. 2020 Sep 14;22(1):98. doi: 10.1186/s13058-020-01334-2.,"RESULTS: From May 2016 to August 2018, 103 patients treated with endocrine therapy and palbociclib were included. Patients had received a median of two prior systemic therapies for MBC (range 0-14). ...CONCLUSION: This study demonstrates the clinical validity of pTKa as a …"
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,"Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.",Pharmacoepidemiol Drug Saf. 2020 Sep 13. doi: 10.1002/pds.5079. Online ahead of print.,Recent examples include the approval of palbociclib in combination with endocrine therapy for male breast cancer and the inclusion of RWE in the label of paliperidone palmitate for schizophrenia. ...
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,Sustained Complete Response to Palbociclib in a Refractory Pediatric Sarcoma With BCOR-CCNB3 Fusion and Germline CDKN2B Variant.,JCO Precis Oncol. 2020 Apr 30;4:PO.19.00258. doi: 10.1200/PO.19.00258. eCollection 2020.,
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,Bullous Skin Rash: A Rare Case of Palbociclib-Induced Dermatological Toxicity.,Cureus. 2020 Sep 3;12(9):e10229. doi: 10.7759/cureus.10229.,"Palbociclib is an FDA-approved cyclin-dependent kinase inhibitor to treat hormone-positive, HER2-negative metastatic breast cancer. ...In such cases, palbociclib should be abruptly discontinued and an early aggressive support should be initiated. We here present a c …"
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.,Int J Oncol. 2020 Sep 2. doi: 10.3892/ijo.2020.5117. Online ahead of print.,"A drug‑screening system (Mix Culture assay) was then applied, revealing that the cells were most sensitive to the MEK inhibitor trametinib among tested drugs, Cetuximab, Panitumumab, Regorafenib, Vemurafenib, BEZ‑235 and Palbociclib. ..."
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.,Int J Mol Sci. 2020 Sep 3;21(17):E6400. doi: 10.3390/ijms21176400.,"Pooled data from each single drug show that palbociclib remains the only class member not showing a statistically significant HR for OS (HR 0.83, 95% CI [0.68-1.02])...."
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,"CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions.",Int J Mol Sci. 2020 Sep 1;21(17):E6350. doi: 10.3390/ijms21176350.,"Palbociclib, ribociclib, and abemaciclib belong to the third generation of cyclin-dependent kinases inhibitors (CDKis), an established therapeutic class for advanced and metastatic breast cancer. ..."
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,Synchronization of human retinal pigment epithelial-1 cells in mitosis.,J Cell Sci. 2020 Sep 17;133(18):jcs247940. doi: 10.1242/jcs.247940.,"Here, we report a protocol to synchronize RPE-1 cells based on sequential treatments with the Cdk4 and Cdk6 inhibitor PD 0332991 (palbociclib) and the microtubule-depolymerizing drug nocodazole. ...Moreover, the cells fully recovered and re-entered the cell cycle after the …"
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy.,Anticancer Res. 2020 Sep;40(9):5291-5294. doi: 10.21873/anticanres.14534.,"Limited information is available regarding the toxicity of palbociclib and concurrent radiation therapy. CASE REPORT: Herein, we report a case of esophageal toxicity in a patient treated with palbociclib and radiation therapy. ...Palbociclib and radiation the …"
2020-09-23T06:04:02Z,https://pubmed.ncbi.nlm.nih.gov/?term=PALBOCICLIB&sort=date&size=20,Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review.,Oncol Ther. 2020 Sep 2. doi: 10.1007/s40487-020-00126-0. Online ahead of print.,"Palbociclib was used in the sixth-line therapy and discontinued after 5 months. We then tried abemaciclib in the 11th-line setting, where it induced a response that lasted 16 months...."
2020-09-23T06:04:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=ZW25&sort=date&size=20,ASCO 2018: highlights in HER2-positive metastatic breast cancer.,Memo. 2018;11(4):280-283. doi: 10.1007/s12254-018-0441-x. Epub 2018 Oct 11.,"ZW25, a bispecific HER2-directed antibody targeting the extracellular domains 2 and 4, showed excellent tolerability and considerable single-agent activity. ..."
2020-09-23T06:04:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=ZW25&sort=date&size=20,ZW25 Effective in HER2-Positive Cancers.,Cancer Discov. 2019 Jan;9(1):8. doi: 10.1158/2159-8290.CD-NB2018-162. Epub 2018 Nov 30.,"A novel anti-HER2 therapy, ZW25, may be effective and well tolerated in patients with a variety of HER2-positive cancers. In a phase I trial, patients treated with the drug-most of whom had gastroesophageal or colorectal cancer-had an objective response rate of 41% and mil …"
2020-09-23T06:04:06Z,https://pubmed.ncbi.nlm.nih.gov/?term=ZW25&sort=date&size=20,Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics.,Drug Deliv. 2017 Nov;24(1):1216-1229. doi: 10.1080/10717544.2017.1367976.,"These two CD123 aptamers (termed as ZW25 and CY30, respectively) can bind to a CD123 peptide epitope and CD123 + AML cells with high specificities and KD of 29.41 nM and 15.38 nM, respectively, while has minimal cross reactivities to albumin, IgG and trypsin. Further, TDT …"
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy.,Kidney Int Rep. 2020 Jul 3;5(9):1515-1518. doi: 10.1016/j.ekir.2020.06.030. eCollection 2020 Sep.,
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma.,Clin Lymphoma Myeloma Leuk. 2020 Aug 22:S2152-2650(20)30435-3. doi: 10.1016/j.clml.2020.08.017. Online ahead of print.,
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,Anti-CD20 treatment for B-cell malignancies: current status and future directions.,Expert Opin Biol Ther. 2020 Sep 15. doi: 10.1080/14712598.2020.1822318. Online ahead of print.,"Areas covered: The novel anti-CD20 antibodies ofatumumab, ublituximab, and obinutuzumab were developed to be differentiated via structural and mechanistic features over rituximab. ...Novel combinations of obinutuzumab, including with chemotherapy-free options are be …"
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering.,J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Sep 2;1159:122359. doi: 10.1016/j.jchromb.2020.122359. Online ahead of print.,"In this study, the physicochemical stability of anti-CD20 rituximab (RTX); originator and biosimilar was compared to its glycoengineered humanized version; obinutuzumab (OBZ). ..."
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,[Advances in antibody therapy for B cell lymphoma].,Rinsho Ketsueki. 2020;61(8):901-911. doi: 10.11406/rinketsu.61.901.,"In this review, molecular mechanisms of the second/third generation anti-CD20 antibodies (ofatumumab and obinutuzumab), anti-CD19 chimeric antigen-receptor T-cells (CAR-T-CD19; tisagenlecleucel, axicabtagene ciloleucel), and the anti-PD-1 antibodies (nivolumab and pembroli …"
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,Treatment of hairy cell leukemia.,Expert Rev Hematol. 2020 Sep 7. doi: 10.1080/17474086.2020.1819231. Online ahead of print.,"AREAS COVERED: Anti-CD22 recombinant immunotoxin Moxetumomab Pasudotox (Moxe), CD20 Mabs rituximab and obinutuzumab, BRAF/MEK inhibitors vemurafenib and dabrafenib-trametinib, and Bruton's tyrosine kinase (BTK) inhibitor ibrutinib have been tested for HCL. ..."
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.",Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5.,"FINDINGS: Between Aug 7, 2015, and Aug 4, 2016, 432 patients were enrolled and randomly assigned to receive either venetoclax plus obinutuzumab (n=216) or chlorambucil plus obinutuzumab (n=216). ...Serious adverse events occurred in 115 (54%) of 212 patients in the …"
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,Venetoclax plus obinutuzumab therapy for front-line treatment of chronic lymphocytic leukaemia.,Lancet Oncol. 2020 Sep;21(9):1128-1130. doi: 10.1016/S1470-2045(20)30484-8.,
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,"Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.",Leuk Lymphoma. 2020 Aug 30:1-8. doi: 10.1080/10428194.2020.1811271. Online ahead of print.,"In the network meta-analysis, acalabrutinib plus obinutuzumab (Aca + Obi) improved PFS than ibrutinib plus obinutuzumab (Ibu + Obi) (HR:0.43, p = .02) and venetoclax plus obinutuzumab (Ven + Obi) (HR:0.30, p < .001) as IRC assessment. ...Among these first- …"
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,"Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL.",Oncotarget. 2020 Aug 11;11(32):3035-3047. doi: 10.18632/oncotarget.27691. eCollection 2020 Aug 11.,"We hypothesize that obinutuzumab vs rituximab will significantly enhance in-vitro and in-vivo cytotoxicity against PMBL. PMBL cells were treated with equal dose of obinutuzumab and rituximab for 24 hours (1-100 μg/ml). ...Similarly, in PMBL xenografted NOD scid gamm …"
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,Development of anti-CD32b antibodies with enhanced Fc function for the treatment of B and plasma cell malignancies.,Mol Cancer Ther. 2020 Aug 26:molcanther.0003.2019. doi: 10.1158/1535-7163.MCT-19-0003. Online ahead of print.,"Additionally, NVS32b CDRs block the CD32b Fc binding domain, thereby minimizing CD32b-mediated resistance to therapeutic mAbs including rituximab, obinutuzumab, and daratumumab. ..."
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,Calcium channel blockers impair the antitumor activity of anti-CD20 monoclonal antibodies by blocking EGR-1 induction.,Mol Cancer Ther. 2020 Aug 26:molcanther.0839.2019. doi: 10.1158/1535-7163.MCT-19-0839. Online ahead of print.,"We show that both rituximab and obinutuzumab induce calcium influx, albeit through different mechanisms, and this influx is crucial for cell death induction. ..."
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,Noninvasive evaluation of CD20 expression using (64)Cu-labeled F(ab')2 fragments of obinutuzumab in lymphoma.,J Nucl Med. 2020 Aug 21:jnumed.120.246595. doi: 10.2967/jnumed.120.246595. Online ahead of print.,Obinutuzumab (obi) is a next-generation FDA-approved humanized monoclonal antibody that targets CD20. Previous studies with 89Zr-labeled obi has successfully imaged CD20 in vivo. ...
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,"Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.",J Clin Oncol. 2020 Aug 14:JCO2000491. doi: 10.1200/JCO.20.00491. Online ahead of print.,"PATIENTS AND METHODS: This phase II study tested a combination regimen of obinutuzumab, ibrutinib, and venetoclax for a total of 14 cycles in both patients with treatment-naïve (n = 25) and relapsed or refractory (n = 25) chronic lymphocytic leukemia to determine the respo …"
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,[Current diagnosis and treatment of chronic lymphocytic leukaemia].,Dtsch Med Wochenschr. 2020 Aug;145(16):1139-1144. doi: 10.1055/a-1039-8472. Epub 2020 Aug 13.,"This combination was shown to be clearly superior to chlorambucil/obinutuzumab and should become the preferred first-line treatment for the so called ""slow-go"" patients. ...Patients with the high-risk parameters deletion 17p or TP53mutation are known to poorly respond to c …"
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,"Design, Synthesis, Conjugation, and Reactivity of Novel trans,trans-1,5-Cyclooctadiene-Derived Bioorthogonal Linkers.",Bioconjug Chem. 2020 Sep 16;31(9):2201-2210. doi: 10.1021/acs.bioconjchem.0c00375. Epub 2020 Aug 11.,"The compounds for stability studies were prepared by conjugation of TCO linkers 6a, 8a, and 10a to mAbs, such as Rituximab and Obinutuzumab, and subsequent labeling with a reactive Cy3-functionalized tetrazine...."
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,New IMiD on the block.,Lancet Haematol. 2020 Sep;7(9):e627-e629. doi: 10.1016/S2352-3026(20)30225-8. Epub 2020 Aug 3.,
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,"Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.",Lancet Haematol. 2020 Sep;7(9):e649-e659. doi: 10.1016/S2352-3026(20)30208-8. Epub 2020 Aug 3.,"We aimed to examine the safety and preliminary activity of avadomide plus obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma. ...INTERPRETATION: Avadomide plus obinutuzumab has a manageable toxicity, being a tolerable treatment option for most …"
2020-09-23T06:04:09Z,https://pubmed.ncbi.nlm.nih.gov/?term=OBINUTUZUMAB&sort=date&size=20,Bivalent binding on cells varies between anti-CD20 antibodies and is dose-dependent.,MAbs. 2020 Jan-Dec;12(1):1792673. doi: 10.1080/19420862.2020.1792673.,"In this study, the binding mechanism of the Type I therapeutic antibodies rituximab (RTX) and ofatumumab (OFA) and the Type II antibody obinutuzumab (OBI) were established by real-time interaction analysis on live cells. ..."
2020-09-23T06:04:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=MORAB-004&sort=date&size=20,A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.,Cancer. 2019 Jul 15;125(14):2445-2454. doi: 10.1002/cncr.32084. Epub 2019 Apr 29.,"In part 2, patients were randomized in a double-blind fashion in 2:1 ratio to ontuxizumab (8 mg/kg) or a placebo with G/D. Randomization was stratified by 4 histological cohorts. ...The combination of ontuxizumab plus G/D was generally well tolerated. CONCLUSIONS: …"
2020-09-23T06:04:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=MORAB-004&sort=date&size=20,"A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors.",Invest New Drugs. 2019 Oct;37(5):1061-1074. doi: 10.1007/s10637-018-0713-7. Epub 2019 Jan 9.,"The study comprised two parts: part 1 (dose-escalation; ontuxizumab 2-12 mg/kg weekly) and part 2 (cohort-expansion; 4 or 8 mg/kg weekly, or 12 mg/kg biweekly). ...Conclusions Ontuxizumab, up to a dosage of 12 mg/kg weekly, was generally safe and well tolerated in t …"
2020-09-23T06:04:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=MORAB-004&sort=date&size=20,Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).,Pediatr Blood Cancer. 2018 May;65(5):e26944. doi: 10.1002/pbc.26944. Epub 2018 Jan 2.,"METHODS: Ontuxizumab was administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle at three dose levels (4, 8, and 12 mg/kg). ...The PK of ontuxizumab does not appear to be significantly different in children compared to adults...."
2020-09-23T06:04:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=MORAB-004&sort=date&size=20,"A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.",Invest New Drugs. 2018 Feb;36(1):103-113. doi: 10.1007/s10637-017-0530-4. Epub 2017 Nov 11.,"Objectives Ontuxizumab (MORAB-004) is a first-in-class monoclonal antibody that interferes with endosialin function, which is important in tumor stromal cell function, angiogenesis, and tumor growth. ...Conclusions Ontuxizumab at both doses was well to …"
2020-09-23T06:04:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=MORAB-004&sort=date&size=20,"A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer.",Clin Cancer Res. 2018 Jan 15;24(2):316-325. doi: 10.1158/1078-0432.CCR-17-1558. Epub 2017 Oct 30.,"Purpose: The purpose of this study was to evaluate the safety and efficacy of ontuxizumab (MORAb-004), a monoclonal antibody that interferes with endosialin (tumor endothelial marker-1) function, in patients with chemorefractory metastatic colorectal cancer a …"
2020-09-23T06:04:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=MORAB-004&sort=date&size=20,Novel antibody probes for the characterization of endosialin/TEM-1.,Oncotarget. 2016 Oct 25;7(43):69420-69435. doi: 10.18632/oncotarget.11018.,"In an effort to further understand its role in cancer, we previously developed a humanized anti-endosialin/TEM-1 monoclonal antibody (mAb), called ontuxizumab (MORAb-004) for testing in preclinical and clinical studies. ..."
2020-09-23T06:04:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=MORAB-004&sort=date&size=20,Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications.,Oncotarget. 2016 Mar 15;7(11):13082-92. doi: 10.18632/oncotarget.7552.,"Currently MORAb-004 (Ontuxizumab), an anti-TEM-1 humanized monoclonal antibody, is in sarcoma clinical trials. Development of positron emission tomography (PET) for in vivo TEM-1 expression may allow for stratification of patients, potentially enhancing clini …"
2020-09-23T06:04:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=MORAB-004&sort=date&size=20,Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature.,Oncotarget. 2015 Sep 22;6(28):25429-40. doi: 10.18632/oncotarget.4559.,"Here, we report that MORAb-004 treatment significantly impacted syngeneic tumor growth and tumor metastasis in the human CD248 knock-in mice. ...These results suggest that MORAb-004 reduced CD248 on pericytes, impaired tumor microvasculature maturation …"
2020-09-23T06:04:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=MORAB-004&sort=date&size=20,Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications.,Cancer Microenviron. 2015 Aug;8(2):111-8. doi: 10.1007/s12307-015-0168-8. Epub 2015 Jun 18.,"Ontuxizumab (MORAb-004) is a humanized recombinant antibody targeting endosialin (TEM-1, CD248). We conducted an analysis of endosialin expression in metastatic melanoma specimens using the anti-endosialin rat anti- MAb 9G5, in order to determine the potentia …"
2020-09-23T06:04:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=MORAB-004&sort=date&size=20,"A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.",Clin Cancer Res. 2015 Mar 15;21(6):1281-8. doi: 10.1158/1078-0432.CCR-14-1829. Epub 2014 Nov 14.,"A humanized monoclonal antibody, MORAb-004, was engineered to target endosialin and is the first agent in clinical development for this mesenchymal cell target. ...MORAb-004 was administered intravenously once weekly in 4-week cycles. Objectives includ …"
2020-09-23T06:04:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=MORAB-004&sort=date&size=20,Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.,Cancer Biol Ther. 2014 Apr;15(4):443-51. doi: 10.4161/cbt.27825. Epub 2014 Feb 19.,"In addition, highly efficient radioiodination of MORAb-004 did not impair its affinity for hTEM1, and [ (124)I]-MORAb-004-PET enabled non-invasive visualization of tumors enriched with hTEM1-positive, but not hTEM1 negative vasculature with high degree …"
2020-09-23T06:04:14Z,https://pubmed.ncbi.nlm.nih.gov/?term=MORAB-004&sort=date&size=20,Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin.,J Nucl Med. 2014 Mar;55(3):500-507. doi: 10.2967/jnumed.113.121905. Epub 2014 Feb 13.,"RESULTS: MORAb-004 was radiolabeled with high efficiency and isolated in high purity. In vitro studies demonstrated specific and sensitive binding of MORAb-004 to MS1 mouse endothelial cells expressing hTEM1, with no binding to control MS1 cells. (125) …"
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,Modification of carboxyl groups converts α-lactalbumin into an active molten globule state with membrane-perturbing activity and cytotoxicity.,Int J Biol Macromol. 2020 Sep 19:S0141-8130(20)34454-8. doi: 10.1016/j.ijbiomac.2020.09.095. Online ahead of print.,"Furthermore, SEM-LA-induced membrane permeability promoted the uptake of daunorubicin and thereby its cytotoxicity. The microenvironment surrounding the Trp residues of SEM-LA was enriched in positive charges, as revealed by iodide quenching studies. ..."
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,Heat Shock Factor 1 (HSF1-pSer326) Predicts Response to Bortezomib-Containing Chemotherapy in Pediatric AML: A COG Study.,Blood. 2020 Sep 21:blood.2020005208. doi: 10.1182/blood.2020005208. Online ahead of print.,"Bortezomib (BTZ) was recently evaluated in a randomized Phase 3 clinical trial which compared standard chemotherapy (cytarabine, daunorubicin, etoposide; ADE) to standard therapy with BTZ (ADEB) for de novo pediatric acute myeloid leukemia. ..."
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,CPX-351 - Daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.,Minerva Med. 2020 Sep 21. doi: 10.23736/S0026-4806.20.07017-2. Online ahead of print.,"In 2017, a new liposomal-encapsulated formulation with daunorubicin and cytarabine (CPX-351) was approved by the US Food and Drug Administration for the treatment of newly diagnosed tAML or AML with myelodysplasia-related changes (AML-MRCs). Based on the findings that rati …"
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.,Int J Mol Sci. 2020 Sep 16;21(18):E6802. doi: 10.3390/ijms21186802.,BACKGROUND: Recent evidence demonstrated that the treatment of acute myeloid leukemia (AML) cells with daunorubicin (DNR) but not cytarabine (Ara-C) results in immunogenic cell death (ICD). ...
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,"Discovery of a cobalt (III) salen complex that induces apoptosis in Burkitt like lymphoma and leukemia cells, overcoming multidrug resistance in vitro.",Bioorg Chem. 2020 Sep 1;104:104193. doi: 10.1016/j.bioorg.2020.104193. Online ahead of print.,"MBR-60 displays synergistic effects with daunorubicin and vincristine and has a selectivity to tumor cells. In comparison to the apoptotic effects of MBR-60 in BJAB lymphoma cells, the cobalt-free ligand 5 does not influence these cells. ..."
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,"CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUP‑B15 cells.",Mol Med Rep. 2020 Jul 20. doi: 10.3892/mmr.2020.11350. Online ahead of print.,"In addition, CD9 knockdown could suppress cell proliferation, adhesion, migration and invasion, and promote apoptosis and the efficacy of chemotherapeutic drugs (such as vincristine, daunorubicin, cyclophosphamide and dexamethasone) and the tyrosine kinase inhibitor imatin …"
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells.,Mol Med Rep. 2020 Jul 17. doi: 10.3892/mmr.2020.11347. Online ahead of print.,"Downregulation of CREBBP increased the IC50 value of daunorubicin; however, no significant affects were observed on the IC50 values of vincristine and L‑asparaginase. ..."
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,SHOC2 scaffold protein modulates daunorubicin-induced cell death through p53 modulation in lymphoid leukemia cells.,Sci Rep. 2020 Sep 16;10(1):15193. doi: 10.1038/s41598-020-72124-1.,"To confirm the specificity of DNA-damage related modulation, several anti-leukemic drugs has been tested and we did confirm that the proposed mechanism impairs cell death upon daunorubicin-induced DNA damage of human lymphoid cells. ..."
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,Energy-resolved HCD fragmentation of daunorubicin-peptide conjugates.,J Mass Spectrom. 2020 Oct;55(10):e4641. doi: 10.1002/jms.4641.,
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,Concurrent Diagnosis of Acute Myeloid Leukemia and COVID-19: A Management Challenge.,Cureus. 2020 Aug 9;12(8):e9629. doi: 10.7759/cureus.9629.,"Therefore, induction was done with liposomal daunorubicin and cytarabine. However, he did not respond to the therapy and was started on re-induction therapy with decitabine and venetoclax. ..."
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,"Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia.",J Pharm Biomed Anal. 2020 Aug 26;191:113576. doi: 10.1016/j.jpba.2020.113576. Online ahead of print.,"This report presents improved analysis methods of daunorubicin (DAUN) and its metabolite daunorubicinol (DAUNOL) in small volumes of plasma, as total and unbound concentrations, as well as in urine. ..."
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,Exosomal CircPRRX1 Enhances Doxorubicin Resistance in Gastric Cancer by Regulating MiR-3064-5p/PTPN14 Signaling.,Yonsei Med J. 2020 Sep;61(9):750-761. doi: 10.3349/ymj.2020.61.9.750.,
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,High Wilms' tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates m6A methylation of MYC mRNA.,J Cancer Res Clin Oncol. 2020 Sep 3. doi: 10.1007/s00432-020-03373-w. Online ahead of print.,"Furthermore, WTAP made AML cells resistant to daunorubicin. In further investigations, m(6)A methylation level was downregulated when knocking down WTAP, and c-Myc was upregulated due to the decreased m(6)A methylation of MYC mRNA. ..."
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer.,Anticancer Res. 2020 Sep;40(9):5295-5299. doi: 10.21873/anticanres.14535.,
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,Mogamulizumab Plus EPOCH Therapy for Patients With Newly Diagnosed Aggressive Adult T-cell Leukemia/lymphoma.,Anticancer Res. 2020 Sep;40(9):5237-5243. doi: 10.21873/anticanres.14527.,
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report.,Medicine (Baltimore). 2020 Aug 14;99(33):e21440. doi: 10.1097/MD.0000000000021440.,
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,Acute pancreatitis induced by combination chemotherapy used for the treatment of acute myeloid leukemia: A case report.,Medicine (Baltimore). 2020 Aug 28;99(35):e21848. doi: 10.1097/MD.0000000000021848.,"After induction chemotherapy of daunorubicin and cytarabine, bone marrow aspiration showed: Acute myeloid leukemia-not relieved (AML-NR). ..."
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,RNA Aptamers Deliver Chemotherapy Directly to Tumors.,JAMA. 2020 Sep 1;324(9):829. doi: 10.1001/jama.2020.14464.,
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,[Effectiveness and safety of polyethylene glycol liposome doxorubicin in the treatment of osteosarcoma].,Zhonghua Zhong Liu Za Zhi. 2020 Aug 23;42(8):692-696. doi: 10.3760/cma.j.cn112152-20190510-00300.,
2020-09-23T06:04:18Z,https://pubmed.ncbi.nlm.nih.gov/?term=DAUNORUBICIN&sort=date&size=20,[Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)].,Zhonghua Zhong Liu Za Zhi. 2020 Aug 23;42(8):617-623. doi: 10.3760/cma.j.cn112152-20200410-00330.,
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft-tissue sarcoma patients.,Ann Oncol. 2020 Sep 14:S0923-7534(20)42444-5. doi: 10.1016/j.annonc.2020.09.003. Online ahead of print.,
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,"A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.",Invest New Drugs. 2020 Sep 16. doi: 10.1007/s10637-020-01001-5. Online ahead of print.,"Results Eleven Japanese patients with advanced solid tumors were enrolled; 4 patients (median age of 64 years) received 25 mg of crenigacestat, and 7 patients (median age of 72 years) received 50 mg of crenigacestat. ...Conclusions Crenigacestat was tolerated …"
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.,Invest New Drugs. 2020 Sep 11. doi: 10.1007/s10637-020-00944-z. Online ahead of print.,"Background Crenigacestat is a potent Notch inhibitor that decreases Notch signaling and its downstream biological effects. Here, we report the results from Part F of study 16F-MC-JJCA designed to evaluate the safety, pharmacokinetics (PK), and antitumor activity of cren …"
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,In Vitro Evaluation of Clinical Candidates of γ-Secretase Inhibitors: Effects on Notch Inhibition and Promoting Beige Adipogenesis and Mitochondrial Biogenesis.,Pharm Res. 2020 Sep 4;37(10):185. doi: 10.1007/s11095-020-02916-7.,"RESULTS: Four compounds (i.e.RO4929097, PF-03084014, LY3039478, and BMS-906024) that efficiently inhibited the expression of Notch target genes in 3T3-L1 preadipocytes were identified. ..."
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer.,Br J Cancer. 2020 Aug 11. doi: 10.1038/s41416-020-1026-0. Online ahead of print.,Notch pathway blocked using γ-secretase inhibitor LY3039478 and anti-JAG2 antibody led to retarded tumour growth and augmented cytotoxic effects of CD8(+) T cells. ...
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,"Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.",Cell Death Differ. 2020 Aug;27(8):2330-2343. doi: 10.1038/s41418-020-0505-4. Epub 2020 Feb 10.,"The effects of Notch pathway suppression by the Crenigacestat (LY3039478)-specific inhibitor were evaluated in human iCCA cell lines and the PDX model. ...In the PDX model, LY3039478 significantly inhibited the Notch pathway and tumor growth to the same exten …"
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,Epigenetic Profiling Identifies LIF as a Super-enhancer-Controlled Regulator of Stem Cell-like Properties in Osteosarcoma.,Mol Cancer Res. 2020 Jan;18(1):57-67. doi: 10.1158/1541-7786.MCR-19-0470. Epub 2019 Oct 15.,"The NOTCH1 inhibitor Crenigacestat (TargetMol, T3633) repressed LIF-mediated activation of the stemness-related genes in osteosarcoma patient-derived primary tissues. ..."
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.,Blood. 2019 Nov 7;134(19):1585-1597. doi: 10.1182/blood.2019000050.,
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,Exogenous mesenchymal stem cells affect the function of endogenous lung stem cells (club cells) in phosgene-induced lung injury.,Biochem Biophys Res Commun. 2019 Jun 30;514(3):586-592. doi: 10.1016/j.bbrc.2019.04.182. Epub 2019 May 4.,"LY3039478 (LY), a specific inhibitor of the Notch signaling pathway, was applied. After MSCs intervention, CCSP levels decreased, and club cell AFI increased, indicating that the secretion of club cells had weakened. ..."
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,"Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.",Invest New Drugs. 2020 Apr;38(2):402-409. doi: 10.1007/s10637-019-00739-x. Epub 2019 Apr 6.,"The phase I trial (I6F-MC-JJCA) investigated the safety and anti-tumor activity of crenigacestat (LY3039478), a selective oral Notch inhibitor, in an expansion cohort of patients with adenoid cystic carcinoma (ACC) who received the dose-escalation-recommended phase …"
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,"Evaluation of the effects of an oral notch inhibitor, crenigacestat (LY3039478), on QT interval, and bioavailability studies conducted in healthy subjects.",Cancer Chemother Pharmacol. 2019 Mar;83(3):483-492. doi: 10.1007/s00280-018-3750-1. Epub 2018 Dec 11.,PURPOSE: Crenigacestat (LY3039478) is a Notch inhibitor currently being investigated in advanced cancer patients. Conducting clinical pharmacology studies in healthy subjects avoids nonbeneficial drug exposures in cancer patients and mitigates confounding effects of …
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.,Eur J Cancer. 2018 Nov;103:88-97. doi: 10.1016/j.ejca.2018.08.012. Epub 2018 Sep 12.,"BACKGROUND: LY3039478 is an orally bioavailable selective Notch inhibitor. This phase 1a/b trial evaluated the safety, pharmacokinetics and antitumour activity of LY3039478 in patients with soft tissue sarcoma (STS) and gastrointestinal stromal tumour (GIST). ...CON …"
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,"First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.",Ann Oncol. 2018 Sep 1;29(9):1911-1917. doi: 10.1093/annonc/mdy244.,"LY3039478 is a novel, potent Notch inhibitor decreases Notch signaling and its downstream biologic effects. In this first-in-human study, we report the safety, pharmacokinetic (PK) profile, pharmacodynamic effects, and antitumor activity of LY3039478 in patients wit …"
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,Reversing effect of NOTCH1 inhibitor LY3039478 on drug-resistance cells SGC7901/DDP of human gastric cancer and its mechanism.,Eur Rev Med Pharmacol Sci. 2018 Jul;22(13):4121-4127. doi: 10.26355/eurrev_201807_15404.,"RESULTS: NOTCH1 inhibitor LY3039478 could inhibit the expression of Hes protein in SGC7901/DDP cells. Under the effect of 1 μmol/L and 2 μmol/L NOTCH1 inhibitor LY3039478, drug sensitivity of SGC7901/DDP cells to cisplatin was increased by 2.2 times and 2.86 times, …"
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,Notch Inhibitor Shows Modest Efficacy.,Cancer Discov. 2017 Feb;7(2):OF3. doi: 10.1158/2159-8290.CD-NB2016-159. Epub 2016 Dec 14.,Data from a phase I study indicate that LY3039478 is modestly effective against a range of advanced or metastatic cancers. The investigational Notch-signaling inhibitor induced partial responses and stable disease in patients with breast cancer and rare malignancies such a …
2020-09-23T06:04:22Z,https://pubmed.ncbi.nlm.nih.gov/?term=LY3039478&sort=date&size=20,Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer.,J Biol Chem. 2017 Jan 20;292(3):837-846. doi: 10.1074/jbc.M116.745208. Epub 2016 Dec 1.,"Treatment with the γ-secretase inhibitor LY3039478 led to inhibition of CCRCC cells in vitro and in vivo In summary, these data reveal the mechanistic basis of NOTCH pathway activation in CCRCC and demonstrate this pathway to a potential therapeutic target...."
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Repurposing Cancer Drugs for COVID-19.,Cancer Discov. 2020 Sep 18. doi: 10.1158/2159-8290.CD-ND2020-016. Online ahead of print.,"For instance, androgen blockade with bicalutamide is being evaluated to tackle viral entry and replication, and it may be useful for patients with mild respiratory symptoms. ..."
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide.,Int J Urol. 2020 Sep 15. doi: 10.1111/iju.14366. Online ahead of print.,OBJECTIVES: To assess the impact of antiandrogen withdrawal syndrome after bicalutamide withdrawal in castration-resistant prostate cancer patients treated with androgen receptor-axis targeted agents. ...CONCLUSIONS: The present data suggest a modest therapeutic efficacy o …
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Iron induces cell death and strengthens the efficacy of anti-androgen therapy in prostate cancer models.,Clin Cancer Res. 2020 Sep 14:clincanres.3182.2020. doi: 10.1158/1078-0432.CCR-20-3182. Online ahead of print.,"We validated the results in vivo in VCaP and PC-3 xenografts and in TRAMP-C2 injected mice treated with iron and/or bicalutamide. ...Bicalutamide-iron combination exacerbated oxidative damage and cell death, triggering protein oxidation also in poorly iron-sensitive …"
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer.,Genomics. 2020 Aug 31:S0888-7543(20)30855-7. doi: 10.1016/j.ygeno.2020.08.034. Online ahead of print.,"Besides, patients in the high-risk group were closely associated with dysregulation of DNA damage repair pathway, copy number alteration, tumor burden mutation, and low-response to cisplatin (P < 0.001), and bicalutamide (P < 0.001). ..."
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,"Anti-androgenic, anti-oxidant and anti-apoptotic effects of the aqueous and methanol extracts of Pterorhachis zenkeri (Meliaceae): Evidence from in vivo and in vitro studies.",Andrologia. 2020 Sep 3:e13815. doi: 10.1111/and.13815. Online ahead of print.,"For the in vivo studies, 70 immature male Wistar rats (n = 10/group) were treated for 2 or 4 weeks with: distilled water (10 ml/kg, per os) plus soya oil (1 ml/kg, sc), bicalutamide (10 mg/kg, per os), aqueous or methanol extract of P. zenkeri (10 mg/kg or 62 mg/kg, per os …"
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,PLCɛ maintains the functionality of AR signaling in prostate cancer via an autophagy-dependent mechanism.,Cell Death Dis. 2020 Sep 2;11(8):716. doi: 10.1038/s41419-020-02917-9.,"Furthermore, a positive correlation between PLCɛ and AR signaling activity was also observed in bicalutamide-resistant CaP samples and in AR-antagonist-resistant CaP cell models. ..."
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair.,Cancers (Basel). 2020 Aug 31;12(9):E2467. doi: 10.3390/cancers12092467.,"This radiosensitization effect was not observable using the first-generation antiandrogen bicalutamide. Inhibition of DNA DSB repair was found to contribute to the radiosensitization effect of second-generation antiandrogens, as demonstrated by a significant increase in re …"
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review.,Onco Targets Ther. 2020 Aug 12;13:8049-8054. doi: 10.2147/OTT.S264347. eCollection 2020.,"He was then treated with androgen deprivation therapy (ADT) comprising bicalutamide and goserelin. Only after 6 months of stable disease, the cancer progressed and the drug was changed to abiraterone; however, no significant therapeutic effect was observed and the disease …"
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer.,Cancers (Basel). 2020 Aug 18;12(8):2325. doi: 10.3390/cancers12082325.,"Antiandrogens, such as bicalutamide and enzalutamide, are also under investigation. Conversely, other studies suggest that the immune modulating properties of androgens could protect from the unfavorable cytokine storm, and that low testosterone levels might be associated …"
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.,Oncogene. 2020 Aug 20. doi: 10.1038/s41388-020-01429-2. Online ahead of print.,"Interestingly, CRPC tumors continue to depend on hyperactive AR signaling and will respond to potent second-line antiandrogen therapies, including bicalutamide (CASODEX(®)) and enzalutamide (XTANDI(®)). ...As such, our work has important implications for CRPC progression a …"
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.,Anticancer Drugs. 2020 Aug 27. doi: 10.1097/CAD.0000000000000986. Online ahead of print.,"Due to liver dysfunction, antiandrogens, both bicalutamide and flutamide, were stopped. The 1-month depot was switched to the 3-month depot in May 2013, but the patient complained of induration and abscess at the infection site. ..."
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Development of Androgen-Antagonistic Coumarinamides with a Unique Aromatic Folded Pharmacophore.,Int J Mol Sci. 2020 Aug 4;21(15):5584. doi: 10.3390/ijms21155584.,"First-generation nonsteroidal androgen receptor (AR) antagonists, such as flutamide (2a) and bicalutamide (3), are effective for most prostate cancer patients, but resistance often appears after several years due to the mutation of AR. ..."
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,A Case of Familial Male-Limited Precocious Puberty with a Novel Mutation.,J Clin Res Pediatr Endocrinol. 2020 Aug 6. doi: 10.4274/jcrpe.galenos.2020.2020.0067. Online ahead of print.,"Because the disorder is so rare, little is known about the long-term effects of treatment; however, studies using bicalutamide and anastrozole have been promising. ..."
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Anti-inflammatory effects of androgens in the human vagina.,J Mol Endocrinol. 2020 Oct;65(3):109-124. doi: 10.1530/JME-20-0147.,"COX2, IL-6, IL-12A and IFNγ), effect significantly blunted by AR antagonist bicalutamide. DHT significantly counteracted the secretion of IL-1RA, IL-2, IL-5, IL-15, FGF, VEGF and TNFα. LPS-induced NF-κB nuclear translocation was significantly inhibited by DHT, an effect co …"
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Recovery From Bicalutamide-Associated Pneumonitis in a Patient With ATM-Deficient Prostate Cancer.,JCO Oncol Pract. 2020 Jul 27:OP2000219. doi: 10.1200/OP.20.00219. Online ahead of print.,
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Tabletting solid dispersions of bicalutamide prepared using ball-milling or supercritical carbon dioxide: the interrelationship between phase transition and in-vitro dissolution.,Pharm Dev Technol. 2020 Aug 5:1-9. doi: 10.1080/10837450.2020.1797787. Online ahead of print.,The studies were aimed at formulating tablets containing bicalutamide-PVP K-29/32 solid dispersions and accessing the interrelationships between the properties of obtained binary systems in the form of powder and compacts. ...Co-processing of the drug substance with the ca …
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,"Treatment gains from the ""sandwich method"" of abiraterone acetate for men with metastatic prostate cancer: a case report and sharing of our experience.",Transl Androl Urol. 2020 Jun;9(3):1448-1458. doi: 10.21037/tau-19-851.,"., goserelin acetate, bicalutamide, docetaxel, and radical prostatectomy (RP), etc.], followed by a significant biochemical response during over 5 years of follow-up. ...This ""sandwich method"" with AA administered initially, withdrawal, and sequentially following Bicalu …"
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Use of lignocellulosic substrate colonized by oyster mushroom (Pleurotus ostreatus) for removal of organic micropollutants from water.,J Environ Manage. 2020 Oct 15;272:111087. doi: 10.1016/j.jenvman.2020.111087. Epub 2020 Jul 16.,"In this study, laccase activity of mushroom substrate colonized by Pleurotus ostreatus was evaluated as a novel wastewater treatment method for removal of OMPs, including diclofenac, bicalutamide, lamotrigine, and metformin at environmentally relevant concentrations. ...Re …"
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,Theoretical study on endocrine disrupting effects of polychlorinated dibenzo-p-dioxins using molecular docking simulation.,J Appl Toxicol. 2020 Jul 12. doi: 10.1002/jat.4039. Online ahead of print.,"The commonalities of these interacting amino acid residues with those utilized by dihydrotestosterone in AR, bicalutamide in AR an, 17β-estradiol in ER α, 17β-estradiol in ER β, cortisol in GR, thyromimetic GC-1 in TR α and thyromimetic GC-1 in TR β are 86%, 74%, 94%, 80%, …"
2020-09-23T06:04:26Z,https://pubmed.ncbi.nlm.nih.gov/?term=BICALUTAMIDE&sort=date&size=20,"How Does the CO(2) in Supercritical State Affect the Properties of Drug-Polymer Systems, Dissolution Performance and Characteristics of Tablets Containing Bicalutamide?",Materials (Basel). 2020 Jun 25;13(12):2848. doi: 10.3390/ma13122848.,"In this paper, we describe the application of scCO(2) in the preparation of binary systems containing poorly soluble antiandrogenic drug bicalutamide and polymeric excipients, either Macrogol 6000 or Poloxamer(®)407. ...The dissolution of bicalutamide was also consi …"
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,"A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.",Medicine (Baltimore). 2020 Sep 18;99(38):e22238. doi: 10.1097/MD.0000000000022238.,"BACKGROUND: Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma. ...CONCLUSION: Evidently, the conclusion of this study will provide an assessment on whether combined procarb …"
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.,Clin Transl Oncol. 2020 Sep 17. doi: 10.1007/s12094-020-02483-8. Online ahead of print.,"Three databases (Medline via PUBMED, SCOPUS, and Cochrane Library) were searched for studies featuring males aged 13-51-years who underwent chemotherapy for HL using ABVD (Adriamycin® (doxorubicin), bleomycin, vinblastine, and dacarbazine) or BEACOPP (bleomycin, etoposide, doxoru …"
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy.,Res Pract Thromb Haemost. 2020 Jul 23;4(6):997-1003. doi: 10.1002/rth2.12415. eCollection 2020 Aug.,"PATIENTS/METHODS: We reviewed patients diagnosed with PCNSL between 1997 and 2018 who received methotrexate, procarbazine, and vincristine ± Rituximab. ..."
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,Chemically induced mutations in a MutaMouse reporter gene inform mechanisms underlying human cancer mutational signatures.,Commun Biol. 2020 Aug 14;3(1):438. doi: 10.1038/s42003-020-01174-y.,"We used this approach to identify 2751 independent lacZ mutations in the bone marrow of MutaMouse animals exposed to four chemical mutagens: benzo[a]pyrene, N-ethyl-N-nitrosourea, procarbazine, and triethylenemelamine. ..."
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review.,Expert Rev Hematol. 2020 Aug 4:1-16. doi: 10.1080/17474086.2020.1793666. Online ahead of print.,"OBJECTIVE: To assess evidence on the safety and efficacy of ABVD (doxorubicin [Adriamycin®], bleomycin, vinblastine, and dacarbazine), BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), and A+AVD (brentuximab vedotin, …"
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,CD59-deficient bone marrow erythroid cells from rats treated with procarbazine and propyl-nitrosourea have mutations in the Pig-a gene.,Environ Mol Mutagen. 2020 Jul 30. doi: 10.1002/em.22402. Online ahead of print.,Procarbazine (PCZ) and N-propyl-N-nitrosourea (PNU) are rodent mutagens and carcinogens. Both induce GPI-anchored marker-deficient mutant-phenotype red blood cells (RBCs) in the flow cytometry-based rat RBC Pig-a assay. ...
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,Consolidation Therapy in Primary Central Nervous System Lymphoma.,Curr Treat Options Oncol. 2020 Jul 28;21(9):74. doi: 10.1007/s11864-020-00758-4.,"We have a preference for a regimen using rituximab, methotrexate (3.5 g/m2), procarbazine, and vincristine (R-MPV) for initial induction therapy, given the favorable balance between toxicities and very high response rates (80-90%), which allow for decreasing disease burden …"
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma.,Neurooncol Adv. 2020 Jun 29;2(1):vdaa077. doi: 10.1093/noajnl/vdaa077. eCollection 2020 Jan-Dec.,"One regimen used for induction is rituximab, high-dose methotrexate (HD-MTX), procarbazine, and vincristine (R-MPV). A common institutional practice is removing vincristine (VCR) from this regimen due to its poor CNS penetration and associated toxicities. ..."
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.,Cancer Med. 2020 Jul 25. doi: 10.1002/cam4.3298. Online ahead of print.,"PURPOSE: We explored the potential overall survival (OS) benefit of bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, and prednisone (BEACOPP) over doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD) …"
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,"Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.",J Clin Oncol. 2020 Jul 24:JCO1902983. doi: 10.1200/JCO.19.02983. Online ahead of print.,"Notably, treatment with postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine) was associated with longer PFS (HR, 0.32; P = .003; HR, 0.13; P < .001) and OS (HR, 0.38; P = .013; HR, 0.21; P = .029) in the IDH-mutant/non-codeleted and IDH-muta …"
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells.,Cancer Discov. 2020 Jun 30:CD-20-0226. doi: 10.1158/2159-8290.CD-20-0226. Online ahead of print.,"Poly(ADP-ribose) polymerases (PARPs) catalyze oligomerization of NAD+ monomers into poly(ADP-ribose) (PAR) chains during cellular response to alkylating chemotherapeutics, including procarbazine or temozolomide. ..."
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,Role of Oxygen and Nitrogen Radicals in the Mechanism of Anticancer Drug Cytotoxicity.,J Cancer Sci Ther. 2020;12(1):10-18. Epub 2020 Jan 24.,"The clinically active antitumor drugs, topotecan, doxorubicin, etoposide, and procarbazine are currently used for the treatment of human tumors. ..."
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,Successful oral desensitization and reintroduction in selected glioma patients with procarbazine-mediated hypersensitivity.,Allergy. 2020 Jun 2. doi: 10.1111/all.14428. Online ahead of print.,
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis.,Medicine (Baltimore). 2020 May 22;99(21):e20048. doi: 10.1097/MD.0000000000020048.,
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.,Jpn J Clin Oncol. 2020 Sep 5;50(9):999-1008. doi: 10.1093/jjco/hyaa073.,"RESULTS: Ninety-five patients treated with rituximab, methotrexate, procarbazine and vincristine (n = 39) or high dose-methotrexate (n = 56) were analysed. The complete response/complete response unconfirmed rate was significantly higher in the rituximab, methotrexate, …"
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,How did lomustine become standard of care in recurrent glioblastoma?,Cancer Treat Rev. 2020 Jul;87:102029. doi: 10.1016/j.ctrv.2020.102029. Epub 2020 May 4.,The most compelling data for lomustine stem from three randomized trials when lomustine was combined with procarbazine and vincristine as the PCV regimen in the newly diagnosed setting together with radiotherapy; improved survival with PCV was restricted to patients with i …
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,"Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2.",Br J Haematol. 2020 Jul;190(1):e1-e3. doi: 10.1111/bjh.16798. Epub 2020 May 25.,
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,Combined modality treatment: Outcome in patients with Hodgkin's lymphoma.,J Cancer Res Ther. 2020 Jan-Mar;16(1):1-6. doi: 10.4103/jcrt.JCRT_465_17.,"Chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) was given to 100 patients, 6 patients received ABVD-like regimen, and 9 patients received cyclophosphamide, vincristine, procarbazine, and prednisone regimen. ..."
2020-09-23T06:04:34Z,https://pubmed.ncbi.nlm.nih.gov/?term=PROCARBAZINE&sort=date&size=20,Increased Brain Serotonin Rather Than Increased Blood Acetaldehyde as a Common Denominator Behind Alleged Disulfiram-Like Reactions.,Int J Toxicol. 2020 May/Jun;39(3):248-255. doi: 10.1177/1091581820918169. Epub 2020 Apr 15.,"Herein, cefamandole, cotrimoxazole, griseofulvin, procarbazine, and propranolol, which are reported to produce a disulfiram-like reaction, as well as disulfiram, were administered to Wistar rats and the hepatic activities of ethanol metabolizing enzymes along with the leve …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Structural Effect on Adjuvanticity of Saponins.,J Med Chem. 2020 Mar 26;63(6):3290-3297. doi: 10.1021/acs.jmedchem.9b02063. Epub 2020 Feb 26.,"With rHagB antigen, it induced a significantly higher IgG2a response than the positive control GPI-0100, a well-studied semisynthetic saponin adjuvant mixture derived from Quillaja saponaria Molina saponins, known for its ability to induce a balanced Th1/Th2 immunit …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Vaccine Adjuvants Derivatized from Momordica Saponins I and II.,J Med Chem. 2019 Nov 14;62(21):9976-9982. doi: 10.1021/acs.jmedchem.9b01511. Epub 2019 Oct 28.,"Its IgG1 and IgG2a production is similar to that of GPI-0100, indicating a potential mixed and antigen-specific Th1/Th2 immune response, which is different from the Th2 immunity induced by the natural saponin MS I. ..."
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease.,Vaccine. 2019 May 16;37(22):2915-2924. doi: 10.1016/j.vaccine.2019.04.043. Epub 2019 Apr 19.,"CpG-adjuvanted TVGV-1 resulted in higher frequencies of IFNγ secreting and degranulating E7-specific T cells compared to GPI-0100-adjuvanted TVGV-1, resulting in marginally increased in vivo efficacy. Despite minor differences in immune response outcomes, we conside …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant.,J Med Chem. 2019 Feb 14;62(3):1669-1676. doi: 10.1021/acs.jmedchem.8b01997. Epub 2019 Jan 18.,"Compound 7 and QS-21 analogues 5 and 6 are presumably the major components of GPI-0100, a widely used complex mixture of semisynthetic derivatives of Quillaja saponaria (QS) Molina saponins. ...These results suggest that QS-17/18 analogue 7 might be the active compo …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation.,Vaccines (Basel). 2017 Jul 27;5(3):19. doi: 10.3390/vaccines5030019.,"However, the impact of the GPI-0100 dose on immune stimulation and the immune mechanisms stimulated by GPI-0100 along with antigen are poorly understood. ...The predominant antibody subtype induced by GPI-0100-adjuvanted vaccine was IgG1. …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Synthesis and Evaluation of QS-21-Based Immunoadjuvants with a Terminal-Functionalized Side Chain Incorporated in the West Wing Trisaccharide.,J Org Chem. 2016 Oct 21;81(20):9560-9566. doi: 10.1021/acs.joc.6b00922. Epub 2016 Oct 13.,Two of the synthetic analogues have been shown to have adjuvant activity comparable to that of GPI-0100. The stand-alone adjuvant activity of the new synthetic analogues again confirmed that it is a feasible way to develop new saponin-based vaccine adjuvants through …
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration.,Eur J Pharm Biopharm. 2015 Jun;93:231-41. doi: 10.1016/j.ejpb.2015.04.004. Epub 2015 Apr 17.,"Yet, only GPI-0100 also enhanced mucosal IgA titers. Moreover, only GPI-0100-adjuvanted WIV provided partial protection against heterologous virus challenge. ...Our results indicate that a GPI-0100-adjuvanted dry powder influenza vaccine …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer.,PLoS One. 2015 Jan 5;10(1):e116389. doi: 10.1371/journal.pone.0116389. eCollection 2015.,"Clinical studies suggest that responses to HPV16 E6E7L2 fusion protein (TA-CIN) vaccination alone are modest, and GPI-0100 is a well-tolerated, potent adjuvant. ...Vaccination with TA-CIN/GPI-0100 i.m. substantially retarded tumor growth and extended s …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.,J Immunother. 2014 May;37(4):237-44. doi: 10.1097/CJI.0000000000000029.,"Folate immune (EC90 vaccine with GPI-0100 adjuvant followed by EC17) is a novel folate-targeted hapten immunotherapy designed to exploit the overexpression of folate receptors on renal cell carcinoma (RCC) cells. ...Following 2 phase I cohorts of 6 patients each, we …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.,Med Microbiol Immunol. 2014 Feb;203(1):47-55. doi: 10.1007/s00430-013-0313-2. Epub 2013 Sep 24.,"Here, we evaluated the adjuvant effect of GPI-0100 on a virosomal influenza vaccine formulation. In contrast to influenza subunit vaccine adjuvanted with GPI-0100, virosomal vaccine supplemented with the same dose of GPI-0100 provided ful …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies.,PLoS One. 2013 Jul 31;8(7):e69649. doi: 10.1371/journal.pone.0069649. Print 2013.,"The study was conducted in BALB/c mice and the vaccine formulation was an influenza subunit vaccine supplemented with GPI-0100, a saponin-derived adjuvant. ..."
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,A phase I study of folate immune therapy (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) in patients with renal cell carcinoma.,J Immunother. 2013 May;36(4):268-75. doi: 10.1097/CJI.0b013e3182917f59.,"In the vaccination phase, patients were given once weekly vaccinations of 0.2 mg of EC90 plus 3.0 mg of GPI-0100 for 3-5 weeks. ...EC90 vaccine with GPI-0100 adjuvant followed by EC17 is safe and well tolerated. The recommended regimen for further stud …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100.,PLoS One. 2012;7(12):e52135. doi: 10.1371/journal.pone.0052135. Epub 2012 Dec 17.,"Here, we used a murine challenge model to evaluate the adjuvant activity of GPI-0100, a saponin-derived adjuvant, on influenza subunit vaccine administered via the intranasal or the intrapulmonary route. Balb/c mice were immunized with 1 µg A/PR/8 (H1N1) subunit ant …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,A mucosal subunit vaccine protects against lethal respiratory infection with Francisella tularensis LVS.,PLoS One. 2012;7(11):e50460. doi: 10.1371/journal.pone.0050460. Epub 2012 Nov 28.,"First, we establish an optimal intranasal immunization regimen in C57BL/6 mice using recombinant DnaK or Tul4 together with the adjuvant GPI-0100. ..."
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines.,Vaccine. 2011 Mar 3;29(11):2037-43. doi: 10.1016/j.vaccine.2011.01.012. Epub 2011 Jan 18.,"Balb/c mice were immunized with different doses of A/PR8 (H1N1) subunit antigen alone or in combination with varying doses of GPI-0100. The addition of GPI-0100 significantly stimulated antibody and cellular immune responses, especially of the Th1 phen …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys.,Clin Vaccine Immunol. 2009 Sep;16(9):1332-7. doi: 10.1128/CVI.00119-09. Epub 2009 Jul 29.,"The vaccine consisted of a recombinant envelope (E) protein truncated at the C-terminal end, resulting in a polypeptide containing 80% of the N-terminal amino acids of the native WNV protein (WN-80E), mixed with an adjuvant (GPI-0100). ...In a separate experiment, g …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.,J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. doi: 10.1093/jnci/djp106. Epub 2009 May 26.,"METHODS: Antibody responses of mice (n = 120) and rabbits (n = 23) to vaccination with HPV-16 amino-terminal L2 polypeptides or multitype L2 fusion proteins, namely, 11-200 x 3 (HPV types 6, 16, 18), 11-88 x 5 (HPV types 1, 5, 6, 16, 18), or 17-36 x 22 (five cutaneous, two mucosa …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,"Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.",Cancer Immunol Immunother. 2009 Sep;58(9):1397-405. doi: 10.1007/s00262-008-0654-7. Epub 2009 Feb 4.,"As expected, mice immunized with unconjugated sLe(a) plus GPI-0100 or unconjugated sLe(a) mixed with KLH plus GPI-0100 failed to produce antibodies against sLe(a). However, mice immunized with sLe(a)-KLH conjugate without GPI-0100 produce …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.,Vaccine. 2009 Feb 11;27(7):1040-9. doi: 10.1016/j.vaccine.2008.11.099. Epub 2008 Dec 16.,"Notably, vaccination with TA-CIN in GPI-0100 protected mice from cutaneous HPV16 challenge as effectively as HPV16 L1 VLP without adjuvant. Formulation of TA-CIN with GPI-0100 enhanced the production of E7-specific, interferon gamma producing CD8(+) T …"
2020-09-23T06:04:38Z,https://pubmed.ncbi.nlm.nih.gov/?term=GPI-0100&sort=date&size=20,Evaluation of widely consumed botanicals as immunological adjuvants.,Vaccine. 2008 Sep 2;26(37):4860-5. doi: 10.1016/j.vaccine.2008.06.098. Epub 2008 Jul 18.,Purified saponin extract QS-21 (Antigenics) and semisynthetic saponin GPI-0100 (Advanced BioTherapies) were used as positive control adjuvants. ...
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras.,Eur J Med Chem. 2020 Aug 26;208:112769. doi: 10.1016/j.ejmech.2020.112769. Online ahead of print.,"Predominantly, instead of thalidomide, we utilized the TD-106 scaffold, a novel cereblon (CRBN) binder that was identified in our previous study. ..."
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells.,Nat Chem Biol. 2020 Sep 21. doi: 10.1038/s41589-020-0645-3. Online ahead of print.,The immunomodulatory drug (IMiD) thalidomide and its derivatives lenalidomide and pomalidomide are therapeutic agents used in the treatment of multiple myeloma. ...
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Emerging immunotherapies in multiple myeloma.,BMJ. 2020 Sep 21;370:m3176. doi: 10.1136/bmj.m3176.,"In the mid-2000s, immunomodulatory drugs thalidomide, lenalidomide, and subsequently pomalidomide were proven to be effective in multiple myeloma and substantially improved survival. ..."
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,"Pregnant women, prescription, and fetal risk.",Handb Clin Neurol. 2020;173:377-389. doi: 10.1016/B978-0-444-64150-2.00027-7.,"Since the historical scandal of thalidomide in the 1960s, practitioners and future mothers are fearful of drugs during pregnancy. ..."
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents.,Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04133-6. Online ahead of print.,"The risk appears to be further increased in patients treated with imunomodulating drugs, such as thalidomide, especially when in combination with dexamethasone or conventional cytotoxic chemotherapies, and lenalidomide. ..."
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Old and new generation immunomodulatory drugs in multiple myeloma.,Panminerva Med. 2020 Sep 21. doi: 10.23736/S0031-0808.20.04125-7. Online ahead of print.,"The development and the introduction of the immunomodulatory drugs (IMiDs) which include thalidomide, lenalidomide, and pomalidomide, has contributed significantly to these improvements. ..."
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia.,Zdr Varst. 2020 Apr 6;59(2):83-91. doi: 10.2478/sjph-2020-0011. eCollection 2020 Jun.,"RESULTS: The sequences were defined by the frontline treatment: MPT (melphalan-prednisone-thalidomide), MPV (melphalanprednisone-bortezomib), CTD (cyclophosphamide-thalidomide-dexamethasone), VCD (bortezomib-cyclophosphamidedexamethasone) and BP (bendamustine-predni …"
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,"Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review.",Ther Adv Musculoskelet Dis. 2020 Sep 3;12:1759720X20947296. doi: 10.1177/1759720X20947296. eCollection 2020.,"In fact, there are other immunosuppressants known with antiviral activities, including cyclosporine A, hydroxyurea, minocycline, mycophenolic acid, mycophenolate mofetil, leflunomide, tofacitinib, and thalidomide. ..."
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,An IMiD-induced SALL4 degron system for selective degradation of target proteins.,Commun Biol. 2020 Sep 18;3(1):515. doi: 10.1038/s42003-020-01240-5.,"Furthermore, 5-hydroxythalidomide as a thalidomide metabolite specifically degradated S4D-tagged protein. These results indicate that the S4D system is a useful tool for cellular biology...."
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma.,Drugs. 2020 Sep 16. doi: 10.1007/s40265-020-01385-x. Online ahead of print.,"Intravenous daratumumab (DARZALEX(®)), a human monoclonal antibody targeting CD38, is approved in the EU and USA for use in combination with bortezomib, thalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma (MM) who are eligible fo …"
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports.,Rev Soc Bras Med Trop. 2020 Sep 11;53:e20190454. doi: 10.1590/0037-8682-0454-2019. eCollection 2020.,"We used search words like ""erythema nodosum leprosum(ENL)"", ""thalidomide"", ""case report"" in different combinations to get relevant reports that focus on thalidomide usage atleast once at any time point during management. ...From the analysis it was found that 7 of t …"
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,The neuroprotective action of lenalidomide on rotenone model of Parkinson's Disease: Neurotrophic and supportive actions in the substantia nigra pars compacta.,Neurosci Lett. 2020 Sep 12;738:135308. doi: 10.1016/j.neulet.2020.135308. Online ahead of print.,"Lenalidomide is a centrally active thalidomide analog that has potent anti-inflammatory and antiangiogenic activities. Currently, it is primarily used in the treatment of multiple myeloma and myelodysplastic syndromes. ...Therefore, in the current study, the effects of len …"
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,"Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents.",Bioorg Chem. 2020 Sep 1;104:104218. doi: 10.1016/j.bioorg.2020.104218. Online ahead of print.,"Thalidomide and its analogs are immunomodulatory drugs that inhibit the production of certain inflammatory mediators associated with cancer. In the present work, a new series of thalidomide analogs was designed and synthesized to obtain new effective antitumor immun …"
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide.,Nat Commun. 2020 Sep 14;11(1):4578. doi: 10.1038/s41467-020-18488-4.,"Thalidomide and its derivatives exert not only therapeutic effects as immunomodulatory drugs (IMiDs) but also adverse effects such as teratogenicity, which are due in part to different C2H2 zinc-finger (ZF) transcription factors, IKZF1 (or IKZF3) and SALL4, respectively. H …"
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces.,Iran J Pharm Res. 2020 Winter;19(1):1-2. doi: 10.22037/ijpr.2020.113369.14259.,
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Risk management of teratogenic medicines: A systematic review.,Birth Defects Res. 2020 Sep 11. doi: 10.1002/bdr2.1799. Online ahead of print.,"A proper estimation of the teratogenic risk was reported for thalidomide (by general practitioners and obstetric/gynecologists), for etretinate (by pregnant women), and for misoprostol (by pregnant and nonpregnant women). ...And over-estimation was reported for thalidom …"
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Protective Effects of Thalidomide on High-Glucose-Induced Podocyte Injury through In Vitro Modulation of Macrophage M1/M2 Differentiation.,J Immunol Res. 2020 Aug 27;2020:8263598. doi: 10.1155/2020/8263598. eCollection 2020.,"Our previous study on diabetic nephropathy rats indicated that thalidomide (Tha) has renoprotective properties. The present study explored the effects of Tha on mRNA and protein expressions of inducible nitric oxide synthase (iNOS), tumor necrosis factor- (TNF-) α, mannose …"
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Case Report: Severe Visceral Leishmaniasis in a Patient with HIV Coinfection Undergoing Treatment for Erythema Nodosum Leprosum.,Am J Trop Med Hyg. 2020 Sep 8. doi: 10.4269/ajtmh.20-0567. Online ahead of print.,We report a case of visceral leishmaniasis (VL)/HIV coinfection in a patient undergoing regular antiretroviral therapy and treatment with thalidomide for erythema nodosum leprosum. ...
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment.,Cancers (Basel). 2020 Sep 5;12(9):E2528. doi: 10.3390/cancers12092528.,"Immunomodulatory drugs (IMiDs) are analogs of thalidomide. They have immunomodulatory, antiangiogenic and proapoptotic properties and exert a role in regulating the tumor microenvironment. ..."
2020-09-23T06:04:42Z,https://pubmed.ncbi.nlm.nih.gov/?term=THALIDOMIDE&sort=date&size=20,Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis.,J Am Acad Dermatol. 2020 Sep 5:S0190-9622(20)32586-X. doi: 10.1016/j.jaad.2020.08.122. Online ahead of print.,"An NMA of 10 treatments revealed that none was superior to supportive care in reducing mortality rates and that thalidomide was associated with a significantly higher mortality rate (Odds ration [OR], 11.67; 95% confidence interval [CI], 1.42-95.96). ..."
2020-09-23T06:09:44Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD4877&sort=date&size=20,"Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.",Invest New Drugs. 2013 Aug;31(4):1001-7. doi: 10.1007/s10637-013-9926-y. Epub 2013 Jan 18.,"PATIENTS AND METHODS: AZD4877 25 mg was administered once-weekly for 3 weeks of each 4-week cycle until disease progression, death, unacceptable toxicity or withdrawal. ...Recruitment was to be halted if ≤ 2 of the first 20 evaluable patients achieved …"
2020-09-23T06:09:44Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD4877&sort=date&size=20,A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.,Invest New Drugs. 2013 Apr;31(2):355-62. doi: 10.1007/s10637-012-9821-y. Epub 2012 May 22.,"METHODS: In this multicenter study, a standard 3 + 3 dose-escalation design was used. AZD4877 was given as an intravenous infusion on days 1, 4, 8 and 11 of each 21-day cycle. ...Dose-limiting toxicity was neutropenia (n = 2 patien …"
2020-09-23T06:09:44Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD4877&sort=date&size=20,p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells.,Cancer Biol Ther. 2012 May;13(7):477-86. doi: 10.4161/cbt.19590. Epub 2012 May 1.,"Here we examined the cytotoxic effects of a novel antimitotic, the Eg5 inhibitor AZD4877, in a molecularly diverse panel of human bladder cancer cell lines. ...Stable knockdown of p63 inhibited cell death induced by either AZD4877 or docetaxel and was associated wit …"
2020-09-23T06:09:44Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD4877&sort=date&size=20,"Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent.",J Med Chem. 2011 Oct 13;54(19):6734-50. doi: 10.1021/jm200629m. Epub 2011 Sep 7.,"Structure-activity relationship analysis identified (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)- …"
2020-09-23T06:09:44Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD4877&sort=date&size=20,"Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors.",Arch Drug Inf. 2011 Jun;4(2):23-31. doi: 10.1111/j.1753-5174.2011.00034.x.,"METHODS: In this Phase I, open-label, dose-escalation study, AZD4877 (10, 15, 20 or 25 mg) was administered as a 1-hour intravenous infusion on days 1, 8 and 15 of repeated 28-day cycles to Japanese patients with advanced solid tumors. ...RESULTS: Of the 21 p …"
2020-09-23T06:09:44Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD4877&sort=date&size=20,"A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors.",Cancer Chemother Pharmacol. 2012 Jan;69(1):165-72. doi: 10.1007/s00280-011-1667-z. Epub 2011 Jun 3.,"In part B, the safety, tolerability, and pharmacokinetic profile of AZD4877 at the MTD were evaluated. RESULTS: In part A, 29 patients received at least one dose of AZD4877 (5 mg, n = 4; 7.5 mg, n = 4; 10 mg, n = 3 …"
2020-09-23T06:09:44Z,https://pubmed.ncbi.nlm.nih.gov/?term=AZD4877&sort=date&size=20,"Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.",Invest New Drugs. 2012 Jun;30(3):1107-15. doi: 10.1007/s10637-011-9660-2. Epub 2011 Apr 15.,"AZD4877 was administered at a range of doses (2, 4, 7, 10, 13, 16 and 18 mg/day) as a 1-hour intravenous infusion on three consecutive days of a continuous 2-week schedule. ...Evidence of monoasters in all but the 4 mg/day dose group prov …"
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,[Current status and progress in novel drug research for gastrointestinal stromal tumors].,Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Sep 25;23(9):911-916. doi: 10.3760/cma.j.cn.441530-20200701-00389.,"New drugs, such as avapritinib and ripretinib, have shown surprising therapeutic efficacy, which may lead to a new situation in the treatment of GIST. ..."
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,[Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor].,Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Sep 25;23(9):880-887. doi: 10.3760/cma.j.cn.441530-20200320-00156.,"Six GIST patients with D842V mutation had tumor recurrence after operation, of whom 4 cases achieved varying degrees of tumor remission after being treated with dasatinib or avapritinib. ..."
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,[Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].,Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Sep 25;23(9):872-879. doi: 10.3760/cma.j.cn.441530-20200706-00405.,"Among all the cases, 66 cases underwent R0 resection without preoperative treatment; two cases underwent emergency operation with R1 resection because of tumor rupture; 2 cases were not operated after the pathological and mutation types were confirmed by biopsy (one case received …"
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,[Updates and interpretations of the NCCN Clinical Practice Guidelines (2019 6th version) on gastrointestinal stromal tumor].,Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Sep 25;23(9):866-871. doi: 10.3760/cma.j.cn.441530-20200731-00454.,"Compared with previous versions, the new version of the guideline highlighted the treatment recommendations of avapritinib, which further promoted the precise targeted treatment of GIST...."
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,Successful treatment with avapritinib in patient with mucosal metastatic melanoma.,Ther Adv Med Oncol. 2020 Jul 31;12:1758835920946158. doi: 10.1177/1758835920946158. eCollection 2020.,"Main toxicities were grade 2 cutaneous vasculitis that required avapritinib discontinuation, and grade 2 uveitis of unknown origin, treated by vitrectomy and empiric antibiotic and antiviral therapy due to negative cultural tests. ...In conclusion, avapritinib prove …"
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,Early Data Supports Avapritinib for Gastrointestinal Stromal Tumors.,Cancer Discov. 2020 Sep;10(9):1251. doi: 10.1158/2159-8290.CD-RW2020-104. Epub 2020 Jul 10.,The TKI avapritinib showed preliminary evidence of efficacy in gastrointestinal stromal tumors....
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.",Lancet Oncol. 2020 Jul;21(7):935-946. doi: 10.1016/S1470-2045(20)30269-2.,"We aimed to assess the safety, tolerability, and antitumour activity of avapritinib, a novel KIT and PDGFRA inhibitor that potently inhibits PDGFRA D842V, in patients with advanced gastrointestinal stromal tumours, including patients with KIT and PDGFRA D842V-mutant gastro …"
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade.,Clin Cancer Res. 2020 Jun 29. doi: 10.1158/1078-0432.CCR-20-1706. Online ahead of print.,The recent arrival of avapritinib and ripretinib to the GIST arena has aimed to further improve on precision kinase inhibition and address tumor heterogeneity in imatinib-resistant GIST. ...
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,New drugs in gastrointestinal stromal tumors.,Curr Opin Oncol. 2020 Jul;32(4):314-320. doi: 10.1097/CCO.0000000000000642.,"Avapritinib is a type I inhibitor synthesized to exerts its activity in the active conformation of the activation loop of KIT and PDFGRα. The relevant activity reported with avapritinib in patients carrying the D842 v mutation represents, for first time, an active t …"
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.,Future Oncol. 2020 Aug;16(22):1639-1646. doi: 10.2217/fon-2020-0348. Epub 2020 Jun 10.,Avapritinib (BLU-285) is a potent KIT and PDGFRA-specific tyrosine kinase inhibitor which has shown >90% response rates in patients with PDGFRA exon 18 D842V-mutated GIST. Results from the Phase I trial of avapritinib have indicated that this drug should be the s …
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates.,Curr Treat Options Oncol. 2020 May 27;21(7):55. doi: 10.1007/s11864-020-00754-8.,"The treatment of advanced GIST is rapidly evolving with the development of novel molecular compounds such as avapritinib and ripretinib, but also promising results have been achieved with cabozantinib in a phase II trial. ...However, for GIST patients with tumours harbouri …"
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,New drugs in gastrointestinal stromal tumors.,Curr Opin Oncol. 2020 May 20. doi: 10.1097/CCO.0000000000000642. Online ahead of print.,"Avapritinib is a type I inhibitor synthesized to exerts its activity in the active conformation of the activation loop of KIT and PDFGRα. The relevant activity reported with avapritinib in patients carrying the D842 v mutation represents, for first time, an active t …"
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,"Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.",Sci Transl Med. 2020 Apr 29;12(541):eaaz2481. doi: 10.1126/scitranslmed.aaz2481.,"AZD3229 has a superior potency and selectivity profile to standard of care (SoC) agents-imatinib, sunitinib, and regorafenib, as well as investigational agents, avapritinib (BLU-285) and ripretinib (DCC-2618). ..."
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap.,Front Pharmacol. 2020 Apr 14;11:443. doi: 10.3389/fphar.2020.00443. eCollection 2020.,"However, the development of new tyrosine kinase inhibitors such as midostaurin or avapritinib with activity against mast cells carrying the D816V KIT mutation, has changed the landscape of this disease...."
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,First Targeted Therapy for Rare Form of GI Stromal Tumors.,Am J Nurs. 2020 May;120(5):23. doi: 10.1097/01.NAJ.0000662792.30228.52.,
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.",Blood. 2020 Apr 16;135(16):1365-1376. doi: 10.1182/blood.2019000932.,"The approval of the multikinase/KIT inhibitor midostaurin has validated the paradigm of KIT inhibition in advSM, and the efficacy and safety of second-generation agents, such as the switch-control inhibitor ripretinib (DCC-2618) and the D816V-selective inhibitor avapritinib …"
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,Avapritinib: First Approval.,Drugs. 2020 Mar;80(4):433-439. doi: 10.1007/s40265-020-01275-2.,Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. ...Clinical development of avapritinib is also underway for the treatment of systemic mastocytosis a …
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,Precision medicine in gastrointestinal stromal tumors.,Discov Med. 2019 Nov-Dec;28(155):267-276.,"Pivotal phase 3 clinical trials are ongoing with two novel agents, avapritinib and ripretinib, based on their remarkable activities in the 4th or greater line settings in phase 1/2 studies of these drugs. ..."
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,Avapritinib Approved for GIST Subgroup.,Cancer Discov. 2020 Mar;10(3):334. doi: 10.1158/2159-8290.CD-NB2020-003. Epub 2020 Jan 23.,The FDA approved avapritinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors with mutations in exon 18 of PDGFRA-genetic alterations that render tumors insensitive to all previously approved therapies for this rare sarcoma of the digestive t …
2020-09-23T06:09:48Z,https://pubmed.ncbi.nlm.nih.gov/?term=AVAPRITINIB&sort=date&size=20,Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor.,Blood Adv. 2019 Dec 10;3(23):4050-4054. doi: 10.1182/bloodadvances.2019000756.,c-KIT activating mutations cause resistance to PARP inhibitor in AML1-ETO–positive leukemias. c-KIT inhibitor avapritinib downregulates BRCA1/2 and DNA-PK catalytic subunit to restore the sensitivity to PARP inhibitor....
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis.,J Clin Med. 2020 Jul 13;9(7):2216. doi: 10.3390/jcm9072216.,An optimal cut-off of 135 pmol/8 × 10(8) RBC for leukopenia was calculated (sensitivity 75.4%; specificity 46.4%). 6-methylmercaptopurine ribonucleotides (6-MMPR) were significantly associated with hepatotoxicity (MD 3241.2 pmol/8 × 10(8) RBC; OR 4.28; 95%CI 3.20; 5.71). L …
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.",J Antimicrob Chemother. 2020 Aug 1;75(8):2031-2043. doi: 10.1093/jac/dkaa136.,"These studies characterized 277 mutations in the genes atpE, mmpR, pepQ, Rv1979c, fgd1, fbiABC and ddn and their association with resistance to one or more of the five drugs. ...Frameshifts in the mmpR homopolymer region nucleotides 192-198 were identified in 52/137 …"
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates.,J Infect. 2020 May;80(5):527-535. doi: 10.1016/j.jinf.2020.01.007. Epub 2020 Jan 23.,Mutations in the mmpR (rv0678) and atpE genes are associated with reduced susceptibility to bedaquiline and have been identified in both in vitro selected strains and clinical isolates. ...CONCLUSIONS: Bedaquiline treatment leads to an elevated bedaquiline MIC and the acqu …
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,Highly sensitive and rapid determination of azathioprine metabolites in whole blood lysate by liquid chromatography-tandem mass spectrometry.,J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jan 1;1136:121802. doi: 10.1016/j.jchromb.2019.121802. Epub 2019 Sep 13.,"In this study, an ultra-performance liquid chromatography tandem mass spectrometry method that was specific, accurate and sensitive was developed to simultaneously determine azathioprine two metabolites, 6-thioguanine nucleotides (6-TGN) and 6-methyl-mercaptopurine riboside (6- …"
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,Different Suture Materials for Arthroscopic Transtibial Pull-out Repair of Medial Meniscal Posterior Root Tears: A Human Biomechanical Study.,Orthop J Sports Med. 2019 Sep 30;7(9):2325967119873274. doi: 10.1177/2325967119873274. eCollection 2019 Sep.,BACKGROUND: Transtibial pull-out repair of the medial meniscal posterior root (MMPR) has been largely assessed through biomechanical studies. Biomechanically comparing different suture types would further optimize MMPR fixation and affect clinical care. PURPOSE/HYPO …
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,Collagenous Ultrastructure of the Torn Medial Meniscus Posterior Root: A Transmission Electron Microscopy Study.,Am J Sports Med. 2019 Nov;47(13):3221-3228. doi: 10.1177/0363546519876110. Epub 2019 Oct 11.,There were 23 specimens taken from patients with an MMPR tear and 20 taken from patients without an MMPR tear served as a control group. ...CLINICAL RELEVANCE: These results might provide a histopathological reason for the low healing rate after MMPR repair.. …
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,Implementation of a multi-modal pain regimen to decrease inpatient opioid exposure after injury.,Am J Surg. 2019 Dec;218(6):1122-1127. doi: 10.1016/j.amjsurg.2019.09.032. Epub 2019 Oct 1.,"After introduction of the MMPR, there was a significant reduction in median total MME administered per patient day from 60 MME/patient day (IQR 36-91 MME/patient day) pre-MMPR implementation to 37 MME/patient day (IQR 18-61 MME/patient day) in 2017, p < 0.01. ... …"
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,Oral antidiabetic medication adherence and glycaemic control among patients with type 2 diabetes mellitus: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia.,BMJ Open. 2019 Jul 23;9(7):e029280. doi: 10.1136/bmjopen-2019-029280.,"PRIMARY AND SECONDARY OUTCOME MEASURES: The modified medication possession ratio (mMPR) was calculated as a proxy measure for adherence of OADs. ...Among the study population, 48.6% had good adherence (mMPR >0.8) and 8.6% had a medication oversupply (mMPR …"
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,Development and testing of a mobile application to support diabetes self-management for people with newly diagnosed type 2 diabetes: a design thinking case study.,BMC Med Inform Decis Mak. 2017 Jun 26;17(1):91. doi: 10.1186/s12911-017-0493-6.,
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.,J Antimicrob Chemother. 2017 Jul 1;72(7):1901-1906. doi: 10.1093/jac/dkx094.,"To identify genetic determinants of resistance, sequencing of the mmpR ( Rv0678 ), atpE , atpC , pepQ , Rv1979c , rrl , rplC and rplD loci was performed. ...Several patients had isolates with elevated MICs of bedaquiline prior to treatment; four of them also bore mutations …"
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,"Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients.",Int J Drug Policy. 2017 Apr;42:30-35. doi: 10.1016/j.drugpo.2017.01.011. Epub 2017 Feb 9.,BACKGROUND: In 2014 Health Canada replaced the Marihuana for Medical Access Regulations (MMAR) with the Marihuana for Medical Purposes Regulations (MMPR). ...This is the first comprehensive survey of patients enrolled in the MMPR. METHODS: Patients registered to pur …
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder.,J Comp Eff Res. 2017 Mar;6(2):109-125. doi: 10.2217/cer-2016-0039. Epub 2017 Jan 25.,"Modified medication possession ratio (mMPR; days medication available/days in period, excluding medication holidays) was assessed; mMPR <0.80 nonadherent. ...Adjusted mean change in mMPR was 0.20 for long-acting versus 0.18 for short-acting stimulants (p = …"
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine.,Pharmacogenomics J. 2018 Jan;18(1):160-166. doi: 10.1038/tpj.2016.87. Epub 2017 Jan 3.,In patients on MP (control group) 6-MMPR levels were comparable (6195 (1551-10712) versus 6544 (1717-11600) pmol/8 × 10(8) RBCs; P=0.84). ...The presence of genetic variants in GSTA1 and GSTA2 was not related to the 6-MMPR and 6-TGN levels....
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.,Aliment Pharmacol Ther. 2017 Feb;45(3):391-402. doi: 10.1111/apt.13879. Epub 2016 Dec 12.,A T1 6-MMPR threshold of 3615 pmol/8 × 10(8) erythrocytes was defined. Analysis of patients on stable thiopurine dose (n = 174) showed that those exceeding the 6-MMPR threshold were at increased risk of hepatotoxicity: OR = 3.8 (95% CI: 1.8-8.0). ...A predictive alg …
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn's disease.,Aliment Pharmacol Ther. 2016 Nov;44(9):967-975. doi: 10.1111/apt.13796. Epub 2016 Sep 8.,"NUDT15 R139C and TPMT were genotyped. 6-TGN/6-MMPR concentrations were measured with high-performance liquid chromatography (HPLC). ...In contrast, no association was found in patients with NUDT15 R139C variant alleles (P = 0.26). 6-MMPR was not correlated with leuk …"
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.,J Crohns Colitis. 2017 Feb;11(2):175-184. doi: 10.1093/ecco-jcc/jjw130. Epub 2016 Jul 9.,"Logistic regression analysis of thiopurine type, threshold concentrations, and concurrent anti-tumour necrosis factor [TNF] therapy revealed that elevations of both T1 6-TGN and 6-MMPR resulted in the highest risk for leukopenia, followed by exceeding only the T1 6-MMPR …"
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.,Ther Drug Monit. 2015 Dec;37(6):797-804. doi: 10.1097/FTD.0000000000000213.,"Median 6-TGN level was 159 pmol/8 × 10 RBC (range, 46-419), median 6-MMPR level was 11,020 pmol/8 × 10 RBC (range, 3610-43,670), and the median 6-MMPR/6-TGN ratio was 72 (range, 29-367). ...Hepatotoxicity occurred more frequently in patients with an extremely skewed …"
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,"Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data.",J Manag Care Spec Pharm. 2014 Jul;20(7):691-700. doi: 10.18553/jmcp.2014.20.7.691.,"Medication adherence was high, with 72.2% adherent using MARS-5 and 77.1% using mMPR measures. The SEMs found that only self-reported medication adherence is associated with weight loss (MARS-5: OR = 1.70, 95% CI = 1.11-2.60), while both self-reported and claims-based medi …"
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.,J Crohns Colitis. 2014 Feb;8(2):120-8. doi: 10.1016/j.crohns.2013.07.004. Epub 2013 Aug 7.,"During the follow-up period of 12 weeks the median 6-TGN and 6-MMPR concentrations did not significantly change compared to baseline. ...In two patients (17%) myelotoxicity was observed within 2-4 weeks, in whom both low therapeutic 6-TGN and 6-MMPR concentrations w …"
2020-09-23T06:09:52Z,https://pubmed.ncbi.nlm.nih.gov/?term=MMPR&sort=date&size=20,Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.,Inflamm Bowel Dis. 2013 Mar;19(3):590-8. doi: 10.1097/MIB.0b013e31827eea8b.,"Red blood cell (RBC) concentrations of 6-TGN, 6-methyl-mercaptopurine ribonucleotides (6-MMPR), and 6-methyl-thioguanine nucleotides (6-MTGN) were indicated as follows: area under the concentration-time curve, average concentration (C av), and concentration at the final st …"
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor.,Sci Rep. 2020 Sep 16;10(1):15195. doi: 10.1038/s41598-020-72290-2.,"Cellular phenotype including proliferation, viability, migration/invasion, and also gene expression were not altered after PT2385 treatment. ...PT2385 as a single-agent was efficacious in vivo, however, an increase in animal survival was not seen with PT2385 …"
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,Marked and rapid effects of pharmacological HIF-2α antagonism on hypoxic ventilatory control.,J Clin Invest. 2020 May 1;130(5):2237-2251. doi: 10.1172/JCI133194.,"Mice carrying a HIF-2α PAS-B S305M mutation that disrupts PT2385 binding, but not dimerization with HIF-1β, did not respond to PT2385, indicating that these effects are on-target. ...Although PT2385 was well tolerated, the findings indicate the need for cauti …"
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,Functions of human liver CD69+CD103-CD8+ T cells depend on HIF-2α activity in healthy and pathologic livers.,J Hepatol. 2020 Jun;72(6):1170-1181. doi: 10.1016/j.jhep.2020.01.010. Epub 2020 Jan 24.,
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma.,Exp Cell Res. 2020 Mar 15;388(2):111845. doi: 10.1016/j.yexcr.2020.111845. Epub 2020 Jan 13.,"Here, we investigated the effect of PT2385-mediated inhibition of ARNT dependent HIF-2 activity. METHODS: Neuroblastoma patient-derived xenograft (PDX) cells were treated with PT2385 and analyzed for HIF-2-dependent gene expression, HIF activity, HIF-2α protein loca …"
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma.,Mol Cancer. 2019 Nov 18;18(1):163. doi: 10.1186/s12943-019-1082-3.,Administration of a HIF-2α antagonist (PT2385) restored YTHDF2-programed epigenetic machinery and repressed liver cancer. CONCLUSION: Our results have characterized the m(6)A-mRNA landscape in human HCC and revealed YTHDF2 as a molecular 'rheostat' in epitranscriptome and …
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,"HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.",Clin Cancer Res. 2020 Feb 15;26(4):793-803. doi: 10.1158/1078-0432.CCR-19-1459. Epub 2019 Nov 14.,PT2385 was safe and active in a first-in-human phase I clinical trial of patients with extensively pretreated ccRCC at UTSW and elsewhere. ...New approaches will be required to target mutant HIF-2 beyond PT2385 or the closely related PT2977 (MK-6482)....
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,"3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma.",J Med Chem. 2019 Aug 8;62(15):6876-6893. doi: 10.1021/acs.jmedchem.9b00719. Epub 2019 Jul 8.,"Our first HIF-2α inhibitor PT2385 demonstrated promising proof of concept clinical activity in heavily pretreated advanced ccRCC patients. However, PT2385 was restricted by variable and dose-limited pharmacokinetics resulting from extensive metabolism of PT2385 …"
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,A Transgenic Mouse Model of Pacak⁻Zhuang Syndrome with An Epas1 Gain-of-Function Mutation.,Cancers (Basel). 2019 May 14;11(5):667. doi: 10.3390/cancers11050667.,"Further, inhibition of HIF2α with its specific inhibitor PT2385 significantly reduced erythropoietin levels in the mutant mice. However, polycythemia persisted after PT2385 treatment, suggesting an alternative erythropoietin-independent mechanism of polycythemia. .. …"
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,A paradoxical method to enhance compensatory lung growth: Utilizing a VEGF inhibitor.,PLoS One. 2018 Dec 19;13(12):e0208579. doi: 10.1371/journal.pone.0208579. eCollection 2018.,
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment.,Int J Mol Sci. 2018 Dec 1;19(12):3834. doi: 10.3390/ijms19123834.,"Various histone deacetylase (HDAC) inhibitors, selenium, and agents like PT2385 and PT2977 are being explored in various clinical trials as potential HIF inhibitors, to ameliorate the outcomes of RCC patients. ..."
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,"Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).",J Med Chem. 2018 Nov 8;61(21):9691-9721. doi: 10.1021/acs.jmedchem.8b01196. Epub 2018 Oct 18.,"Herein we disclose our structure based drug design (SBDD) approach that culminated in the identification of PT2385, the first HIF-2α antagonist to enter clinical trials. ...Evaluation of select compounds from two structural classes in a sequence of PK/PD, efficacy, PK, and …"
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,Hypoxia-inducible factor 2α: a novel target in gliomas.,Future Med Chem. 2018 Sep 1;10(18):2227-2236. doi: 10.4155/fmc-2018-0163. Epub 2018 Aug 9.,"A first-in-class HIF2α inhibitor, PT2385, is in clinical trials for renal cell carcinoma, and provides the first opportunity to therapeutically target this important pathway in glioma biology...."
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,HIF2 Inhibitor Joins the Kidney Cancer Armamentarium.,J Clin Oncol. 2018 Mar 20;36(9):908-910. doi: 10.1200/JCO.2017.77.5254. Epub 2018 Jan 31.,
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro.,Drug Metab Dispos. 2018 Apr;46(4):336-345. doi: 10.1124/dmd.117.079723. Epub 2018 Jan 23.,It is of great importance to characterize the metabolism of PT2385 and identify its effect on systemic homeostasis in mice. High-resolution mass spectrometry-based metabolomics was performed to profile the biotransformation of PT2385 and PT2385-induced change …
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,HIF2α Antagonism Has Antitumor Activity in Advanced ccRCC.,Cancer Discov. 2018 Feb;8(2):OF6. doi: 10.1158/2159-8290.CD-RW2018-007. Epub 2018 Jan 12.,The HIF2α antagonist PT2385 achieved responses in 14% of patients with heavily pretreated ccRCC....
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.,J Exp Clin Cancer Res. 2020 Jul 25;39(1):143. doi: 10.1186/s13046-020-01644-5.,"Drug-sensitivity of cervical cancer cells to PARP1 inhibitors, olaparib or veliparib, was analyzed by CCK-8 cell viability assays, and the 50% inhibitory concentration (IC50) was quantified using GraphPad Prism. ..."
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,"Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.",J Clin Oncol. 2018 Mar 20;36(9):867-874. doi: 10.1200/JCO.2017.74.2627. Epub 2017 Dec 19.,"PT2385 is a first-in-class HIF-2α antagonist. Objectives of this first-in-human study were to characterize the safety, pharmacokinetics, pharmacodynamics, and efficacy, and to identify the recommended phase II dose (RP2D) of PT2385. ...PT2385 was administered …"
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis.,Nat Med. 2017 Nov;23(11):1298-1308. doi: 10.1038/nm.4412. Epub 2017 Oct 9.,"PT2385, a HIF-2α-specific inhibitor, had preventive and therapeutic effects on metabolic disorders that were dependent on intestine HIF-2α. ..."
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,"Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals.",Cell Death Dis. 2017 Oct 12;8(10):e3095. doi: 10.1038/cddis.2017.411.,
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.,Cancer Res. 2017 Nov 15;77(22):6321-6329. doi: 10.1158/0008-5472.CAN-17-1589. Epub 2017 Sep 26.,"Recently, HIF2α antagonists PT2385 and PT2399 were developed and are being evaluated in a phase I clinical trial for advanced or metastatic clear cell RCC (ccRCC). ..."
2020-09-23T06:10:00Z,https://pubmed.ncbi.nlm.nih.gov/?term=PT2385&sort=date&size=20,HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions.,Eur J Cancer. 2017 Nov;86:1-4. doi: 10.1016/j.ejca.2017.08.023. Epub 2017 Sep 22.,"Hypoxia-inducible factor 2alpha (HIF-2α) antagonists -PT2385, and PT2399 have been shown to have promising results in the management of clear cell renal cell carcinoma by targeting the HIF-2α pathway in recent and ongoing clinical trials (PT2799). ..."
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,"Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study.",J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 1;1154:122195. doi: 10.1016/j.jchromb.2020.122195. Epub 2020 May 30.,Veliparib was used as internal standard. FLG was extracted from HLMs by precipitation. An electrospray ionization source was used to assay of FLG. ...
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,Role of Poly [ADP-ribose] Polymerase 1 in Activating the Kirsten ras (KRAS) Gene in Response to Oxidative Stress.,Int J Mol Sci. 2020 Aug 28;21(17):E6237. doi: 10.3390/ijms21176237.,"This mechanism is confirmed by the finding that when PARP-1 is silenced by siRNA or auto PARylation is inhibited by Veliparib, the expression of KRAS is downregulated. ..."
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,What is the role of PARP inhibitors in pancreatic cancer?,Expert Rev Anticancer Ther. 2020 Sep 11:1-6. doi: 10.1080/14737140.2020.1816174. Online ahead of print.,
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.",Lancet Oncol. 2020 Aug 27:S1470-2045(20)30447-2. doi: 10.1016/S1470-2045(20)30447-2. Online ahead of print.,"In the intention-to-treat population (n=509), 337 patients were assigned to receive veliparib plus carboplatin-paclitaxel (veliparib group) and 172 were assigned to receive placebo plus carboplatin-paclitaxel (control group). Median follow-up at data cutoff (April 5 …"
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial.,Cancer Med. 2020 Aug 28. doi: 10.1002/cam4.3416. Online ahead of print.,"Secondary trial endpoints included comparison of the incidence and severity of neurotoxicity, hypothesized to be lower in the veliparib arm, and tolerability of the addition of veliparib to CE. ...The addition of veliparib to CE appeared tolerable, though wea …"
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,"PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective.",Oncol Lett. 2020 Oct;20(4):90. doi: 10.3892/ol.2020.11951. Epub 2020 Aug 6.,"Three PARP inhibitors, olaparib, rucaparib and niraparib, have been recently approved by the Food and Drug Administration for clinical use in EOC patients, though with different clinical indications and profiles of toxicity, while two other molecules, veliparib and talazop …"
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.,Int J Gynecol Cancer. 2020 Aug 19:ijgc-2020-001373. doi: 10.1136/ijgc-2020-001373. Online ahead of print.,"INTRODUCTION: We aimed to evaluate poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) regimens in BRCA-mutated ovarian cancer for patients responsive to front-line platinum (bevacizumab and olaparib, veliparib and chemotherapy, olaparib) or platinum-sensitive relapsed ( …"
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,The emerging role of PARP inhibitors in prostate cancer.,Expert Rev Anticancer Ther. 2020 Aug;20(8):715-726. doi: 10.1080/14737140.2020.1797497. Epub 2020 Aug 6.,"Several PARP inhibitors (PARPi) are under development, such as olaparib, talazoparib, niraparib, rucaparib, and veliparib. In metastatic castration resistant prostate cancer (mCRPC), olaparib has been the most studied and its clinical efficacy has been validated in a phase …"
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer.,Front Oncol. 2020 Jul 3;10:954. doi: 10.3389/fonc.2020.00954. eCollection 2020.,
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,In Vitro and In Vivo Efficacy of DNA Damage Repair Inhibitor Veliparib in Combination with Artesunate against Echinococcus granulosus.,Dis Markers. 2020 Jul 1;2020:8259820. doi: 10.1155/2020/8259820. eCollection 2020.,"., Veliparib) in combination with artesunate (AS) on hydatid cysts. For the in vitro assay, protoscoleces of E. granulosus (E.g PSCs) were incubated with low AS (AS-L, 65 μM), moderate AS (AS-M, 130 μM), and high AS (AS-H, 325 μM), AS-L/M/H+Veliparib (10 μM), and AB …"
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.,Clin Cancer Res. 2020 Jul 15. doi: 10.1158/1078-0432.CCR-20-1301. Online ahead of print.,"Thirty-one patients were enrolled in a phase I dose escalation of veliparib (40 mg to 250 mg twice a day, days 1-7 of each 14-day cycle), to identify the recommended phase II dose (RP2D) of veliparib for the combination. ...RESULTS: The combination of veliparib …"
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,DNA Repair and Prostate Cancer: A Field Ripe for Harvest.,Eur Urol. 2020 Oct;78(4):486-488. doi: 10.1016/j.eururo.2020.06.020. Epub 2020 Jul 5.,"Additional clinical trials are in progress for talazoparib, veliparib, and niraparib. More progress can be anticipated in the near future...."
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer.,Pharmacogenomics. 2020 Jul;21(10):721-727. doi: 10.2217/pgs-2019-0178. Epub 2020 Jun 29.,"Olaparib, niraparib and veliparib were evaluated and showed an increase in the duration of progression-free survival: 22.1 months (hazard ratio [HR] = 0.59), 13.8 (HR = 0.62) and 23.5 (HR = 0.68) with olaparib, niraparib and veliparib, respectively. ..."
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?,Front Oncol. 2020 Jun 12;10:782. doi: 10.3389/fonc.2020.00782. eCollection 2020.,"At the last European Society for Medical Oncology (ESMO) Congress, results from three trials testing three different poly-adenosine-diphosphate-ribose-polymerase (PARP) inhibitors (olaparib, niraparib, veliparib) in first-line therapy of OC have been presented. ..."
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma.,Oncotarget. 2020 Jun 9;11(23):2141-2159. doi: 10.18632/oncotarget.27329. eCollection 2020 Jun 9.,"In a panel of neuroblastoma cell lines, MYCN amplification or MYCN expression resulted in increased cell death in response to a range of PARP inhibitors (niraparib, veliparib, talazoparib and olaparib) compared to the response seen in non-expressing/amplified cells. ..."
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,The forefront of ovarian cancer therapy: update on PARP inhibitors.,Ann Oncol. 2020 Sep;31(9):1148-1159. doi: 10.1016/j.annonc.2020.06.004. Epub 2020 Jun 20.,"RESULTS: Four phase III trials (SOLO-1, PAOLA-1/ENGOT-OV25, PRIMA/ENGOT-OV26 and VELIA/GOG-3005) demonstrated remarkable improvements in progression-free survival with PARP inhibitor therapy (olaparib, niraparib or veliparib) for newly diagnosed ovarian cancer. ..."
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.,Expert Opin Emerg Drugs. 2020 Jun;25(2):165-188. doi: 10.1080/14728214.2020.1773791. Epub 2020 Jun 22.,
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.,Cancer Treat Rev. 2020 Jul;87:102040. doi: 10.1016/j.ctrv.2020.102040. Epub 2020 May 26.,
2020-09-23T06:10:11Z,https://pubmed.ncbi.nlm.nih.gov/?term=VELIPARIB(ABT-888)&sort=date&size=20,Poly (ADP-ribose) polymerase 1 inhibition prevents neurodegeneration and promotes α-synuclein degradation via transcription factor EB-dependent autophagy in mutant α-synucleinA53T model of Parkinson's disease.,Aging Cell. 2020 Jun;19(6):e13163. doi: 10.1111/acel.13163. Epub 2020 May 31.,"Also, oral administration of PARP1 inhibitor Veliparib prevented neurodegeneration and improved motor ability in α-synucleinA53T transgenic mice. ..."
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review.,JBI Database System Rev Implement Rep. 2017 Aug;15(8):2113-2152. doi: 10.11124/JBISRIR-2016-003105.,"TYPES OF INTERVENTIONS AND COMPARATORS: This review focused on intravenous infusion of either of the pharmaceutical formulations of mifamurtide (MTP-PE or L-MTP-PE) in addition to standard chemotherapy, and the comparator was chemotherapy …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.,Curr Treat Options Oncol. 2017 Apr;18(4):24. doi: 10.1007/s11864-017-0464-2.,"Specifically, liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE), a macrophage and monocyte activator, improved 10-year overall survival for patients with localized disease, with a similar pattern of response in patients with metasta …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.,Am J Cancer Res. 2016 Feb 15;6(3):677-89. eCollection 2016.,"No interference between the two drugs could be observed on ZA-induced bone protection and on L-mifamurtide-induced inhibition of lung metastasis development. Unexpectedly, ZA and L-mifamurtide association induced an additional and in some cases synergi …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.,Adv Exp Med Biol. 2014;804:307-21. doi: 10.1007/978-3-319-04843-7_17.,"Addition of a peptide to MDP resulted in muramyl tripeptide (MTP) which allowed incorporation into liposomal membranes. The resulting pharmaceutical, liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE or mifamurtide) showed activit …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.,J Exp Clin Cancer Res. 2014 Mar 10;33(1):27. doi: 10.1186/1756-9966-33-27.,"Likewise, stimulation of M1-like macrophages with liposomal muramyl tripeptide (L-MTP-PE) inhibited tumor growth, but only when combined with IFN-γ. ...Our observation that the induction of macrophage anti-tumor activity by L-MTP-PE requi …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Synthesis of isotopically labeled versions of L-MTP-PE (mifamurtide) and MDP.,J Labelled Comp Radiopharm. 2013 Jul-Aug;56(9-10):475-9. doi: 10.1002/jlcr.3078. Epub 2013 Jul 9.,"L-MTP-PE (1), an immunomodulator and its metabolite MDP (4) were synthesized from labeled l-alanine and its protected derivative, respectively. The key intermediate product for the labeled L-MTP-PE synthesis, [(13) C3 ,D4 ]-alanyl- …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment.,Br J Clin Pharmacol. 2014 Jun;77(6):986-97. doi: 10.1111/bcp.12260.,"AIMS: To evaluate the pharmacokinetics and pharmacodynamics following a single dose of liposomal mifamurtide (L-MTP-PE, MEPACT(®)) in adult subjects with mild (calculated creatinine clearance [CLcr ] of 50-80 ml min(-1)) or moderate (CLcr 30-50 ml min( …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,"Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.",Pediatr Blood Cancer. 2014 Feb;61(2):238-44. doi: 10.1002/pbc.24686. Epub 2013 Aug 31.,"PURPOSE: This non-randomized, patient-access protocol, assessed both safety and efficacy outcomes following liposomal muramyl-tripeptide-phosphatidylethanolamine (L-MTP-PE; mifamurtide) in patients with high-risk, recurrent and/or metastatic osteosarco …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,"A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.",Eur J Clin Pharmacol. 2012 Oct;68(10):1347-55. doi: 10.1007/s00228-012-1262-1. Epub 2012 Mar 30.,"PURPOSE: This study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), safety/tolerability, and cardiac safety of liposomal muramyl tripeptide phosphatidyl-ethanolamine [mifamurtide (L-MTP-PE)] in healthy adults. ...L-MTP-PE …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Mifamurtide for the treatment of nonmetastatic osteosarcoma.,Expert Opin Pharmacother. 2011 Feb;12(2):285-92. doi: 10.1517/14656566.2011.543129.,"AREAS COVERED: Mifamurtide (liposomal muramyl tripeptide phosphatidylethanolamine; L-MTP-PE) is a new agent. L-MTP-PE is a nonspecific immunomodulator, which is a synthetic analog of a component of bacterial cell walls. ...Informat …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Mifamurtide in osteosarcoma--a practical review.,Drugs Today (Barc). 2010 May;46(5):327-37. doi: 10.1358/dot.2010.46.5.1500076.,"Mifamurtide, also known as liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE), has been approved for the treatment of osteosarcoma in Europe. Mifamurtide's rational drug design employs MTP-PE for macrophage activatio …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Imunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole.,Parasitol Res. 2008 Sep;103(4):919-29. doi: 10.1007/s00436-008-1077-2. Epub 2008 Jun 29.,"On the contrary, Th2 response (cytokine IL-5) in infected mice treated with L-MTP-PE was inhibited since week 8 p.i., but a significant long-term decrease in IL-5 concentration was found after combined L-MTP-PE+ABZ therapy until the end o …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,"Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine.",Drugs R D. 2008;9(2):131-5. doi: 10.2165/00126839-200809020-00007.,Mifamurtide is being reviewed by regulatory authorities in the US and EU for this indication.CIBA-Geigy originally developed mifamurtide in the early 1980s and the agent was subsequently outlicensed to Jenner Biotherapies in the 1990s. ...The company expects that th …
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.,Expert Rev Anticancer Ther. 2008 Feb;8(2):151-9. doi: 10.1586/14737140.8.2.151.,Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) is a new agent that improves overall osteosarcoma survival (chemotherapy without L-MTP-PE 70% versus with L-MTP-PE 78%; p = 0.03). L-MTP- …
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.,Future Oncol. 2006 Jun;2(3):333-43. doi: 10.2217/14796694.2.3.333.,Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) is a synthetic biological investigational agent used for treating osteosarcoma. ...L-MTP-PE has been well tolerated using the concept of biological cancer therapy during ch …
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.,Curr Cancer Drug Targets. 2006 Mar;6(2):123-33. doi: 10.2174/156800906776056473.,"L-MTP-PE has undergone clinical development in humans. In early trials, most side effects of L-MTP-PE were minimal. L-MTP-PE showed signs of efficacy in treatment of patients with recurrent osteosarcoma and the encour …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Chemo-immunotherapy of ovarian cancer in a murine tumour model.,Anticancer Res. 2000 Jul-Aug;20(4):2585-92.,"RESULTS: An i.p. injection of L-MTP-PE in non-tumour bearing mice resulted in an approximately 10-fold increase in the number of peritoneal cells, which were highly cytotoxic. ...CONCLUSION: Although L-MTP-PE showed an enormous increase i …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.,Cancer Biother Radiopharm. 1998 Oct;13(5):363-8. doi: 10.1089/cbr.1998.13.363.,Liposome-encapsulated muramyl tripeptide-phosphatidyl ethanolamine (L-MTP-PE) was used in a pilot study for resectable melanoma patients who were at high risk for relapse. ...L-MTP-PE was given for 4 weeks prior to surgical resection and …
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.,Cancer Biother Radiopharm. 1999 Apr;14(2):121-8. doi: 10.1089/cbr.1999.14.121.,"We also evaluated the in vivo tumoricidal activity of PAM from dogs treated with the macrophage activator, liposome-encapsulated muramyl tripeptide-phosphatidyl-ethanolamine (L-MTP-PE) alone or in combination with doxorubicin (DOX). This study demonstrated th …"
2020-09-23T06:10:15Z,https://pubmed.ncbi.nlm.nih.gov/?term=MIFAMURTIDE(L-MTP-PE)&sort=date&size=20,Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma.,Anticancer Res. 1998 Mar-Apr;18(2A):1015-9.,"Thirteen dogs were entered in the L-MTP-PE group and fourteen dogs in the placebo control group. Only minor toxicities (fever and shivering during 10-24 hours) were seen in six dogs treated with L-MTP-PE, these being mainly of the smaller …"
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial.,Oncoimmunology. 2018 Feb 12;7(6):e1428157. doi: 10.1080/2162402X.2018.1428157. eCollection 2018.,"Patients and methods: Serum IgG antibodies were measured against a panel of 43 antigens by a bead-based multiplex assay in 970 stage II melanoma patients of the EORTC18961 trial, evaluating adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation. ...A set …"
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,Synthesis and Evaluation of GM2-Monophosphoryl Lipid A Conjugate as a Fully Synthetic Self-Adjuvant Cancer Vaccine.,Sci Rep. 2017 Sep 12;7(1):11403. doi: 10.1038/s41598-017-11500-w.,"This GM2 derivative was covalently linked to keyhole limpet hemocyanin (KLH) and monophosphoryl lipid A (MPLA) to form novel therapeutic cancer vaccines. ...Based on these results, it was concluded that both GM2-MPLA and GM2-KLH are promising ca …"
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa.,Melanoma Res. 2014 Apr;24(2):150-7. doi: 10.1097/CMR.0000000000000050.,"In E2696, patients with resectable high-risk melanoma were randomized to receive vaccination with GM2-KLH/QS-1 (GMK) plus concurrent HDI, GMK plus sequential HDI, or GMK alone. ..."
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,"A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma.",J Transl Med. 2014 Jan 23;12:19. doi: 10.1186/1479-5876-12-19.,BACKGROUND: E1694 tested GM2-KLH-QS21 vaccine versus high-dose interferon-α2b (HDI) as adjuvant therapy for operable stage IIB-III melanoma. ...
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.,J Clin Oncol. 2013 Oct 20;31(30):3831-7. doi: 10.1200/JCO.2012.47.9303. Epub 2013 Sep 9.,PURPOSE: The GM2 ganglioside is an antigen expressed in the majority of melanomas. The GM2-KLH/QS-21 vaccine induces high immunoglobulin M (IgM) and IgG antibody responses. ...CONCLUSION: GM2-KLH/QS-21 vaccination does not improve outcome for pa …
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,QS-21: a water-soluble triterpene glycoside adjuvant.,Expert Opin Investig Drugs. 1998 Sep;7(9):1475-82. doi: 10.1517/13543784.7.9.1475.,This includes a Phase II evaluation of a QS-21 adjuvanted pneumococcal polysaccharide vaccine and a Phase III evaluation of a QS-21 adjuvanted GM2-KLH (ganglioside GM2 vaccine) immunotherapeutic product for melanoma. ...
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer.,Ann Surg Oncol. 2001 Oct;8(9 Suppl):38S-40S.,"In trial EORTC 18961 for stage II melanoma, GM2-KLH/QS-21 vaccination is compared with observation (1300 patients); in trial EORTC 18991 for stage III melanoma, 5-year treatment with pegylated interferon alfa-2b (PEG-Intron) is compared with observation (900 patient …"
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.,J Clin Oncol. 2001 May 1;19(9):2370-80. doi: 10.1200/JCO.2001.19.9.2370.,"The GM2 ganglioside is a well-defined melanoma antigen, and anti-GM2 antibodies have been associated with improved prognosis. ...Antibody responses to GM2 (ie, titers > or = 1:80) at days 29, 85, 365, and 720 were associated with a trend toward improved RF …"
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.,J Clin Oncol. 2001 Mar 1;19(5):1430-6. doi: 10.1200/JCO.2001.19.5.1430.,GM2-KLH/QS-21 (GMK) is a chemically defined vaccine that is one of the best developed of a range of vaccine candidates for melanoma. ...
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.,Clin Cancer Res. 2000 Mar;6(3):874-9.,"To optimize the immune response against GM2, a reformulated vaccine was produced conjugating GM2 to keyhole limpet hemocyanin (KLH) and using the adjuvant QS21 (GM2-KLH/QS21). ...We conclude that the GM2-KLH/QS21 formulation is mor …"
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,Ganglioside vaccines with emphasis on GM2.,Semin Oncol. 1998 Dec;25(6):636-45.,Induction of antibodies against GM2 by vaccination has correlated with an improved prognosis in American Joint Committee on Cancer (AJCC) stage III melanoma patients and vaccines containing GM2 chemically conjugated to keyhole limpet hemocyanin (KLH; GM2 …
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,Adjuvant therapy of melanoma.,Semin Surg Oncol. 1998 Jun;14(4):302-10. doi: 10.1002/(sici)1098-2388(199806)14:4<302::aid-ssu6>3.0.co;2-6.,"Recent data with vaccines have been encouraging, and the GM2-KLH vaccine is the focus of ongoing intergroup study comparing this treatment with IFNalpha in resected Stage IIB and III melanoma. ..."
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,"The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxicity and costs.",Melanoma Res. 1997 Aug;7 Suppl 2:S127-31.,"In patients with a moderate risk (about 35%) of having micrometastatic disease, EORTC trial 18961 will investigate placebo versus vaccination with the ganglioside GM2 vaccine (GM2-KLH/QS-21) in 1000 patients with stage IIA melanoma (T3N0M0). ..."
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.,Cancer Immunol Immunother. 1997 Jan;43(6):324-30. doi: 10.1007/s002620050340.,"A vaccine containing GM2 covalently attached to keyhole limpet hemocyanin (KLH) plus the immunological adjuvant QS-21 now induces higher-titer, longer-lasting IgM antibodies against GM2 and has recently entered phase III clinical trials. ...These findings sug …"
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.,Cancer Res. 1995 Jul 1;55(13):2783-8.,"To increase immunogenicity, we conjugated GM2 covalently with keyhole limpet hemocyanin (KLH). GM2-KLH vaccine was given to melanoma patients alone or with one of the three adjuvants: Bacillus Calmette-Guérin, DETOX, or QS-21. ...It also induced the hi …"
2020-09-23T06:10:21Z,https://pubmed.ncbi.nlm.nih.gov/?term=GM2-KLH&sort=date&size=20,Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.,Immunol Rev. 1995 Jun;145:147-66. doi: 10.1111/j.1600-065x.1995.tb00080.x.,"Based on these encouraging clinical results and the clearly improved immunogenicity of the GM2-KLH plus QS-21 vaccine compared to the previous GM2/BCG vaccine, the following two large clinical trials are anticipated to begin in 1995-1996. ...Also to be tested …"
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.,J Clin Pharmacol. 2020 Aug 20. doi: 10.1002/jcph.1711. Online ahead of print.,"Molibresib (GSK525762), an orally bioavailable small molecule with 2 major equipotent active metabolites, is being developed for the treatment of cancers. ...PBPK simulation guided the molibresib dose (5 mg) to be administered along with itraconazole in part …"
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,"Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.",JNCI Cancer Spectr. 2019 Nov 6;4(2):pkz093. doi: 10.1093/jncics/pkz093. eCollection 2020 Apr.,"This first-in-human study evaluated the safety, recommended phase II dose, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the bromodomain and extra-terminal domain inhibitor molibresib (GSK525762) in patients with nuclear protein in testis …"
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma.,Pediatr Blood Cancer. 2020 Jun;67(6):e28267. doi: 10.1002/pbc.28267. Epub 2020 Apr 19.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction.,Nat Commun. 2020 Apr 14;11(1):1833. doi: 10.1038/s41467-020-15290-0.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,Evaluation of linker length effects on a BET bromodomain probe.,Chem Commun (Camb). 2019 Aug 20;55(68):10128-10131. doi: 10.1039/c9cc05054j.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,Analysis of unstable degradation impurities of a benzodiazepine and their quantification without isolation using multiple linear regression.,J Pharm Biomed Anal. 2019 Apr 15;167:1-6. doi: 10.1016/j.jpba.2019.01.028. Epub 2019 Jan 17.,This manuscript presents a novel methodology for calculating the relative response factors (RRFs) of unstable degradation impurities of molibresib (1). ...
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,"Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells.",Endocrine. 2019 Mar;63(3):545-553. doi: 10.1007/s12020-018-01836-2. Epub 2019 Jan 19.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,"Biological and molecular effects of bromodomain and extra-terminal (BET) inhibitors JQ1, IBET-151, and IBET-762 in OSCC cells.",J Oral Pathol Med. 2019 Mar;48(3):214-221. doi: 10.1111/jop.12824. Epub 2019 Jan 24.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma.,Cell Oncol (Dordr). 2019 Apr;42(2):143-155. doi: 10.1007/s13402-018-0416-2. Epub 2018 Dec 11.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.,Int J Cancer. 2019 Feb 15;144(4):755-766. doi: 10.1002/ijc.31898. Epub 2018 Dec 4.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.,Sci Rep. 2018 May 25;8(1):8102. doi: 10.1038/s41598-018-26496-0.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,A super-enhancer maintains homeostatic expression of Regnase-1.,Gene. 2018 Aug 30;669:35-41. doi: 10.1016/j.gene.2018.05.052. Epub 2018 May 16.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.,Oncogenesis. 2018 Apr 20;7(4):35. doi: 10.1038/s41389-018-0043-9.,Here we investigate the biomarkers of activity of the clinical BET inhibitor GSK525762 (I-BET; I-BET762) across cancer cell lines and demonstrate that KRAS mutations are novel resistance biomarkers. ...GSK525762 treatment up-regulated p-ERK1/2 levels in both RAS pat …
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.,Antiviral Res. 2018 Jun;154:158-165. doi: 10.1016/j.antiviral.2018.03.012. Epub 2018 Apr 11.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,Spinal bromodomain-containing protein 4 contributes to neuropathic pain induced by HIV glycoprotein 120 with morphine in rats.,Neuroreport. 2018 Apr 11;29(6):441-446. doi: 10.1097/WNR.0000000000000992.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.,Oncol Rep. 2018 Feb;39(2):582-588. doi: 10.3892/or.2017.6152. Epub 2017 Dec 12.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762.,Cancer Prev Res (Phila). 2018 Mar;11(3):143-156. doi: 10.1158/1940-6207.CAPR-17-0264. Epub 2017 Dec 15.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,A BET Bromodomain Inhibitor Suppresses Adiposity-Associated Malignant Transformation.,Cancer Prev Res (Phila). 2018 Mar;11(3):129-142. doi: 10.1158/1940-6207.CAPR-17-0262. Epub 2017 Dec 15.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,Click Chemistry: Novel Applications in Cell Biology and Drug Discovery.,Angew Chem Int Ed Engl. 2017 Dec 4;56(49):15504-15505. doi: 10.1002/anie.201710195. Epub 2017 Oct 25.,
2020-09-23T06:10:25Z,https://pubmed.ncbi.nlm.nih.gov/?term=GSK525762&sort=date&size=20,Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.,Nat Med. 2017 Sep;23(9):1063-1071. doi: 10.1038/nm.4378. Epub 2017 Aug 14.,
